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The global prevalence of type 2 diabetes (T2DM) and obesity is increasing, with obesity the 
most important predisposing factor contributing to the development of T2DM. 
Epidemiological and genetic evidence supports a major genetic component in both 
multifactorial and heterogeneous disorders. The identification of disease susceptibility genes 
in humans could greatly assist in the elucidation of underlying pathophysiological 
mechanisms and allow the development of more effective preventative and therapeutic 
strategies for these conditions. 
Three candidate genes, uncoupling proteins 2 and 3 (UCP2; UCP3) and calpain 10 
(CAPN10), are proposed and the rationale for their selection discussed. Gene variants were 
identified in UCP2 and UCP3. These variants were tested for association with T2DM, 
obesity and intermediate quantitative traits in a South Indian population and family 
collection, and also a cohort of British obese case/control subjects. No variant was 
associated with T2DM. However, investigations revealed positive associations with a UCP2 
3'UTR 45bp Ins/Del and a novel UCP3 promoter variant (-55C/T) with variation in body 
mass (BMI) and fat distribution (WHR) respectively. The results support the view that 
uncoupling proteins may influence weight gain and hence progression to obesity/T2DM. A 
significant correlation with plasma leptin levels and the UCP2 Ins/Del variant might indicate 
one potential mechanism whereby weight could be modulated by uncoupling proteins. 
A linkage study in affected sibling pairs of North European descent, was negative for the 
putative T2DM susceptibility gene region, NIDDMI. In contrast, haplotypes of four 
sequence variants of a T2DM susceptibility gene (CAPN10) identified in this region 
positively associated with T2DM in a South Indian population. 
In conclusion, these investigations provide evidence that the three genes studied may 
contribute to susceptibility for development of T2DM or obesity. However, the findings are 
in agreement with the most likely genetic model for non-Mendelian complex diseases, that 
many genes are involved in determining susceptibility to disease with no single gene 
capable of determining the overall disease phenotype. 
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CHAPTER 1: INTRODUCTION 
1.1 GLOBAL IMPORTANCE OF TYPE 2 DIABETES AND OBESITY 
Diabetes is a disease affecting between 100-150 million people world-wide. Type 2 diabetes 
mellitus (T2DM), also know as non-insulin dependent diabetes, is defined by the World 
Health Organisation as the predominant sub-type of diabetes accounting for 97% of diabetic 
cases [Alberti et al 1998a]. T2DM is not only an important cause of morbidity in respect of 
microvascular, macrovascular and neurological complications, but is also associated with an 
increase in mortality and a 2-3 fold increase in risk to cardiovascular disease. Although the 
global prevalence of T2DM is approximately 2.1% [Amos et al 1997], there is a broad 
spectrum of disease prevalence with frequencies ranging from 2% to 6% in Caucasian 
populations and exceeding 30% in some ethnic groups. 
Global prevalence is also increasing and this has been mainly attributed to increasing 
obesity as a result of changing dietary intake and life style. The acquisition of a 
`Westernised' life style with a more sedentary existence through a reduction in physical 
activity and combined with high calorie dietary intake have been implicated in accounting 
for the increased prevalence of obesity (Helmrich et al 1991; Eriksson et al 1996; Zimmet 
1992; Aspray et al 2000]. This is clearly reflected in the migration from and urbanisation of 
populations in developing countries. Urbanized and migrated South Indian populations 
having an increased prevalence of T2DM compared to rural populations following more 
traditional lifestyles (figure 1.1.1) [Ramachandran et al 1997a; Mckeigue et al 1991 ]. 
T2DM has a close relationship with obesity, atherosclerosis and hypertension, with the 
severity of the complications being proportional to the degree of obesity. The inverse is also 
true with dramatic decreases in disease frequency on reduction of obesity (50-75%) and 
increased physical activity (30-50%) [Manson & Spelsberg 1994; Houmard et al 1994]. 
Obesity is also associated with an increased mortality, morbidity and decreased quality of 
life especially amongst middle-aged and older individuals. In the USA more than half the 
US population over 20 years old are overweight and nearly a quarter are clinically obese in 
terms of BMI [Kuczmarski et al 1994]. The excessive intake of calories in the USA is 
second only to smoking as the greatest cause of mortality [McGinnis et al 1993]. The 
modem medical case against obesity began in 1959 with the publication of the Metropolitan 
Life Insurance Company tables. These showed that the risk of premature death elevated 
steadily as weight increased above a BMI of 22.0 in males and BMI of 21.5 in females. 
Eighty percent of Americans now exceed these levels. Furthermore, a prospective study of 
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115,000 nurses found mortality rate increased with progressive increase in BMI with the risk 
of death increasing by more than 100% for BMI's over 29 [Manson & Spelsberg 1994]. The 
future gravity of the situation is further exemplified in that 25% of children in the USA are 
already overweight or obese [Kuczmarski 1993]. The economic costs of T2DM and obesity 
to countries for treatment in health care systems are enormous. In addition about $40billion 
/annum is spent in the USA on weight loss treatments, mostly in the form of diets with little 
or no success. 
Ethnic Populations 
Figure 1.1.1: Urbanisation and migrational effects on the prevalence of T2DM 
1.2 DISEASE PHENOTYPES 
1.2.1 Type 2 diabetes mellitus 
Diabetes mellitus is a complex metabolic disorder incorporating many syndromes. The 
phenotype is characterised by elevated glucose levels in the blood and urine. Glucose is 
excreted in the urine when the blood glucose levels exceed the re-absorptive capacity of the 
renal tubules. Water accompanies the excreted glucose, and so an untreated diabetic in the 
acute phase of the disease is hungry and thirsty. Diabetes mellitus was originally 
differentiated into two groups; those patients having autoimmune destruction of the insulin 
secreting pancreatic 0-cells, and thus requiring an external supply of insulin, Insulin 
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Dependent Diabetes mellitus or type 1 diabetes (T1DM). Traditionally the remaining 
diabetic patients with no insulin requirement in the early stages of the disease, the non- 
insulin dependent diabetics were classified as T2DM. 
T2DM patients are islet cell antibody negative and their hyperglycaemia may be initially 
controlled with diet and/or pharmaceutical hypoglycaemic agents but may eventually require 
insulin. Subjects tend to present in mid to old age (age 50-60 years), unless they are 
screened in pregnancy or present with another illness. T2DM patients may share a common 
final clinical phenotype of deteriorating glucose tolerance and associated diabetic 
complications, but this probably represents a heterogeneous group of diverse conditions. 
This view is supported by the identification of approximately 10% of T2DM patients with a 
primary autoimmune aetiology characterized by the presence of autoantibodies [Turner et al 
1997]. In addition, other sub-groups exist where the diabetes is the result of single gene 
defects primarily affecting the ß-cell, as with maturity onset diabetes of the young (MODY) 
[Froguel et al 1992; Yamagata et al 1996ab; Hattersley 2000]. 
Glucose tolerance is determined by the capacity of the pancreatic ß-cell to secrete insulin in 
response to secretagogues and the ability of the secreted insulin to induce multiple actions in 
peripheral tissues, most importantly in skeletal muscle, liver and adipose tissue [Kahn & 
Folli 1993; Reaven 1993]. Although in MODY, a ß-cell defect alone appears to be the 
primary cause [Taniguchi et al 1992; Amer et al 1991; O'Rahilly & Turner 1988b], patients 
with established T2DM display defects in both insulin secretion and insulin action [Taylor et 
al 1994]. Insulin resistance alone is not sufficient to cause diabetes and a complex 
relationship involving compensatory mechanisms exists between the two phenotypic 
characteristics [Bruning et al 1998; Garvey et al 1985; Lillioja et al 1993; O'Rahilly et al 
1988a; Weigle & Goodner 1986]. As a consequence neither pathway can yet be defined as 
the primary defect of T2DM [Bergman 1997]. The heterogeneous nature of T2DM is 
possibly one of the reasons why the underlying physiological basis of T2DM still remains 
relatively unknown, with no biochemical markers presently capable of predicting future 
glucose intolerance. 
1.2.2 Obesity 
The measurement of Body Mass Index (BMI) is used clinically to determine normality of 
body weight and is calculated by dividing body weight by height squared (kg/m2). Subjects 
are classified according to BMI as underweight <18.5; normal 18.5-24.9; overweight 25.0- 
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29.9; obesity 730.0; morbidly obese 740.0 [Katsilambros 2000]. The WHO has adopted 
30kg/m2 as the lowest limit for definition of obesity as the correlation between BMI and 
total body fat or percent body fat is only high in large and heterogeneous samples when BMI 
is above this level [Bouchard 1995]. 
However, BMI as a measure of body fat is not always entirely valid, as the measure of 
variance in percent body fat explained by BMI is only between 40% to 60% with a closer 
correlation at extremes of body fat content [Bouchard 1995]. Obesity is also a heterogeneous 
disease phenotype displaying a number of patterns of distribution of excess fat. The different 
phenotypes may be each modulated by a different set of causal factors. There is no unified 
classification of the individual obesity phenotypes based on heterogeneous clinical 
manifestations, although obesity can be sub-divided by body fat topography. 
Patients can have peripheral obesity with anatomically excess fat deposited in the gluteal 
and femeral areas (lower body or gynoid- female type or subcuraneous-type). Alternatively 
they may have central obesity (upper body or male type or splanchnic or abdominal or intra- 
abdominal obesity) [Katsilambros 2000]. Endocrine abnormalities such as increased insulin 
levels, insulin resistance, cortisol levels, testosterone and androstenedione, and decreased 
growth hormone and progesterone are much more pronounced in the latter condition. 
However phenotypes are not fully independent as the level of covariation amongst the 
obesity types range from 30% to 50%. Fat distribution and age considerations are also of 
equal importance to overall increase in mass, this being particularly relative in ethnic groups 
where average body mass have not reached proportions seen in the westernised societies. 
The anthropomorphic measurement of waist-to-hip circumference ratio (WHR) positively 
correlates with abdominal visceral fat deposition, and upper body adiposity and is therefore 
a phenotypic indicator of regional fat distribution. However WHR is also confounded by a 
high degree of heterogeneity. Any studies both epidemiological and genetic are impeded by 
the limitations of the primary clinical diagnosis. Direct measurements of fat mass such as 
with bioelectrical impedience, rather than indirect/partial methods, allow indexes such as fat 
free mass (FFM) to be defined and allows a refinement in determining traits that influence 
body weight homeostasis. 
1.2.3 Relationship between type 2 diabetes and obesity 
Epidemiological evidence strongly supports a relationship between T2DM and obesity. The 
WHO in 1980 [WHO expert committee 1980] cited obesity as the most important risk factor 
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in the development of T2DM with this association transcending ethnicity, differences in 
measurements of adiposity and criteria for diagnosis of T2DM [Prentice & Jebb 1995]. 
Progressively increasing body mass is positively correlated with both elevated fasting 
plasma insulin and impaired glucose tolerance (IGT), negatively correlated with whole body 
insulin sensitivity and therefore increases risk to T2DM [Kolterman et al 1980; Kissebah et 
al 1982]. This increased risk has been demonstrated in a number of ethnic groups including, 
Western Samoan [Collins et al 1994], Afro-Carribbean [McKeigue et al 1992], Asian 
Indian [Shelgikar et al 1991], Tanzanian [Aspray et al 2000] and South Indian populations 
[Ramachandran et al 1992]. 
However, other factors also contribute to the increased risk and modify the influence of 
adiposity, such as distribution of body fat, duration of obesity, fitness, ethnicity, and family 
history. Central adiposity is particularly associated with an increased risk to the 
development of both insulin resistance and diabetes [Bjorntorpl99l]. Phenotypic patterns 
of fat distribution are determined by both ethnicity and gender and this may influence onset 
of disease. In South Indians fat distribution is far more important in influencing the 
prevalence of glucose intolerance than overall fatness and increased abdominal fat 
deposition found in females is associated with a lower efficiency in breaking down glucose 
[McKeigue et al 1992; Kissebah et al 1982]. 
Accordingly, weight loss markedly enhances metabolic control improving both insulin 
action in liver and muscle and restoring more efficient regulation of lipolysis, delaying the 
onset of diabetes [Viswanathan et al 1997; Reynisdottir et al 1995; Lonnqvist et al 1995]. 
Although a single metabolic aberration is unlikely to be sufficient to give rise to multiple 
functional defects that precede overt diabetes, the exposure of various organs to increased 
plasma lipids, specifically elevated free fatty acids (FFA) has been postulated to be a 
potential candidate [Reviewed by Bergman 2000]. The levels of FFA's are determined by 
the differences in the lipolytic activity of regional fat deposits with elevated FFA levels 
predictive for conversion from a state of impaired glucose tolerance to diabetes [Martin & 
Jensen 1991; Reynisdottir et al 1994; Coppack et al 1992; Charles et al 1997; Paolisso et a] 
1995; Krotkiewski et al 1983; Bjorntorp 1991]. The accumulation of fat deposits as a result 
of elevated plasma FFA in tissues such as muscle, liver and pancreatic ß-cells may interfere 
with metabolic signalling pathways, including insulin, resulting in insulin resistance and 
impaired glucose utilisation [Nyholm et al 1999; Unger 1995; Campbell et al 1994; Peiris et 
al 1986; Baron 1994; Steinberg et al 1997 & 2000; Bergman 1997; Hamilton-Wessler et al 
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1999; Randle et a] 1994; Baldeweg et al 2000; Boden 1997]. Although initially pancreatic [3- 
cells could compensate for increased glucose levels by increasing insulin secretion, with 
acute exposure to elevated FFA levels stimulating insulin secretion [Steinberg et al 1997; 
Boden & Chen 1999]. Chronic hyperlidaemia can directly impair insulin secretion and the 
increasing levels of NEFA would further decrease glucose uptake by muscle, increase 
hepatic NEFA oxidation and stimulate gluconeogenesis eventually compromising 0- cell 
function [Reaven 1995; Sako & Grill 1990; Unger 1995; Mason et al 1999]. 
However, alternative hypotheses have been postulated that implicate the disruption of the 
diurnal rhythm of cortisol by increased fatness in determining insulin resistance and 
increased risk to T2DM [Bjorntorp 1991]. 
Central obesity and associated risk factors such as hyperinsulaemia, hypertension and 
hypertriglyceridaemia, can also confer an increased population susceptibility to coronary 
heart disease [McKeigue et al 1992 & 1991; UKPDS1994]. The epidemiological 
observation of the frequent simultaneous occurrence of T2DM and obesity with a number of 
other associated phenotypes, including hyperinsulaemia, glucose intolerance, hypertension, 
dyslipidaemias and coronary heart disease suggests there is a relationship between these 
disorders [Reaven 1988]. This has given rise to the concept that these disorders constitute a 
single metabolic syndrome `Syndrome X'. However, the evidence for this epidemiological 
association is not always consistent, [Jarrett 1992; Zimmet et al 1994] particularly between 
different ethnic groups [Saad et al 1991]. Finally, Neel et al has postulated that a BMI- 
hypertension interaction is more likely to drive this relationship rather than the existence of 
a Syndrome X [Neel et al 1998]. 
1.3 GENETIC EPIDEMIOLOGY 
Evidence suggests that the development of T2DM is a result of both an interaction between 
diverse environmental factors on a background of heterogeneous genetic predisposition. 
Increasing body weight is the most important factor influencing progression to impaired 
glucose tolerance and T2DM, with body weight homeostasis and obesity both themselves 
determined by genetic and environmental components, some possibly the same as for 
diabetes. The complexity and mechanisms involved in the gene-environment interaction and 
the mode of inheritance of both T2DM and obesity are still largely unknown. The 
heterogeneity of the diseases at phenotypic and pathophysiological levels almost certainly 
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indicates that the genetic component is likely to be heterogeneous with no single locus 
accounting for the disease. 
1.3.1 Segregation Analysis 
Segregation analyses, the inference of susceptibility loci from the distribution of phenotypic 
variance in pedigrees, have been utilised to attempt to understand the genetic model and 
mode of inheritance of both T2DM and obesity. Early segregation analyses using simple 
correlation methods failed to take into account factors such as age related prevalence and 
environmental effects and in consequence a variety of genetic models were proposed. Later 
analyses utilising path or variance components have facilitated the generation of models that 
attempt to breakdown observed familial aggregation into separate genetic and environmental 
effects or heritabilities. Although relatively few formal segregation studies have been 
performed on T2DM, these studies have suggested the presence of major genes for 
quantitative traits related to diabetes. Several studies have proposed that an autosomal 
recessive or dominant transmission of a gene could account for approximately 30% of the 
variance of fasting plasma insulin levels in Caucasians and Mexican-Americans respectively 
[Schumacher et al 1992; Mitchell et al 1994]. Modelling has also provided evidence for a 
major T2DM susceptibility gene in Naurans [Serjeantson & Zimmet 1991] and a gene 
determining early onset of disease in both Pima Indians and Mexican-Americans [Hanson et 
al 1995; Stem et al 1996a]. 
Multifactorial studies in obesity have also shown significant familial aggregation of the 
disease. A number of adoption studies have supported a strong genetic component with 
major gene effects for both BMI and obesity suggested [Biron et al 1977; Stunkard et al 
1986 & 1990; Price et al 1987,1990,1991; Vogler et al 1995; Ness et al 1991]. In contrast 
other studies have placed more importance on the familial environment [Khoury et al 1983; 
Annest et al 1983; Longini et al 1984]. Overall fatness and fat distribution have estimated 
heritabilities of between 29-69% depending on the ethnic background of the population 
[Tambs et al 1992; Longini et al 1984; Katzmarzyk et al 2000; McLaughlin 1991; Luke et al 
2001]. 
However, a study on variance in glucose tolerance in European pedigrees with T2DM 
probands, concluded that the disease is unlikely to be due to a single autosomal dominant 
gene with high penetrance [Cook et al 1994]. Similar studies in obesity also found no 
evidence for a single major gene effect [Karlin et al 1981; Zonta et al 1987; Tiret et al 1992; 
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Rice et al 1993]. There may be several major genes each explaining a substantial proportion 
of the variability of disease susceptibility ('oligogenic' inheritance), which when combined 
explain a majority of the susceptibility. However there is insufficent evidence to exclude the 
possibility that potentially a large number of genes may be involved in susceptibility to the 
diseases, with each gene having only a minor contribution to the overall susceptibility. A 
further possibility also exists that overall susceptibility is due to a single or several 
oligogenes in combination with a background of numerous minor polygenic contributors or 
modifiers. 
The genetic architecture of T2DM may be further complicated by the contribution of multi 
alleleic effects within genes, epistatic interactions between genes, and additive or 
multiplicative effects. However, complex segregation analysis in South Indian families 
[McCarthy et al 1994] which have a strong familial aggregation of diabetes [Viswanathan et 
al 1996; Ramachandran et al 1998] using the computer programmes which implement 
various genetic models that can account for environmental contributions (POINTER and 
COMDS) did not entirely reject a single major gene model but favoured other models in 
preference. Results from these studies tended to favour multifactorial and oligogenic 
models, and were inagreement with the best-fit model for T2DM proposed by Rich [ 1990], 
that susceptibility involved only a few genes with a moderate effect, superimposed on a 
polygenic background [McCarthy et al 1994]. 
1.3.2 Family Studies 
The earliest family studies are generally unreliable as most predate a formal classification of 
diabetic subtypes and standardised methods to diagnose glucose intolerance. A German 
family study found that there were increased affection rates in siblings, parents and their 
offspring of 37.9%, 20.8% and 32.2% respectively, compared to the population disease 
prevalence [Köbberling & Tillil 1982]. Similarly in South Indian families where one and 
both parents were T2DM, a third and a half of offspring respectively were affected 
[Ramachandran et al 1988; Viswanathan et al 1985]. Moreover, in Pima Indians a parental 
history of disease associated with increased risk in siblings, independent of the increased 
risk associated with increasing obesity [Knowler et al 1990]. In this latter study an even 
greater risk to disease was conferred to offspring if there was a maternal family history or if 
either parents had an early-onset of disease. Data from the San Antonio Family Diabetes 
Study found family members had a varying degree of risk depending on their relationship 
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with the diabetic proband, with first-degree relatives having almost double the population 
risk [Mitchell et al 1994]. A generally accepted view is an estimated lifetime risk of a first 
degree relative is 35%, with a relative risk of 3 to 4 fold compared to the general population. 
The observation of familial correlations demonstrates an aggregation of T2DM in families, 
and this is generally assumed to support disease transmission via a genetic component. 
However, family members share both genes and environment (the latter especially in early 
life), and unless a formal segregation analysis is applied, such as a path type analysis with an 
`environmental index', then the genetic and environmental components cannot be entirely 
separated or accounted for. The use of additional familial relationships, such as twins and 
adoptees, could also be used to circumvent this problem but these are also confounded by 
similar problems. 
1.3.3 Studies in Twins. 
Twin studies theoretically allow for the separation of the genetic component of variance, 
since monozygotic (MZ) twins share 100% of their genes, whilst non-identical dizygotic 
twins (DZ) only share half on average. Therefore observations of differences in the rates of 
concordance for diabetes between MZ and DZ twins have historically been interpreted as 
evidence that the disease has a genetic basis. Later studies that have endeavoured to avoid 
the selection bias present in the earlier studies, have found initial MZ concordance rates 
double that of DZ rates. A study of twins in Finland found rates of concordance of 34% and 
16% for MZ and DZ twins respectively [Kaprio et al 1992], whereas in another study rates 
were 28.6% and 14.3%, for MZ and DZ twins respectively [Newman et al 1987]. In the 
latter study after a 10-year follow-up an overall concordance rate of 58% was observed in 
MZ twins. 
Although concordance rates of MZ twins are consistently greater than DZ twins even under 
the assumption that both twin types have been subjected to a shared environment. However, 
the overall contribution of the genetic component is difficult to assess as other underlying 
factors such as non-additive genetic effects and the sharing of placental/neo-natal 
environment in MZ twins could also influence differences in concordance rates between 
twins (see 1.5 Epigenetic Effect). Two recent studies also identified differences in 
concordance rates between MZ and DZ twins in Danish [Poulsen et al 1999] and in British 
T2DM subjects [Medici et al 1999]. However, Poulsen et al observed that differences in 
concordance rates were significantly greater in abnormal glucose tolerant twins compared to 
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T2DM twins and proposed that genetic predisposition was more important for the 
development of abnormal glucose tolerance, and that non-genetic factors may predominate 
in controlling whether a genetically predisposed individual progresses to overt T2DM. 
In respect of obesity an overview of fifty studies on the heritability of body fat/ obesity 
including both nuclear families and twin studies found heritability levels of 30-40% and 50- 
80% respectively [Bouchard & Perusse 1993]. However it has been suggested that only a 
true unbiased estimate of heritability (both additive and non-additive combined) can be 
achieved if the MZ twins were reared separately. Examples of these are rare, especially for 
T2DM, but strong correlations have been observed for obesity related phenotypes between 
MZ twins reared together and apart, suggesting the presence of strong shared genetic 
determinants [Stunkard et al 1990; Price et al 1991]. However, the magnitude of heritability 
levels for body fat in all adoption studies combined was calculated to be less than expected, 
at between 10% and 30% [Bouchard 1995]. 
1.3.4 Gene effects on prevalence 
The marked difference in prevalence between racial groups in the USA [Harris et al 1998] 
and the effects of progressive admixture on relative risk to disease, usually as a result of 
migration, both provide supporting evidence that T2DM has a genetically determined 
component. Admixed populations comprising of both an ethnic group at extremely high risk 
to T2DM, such as Native American Indians and a low disease risk group eg. Caucasians, 
create an intermediate disease rate status [Brosseau et al 1979; Knowler et al 1990]. Under 
these circumstances it is hypothesised that the high-risk ethnic group have a high frequency 
of disease susceptibility genes and the rate of disease in the admixture population is 
proportional to the percentage of the gene pool derived from this ethnic population. In full- 
blood Nauruans the prevalence of diabetes after the age of 60 years is 83%, whereas it is 
17% in those inhabitants who have a Caucasian ancestral gene lineage [Zimmet et al 1982]. 
1.3.5 Environmental-gene interaction on prevalence 
In some isolated populations in which T2DM was previously virtually unknown, for 
example the Pima Indians of Arizona, the Nauruans of Micronesia, and Western Samoans, 
the prevalence of T2DM has dramatically increased to over 30% in the last 50 years 
[Zimmet 1992; Hodge et al 1994]. These increases have been associated with changes in 
lifestyle, from an active traditional rural hunter-gatherer way of life to the more sedentary 
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westernised existence (figure 1.1.1)[Hodge et al 1994; Taylor et al 1985]. Low levels of 
physical activity, modern comforts, combined with unlimited easily accessible supplies of 
highly palatable energy dense foods, leads to energy intake grossly exceeding energy 
expenditure pave the way to obesity. The overall effect of urbanisation varies depending on 
ethnicity of the populations, with genetic admixture and other environmental effects 
influencing susceptibility [Zimmet et al 1982; Hodge et al 1994]. 
The "thrifty genotype" hypothesis proposed by Neel [Neel JV 19621 endeavours to explain 
the increase in prevalence as a result of westernization due to an interaction of both genes 
and environment. Humans in the last 6-7 million years committed to their evolutionary 
survival, would have selected genes in the course of adaptation to a hunter-gatherer 
existence. Genes that allowed the development of physiological mechanisms to promote 
accumulation of energy stores when food was abundant so as to prevent depletion of body 
energy stores during periods of starvation or limited /seasonal food resources would have 
been advantageous. The change in lifestyle to one with a continual and abundant supply of 
high energy density food unaffected by seasonal availability, combined with improvements 
in health, hygiene and dietary intake, in human evolutional terms has been extremely recent. 
The "thrifty genotype" favours mechanisms that promote high efficiency in the storage of 
energy as fat and glycogen, yet under the recent major shift in human habits these genes 
could now have deleterious effects. Humans only have a limited capacity to adjust to these 
recent changes with a part of an individual's ability to adjust likely to be determined by 
genetic factors (figure 1.3.1). 
1.3.6 Epigenetic Effects 
The `thrifty genotype' concept is considered highly contentious in some quarters, with an 
alternative hypothesis proposed that the transmission of diabetes to subsequent generations 
is the result of a `thrifty phenotype'. Studies in rodents and humans show that the 
development of a foetus in an abnormal intrauterine environment can have major 
consequences on the metabolism of the offspring in later life, including the possible 
development of diabetes [Pettitt et al 1993; Barker et al 1993; Phillips 1998]. Furthermore, 
the offspring themselves later in adulthood can also develop abnormal intrauterine 
environments during gestation, providing a means of transmission of a diabetogenic effect to 
subsequent generations without genetic interference (Figure 1.3.1) [Aerts & Van Assche 
1977; Aerts et al 1990; Holemans et al 1996]. Factors that alter intra-uterine nutrition, such 
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as starvation and protein deficient diets may affect the development of the foetal pancreas 
and so alter the adult pancreatic reserve [Hales et al 1991& 1992; Holemans et al 1996]. 
Low birth weight presumed to be the result of malnutrition or low protein diet during 
pregnancy also appears to predispose to the development of impaired glucose tolerance, 
insulin resistance, hypertension and obesity in later adult life [Phillips et al 1998 & 2000a]. 
Studies in the Pima Indians found that offspring had a greater risk of developing T2DM if 
the mother was diabetic, particularly if diabetic rather than prediabetic during pregnancy, 
possibly indicating an intrauterine effect [Pettitt et al 1993; Dorner et al 1987]. Studies in 
several other ethnic groups have also correlated a reduced foetal growth with loss of glucose 
tolerance in adults [Hales 1991 et al; Barker et al 1993; Phillips 1998; McCance et al 1994]. 
It has also been postulated that the increased concordance rates observed in MZ twins are 
attributable to differences in the intrauterine environment, as MZ twins more frequently 
share a chorion and amnion than DZ twins [Phillips et al 1998]. Size at birth may also 
dictate both plasma leptin and cortisol concentrations in adult life [Phillips et al 1999 & 
2000b]. In a Danish study, the diabetic patients within both discordant MZ and DZ twins 
had a lower birthweight compared to their unaffected co-siblings providing further evidence 
that the development of diabetes could occur independently of a genetic cause [Poulsen et al 
19971. 
However it is debatable whether the individual phenotypic outcome of these epigenetic 
effects is not also the result of an interaction with genotype. Half of foetal birth-weight 
variation is due to the genotype of the foetus with 20% related to the parental genome. One 
alternative explanation for the `foetal programming' observations is that genetically 
predetermined dysfunctional insulin secretion and insulin resistance results in impaired 
insulin-mediated growth in the foetus as well as insulin resistance and diabetes in adult life 
[Hattersley & Tooke 1999]. Insulin secreted by the foetal pancreas in response to maternal 
glucose concentrations is a key growth factor. Monogenic diabetic syndromes due to either 
decreased beta cell function or a defect in insulin action have also been found associated 
with impaired foetal growth [Hattersley & Tooke 1999]. Single gene defects that have been 
shown to detrimentally affect foetal growth include insulin growth factors (IGF) I& II 
genes, glucokinase (GCK), IGF I Receptor gene, and Insulin gene 5' VNTR [Woods et al 
1997; Hattersley et al 1998; Johnston et al 1999 & 2000; Dunger 1998]. 
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1.3.7 Non-genetic effects 
Viral infections have also been implicated in both T2DM and obesity. The increased 
frequency of cytomegalovirus (CMV) in T2DM subjects compared to controls [Lohr & 
Oldstone 1990] has suggested that a low level chronic infection of 0-cells could be 
responsible for the relative hyposecretion of insulin. However, other studies have failed to 
replicate these observations and there is suspicion that pancreatic sections were 
contaminated in the original study [Hattersley et al 1992a]. There are also four animal 
models of viral induced obesity, including canine distemper, Rous associated virus 7, Boma 
disease virus and a chicken adenovirus [Lyons et al 1982; Bernard et al 1988; Gosztonyi et 
al 1995; Dhurandhar et al 1992]. Recently a human adenovirus (AD36) was also implicated 
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Figure 1.3.1: The `Thrifty' hypotheses underlying a Genetic and/or Epigenetic 
intergenerational transmission of susceptibility to T2DM 
1.4 GENETIC EVIDENCE FOR AN INHERITED SUSCEPTIBILITY 
Epidemiological evidence supports the concept that T2DM and obesity are both 
heterogeneous and multifactorial disorders with a genetic predisposition. The plausibility of 
`THRIFTY PHENOTYPE' 
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a genetic contribution to T2DM has been further strengthened through the study of animal 
models and the identification of human monogenic syndromes of T2DM. However, as 
mentioned previously it is likely that in the case of the idiopathetic T2DM a number of 
genes, some with substantially more effect than others, and many with relatively minor roles 
will be responsible for an inherited susceptibility. 
1.4.1 Animal Models of Type 2 Diabetes and Obesity. 
Animal models can offer distinct advantages in understanding the causes, consequences and 
underlying physiological mechanisms involved in disease. Rodent models with single gene 
defects, Zucker, ob/ob, db/db, Yellow (Ay/a) agouti, tubby tb/tb, Cpefa`/Cpefa` and Fatty fa/fa 
rats and polygenic models, Goto-Kakizaki (GK) and Otsuka long Evans Tokushima fatty 
rats (OLETF), have provided evidence that genes can initiate biochemical abnormalities that 
can lead to both T2DM and obesity [Zhang et al 1994; Bultman et al 1992; Naggert et al 
1995; Coleman & Eicher 1990; Kelyn et al 1996; Gauguier et al 1996]. 
At least seven loci controlling diabetes related sub-phenotypes have been identified in the 
GK rat [Gauguier et al 1996; Galli et al 1996] and gene knockout studies in rodents have 
lead to the identification of potential human T2DM susceptibility genes, an example being 
the transcription factor NeuroD/Beta 2 that modulates insulin gene transcription [Naya et al 
1997; Malecki et al 1999]. 
However, the manifestation of different phenotypes between strains of the same species and 
between species with the same gene defects as a result of differing individual relationships 
between genes, gene modifiers, biochemical factors and interaction with environmental 
influences, overall emphasises the complexity of the physiological processes involved. 
Moreover, the relevance of findings from animal models when extrapolated to humans is 
uncertain. Currently animal models have not identified any genes that predispose to the 
common human forms of either T2DM or obesity. 
1.4.2 Monogenic forms of T2DM 
In humans a substantial part of the knowledge of the genetic component of diabetes has been 
based on rare conditions caused predominantly by single gene defects. These result in either 
ß-cell dysfunction or less frequently insulin resistance. These sub-groups include only a 
minority (2-5%) of T2DM patients and comprise of two main genetic subtypes, MODY and 
maternally inherited diabetes and deafness (MIDD). 
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MODY: MODY is clinically defined as having an age of onset before the age of 25 years in 
at least two family members with an autosomal dominant mode of inheritance [Hattersley et 
al 2000]. MODY accounts for approximately 2-5% of T2DM in Caucasians and mutations 
have been identified in five or six different genes so far (table 1.4.1) mainly consisting of 
transcription factors, in particular the hepatocyte nuclear factor family (HNF) (table 1.4.1). 
Mutations in genes leading to MODY might also predispose to the late onset diabetes. 
Homozygous mutations of the insulin promoter factor I gene (IPFI) give rise to the 
MODY4 phenotype, whereas heterozygous subjects may be more predisposed to a late-onset 
form of T2DM [Hani et al 1999; Macfarlane et al 2000; Hattersley et al 2000]. However, 
mutations in the genes for HNF4a, glucokinase (GCK), HNF1a, and HNF1P have not been 
implicated in T2DM in any ethnic population so far studied [Malecki et al 1998]. 
MODY Sub- ou GENE CHROMOSOME MODY-Frequency 
MODY 1 HNF4a (TCF]) 20q rare 
MODY 2 GCK 7 10-65% 
MODY 3 HNFla 12q 20-75% 
MODY 4 IPFI 13 rare 
MODY 5 HNF1 (TCF2) 17q very rare 
MODY 6? NeuroDBeta2 2q32 rare 
Table 1.4.1: Known MODY Sub-genotypes. 
A novel basic helix-loop-helix transcription factor, neurogenic differentiation 1 
(NeuroDBeta2), involved in pancreatic endocrine cell differentiation and the tissue-specific 
regulation of the insulin gene [Naya et al 1995] has been proposed as a possible MODY 6 
gene [Fajans et al 2001]. Two heterozygous mutations in NeuroDl have been described 
which associate with the development of T2DM [Malecki et al 1999]. One variant (residue 
206+C) gives rise to a truncated polypeptide lacking the C-terminal transactivation domain, 
a region that associates with the two coactivators, CBP and p300. The clinical profile of 
patients with the truncated NeuroDl polypeptide was found to be more severe and 
suggestive of MODY rather than late onset T2DM [Malecki et al 1999]. 
MIDD: MIDD is another early onset form of T2DM, frequently characterised by 
progressive ß-cell degeneration and deafness. Variants within the mitochondrial genome are 
associated with the disruption of oxidative phosphorylation processes consequently affecting 
intracellular calcium levels and exocytosis of insulin granules by depolarisation of the cell 
membrane. Mitochondrial DNA (mtDNA) is only maternally inherited because sperm 
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contribute almost no cytoplasm to the zygote [Giles et al 1980]. Consequently mtDNA 
associated diseases have a maternal dominant inheritance pattern with variable penetrance 
and clinical phenotypes due to heteroplasmy. 
The most prevalent characterised mutation is at position 3243 tRNA (Leu, UUR) [van den 
Ouweland et al 1992]. This mutation is implicated in several disease phenotypes including 
the neurological disorder MELAS mitochondrial syndrome (myopathy, encephalopathy, 
lactic acidosis and stroke-like episodes), and both chronic progressive external 
opthalmogepia (CPEO) and Kearns-Sayre syndrome (KSS) [Goto et al 1990]. The 3243 
mutation has a frequency of 1-3% in French and Japanese subjects with family histories of 
diabetes, but only occurs in 0.1-0.2% of British Caucasian T2DM patients and is virtually 
absent in South Indians [Saker et al 1997; McCarthy et al 1996; Smith et al 19971. 
1.4.3 Monogenic forms of obesity 
Obesity is also characteristic of a number of monogenic disorders in humans. Heterozygous 
mutations of the melanocortin 4 receptor gene (MCR4) are possibly responsible for the most 
common monogenic cause of human obesity, although no homozygous subjects have yet 
been identified [Farooqi et al 2000]. 
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive disorder (< 1: 100,000), with a 
broad spectrum of clinical phenotypic traits that include both obesity and diabetes. At least 
six different genetic loci have been linked to the disease (table 1.4.2) with causative 
mutations identified in a chaperonin gene responsible for McKusick-Kaufman syndrome 
(MKKS) [Mykytyn et al 2001; Slavotinek et al 2000; Katsanis et al 2000; Beales et al 2001; 
Nishimura et al 20011. Recent studies on the BBS 6-MKKS gene suggests that phenotype is 
probably determined by interactions of more than one BBS locus, and that BBS may not be 
a `simple' monogenic disease [Katsanis et al 2001]. It has also been hypothesised that 
heterozygous mutations of BBS genes may account for 1-2% of the severely obese patients 
and are therefore potential obesity candidate genes [Croft et al 1995]. 
The human obesity gene map for the year 2000 reported that forty-seven cases of obesity 
were caused by single gene mutations in six different genes. In addition, twenty-four 
Mendelian disorders have been mapped that exhibit obesity as one of their clinical 
manifestations and 115 different relevant quantitative loci in animal models have been 
identified [Perusse et a! 2001b]. 
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BBS Sub-group GENE CHROMOSOME 
BBS 1 Not known 11g13 
BBS2 BBS2 16 
BBS3 Not known 3pl3-pl2 
BBS 4 BBS4 15q22.3-q23 
BBS 5 Not Known 2g31 
BBS6 MKKS BBS6 20p12 
Table 1.4.2: Known BBS sub-types. 
1.4.4 Linkage Studies and Genome Scans 
Classical parametric linkage analysis studies in simple Mendelian monogenic disorders have 
had sufficient power and have also been robust with low false-positive rates to enable 
identification of susceptibility loci in many chromosomal regions [Rao et al 1978; Risch 
1990]. Examples of successfully positionally cloned disease genes include cystic fibrosis, 
familial polyposis, BBS6 and MODY [Kerem et al 1989; Groden et al 1991; Katsanis et al 
2000; Hattersley et al 1992a]. 
However, classical linkage analysis methods using extended pedigrees can be problematic in 
complex diseases such as T2DM and obesity. Hence it has become commonplace to utilize a 
model free non-parametric approach using affected sibling pairs (ASP) in the search for 
diabetogenic genes. The principles and methodology of linkage analysis when applies to 
complex diseases are discussed in Chapter 3, section 3.8.1. 
Genome scans for T2DM susceptibility loci have been performed on both ASP sets and 
extended families. Evidence of linkage has been found to a number of chromosomal regions 
in several diverse ethnic populations (table 1.4.3). In a number of chromosomal regions 
evidence of linkage has been replicated leading to the identification of regions harbouring 
potential disease susceptibility genes. 
Potential candidate T2DM susceptibility genes that have been identified include the protein 
kinase C substrate (PEA 15) and potassium inwardly rectifying channel subfamily J member 
9 gene (KCNJ9) to 1g21-24, insulin degrading enzyme (IDE) to 1Og23-25, MODY 3 to 
12q24, and calpain 10 to 2q37 [Wolford et al 2000; Wiltshire et al 2001; Ehm et al 2000; 
Horikawa et al 2000; Permutt & Hattersley 2000a]. 
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Tab 
Ethnic Population Chromosomal region Reference Linkage 
Mormon Caucasian USA 1g21-23 Elbein 1999 N 
French Caucasian 1g21-24 Vionnet 2000 N 
UK Caucasian 1g24.2 Wiltshire 2001 N 
Pima Indian l q25.3 Hanson 1998 S 
Indigenous Australians 2q24.3 Busfield 2002 S 
Mexican American 2q37 (NIDDMI) Hanis 1996 S 
French Caucasians 2q37 Hani 1997 N 
Mexican American 3q27 Ehm 2000 S 
French Caucasians 3q27 Vionnet 2000 S 
Ashkenazi Jews 4q Permutt 2001 N 
Botnian Finnish 32 33 Lindgren 2002 N 
USA Europeans 5g13 Ehm 2000 N 
UK Caucasian 5q13 Wiltshire 2001 N 
UK Caucasian 5q32 Wiltshire 2001 N 
French Caucasian 5 31-33 Vionnet 2000 N 
UK Caucasian 8p2l. 3-22 Wiltshire 2001 S 
Mormon Cauc USA 8p21.3 Elbein 1999 N 
Indigenous Australians 8p22 Busfield 2002 N 
Botnian Finns 9p13-q21 Lindgren 2002 S 
UK Caucasian 1Og23.3 Wiltshire 2001 N 
Finnish (FUSION) 10g23.33-24.32 Ghosh 1999 S 
French Caucasian 1Og26.3 Vionnet 2000 N 
Mexican American 10 26.12 Duggirala 1999 N 
Mexican American 11 15.4 Stern 1996 S 
Pima Indian 1l q22-23 Hanson 1998 N 
Caucasians 12g15 Bektas 1999 S 
USA Europeans 12 15 Ehm 2000 N 
Botnian Finnish 12q24 (NIDDM2) Mahtani 1996 S 
Botnian Finnish 12g24 Bowden 1997 N 
Australians 12q24 Shaw 1998 S 
USA Whites 12q24 Ehm 2000 N 
USA Europeans 12q2 4 Lindgren 2002 N 
Finnish (FUSION) 20 12 Ghosh 2000 N 
USA Europeans 20q12-13 (NIDDM3) Bowden 1997 N 
USA Europeans 20q12-13 Ji 1997 S 
Finnish 20g12-13 Ghosh 1999/ 2000 S 
USA Europeans 20q12-13 Zouali 1997 N 
Mormon Caucasian 20q12-13 Elbein 1995 N 
French Caucasians 20g12-13 Hani 1997 N 
Ashkenazi Jews 20q12-13 Permutt 2001 N 
USA Europeans 20 13.1-13.2 Klupa 2000 S 
le 1.4.3! Autnsnmal Chrmmnenmgl regions with evidence of linkage for a T2D11 
susceptibility locus in humans. Loci with either suggestive linkage, replicated nominal 
evidence of linkage, or regions with maximum evidence for linkage within a given study 
have been included. S=LOD (or equivalent) >3.0; N=LOD (or equivalent) >1.0. 
The replication of evidence for linkage to 20g12-13 in eight studies has supported the 
designation of this susceptibility region as NIDDM3. The most obvious candidate gene 
located in this interval was the MODYI-HNF4a gene. However, subsequent association 
studies on the gene did not support a role as a common determinant for susceptibility to 
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T2DM [Malecki et al 1998]. The NIDDM3 interval contains at least twenty genes and one 
other candidate gene has been proposed, the melanocortin receptor 3 gene (MC3R) [Hani et 
al 2001]. A study in French Caucasians families identified two missense mutations that 
associated with insulin and glucose levels in normoglycemic subjects. However, neither 
MCR3 coding variant associated with overt T2DM or obesity [Hani et al 20011. 
In respect of obesity there is also evidence of linkage to a number of chromosomal regions, 
including 12q24.3 in French Canadians, lop in French and German Caucasians, 11g21-22 in 
Pima Indians, Xq24 and 18g21 in Finnish, and 3p in old order Amish [Perusse et al 2001 a; 
Hager et al 1998; Norman et al 1998; Ohman et al 2000; Hsueh et al 2001 ]. Nevertheless at 
present there appears to be very little duplication of linkage results. The year 2000 human 
obesity gene map summarises that 113 loci have been linked to obesity indicators in genome 
scans, with putative loci found on all chromosomes except the Y chromosome, and in 
addition there are positive associations with 48 different candidate genes [Perusse et al 
2001b]. 
1.4.5 Candidate disease genes 
Besides the pinpointing of `candidate' disease susceptibility loci through whole genome 
searches and linkage studies, candidate genes have been selected on the basis of a rational 
hypothesis. These have been examined by utilizing techniques that rely on linkage 
disequilibrium, this phenomenum and associated analytical methodologies are discussed in 
Chapter 3 (3.8.2). 
Amongst the various candidate genes that have been selected include those genes that cause 
diabetes in animal models or are implicated in the human monogenic forms of the disease. 
Examples of some of the more promising candidate genes are discussed below. However, 
out of the numerous candidate genes studied so far only a few genes examined have been 
consistently culpable, and all so far only appear to play minor roles in common idiopathic 
T2DM. 
A candidate gene for insulin resistance: The presence of insulin resistance in type 2 
diabetics by inference has implicated the insulin receptor (IR), and other crucial factors 
involved in post-receptor signal transduction pathways such as insulin receptor substate-I 
(IRS-1), IRS-2, and phosphatidylinositol-3-kinase (P13-K). Homozygous disruption of either 
the IR or IRS-2 genes causes mice to become severely insulin resistant and die shortly after 
birth, whereas mice that have a combined heterozygous knockout of IR and IRS-1 
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progressively develop hyperinsulaemia and eventually diabetes [Bruning et al 1997; Withers 
et al 1998]. More than fifty coding polymorphisms have been identified in the human IR 
gene, some associating with familial hyperinsulimaemia. A common coding variant of IRS- 
1, Gly972Arg has been implicated in insulin-resistance in both human obesity and T2DM, 
possibly in combination with a variant of IRS-2 (Glyl057Asp) [Taylor 1992; Almind et al 
1993; Hitman et al 1995]. However, associations have been inconsistent with a lack of 
replication and absence of evidence of linkage from genome scans for all three genes, 
suggesting that they are not major susceptibility loci for T2DM [Sesti et al 2001; Hitman et 
al 1995]. 
Candidate genes for insulin secretion: A consistently strong contender for an insulin 
secretory susceptibility locus is the sulphonylurea receptor-1 (SUR-1) [Inoue et al 1996; 
Hart et al 1999]. SUR-1 is a high affinity receptor for sulphonylureas that are expressed on 
pancreatic ß-cells. SUR-Iplays a crucial role in regulating glucose-induced insulin secretion 
by controlling K+-ATP channel activity of the ß-cell membrane with a ATP-sensitive 
potassium channel Kir6.2. However, genome scans and specific regional linkage analysis 
have provided little evidence of linkage to l 1p15.1 and the SUR1 gene [table 1.4.3; Stirling 
et al 1995]. In humans sequence variants within the cytoplasmic domain have been shown to 
disrupt the regulation of insulin secretion. A splice variant that results in protein truncation 
through removal of the second nucleotide-binding fold causes a rare autosomal recessive 
disorder familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI) [Thomas et al 
1995]. Although gene variants are rare, often specific to one family, over 20 mutations have 
been identified in the SUR gene. Homozygotes for these variants invariably manifest 
clinically as hyperinsuliaemia. In addition, a common coding variant (exon 16-3t) appeard to 
be associated with T2DM in Dutch Caucasians but replication studies have been lacking 
[Nestorowicz et al 1998; Hart et al 1999]. 
Genes implicated in human monogenic T2DM are potential candidates for dysfunctional 
insulin secretion. Subjects who are heterozygous for variants of the IPFlgene (MODY4) do 
appear to be predisposed to late-onset T2DM [Hani et al 1999; Macfarlane et al 2000; 
Hattersley et al 2000]. Although there is little evidence of linkage to chromosome 13q in any 
human T2DM genome scans (table 1.4.3). Similarly, mice with a targeted disruption of the 
NeuroDl gene have a striking reduction in pancreatic ß-cells which have impaired cellular 
development resulting in severe diabetes and premature death [Naya et al 1997]. A variant 
in the human NeuroDl gene predisposes to a clinical form of diabetes that resembles 
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MODY and another variant appears to be associated with T1DM in Danish subjects 
[Malecki et al 1999; Hansen et al 2000]. In contrast, a different missense variant 
(Arg1IILeu) that disrupts the DNA-binding domain and abolishes the E-box binding 
activity of NeuroDl, was identified in patients who developed a form of diabetes more 
typical of T2DM, suggesting also a role in this disorder [Malecki et al 1999]. 
Positive linkage and association results for candidate susceptibility genes can provide 
substantial evidence that a gene may play a role in the disease aetiology. However, they 
cannot provide definitive proof for causality even if there is complete penetrance of the 
disease allele. Further, study designs that investigate function are required to provide 
scientific consensus that the aberrant gene/protein actually disrupts physiological pathways 
leading to the disease or to a related sub-phenotypic state. 
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CHAPTER 2: 
CANDIDATE GENES STUDIED 
2.1 UNCOUPLING PROTEINS 
2.1.1 Cellular Respiration 
Cellular energy is produced by the metabolism of foods and oxygen to carbon dioxide and 
water. ATP is generated by stepwise fuel oxidation via the electron transport processes of 
the respiratory chain in mitochondria. The increasing redox potential at complexes I, III and 
IV, pump H+ protons out of the matrix to the inner membrane mitochondrial space (Figure 
2.1.1). This increases mitochondrial membrane potential by generating an electrochemical 
proton gradient (0µH+) across the inner membrane. The increased membrane potential 
drives protons back into the matrix via the ATPsynthase, in a reaction that is tightly linked 
to the coupling of fuel oxidation to energy production by the oxidative phosphorylation of 
ADP to ATP [Nicholls 1974]. 
A key challenge to organisms is maintaining efficient energy use by balancing rates of fuel 
oxidation and ATP production with rates of ATP utilisation. The chemiosmotic theory of 
Mitchell [1979] based on observations in isolated mitochondria, gave rise to the hypothesis 
that when cells are inactive and rates of ATP consumption are reduced, ADP should be low. 
As proton entry into the matrix via ATPsynthase requires ADP this flux will be also 
reduced. Continued electron transport however continues to increase 0µH+ in the inter- 
membrane space, thus causing a "back pressure" on the proton pumps at complexes I, III, 
and IV and consequently fuel oxidation is inhibited. This theoretically links respiration to 
ADP availability, so fuel consumption only occurs when cells have been working ie. 
converting ATP to ADP. 
2.1.2 Uncoupling Protein Activity 
According to the Mitchell theory, protons are unable to enter into the matrix via 
ATPsynthase in the absence of ADP. However, mitochondria both isolated and in situ, 
continue to consume oxygen even in the absence of ADP phosphorylation ie. State IV 
respiration [Brown et al 1990]. Conclusions were made that mitochondrial coupling of 
respiration to ATP synthesis may only be partial in most cells and oxygen consumption may 
be controlled by an inner mitochondrial membrane permeability to protons [Nicholls 1974; 
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Brand et al 1990 & 1999; Boss et al 1998b; Porter et al 1999]. Studies have since established 
the existence of a basal proton conductance or proton leak across the inner membrane 
independent of the ATPsynthase pathway. The magnitude of the i tH+ drives both the 
proton leak and determines its rate by controlling inner membrane conductivity to protons 
[Brand 1994 & 1990; Porter et al 1995; Rolfe & Brand 1997; Rolfe & Brown 1997; Brown 
et al 1992; O'Shea & Chappell 1984]. 
Figure 2.1.1: Mitochondrial Energy Metabolism showing two proposed uncoupling 
mechanisms. Klingenberg (Green) and Garlid (Red). Diagram modified from Boss et al 
[2000] 
The presence of an independent proton pathway does account for some of the flaws evident 
in Mitchell's theory where control of ATP production/utilisation is based on ADP 
availability. Additional mechanisms are necessary when there is a massive increase in ATP 
utilisation such as during muscle contraction with a 100-fold increase in energy demand. 
The rapid increase in ATP synthesis required could not be the result of a series of 
retrospective mass-action effects on metabolism, all initiated by an increase in ADP 
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at all under conditions when cellular respiration is significantly stimulated [Balaban 1990]. 
The rates of ATP production are also strongly controlled by factors other than ATP 
utilisation, eg, rates of fuel oxidation [Brand 1997] and can exert strong controlling effect 
on rates of ATP utilisation contrary to that predicted by the Mitchell theory [Ainscow & 
Brand 1999]. Rolfe and Brand [1997] proposed that the partial uncoupling observed in 
mitochondria could be a mechanism to increase the sensitivity and rate of response of 
oxidative phosphorylation to a variety of effectors. 
Currently, two theoretical mechanisms have been proposed to account for an independent 
basal proton conductance [Ricquier & Bouillaud 2000; Stuart et al 2001]. Firstly, slippage 
where proton leakage is due to the modified properties of the respiratory chain, such as 
failure of proton pumps, or changes in the physical properties of phospholipid fatty acid 
bilayers or proteolipid bilayers juxataposed to the inner membrane [Brookes et al 1997a]. 
However, neither the composition of the inner membrane [Brookes et al 1998; Porter et al 
1996], nor mediated changes via the proton-pumping respiratory complexes [Brown & 
Brand 19911 appears to account for differences in proton conductance. 
Alternatively, proton transport across the mitochondrial inner membrane may be catalysed 
by one or more specific physical carriers. These carriers might cause dissipation of the 
transmembrane 0µH+ through by-passing the ATPsynthase pathway and therefore 
uncoupling respiration from oxidative phosphorylation of ADP to ATP. The major 
consequence of uncoupling respiration by either mechanism would be the activation of 
increased substrate oxidation and the allowance of energy to be dissipated as heat at 
physiologically important levels ie Thermogenesis [Boss et al 1998b]. 
Basal conductance only accounts for approximately 5% of the proton leak flux in all 
mitochondria in rats [Brookes et al 1997b]. It has been demonstrated that heat production in 
rodent Brown Adipose Tissue (BAT) can also be the result of specific and regulated 
uncoupling processes in mitochondria [Nicholls 1979 & 1984]. Mitochondria in BAT are 
highly uncoupled, and uncoupled respiration was found to be both inducible, that is 
activated by non-estified fatty acids (NEFA) and also almost entirely inhibited by purine 
nucleotides, mainly GDP. Observations that uncoupled processes could be regulated 
supported the existence of an uncoupling protein. The exploitation of the high affinity of the 
purine nucleotide to binding sites on the inner membrane of BAT mitochondria, enabled the 
identification of a 32Kd protein [Heaton et al 1978; Klingenberg 1990]. This protein was 
originally named Thenmogenin and later renamed uncoupling protein 1(UCP1) [Fleury et al 
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1997]. UCP1 has been characterised in a number of species [Lin et al 1980; Ricquier et al 
1982; Jacobsson et al 1985; Bouillaud et al 1986; Aquila et al 1985]. 
UCP1 is a member of anion transport family of genes commonly having six transmembrane 
helices straddling the inner mitochondria) membrane with C-and N-termini protruding into 
the cytosolic site. Theoretically these proteins catalyse fatty acid dependent electrophoretic 
proton flux across the inner membrane. Two uncoupling mechanisms for UCP's have been 
proposed, both based on the absolute requirement of fatty acids for UCP H+ transport. 
Klingenberg Model: It is postulated that in a proton buffering models, protons could be 
conducted through a hydrophilic aqueous pathway within the UCP protein. This 
translocation channel would be lined with the fatty acid carboxyl head groups of the protein 
in conjunction with the resident H+ conducting amino acids such as histidines, and together 
they would buffer the protons across the inner membrane (figure 2.1.1) [Klingenberg & 
Huang 1999; Winkler & Klingenberg 1994]. 
Garlid Model: In the fatty acid protonophore model proposed by Garlid et al [1996], UCP 
does not actually conduct protons but instead acts as an anion transporter. A variety of 
anions are transported, but the physiologically important substrates are fatty acid anions. 
The monovalent negatively charged fatty acid carboxylate head groups are translocated by 
UCP straddling the membrane from the matrix side across the inner membrane to the 
cytosolic side, driven by the high inside-negative mitochondrial membrane potential. Once 
the carboxylic anion head has crossed the membrane it picks up a proton from the cytosol. 
The protonated electro-neutral fatty acid then rapidly crosses the membrane bilayer to the 
matrix side by non-ionic diffusion independently of the UCP, hence delivering charged 
protons to the matrix. This `Flip Flop' mechanism permits fatty acids to behave as regulated 
cycling protonophores, releasing H+ protons in the matrix independently of ATP synthesis, 
thus dissipating the proton gradient and generating heat, uncoupled thermogenesis (figure 
2.1.1) [Garlid et al 1998; Skulachev et al 19911. The Garlid model tends to be more 
favoured with the mechanistic integration of both proton and anion transport consistent with 
the anion transporting function of other members of the gene family. 
UCPI is exclusively expressed in BAT, a tissue primarily concerned with heat generation. A 
considerable number of studies using a variety of methods have conclusively confirmed that 
UCP1 catalyses proton conductance in rodents [Nicolls & Locke 1984; Klingenberg 
1990,1999; Himms-Hagen 1990; Gonzalez-Barroso et al 1996; Fleury et al 1997; Brand et al 
1999]. 
39 
2.1.3 UCP2 and UCP3 homologues of UCP1 
In 1997 two homologues of the UCP1 gene were discovered, cloned, sequenced and 
characterised namely UCP2 and UCP3 [Fleury et al 1997; Gimeno et al 1997; Boss et al 
1997b & 1998d; Vidal-Puig et al 1997; Gong et al 1997; Argyropoulos et al 1998a; Tu et al 
1999a; Pecqueur et al 1999; Liu et al 1998; Matsuda et al 1997; Solanes et al 1997]. In 
humans UCP2 and UCP3 both mapped to the distal segment of 11813 (Figure 2.1.2) 
separated by 7kb (8kb in mice) [Pecqueur et al 1999; Surwit et al 1998; Liu et al 1998]. 
Amino Acid Homology 
Amino acid number in monomer 
2Six transmembrane domains 
3ALLBNB motif 
UCP1 UCP2 UCP3 (L) 
f- 59% 
57% 
ý"'- 1737o -O' 





Gene Length (kb) 8.0 6.3 8.5 
Number of exons 687 
mRNA Splice variants None None 5Two 
6Main Tissue Expression BAT Ubiquitous Skeletal 
Muscle 
Table2.1.1: Comparison of UCP homologues UCP1, UCP2 and UCP3 
Additional information pertaining to table 2.1.1: 
'UCP2 and UCP3 proteins are very similar with many of the non-identical residues in the 
UCP3 protein being conservative substitutions, which in most cases correspond to residues 
found in either UCP2 or UCPI in various species [Boss et al 1997b; Vidal-Puig et al 1997; 
Gong et al 1997; Liu et al 1998; Matsuda et al 1997]. 
2A11 three UCP homologues share common features with members of the mitochondrial. 
carrier protein superfamily, including possession of six transmembrane domains [Solanes et 
al 1997]. UCP proteins are homodimers with each monomer having three repeat units of 
approximately 100 amino acids long. Each unit contains two transmembrane domains with 
intervening amino acids looped into the membrane [Walker & Runswick 1993]. 
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3 Immediately following the first transmembrane domain of each repeat unit is a highly 
conserved basic motif ALLBNB (Acidic, Lipophilic, Basic, Neutral) [Klingenberg 1993; 
Liu et a] 1998]. This motif is perfectly conserved in human UCP1, UCP2 and UCP3 and in 
the three murine UCP1, -2, -3 proteins. 
4 Human and mouse UCP2 genes both differ from UCP1 in having two additional non- 
coding untranslated exons in the 5' region. 
5 Human UCP3 gene is characterised by having two transcripts generated from a single gene 
by alternative splicing. One transcript produces a protein with 312 amino acids, UCP3L. The 
other short isoform, UCP3S, loses 37 C-terminal residues encoded by exon 7 producing a 
truncated protein of 275 amino acids lacking the COOH terminal region. Premature 
termination occurs in approximately 50% of the transcripts with intron 6 providing an 
alternative polyadenylation site AATAAA. The region extending to the other AATAAAL 
signal located approx 1.1 kb downstream of exon 7 in the long form (figure 4.4.1) is thought 
to be homologous to the domain in UCP1 and UCP2 that mediates inhibition of uncoupling 
activity by purine nucleotides and provides the sixth transmembrane domain [Boss et al 
1998d; Solanes et al 1997]. 
6 UCPl is exclusively expressed in BAT, similarly UCP3 is almost exclusively restricted to 
skeletal muscle but at a level 2.5-5 fold greater in abundance than UCP2 [Boss et al 1997b]. 
UCP3 is also expressed in heart muscle but at less than 1% of the level found in skeletal 
muscle. In humans it is virtually absent from subcutaneous WAT but in mice expression is 
equally abundant in both skeletal muscle and BAT, and to a lesser extent in WAT and heart 
[Vidal-Puig et al 1997]. UCP2 is ubiquitously expressed in both humans and rodents. UCP2 
expression is most abundant in WAT, BAT, but it is also expressed at high levels in heart, 
kidney and brain tissues with a relatively high level in the spinal cord and medulla, also in 
tissues throughout the immune system including spleen, thymus, bone marrow, trachea, 
leucocytes, macrophage and lymph nodes [Fleury et al 1997; Richard et al 1999]. It is found 
in less abundance in skeletal muscle, testis, Kupffer cells, stomach/gut cells and pancreatic 
islets [Larrouy et al 1997; Richard et al 1998; Ricquier 1997; Fleury et al 1997; Gimeno et 
al 1997; Chan et al 1999]. 
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2.1.4 Uncoupling activity of UCP1 Homologues 
Mitochondrial proton leaks have also been detected in a number of major oxygen consuming 
tissues other than BAT including WAT, liver, kidney, brain and skeletal muscle, with this 
latter tissue the major site of adaptive thermogenesis [Astrup et al 1985 & 1989; Zurlo et al 
1990; Spraul et al 1993]. UCP2 and UCP3 are also predicted to have uncoupling activity 
this is summarised in table 2.1.2. 
EVIDENCE FOR UNCOUPLING UCP1 UCP2 UCP3 UCP3 
ACTIVITY (L) (S) 
Structural Similarities + + + 
Immunohistochemically located to + - - - 
mitochondria 
Immunological detection to + + + + 
U mitochondrial fraction in Yeast 
Z-, Proton transport activity NK + + + 
demonstrated in liposomes 
Increase in respiratory rate and + + + + 
M decreased respiratory control ratio in 
recombinant yeast ä 
o Decrease in mitochondrial + + + + 
membrane potential in recombinant 
east expressing gene 
Purine Inhibition of Uncoupling +++ + + 
yc ' 
activity 
> Fatty Acid stimulation of ++ +++ +++ 
Uncoupling Activity 
Retinoic Acid stimulation of +++ +++ NK NK 
Uncoupling Activity 
Table 2.1.2: Evidence for UCP2 and UCP3 mitochondrial uncoupling activity. NK=Not 
known 
Additional information pertaining to table 2.1.2: 
'The region that is spliced out in the UCP3S is predicted to be critical for uncoupling 
activity, and provides the sixth transmembrane domain that might be crucial for insertion of 
the protein into the mitochondrial inner membrane. It has therefore been postulated that the 
activity of the UCP3S isoform is markedly different from the UCP3L isoform [Boss et al 
1998d; Solanes et al 1997]. 
2 Immunohistochemical techniques have been unable to locate either UCP2 or UCP3 
proteins to mitochondria due to the lack of specific antibodies. 
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3 [Larrouy et at 1997; Hinz et at 1999a]. In addition there is subcellular localisation of UCP3 
in mitochondria in human breast carcinoma MCF7 cells [Boss et at 1999]. 
4 Effects on growth rates of yeast are correlated with uncoupling activity [Gonzalez-Barroso 
et at 1996]. Expression of UCPI, -2 and -3 in heterologous yeast expression systems show 
similar quantitative effects consistent with the homologues having uncoupling activity 
[Fleury et at 1997; Bouillard et at 1994; Gimeno et at 1997; Liu Q et at 1998]. In vitro 
experiments that measure State IV respiration rate ie. respiration in the absence of ADP/ 
ATP synthesis, are purported to be controlled by both proton conductance and substrate 
oxidation [Brand 1990] 
S In vivo experiments using flow cytometry with direct measurements of ßµH+ by the uptake 
of mitochondrial membrane specific electrochemical potential-sensitive fluorescent dyes 
[Gimeno et at 1997; Fleury et at 1997; Gong et at 1997; Hinz et at 1999a; Hagen et at 1999; 
Zhang et at 1999; Jaburek et at 1999]. 
6 Amino acid sequences located in the carboxy-terminal region, within and between the fifth 
and sixth transmembrane domains of UCP1 have been implicated not only in the activation 
of uncoupling activity by FFA but also in the purine nucleotide inhibition of activity 
[Gonzalez-Barroso et at 1996; Winkler & Klingenberg 1992; Bienengraeber et at 1998; 
Modriansky et at 1997]. Variation in residues in this region between UCPI, UCP2, and 
UCP3 and their different effects, suggests the biochemical regulation of the two homologues 
is distinct from UCP1 [Liu et at 1998]. Although the proton transport properties of UCP2 
have been physiologically considered to be qualitatively identical to that of UCP1 [Rial et at 
1999; Mang et at 1999] studies have suggested that both UCP2 and UCP3L may have 
greater uncoupling activity than UCPI, with increased sensitivity to free fatty acids and 
decreased inhibition by purine nucleotides [Gonzalez-Barroso et at 1996 & 1998; Bouillaud 
et at 1994; Nicolls 1974 & 1984; Huang et at 1995a & 1995b; Hinz et at 1999; Jaburek et at 
1999; Echtay et at 1997 &1998; Zhang et at 1999]. UCP3L and UCP3S isoforms were also 
found to have qualitatively similar biochemical activities, with some studies showing 
UCP3S having less activity than UCP3L [Hagen et at 1999] and other studies higher activity 
[Hinz et at 1999b]. Whilst in contrast some investigations have found also the magnitude of 
the uncoupling effects of UCP3L overall were greater than that of either UCPI or UCP2 
[Zhang et at 1999]. 
The acceptance of the theoretical models of either Klingenberg or Garlid assumes the 
obligatory involvement of fatty acids in influencing uncoupling activity [Klingenberg 1988; 
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Winkler & Klingenberg 1994; Bienengraeber et al 1998; Jezek et al 1994; Garlid et al 1996]. 
In vitro experiments on respiration in isolated BAT mitochondria have shown that free fatty 
acids (FFA), excluding those with esterified carboxyl groups, are prequisiste for UCP1 
mediated H+ transport, with further supportive studies in mammalian BAT [Ricquier et al 
1997]. It has been suggested that fatty acids stimulate protonophoric activity by acting as 
regulatory ligands with UCP1 [Bienengraeber et al 1998; Kopecky et al 1984]. 
However most of these studies showing the effects of FFA's on uncoupling activity are in 
yeast or isolated liposomes and it may be different in other organisms or tissues. In 
mammalian C2C12 myoblasts, the uncoupling activity of UCP3 appears to be under much 
tighter control than in yeast [Brustovetsky et a] 1992; Boss et al 1998c] suggesting that there 
may be tissue specific differences in factors controlling uncoupling activity and these may 
be specific for each UCP [Hagen et al 1999]. 
7The human UCP3S isoform lacks the C-terminal region but is still capable of inserting 
itself into the inner mitochondrial membrane. Therefore the putative purine nucleotide 
binding domain may not be obligatory for uncoupling activity and its absence may actually 
enhance uncoupling activity [Bouillaud et al 1994; Renold et al 2000]. 
8 Although it is thought that increased UCP uncoupling activity and stimulation of 
transcription of the UCP gene may be mediated by cAMP induced increased intracellular 
FFA concentration and /or sympathetic nervous stimulation [Bukowiecki et al 1981] some 
studies suggest a role for either fatty acids or the inhibitory purines nucleotides on UCP 
uncoupling activity to be inconclusive [Gonzalez-Barrroso et al 1998; Rial et al 1983 & 
1999; Zhang et al 1999; Baumruk et al 1999]. Alternative or additional factors may also be 
of equal importance although data is scarce. Retinoic acid appears also to be a strong 
promoter of uncoupling activity of both UCP1 and UCP2 in yeast expression vectors, with 
the latter positively regulated in a pH dependent manner. Furthermore, these experiments 
also suggested that retinoic acid was possibly more potent than fatty acids [Rial et al 1999]. 
In addition, to this extensive evidence supporting uncoupling activity for both UCP2 and 
UCP3, increased thermogenesis has also been recorded in yeast over-expressing UCP2 
[Paulik et al 1998] and using direct microcalorimetric measurement of the thermogenic 
power of cells thermogenesis was increased in yeast transformed and overexpressing the 
UCP3L form when compared to controls [Hinz et al 1999a]. 
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2.1.5 Physiological roles of UCP2 and UCP3 
The potential biological roles for both UCP2 and UCP2 have initially been postulated based 
on their close structural and functional similarity to UCP1. However, accumulating data 
suggests they may have a number of physiological functions that differ from UCP1, 
although none to date has been entirely proven. 
Thermogenic Role: 
The known physological role of UCP1 could implicate both UCP homologues in obligatory 
or adaptive thermogenesis, and thus a role in mediating whole body energy homeostasis 
through the modulation of energy expenditure [Astrup et al 1985 & 1989; Zurlo et al 1990; 
Spraul et al 1993; Ravussin et al 1992; Vidal-Puig et al 1997; Boss et al 1997b]. Total 
energy expenditure results from a combination of three components [Ravussin 1995]. 
1. Basal or resting metabolic rate (RMR/BMR) is the obligatory energy expenditure essential 
for body cellular, biochemical, and physiological functions, accounting for approximately 
60% of the total energy usage. Physiological processes include maintenance of ion 
gradients, protein synthesis, muscle activity and heat generation with consumption of energy 
largely dependent on adenosine triphosphate (ATP) production [Brand 1990]. 
2. Energy expenditure via thermogenesis induced by physical activity/exercise 
3. Adaptive thermogenesis, the component of energy expenditure that changes in response to 
environmental stimuli such as cold induced shivering and non-shivering thermogenesis, 
chronic dietary excess or dietary imbalance, or microbial/viral infection-fever. 
Obligatory Thermogenesis: 
An obligatory cellular basal proton leak occurs in mitochondria of different tissues across 
many species and has been considered to contribute greatly to overall energy expenditure 
and metabolic rate (table 2.1.3) [Porter & Brand 1993; Rolfe et al 1994; Simonyan & 
Skulachev 1998]. This has been particularly reflected in rat hepatocyte and leg muscle 
studies in which basal proton conductance accounted for between 26% and 50% respectively 
of the total resting energy expenditure [Brand 1994; Rolfe et al 1999]. A two-fold 
stimulation of the respiration rate by induction of glucose/urea production and muscle 
contraction in these hepatocytes and muscles respectively, reduces this contribution to 22% 
and 34% respectively, commensurate with a compensatory basal proton conductance 
mechanism [Rolfe & Brand 1997a]. It has been postulated that in humans 18-22% of 
basal/resting metabolic rate could be attributed to a mitochondrial proton leak, with total 
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body adipocyte thermogenesis likely to contribute 5% (7% under stimulated conditions) and 
skeletal muscle approximately 14% [Rolfe et al 1996 & 1999]. 













Table 2.1.3: Cross species percentage contribution of basal mitochondrial proton leak 
to hepatocyte respiration 
Variation in this obligatory energy cost resulting from the maintenance of physiological and 
cellular functions in humans appears to have a degree of familial heritability [Bogardus et al 
1986; Bouchard et al 1989 & 1993]. There is considerable evidence to suggest that primary 
abnormalities in energy balance could contribute to the pathogenesis of both diabetes and 
obesity [Ravussin & Bogardus 1992]. Meta-analysis of eleven studies on energy expenditure 
and obesity, found resting energy expenditure in post obese subjects to be significantly 
lower than that in normal weight controls, although fat tissue mass is increased in obese 
subjects. It was postulated that the marked differences in BMI between subjects could be 
due to variation in energy expenditure over a long period [Ravussin et al 1988; Astrup et al 
1996]. Accordingly, computer generated simulation studies suggest that only small 
reductions (20%) in RMR under conditions of constant energy intake could convert a lean 
person to an obese state [Weinsier et al 1993]. A genotypic variation that could cause a 
reduction in expression or diminish the thermogenic activity of UCPI, UCP2 and/or UCP3 
could underlie an inherited propensity to weight gain. However, the situation may not be so 
clear cut in humans, as paradoxically a reduction in energy expenditure has also been 
observed accompanying weight loss [Leibel et al 1995]. 
Adaptive thermogenesis: 
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BAT is a specialised thermogenic tissue with diffuse deposition throughout the whole body 
of mammals, with increased deposition in certain mammals, such as rodents as an adaptive 
mechanism for survival. BAT owes its thermogenic capacity to an abundance of 
mitochondria, hence providing a high oxidative capacity, high content of cytochrome 
oxidase and low content of ATP synthetase. In addition there is an unique stoichiometry of 
protein complexes on the inner membrane including the exclusive expression of UCP1. In 
certain mammals BAT-UCP1 activity and the generation of body heat, the process of cold or 
diet induced non-shivering thermogenesis, is a crucial adaptation in newborn mammals, 
cold-adapted rodents and in animals emerging from hibernation. The heat generated is 
circulated throughout the body via arteriovenous anastomoses present in BAT to achieve an 
overall thermoregulation and hence this tissue has a major role in regulating whole body 
temperature and weight in certain animals [Stuart et al 2001]. 
The biological pathway involved in heat induction appears to be primarily controlled by the 
hypothalamus acting through thermoregulatory centres with direct sympathetic nerve system 
(SNS) innervation of brown adipocytes by cell surface ß-adrenergic receptors [Rothwell & 
Stock 1987; Ricquier et al 1986]. Exposure to cold and ß3 adrenergic receptor agonists 
upregulate UCP1 expression and increase the insertion of the protein into the mitochondrial 
inner membrane [Silva & Rabelo 1997; Nagase et al 1996; Rehnmark et al 1990; Trayhurn 
et al 1987; Geloen 1990]. Cold activation of the SNS causes a cAMP dependent stimulation 
of lypolysis, through the possible action of the (3-adrenergic receptor agonist, noradrenaline 
resulting in increased release and oxidation of fatty acids [Himms-Hagen 1995]. Increased 
intracellular FFA levels may increase both H+ conductivity of UCP1 similar to that of 
catecholamines and also provide fuel for mitochondrial respiration [Prusiner et al 1968; 
Bukowiecki et al 1981; Reed 1968]. Transgenic mice that are UCP1 deficient develop 
hypothermia both under cold conditions and when lacking the stimulatory effects of both 
FFA and norepinephrine [Enerback et al 1997; Cannon et al 1999; Boss et al 2000]. 
It has been proposed that BAT could also play an essential role in thermoregulation in 
humans particularly after birth and during feeding in newborns [Himms-Hagen 1995]. 
Furthermore, it has been shown that BAT has a wide spread representation in the adult 
human body, although only in small deposits. Therefore a relationship between BAT and 
energy balance or body weight regulation in adult humans cannot be completely excluded 
[Garruti & Ricquier 1992]. It has been suggested that BAT could be responsible for up to 1- 
2% of energy expenditure in humans, and that if there was an uncompensated defect in this 
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pathway, hypothetically there could be a1 to 2kg gain in weight per annum [Lean 1989]. 
Therefore theoretically a dysfunctional UCP1 gene could lower the rate of energy 
expenditure resulting in small calorific inequalities over an entire life span, leading to an 
increase in fat storage and predispose an individual to the development of obesity [Ravussin 
et al 1988; Griffiths et al 1990]. Although depressed thermogenic responses have been 
observed in some subgroups of obese patients (Jequier & Schutz 1985] in thermo-neutral 
humans and large mammals there is less deposition of BAT except in neonates and it is 
unlikely that UCP1-BAT in adult humans has. a major role in whole body energy 
homeostasis as found in rodents and hibernating mammals. [Lean et a] 1985]. 
The idenfication of other uncoupling proteins expressed in tissues other than BAT has led to 
the concept that other cell types may also have important thermogenic properties [Harper & 
Brand 1995; Brand 1997]. UCP2 is expressed in a number of tissues implicated in the 
regulation of energy balance, including BAT, WAT and skeletal muscle. Although white 
adipose tissue (WAT) shares several characteristics with BAT such as the ability to 
synthesis and store triglycerides and release NEFA's. WAT is primarily concerned with 
storage and possesses relatively few mitochondria and is therefore unlikely to have a similar 
thermogenic activity to BAT. In contrast skeletal muscle, in which both UCP2 and to a 
greater extent UCP3 is selectively expressed, is quantitatively the major site of adaptive 
thermogenesis and energy expenditure, with fat-free mass mainly comprised of skeletal 
muscle accounting for 80% of the variation of resting energy expenditure between 
individuals [Ravussin 1992; Zurlo et al 1990]. 
In rodent BAT both UCP2 and UCP3 have been induced by cold exposure, although the 
response varies between species and strain and appeared to be dependent on the temperature 
and length of exposure [Himms-Hagen 1990; Denjean et al 1999; Larkin et al 1997; Boss et 
al 1997a, 1997b & 2000; Carmona et al 1998; Emilsson et al 1998; Yoshitomi et al 1998a; 
Enerback et al 1997]. However, evidence is inconsistent and scant in rodents and humans 
that tissues other than BAT, and the uncoupling protein homologues are involved in cold 
adaptation mechanisms (table 2.1.4) [Fleury et al 1997; Boss et al 1997a & 1998c; Larkin et 
al 1997; Carmona et at 1998]. Nevertheless, UCP2 expression has been observed to be up- 
regulated in specific tissues (table 2.1.4) in response to cold apparrently as part of the 
recovery of body temperature following endotoxin-mediated hypothermia in mice. It has 
been proposed that localised thermogenic effects may exist to maintain function, or protect 
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essential tissues from damage under conditions of extreme cold [Adams 2000; Simonyan et 
al 1998; Skulachev et al 1998; Richard et al 1998]. 
The regulation of energy homeostasis / body fat equilibrium in mammals is dependent on a 
balance between diet, regulated by energy input through appetite control, and energy 
expenditure. It has been proposed that there is operative in rodents an adaptative 
thermogenic mechanism provided by BAT and mediated by UCPI activity that controls 
dietary imbalance. Facultative diet induced thermogenesis (DIT) in BAT could be 
responsible for preventing obesity in rodents by buffering excess calorific intake by 
regulating energy expenditure, and body fat levels [Rothwell & Stock 1979 & 1981; Segal et 
al 1992; Himms-Hagen 1990]. 
It has been observed that high fat feeding induces non-shivering thermogenesis in rodents 
with a concomitant increase in BAT-UCP1 [Rothwell & Stock 1979]. Furthermore, 
evidence suggests that rodent strains which are prone to obesity may have a reduced 
thermogenic activity possibly as a result of defective BAT thermogenesis or reduced tissue 
deposits, compared to those that are relatively resistant following a high fat diet [Schemmel 
et al 1970; Hamann et al 1996; Himms-Hagen 1990; Seydoux et al 1982]. Studies that 
involved the ablation of BAT (60-95%) through the expression of a dipteria toxin gene with 
a UCP1 promoter (UCP-DTA) found a reduction (50%) in BAT thermogenesis that 
augmented obesity, hyperphagia and insulin resistance in the transgenic mice [Lowell et al 
1993]. Furthermore, a reciprocal experiment in which gene constructs (aP2-UCP) in mice 
up-regulate UCP1 expression in both BAT and ectopically in WAT, adiposity was reduced 
and transgenic mice became resistant to high fat diet induced obesity [Kopecky et al 1995 & 
1996; Baumruk et al 1999]. The UCPI-DTA transgenic mice were also leptin resistant 
suggesting that leptin may a play a role in thermogenic pathways, with possible direct 
effects on UCP1 expression or via sympathetic outflow [Mantzoros et al 1998; Elmquist et 
al 1998; Haynes et al 1997; Haque et al 1999; Satoh et al 1999]. 
Overall the evidence above suggests a role for UCPI in body weight regulation in rodents. 
However, UCPI-DTA mice raised at thermoneutrality do not become hyperphagic or obese 
and UCPI knockout mice also do not become obese suggesting the existence of other 
compensatory adaptative mechanisms [Melnyk et al 1997; Enerback et al 1997]. Regulated 
energy expenditure is controlled largely by adrenergic stimulation with skeletal muscle the 
most important site of catecholamine and diet induced thermogenesis in both rats and 
humans [Thurbly & Trayhurn 1979; Astrup et al 1986; Simonsen et al 1993]. Therefore 
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following the discovery of UCP2 and UCP3 many investigations have been carried out to 
determine whether these uncoupling proteins in other tissues also play a role in energy 
homeostasis. 
In rodents the regulation of UCP2 or UCP3 mRNA expression appears to influenced by 
many different dietary and related hormonal factors including thyroid hormone, leptin, 
insulin, 03-adrenergic stimulation, high fat diet, plasma FFA, fasting and exercise (table 
2.1.4)[Gong et al 1997; Larkin et al 1997; Astrup et al 1985 & 1989; Spraul et al 1993; Boss 
et al 1998c & 1999; Millet et al 1997; Weigle et al 1998; Cortez-Pinto et al 1999; Savontaus 
et al 1998]. Some inducers such as thyroid hormones are established effectors of 
thermogenesis and metabolic rate and correlate positively with mitochondrial uncoupling 
activity in both liver and skeletal muscle, and may have direct action on mitochondria 
[Harper & Brand 1995; Lanni et al 1999; Goglia et al 1999; Jekabsons et al 1999]. The 
thyroid hormones L-thyroxine (T4) and triiodo-L-thyronine (T3) both have marked 
thermogenic effects and promote both UCP2 and UCP3 mRNA expression in certain tissues, 
independently of the effects of leptin [Goglia et al 1999]. Furthermore, in a variety of rodent 
tissues the expression of UCP2 increases and decreases in response to hyperthyroid and 
hypothyroid states respectively [Lanni et al 1997; Masaki et al 1997]. 
Plasma leptin also increases energy expenditure, suppresses apetite, and induces a 
concommitant up-regulation of BAT UCPI expression in rodents [Mantzoros et al 1998; 
Scarpace et al 1997]. In the leptin deficient obese ob/ob mice, the effect of infusion of leptin 
on these pathways leads to a significant reduction in body weight. Leptin also regulates 
UCP2 expression and FFA metabolism in adipocytes (table 2.1.4)[Zhou et al 1997; Halaas 
et al 1995; Hwa et al 1996 & 1997]. However, the mechanisms are not entirely elucidated as 
contrary to what would be expected leptin appears to suppress UCP2 expression in both 
rodent WAT and hepatocytes, although increased uncoupling activity is detected in both 
these tissues [Gimeno et al 1997; Larrouy et al 1997; Chavin et al 1999; Melia et al 1999]. 
In contrast to the effects on UCP2, transfected ob/ob mice expressing leptin UCP3 
expression skeletal muscle was increased. Supporting this observation, in fa/fa rats that are 
leptin receptor deficient, UCP3 mRNA levels were decreased [Boss et al 1998c; Liu et al 
1998; Gong 1997]. Moreover, infra-cerebroventricular infusion of leptin during food 
restriction prevented both an expected decrease in UCP3 expression in muscle and increased 
UCP3 mRNA levels in BAT [Cusin et al 1998]. 
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Studies in rodents that are prone and resistant to obesity, show that high fat diet in addition 
to induction of UCPI in BAT also up-regulated UCP2 expression in WAT, suggesting a role 
for UCP2 in mediating energy expenditure, regulation of body and the delay of onset of 
obesity in resistant strains [Fleury et al 1997; Gong et al 1999; Matsuda et al 1997; Surwit et 
al 1998, Rippe et at 2000]. Furthermore, UCP2 may have played a compensatory role in 
stemming the progression to obesity in mice where UCPI was knocked out [Enerback et al 
1997]. However, high levels of UCP2 mRNA are maintained in tissues under conditions of 
suppressed thermogenesis, and observed increases in UCP2 expression in WAT in response 
to high fat diet are actually very modest [Rippe et al 2000; Gong et at 1999]. This suggests 
that unlike UCPI, modulation of UCP2 alone in rodents would be insufficient to prevent 
obesity. Furthermore, the relationship of UCP2 with dietary intake is not entirely clear as 
UCP2 expression responds variably to different dietary components in different tissues, with 
expression being downregulated in some mouse tissues, such as stomach and intestines in 
response to high fat diet (table 2.1.4) [Tsuboyama-Kasaoka et al 1999; Rippe et al 2000]. 
UCP3 expression in rodent skeletal muscle was also induced by high fat diet, although 
observations have been inconsistent with strain and/or species dependent effects [Gong et al 
1999; Matsuda et al 1997; Tsuboyama-kasaoka et at 1999; Surwit et at 1998; Fleury et at 
1997]. However, on comparison of lean rats to an obese rodent model (Zucker fa/fa rats) a 
decreased thermogenic capacity was detected that correlated not only with decreased 
expression of UCPI in BAT, but also with down-regulation (40%) of UCP3 mRNA 
expression in both BAT and soleus muscle [Himms-Hagen 1990; Boss et at 1998c]. Studies 
with transgenic mice over-expressing human UCP3 protein in skeletal muscle, the mice 
weighed less than their wild type litter-mates despite being hyperphagic [Clapham et al 
2000]. This study suggested that UCP3 could be a determinant of human energy expenditure 
and metabolic efficiency and hence contributing to body weight regulation. 
Variation in rodent experimental data for UCP2 and UCP3 could be due to the genotype of 
the animals influencing mRNA levels. However, changes in UCP2 or UCP3 mRNA levels 
may not be primary determinants of body fat content but a reflection of metabolic responses 
to changes in fat intake and body composition. The magnitude of diet induced increased 
expression of both UCP2 and UCP3 reported were also considered to be only modest when 
compared to other effects such as starvation, exercise and thyroid hormone. 
Experimental studies in starvation have shown that in response to a severe energy deficit, 
energy expenditure falls by a magnitude greater than can be accounted for by the loss of 
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metabolically active tissues [Gaesser & Brooks 1984]. It is generally conceptualised that this 
disproportionate reduction in metabolic rate results from the autoregulatory suppression of 
basal thermogenesis, as a means to increase metabolic efficiency and provide a buffer 
against the energy deficit. Experiments involving diet restriction in rodents show differences 
in thermogenic activity in response to diet, possibly as a result of defects in the mechanisms 
necessary for the activation of thermogenesis [Himms-Hagen 1995; Champigny & Ricquier 
1990]. Most studies in rodents have found acute calorific restriction causes a down- 
regulation of UCP1, UCP2 and UCP3 mRNA expression in BAT, consistent for true 
thermogenic roles for these proteins [Trayhurn et at 1987; Boss et at 1998c]. However, 
paradoxically under the same acute fasting conditions UCP3 expression was unexpectedly 
increased in skeletal muscle and UCP2 expression increased in skeletal muscle, WAT and 
pancreatic islets in rodents (table 2.1.4) [Bao et at 1998; Boss et at 1997a, 1998b & 1998c; 
Aubert et at 1997; Camirand et at 1998; Samec et at 1998a; Matsuda et al 1997 & 1998]. In 
contrast chronic long-term diet restriction results in decreased expression of UCP's (table 
2.1.4)[Cusin et at 1998; Samec 1998; Cortright et at 1998; Esterbauer et at 1999; Boss et at 
1998c]. 
Parallel differences in the regulation of UCP3 expression have also been observed during 
exercise in rodents (table 2.1.4)[Cortright et at 1999; Tsuboyama-Kasaoka et at 1998]. 
Acute short-term exercise, a one hour long bout, causes a transient increase of muscle UCP3 
mRNA levels with expression peaking at 3 hours after the end of exercise, and completely 
disappearing after 22 hours. This is accompanied by acute metabolic and hormonal response 
similar to that observed with short-term calorific restriction [Tsuboyama-Kasaoka et at 
1998]. However, following endurance training UCP3 expression was down-regulated [Boss 
2000]. The observed differences in uncoupling protein expression are almost certainly due 
to the influence of other fluctuating factors determined by the feeding or exercise states. It is 
postulated that fasting increases muscle sympathetic nervous system tone, circulating 
catecholamines, and also induces adipose tissue lipolysis and lipoprotein lipase activity 
causing the release of fatty acid stores and hence elevating circulating FFA levels [Stich et 
at 1997]. The increased expression of UCP2/UCP3 under fasting conditions could be 
strongly under the influence of circulating plasma FFA levels and FFA fluxes towards 
tissues [Boss et at 1998b]. The thermogenic role of both UCP2 and UCP3 in rodents still 
remains highly contentious, but evidence from rodents does suggest an involvement in 
metabolic pathways concerned with dietary intake and energy balance. 
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Thermogenic role in humans: 
The implication that uncoupling proteins other than UCP1 can modulate proton leaks in 
other tissues and hence energy expenditure in rodents has led to many studies trying to 
correlate UCP transcriptional and/or thermogenic activity with overall weight gain or loss in 
humans. In humans UCP2 expresses at its highest level in adipose tissue and decreased 
thermogenesis has coincidentially been observed in WAT of obese individuals [Gimeno et al 
1997; Boucher & Furst 1997]. However studies in humans have found paradoxically that 
UCP2 mRNA levels positively correlated with increased fat mass and BMI, and so 
consequently there was no relative difference between lean and obese subjects (table 2.1.4) 
[Millet et al 1997]. Therefore, it appears that there is no UCP2 related reduction in 
thermogenic capacity in obese subjects. A similar strong positive correlation with UCP2 
expression with subcutaneous adipose mass was also reported in premenopausal obese 
women on a very low calorie diet [Barbe et al 1998], however in another study in the same 
tissue there was no correlation [Millet et al 1998]. In contrast, examination of visceral 
(intraperitoneal) and extraperitoneal adipose tissues, found decreased and increased UCP2 
expression respectively in morbidly obese subjects compared to lean subjects (table 
2.1.4)[Oberkofler et al 1998]. It is apparent that overall, correlations with basal energy 
expenditure, obesity and UCP2 expression in human adipose tissue have been inconsistent. 
Nevertheless, some of these differences may reflect differential tissue specific expression of 
UCP2 in regional adipose deposits. Interestingly, higher levels of UCP2 mRNA were also 
observed in WAT in both ob/ob and db/db obese mouse models compared to their 
equivalent lean littermates, although these observations may be influenced by the lack of a 
complete leptin signalling pathway in both models [Gimeno et al 1997]. 
Correlations of UCP2 mRNA expression in skeletal muscle have also been inconsistent, 
with positive correlations with BMI, percentage of body fat and several other indices of 
human obesity in some studies [Bao et al 1998] and no variation of UCP2 mRNA levels in 
obese subjects in other studies (table 2.1.4) [Millet et al 1997]. The differences in expression 
of muscle UCP2 could also be due to muscle types, as contrary to the other studies 
decreased expression of UCP2 (28%) was observed in the abdominal muscle of obese 
subjects [Nordfors et al 1998]. Similarly, expression patterns of UCP3 in skeletal muscle 
and obesity in humans are also inconsistent with no correlation between BMI/obesity and 
UCP3 mRNA levels in muscle reported in several studies [Millet et al 1998; Nordfors et al 
1998]. However, in Pima Indians expression of both the UCP3L and UCP3S isoforms did 
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negatively correlate with BMI, with increased expression associated with a reduction in 
body mass [Schrauwen et al 1999a]. Furthermore, there was a positive correlation between 
UCP3L expression and sleeping metabolic rate [Schrauwen et a! 1999a]. 
There have been very few studies examining the effect of dietary intake on uncoupling 
protein expression in humans (table 2.1.4). However, observations that infusion of a 
triglyceride emulsion into both rats and humans elevated circulating levels of both FFA's 
and skeletal muscle UCP3 expression, but without a similar effect on UCP2 expression in 
either skeletal muscle or adipose tissue, suggested a role for UCP3 cannot be completely 
dismissed [Weigle et al 1998; Khalfallah et al 2000]. FFA's up-regulated uncoupling protein 
expression, with high levels of plasma NEFA correlated with increased UCP3 expression in 
muscle of obese subjects might also suggest a role in a compensatory mechanism to prevent 
weight gain [Boss et al 1998a]. 
Studies in humans on the effects of food deprivation on uncoupling protein expression have 
found effects similar to that observed in rodents (table 2.1.4). Similarly there appeared to be 
a biphasic effect with acute calorific restriction up-regulating UCP3 expression in skeletal 
muscle, and UCP2 expression in both adipose tissue and skeletal muscle in both lean and 
obese subjects (table 2.1.4) [Millet et al 1997 & 1998]. In contrast, expression of UCP3 and 
UCP2 in skeletal muscle and WAT respectively are decreased in both non-diabetic and 
T2DM obese subjects following a prolonged and stable weight reduction by a very low 
calorific diet (table 2.1.4) [Vidal-Puig et al 1999; Schrauwen et al 2000]. Similar effects 
have also been observed on uncoupling protein expression following gastric banding surgery 
in humans and in mouse tibialis anterior muscle when animals are maintained in a 
thermoneutral environment [Esterbauer et al 1999; Boss et al 1998c]. 
The differences in expression observed under varying conditions of dietrary deprivation in 
humans may be related to fluctuating levels of plasma FFA'. Increased FFA levels have 
been correlated positively with the up-regulation of UCP3 expression in both rodents and 
humans in various tissues including WAT, BAT, muscle and pancreatic islets [Boss et al 
1997b & 1998a; Gong et al 1997; Gimeno et al 1997; Hidaka et al 1999; Weigle et al 1998; 
Millet et al 1997; Khalfallah et al 2000; Matsuda et al 1997 & 1998; Warden et al 1993; 
Surwit et al 1998; Fleury et al 1997; Carmona et al 1998b; Hwang et al 1999; Shimabukuro 
et al 1997; Vigueriie-Bascands et al 1999]. Similarly, acute exercise induced UCP3 up- 
regulation is accompanied by raised plasma FFA levels [Cortright et al 1999; Tsuboyama- 
Kasaoka et al 1998]. In contrast to acute fasting, during long stable food restriction plasma 
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FFA levels remained unchanged suggesting that under these conditions modulation of UCP3 
expression appears to be independent of FFA levels. However, chronic dietary effects and 
correlations of plasma FFA levels with induction of UCP2 expression have been less 
consistent in both rodents and humans [Boss et al 1998c; Vidal et al 1999; Barbe et al 1998; 
Khalfallah et al 2000]. 
FFA's may have a direct action on UCP expression being controlled by the intracellular 
metabolism and oxidation of lipids. Alternatively the recruitment of intermediary nuclear 
receptors may be involved in mediating expression. Factors that have been implicated are 
members of peroxisome proliferator-activated receptor (PPAR) family. PPAR's are involved 
in adipogenesis energy homeostasis and transcriptional activation of lipid-regulated genes 
[Brun et al 1996; Willson et al 1996]. The activity PPAR isoforms in response to changes in 
plasma levels and muscle uptake of specific fatty acids could have a direct action on UCP 
expression, without the involvement of lipid oxidation [Schoonjans et al 1996]. In human 
skeletal muscle two PPAR subtypes predominant, PPARa and PPARI, with the former 
expressed at high levels [Auboeuf et al 1997; Costet 1998]. PPARa, PPARß and PPAR'y 
have all been implicated in the regulation of UCP1, -2 and -3 mRNA (table 2.1.4) [Brun et 
al 1999b; Kelly et al 1998; Aubert et al 1997; Camirand et al 1998; Viguerie-Bascands et al 
1999]. In addition peroxisome proliferator-activated receptor response elements (PPRE) 
including RXR/PPAR hetereodimer sites have been identified in the promoters of UCP 
genes [Solanes et al 2001; Tu et al 1999b & 2000]. In in vitro studies, administration of a 
retinoid receptor RXR agonist LGD1069 has an additive effect on UCP expression [Kliewer 
et al 1997; Carmona et al 1998a; Solanes et al 2001; Tu et a! 2000]. The observations that a 
deficiency in PPARa could to lead to obesity might indicate possible interactions between 
PPAR's, uncoupling proteins and weight gain [Su 1998; Costet 1998]. 
There is considerable evidence implicating FFA's in modulating UCP expression in certain 
tissues under different dietary conditions. Plasma glucocorticoids levels can also have 
similar effects to plasma FFA levels during acute fasting and long-term food restriction 
[Ohno et al 1990; Guezennec et al 1988]. Furthermore, factors such as leptin and insulin 
may also be involved in metabolic pathways modulating UCP expression under different 
dietary conditions. The results of one study inferred that up-regulation of UCP2 by leptin in 
adipocytes may contribute to the stimulation of acetate and fatty acid degradation by leptin 
[Ceddia et al 2000]. A reduction in FFA levels could consequently also down regulate UCP 
expression, suggesting the possible existence of a feedback loop. In rodents insulin is also 
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positively correlated with UCP2/UCP3 expression in skeletal muscle and WAT [Pederson et 
al 2000; Savontaus et al 1998] and pancreatic islet insulin status in rats has been correlated 
with UCP2 mRNA levels [Kassis et al 2000]. However in humans the infusion of insulin 
during calorific restriction appears not to modify UCP2/UCP3 mRNA levels [Millet et al 
1997]. 
The inconsistent and unexpected effects of diet and dietary restriction on proteins that 
presumably have thermogenic activity could be due to a number of reasons. The suppression 
of uncoupling protein expression following long term chronic food restriction and gradual 
weight loss may be part of a mechanism to assist rapid recovery in body weight by reducing 
whole body energy dissipation and decreasing energy expenditure. this would be consistent 
with a thermogenic role for UCP2 and UCP3 [Leibel 1995]. A role for UCP3 was further 
supported in that it is downregulated following endurance training and associated with a 
decreased diet-induced thermogenesis in rats [Boss et a] 2000; LeBlanc et a] 1982]. The 
observations under conditions of acute starvation are contrary to a thermogenic role. 
However, studies using direct microcalorimetric measurements in mice suggest that up- 
regulation of UCP3 expression during fasting is not necessarily reflected in changes in 
muscle basal heat production rate, which was found to remain unchanged [Boss et a] 1998c]. 
This concurrs with findings that decreased expression in skeletal muscle of UCP3 mRNA is 
not reflected in a reduced cell uncoupling protein levels [Schrauwen et al 2000]. 
Furthermore, following induction of uncoupling using a chemical uncoupler, FCCP 
(carbonyl-cyanide p- trifluoromethoxyphenylhydrazone), muscle heat production rates are 
diminished (31%) in fasted mice compared to mice fed ad libitum. Thermogenesis by 
anabolic-catabolic pathways may therefore be reduced during fasting and it is possible that 
up-regulation of UCP3 is a compensatory mechanism to maintain normal heat production 
under these conditions [Boss et al 1998c]. In addition some of the inconsistencies observed 
with both UCP2 and UCP3 expression in skektal muscle may be due to specific effects in 
muscle types. Fasting in rats only increased UCP2 mRNA in soleus muscle and not in other 
muscle types [Samec et al 1998a] and studies on UCP3 expression in both fasted rats and 
humans found induction of expression was dependent primarily on the constitution of 
muscle as either type I fibres or type II fibres [Samec et al 1998b & 1999; Vidal et al 1999]. 
In addition completely opposite effects on UCP3 expression were observed within the same 
muscle tissue (gastrocnemius) following denervation between rodent species (rat and 
mouse) (table 2.1.4) [Cortright et al 1999]. 
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Finally the inconsistent observations on UCP mRNA expression between all these studies 
could be the result of differences in the relative stage of progression to the disease state 
[Simoneau et al 1998]. Alternatively the expressed levels of mRNA do not truly reflect 
cellular uncoupling protein content and are not necessarily indicative of the quantity of 
`active' uncoupling protein that is actually inserted into the mitochondrial inner membrane. 
Indeed, in one study in human skeletal muscle it was demonstrated that cellular levels of 
UCP3L mRNA were not equivalent to active UCP3 protein content [Schrauwen et al 2000]. 
Alternatively UCP2 and UCP3 may not be involved in obligatory or adaptive thermogenesis 
and other roles have been proposed below. 
Fuel Utilisation: 
Observations that there were concomitant increased uptake and utilisation of lipids as fuel 
substrates by skeletal muscle with UCP expression has been interpreted as a possible 
alternative functional role for uncoupling proteins [Boss et al 1998b; Samec et al 1998a & 
1998b], Mixed muscle tissue consisting of both type I and II fibres have a high capacity to 
switch between glucose and lipids as fuel substrates under fasting conditions. Studies 
investigating the effects of starvation on UCP2/UCP3 expression in this type of muscle in 
humans and rats suggested that effects on UCP expression correlated with fuel utilisation 
[Millet et al 1997 & 1998; Samec et 1998]. Re-feeding following starvation, down-regulated 
expression of UCP's that correlated with a reduced requirement for lipids as fuel substrates. 
This mechanism could also be equally applicable to the observations following gradual 
weight loss of decreased UCP3 expression, as in one particular study there was no actual 
decrease in UCP3 protein levels in muscle, but expression was correlated with levels of 
fatty-acid binding protein (FABP) content [Schrauwen et al 2000]. Changes in skeletal 
muscle cytosolic-FABP is related to uptake and oxidation of FFA by skeletal muscle 
[Veerkamp & van Moerkerk 1993], and maintaining oxidation levels following weight loss 
would facilitate further weight loss, suggesting also a role for UCP3 in the handling of lipids 
as fuels [Schrauwen et al 2000]. Furthermore, it has been proposed that the occurrence of a 
higher content of UCP2 in skeletal muscle in obese humans [Simoneau et al 1998], is in 
accord with a reduced postabsorptive lipid utilisation by muscles and consistent with a role 
in the regulation of lipids as fuel substrates [Boss et al 1998a & 1998c; Samec et al 1998a]. 
In humans heterozygote carriers of an exon 6 splice donor mutation in the UCP3 gene, 
which produces a protein identical to hUCP3S, were associated with a reduction (50%) in 
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fat oxidation capacity and an elevated non-protein respiratory quotient [Argyropoulos et al 
1998b]. Coincidentally the mutation had double the allele frequency in obese subjects 
compared to lean controls in the African-American group studied. Finally, further evidence 
in favour of a role in body weight regulation through fuel partitioning and insulin sensitivity 
was provided by measurements of UCP2 and UCP3 mRNA levels in muscle biopsies. 
Levels correlated with the promotion of carbohydrate oxidation and insulin-stimulated 
glucose disposal rates, rather than influencing basal energy expenditure or insulin-induced 
thermogenesis in both T2DM and non-T2DM subjects [Willi et al 1998]. 
Control of Reactive Oxygen Species (ROS): 
It has been postulated that uncoupling proteins may also have physiological roles in 
antioxidant activity by the maintaining low levels of the reactive oxygen species (ROS) that 
could cause oxidative damage to cells [Skulachev et al 1998]. The high expression of UCP2 
in cells of the immune system suggested a putative role in immunity and /or 
thermoregulatory response to infection ie. fever [Fleury et al 1997]. Subsequent studies 
relying on the sensitivity of UCP2 to GDP in immune system cells, proposed that UCP2 
could be involved in the control of hydrogen peroxide production [Negre-Salvayre et al 
1997]. Elevated UCP2 expression in ob/ob obese mouse hepatocytes in addition to helping 
to balance ATP supply may also protect the liver from increased ROS generation as a result 
of increased substrate supply and fat oxidation [Chavin et al 1999]. Studies using UCP2 
[Arsenijevic et al 2000] and UCP3 [Vidal-Puig et al 2000; Gong et al 2000] knockout mice 
have also provided further evidence that the control of activity and /or expression of UCP's 
may modulate levels of ROS in tissues. Reduced UCP2 levels in macrophages increases 
ROS production and this could act as a bactericidal agent during infection, whereas 
increasing UCP levels in other tissues in response to infection, food restriction, or exercise 
might prevent the effects of excessive oxidative stress. Finally, cytokines involved in 
inflammation processes such as tumour necrosis factor (TNFa) also appear to regulate 
expression of uncoupling proteins [Masaki et al 1999]. 
2.1.6 Potential role of UCP2-UCP3 inT2DM 
Normoglycaemic women at increased risk of future diabetes display defective post-prandial 
thermogenesis [Robinson et al 1992 & 1994] and there is evidence of linkage to UCP/ UCP3 
chromosomal region with post-glucose load insulin levels in Pima Indians [Pratley et al 
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1998]. Uncoupling proteins have been implicated in glucose utilisation, insulin resistance 
and insulin secretion. It has been postulated that UCP's may provide not only a defense 
mechanism against high fat induced obesity but also against impairment of glucose 
metabolism [Matsuda et al 1997]. Studies with transgenic mice over-expressing the human 
UCP3 gene in skeletal muscle found that there was not only a reduction in weight, despite 
being hyperphagic, but mice also exhibited lower fasting plasma glucose, lower insulin 
levels and increased glucose clearance rates [Clapham et al 2000]. 
Studies of UCP2 or UCP3 expression in human skeletal muscle found no difference in 
induction between obese and lean subjects under conditions of food restriction [Millet et al 
1997; Boivin et al 2000]. In contrast studies in matched obese T2DM and non-T2DM 
subjects under a 5-day calorific restriction found skeletal muscle UCP2 and UCP3 
expression was only induced in the non-diabetic subjects, despite diabetics having relatively 
elevated skeletal muscle UCP2 and UCP3 mRNA levels compared to non-diabetics under 
normal dietary conditions [Vidal et al 1999]. Vidal et al proposed that the lack of up- 
regulation of expression in the diabetics could be due to both the absence of increased 
plasma NEFA levels and the lack of up-regulation of expression of adipose tissue hormone 
sensitive lipase (HSL), which are both normally elevated by acute calorific restriction [Vidal 
et al 1999]. HSL is a rate-limiting enzyme of lipolysis that promotes the hydrolysis of 
triglyceride stores in the adipose tissue and hence increases the release of fatty acids. 
Obesity and T2DM are both pathologically characterised by abnormalities of lipid 
metabolism, with reduced lipid utilization and oxidation associated with diminished plasma 
fatty acid uptake by skeletal muscle resulting in increased plasma NEFA levels and fuel 
partitioning associated with insulin resistance [Kelley & Simoneau 1994; Blaak et al 1999]. 
If lipid metabolism and uncoupling expression are closely linked in muscle, an altered 
expression/regulation could occur in diabetic muscle. Further analysis of the relative mRNA 
levels of the two splice variants of UCP3 in skeletal muscle found that whereas in the non- 
T2DM obese subjects levels of transcripts were similar, in the diabetics the UCP3S isoform 
was 2 fold (7fold more than non diabetics) more abundant than the L isoform (3fold greater 
than in non-diabetics). This resulted in the UCP3S isoform accounting for two-thirds of the 
total UCP3 mRNA in diabetics [Vidal et al 1999]. Overall, under normal dietary conditions 
UCP3 mRNA levels were higher in diabetics, however the increased ratio of the UCP3S 
isoform might result in a possible impairment of function. The exon 6 splice variant 
mutation has been implicated in diminished fatty acid uptake and fat oxidation capacity 
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[Argyropoulos et al 1998b]. Acute calorific restriction only increased UCP3 expression in 
the non-diabetics and not diabetics, but this was entirely the due to the up-regulation of the 
UCP3L isoform, which was also positively correlated with a concomitant increase in NEFA 
and HSL mRNA levels [Vidal et al 1999]. A similar increased ratio of UCP3S to UCP3L 
isoforms in diabetics has been observed in another study, although in contrast to the Vidal et 
al study, steady state UCP3 muscle mRNA levels were significantly lower in the diabetics 
compared to controls [Bao et al 1998]. A significant reduction in UCP3 muscle mRNA 
levels in diabetics was also reported in another study, although the ratio of splice isoforms 
were not analysed [Krook et al 1998]. 
In respect of muscle UCP2 levels these have been recorded as being either increased or no 
different in diabetics compared to non-diabetics [Vidal et al 1999; Bao et al 1998; Krook et 
al 1998]. However, elevated levels of muscle UCP2 mRNA have been positively correlated 
with insulin stimulated glucose uptake and GLUT4 levels, suggesting a link with glucose 
utilisation in muscle [Tsuboyama-Kasaoka et al 1998; Cortright et al 1999; Boss et al 
1998e]. This is further supported by the demonstration in rats that thiazolidinediones 
increased glucose catabolism purportedly by up-regulating skeletal muscle UCP2 expression 
possibly through intermediatory PPAR activity [Shimokawa et al 1998]. 
UCP2 is also expressed at high levels in rat pancreatic islets. Over-expression of the UCP2 
gene in rat islets normalised the diminished glucose stimulated insulin secretion present in 
the Zucker diabetic fatty rat [Wang et al 1999] and inhibited it in normal rats [Chan et al 
1999]. These findings implicate UCP2 in modulating ß-cell function and insulin secretion 
possibly by controlling fluctuations in cellular ATP content. Up-regulation of UCP2 
expression by factors such as increased plasma FFA levels, in the pre-diabetic state could 
contribute to the loss of glucose responsiveness in the pancreatic islets [Chan et a! 2001]. 
2.1.7 Linkage and association studies in UCP homologues 
Genetic studies have reported associations of human UCPI variants, primarily the A3826G 
variant, with effects on body composition and obesity. Positive associations have been found 
with; fat gain over time [Oppert et al 1994; Cassard-Doulcier et al 1996]; synergistic effect 
of the Trp64Arg mutation of the 03 adrenergic receptor gene with weight gain in morbid 
obesity [Clement et al 1996]; resistance to weight loss in obese subjected to a low calorie 
diet [Fumeron et at 1996] and effects on RMR in obese Finns [Valve et al 1998]. However, 
these studies have been inconsistent and inconclusive, with equally as many negative 
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association studies in various ethnic groups [Urhammer et al 1997a; Gagnon et al 1998; 
Schaffler et al 1999; Hamann et al 1998]. However, differences in the expression of UCPl 
has been shown in intraperitoneal tissue between obese and lean subjects [Oberkofler et at 
1997] with common sequence variation of UCPI gene accounting for variability of UCP1 
mRNA abundance [Esterbauer et at 1998]. 
Evidence of linkage to quantitative trait loci (QTL) relevant to obesity and T2DM have been 
found in humans between markers mapped to the chromosomal region encompassing the 
human UCP2/UCP3 gene cluster on 11g13. Studies in a French Canadian population has 
revealed highly significant linkage with resting metabolic rate (RMR) with two 
microsatellite markers D1 1S911 p<0.000002 and D1 1S916 p=0.006 (figure 2.2) [Bouchard 
et al 1997] and suggestive linkage (p=0.02-0.04) with DIIS1321 with quantitative traits of 
percentage fat and fat mass. D11S911 and Dl1S916 closely flank the UCP2-UCP3 cluster 
and also have strong evidence for linkage with the eating disorder anorexia nervosa at 
significance levels of p=0.0002 and p=0.09 respectively [Campbell et al 1999]. Evidence for 
suggestive linkage has also been found to markers (D11S2000 and D11S1975) in close 
proximity to human UCP2/UCP3 region with a prediabetic phenotype, (2hr OGTT insulin 
concentrations) in Pima Indians [Pratley et al 1998]. A putative type I diabetic gene, IDDM4 
is also mapped to D11S1917 within this same 30cM chromosomal region [Hashimoto et al 
1994]. Suggestive linkage (MLS of 2.6) was also found at D11S1337 and it has been 
postulated that there could be a susceptibility locus within 15cM of this marker. 
Interestingly Dl1S916 and Dl1S911 are mapped to within 5 to 10 cM of this marker. 
Murine UCP2 is mapped to a region on chromosome 7 that is syntenic to the human 
chromosome l 1g13 [Boss et al 1998d]. There has been several quantitative trait loci (QTL) 
associated with obesity and diabetes linked to this mouse region [Yoshioka et al 1997; 
Surwit et at 1998]. The region is also co-insides with a QTL's for obesity in three 
independent mouse models and one congenic strain [Warden et al 1993 & 1995; Seldin et al 
1994; Taylor et al 1996]. Furthermore, the region harbours QTL's for both diet induced 
obesity and diabetes in the C57BIJ6J (B6) mouse [Surwit et al 1988). QTL's for plasma 
hyperinsulaemia and glucose are tightly linked to the tubby mutation also found in this 
region, but are thought to be independent of the tubby mutation [Pecqueur et al 1999]. In 
rats the UCP2 and UCP3 genes have been localised to a region of chromosome I which has 
been linked to glucose intolerance and adiposity in the Goto-Kakizaki (GK) type II diabetic 
rat model [Kaisaki et al 1998]. 
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A common human variant identified in exon 4 (C164T) of UCP2 causes an alanine to valine 
(A55V) amino acid change has been associated with variation in sleeping metabolic rate in 
Pima Indians [Walder et al 1998]. In addition, two further independent studies in Danish 
Caucasians found subjects homozygous for the valine allele had a lower 24 hour resting 
energy expenditure, enhanced metabolic efficiency, and lower fat oxidation [Astrup et al 
1999] and with heterozygous subjects associated with lower BMI [Urhammer et al 1997b]. 
These findings suggest that variants of UCP2 could influence body weight regulation, 
progressive weight gain and hence an increased risk to obesity and/or T2DM in humans. 
At the inception of this thesis no UCP2/UCP3 gene variants had been identified nor had any 
association studies been published. 
2.1.8 Aim of studies on the UCP2 and UCP3 genes 
The aim of this section of the thesis was initially to identify polymorphic variation within 
the UCP2 and UCP3 genes in two different ethnic groups. Common variants would then be 
further investigated to determine whether genetic variation in either gene is associated with 
susceptibility to obesity, T2DM or intermediate quantitative traits that predispose to either 
disease. A cohort of British obese and lean subjects would be used to analyse relationships 
with overt obesity and with traits such as an underlying indices of energy expenditure. 
Secondly a complementary family and population based South Indian study groups were to 
be utilised to analyse association of uncoupling protein variants with T2DM and related 
intermediate quantitative traits. Hypothetically a South Indian study group not fully 
exposed to obesity promoting environmental factors should offer certain advantages 
[Ramachandran et al 1992]. In Caucasian populations of European or North American 
extraction the majority of the recent rise in the prevalence of obesity can be explained by 
modem lifestyle. The effect of genotype on a phenotypic trait might be more detectable in a 
population not subjected to the same extent the compounding effects of `westernisation'. 
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2.2 CALPAIN 10 
2.2.1 Linkage to NIDDMI 
The eventual positional cloning of the first potential T2DM gene, calpain 10 (CAPN10) to 
the NIDDMI region at the distal long arm of chromosome 2 was achieved as a direct result 
of the information gained from the first genome wide scan for T2DM [Hanis et al 1996; 
Horikawa et al 2000]. The original genome scan was a biphasic study of two Mexican 
American (MA) groups, with a primary study group consisting of 330 affected pairs from 
170 sibships and 408 individuals, and a second phase group of 110 Mexican American 
affected sibpairs both from Starr County Texas. The MA population represented had a high 
frequency of T2DM approximately three times that of the general US population. The 
prevalence of disease in Native Amerindians is ten times higher than the general US 
population [Knowler et al 1990; King & Rewers 1993; Gardner etal 1984; Stern et al 1990]. 
Genes predisposing MA to T2DM are derived from their Native Amerindian ancestors, with 
31% of their contemporary gene pool from this ancestry. Therefore the risk of acquiring 
these genes is roughly proportional to the percent of the gene pool derived from this 
ancestral source. 
The primary scan utilising 490 markers found 19 markers with nominal evidence for linkage 
(MLS >0.74, p<0.05). One region on Chromosome 2q (D2S125) showed the overall 
strongest evidence of suggestive linkage with a MLS of 3.2 (p<0.0005) and combined with 
the second phase generated a combined MLS of 4.1. Marker D2S126,28cM proximal to 
D2S125 had the second highest MLS with an MLS of 2.58. Multipoint analysis was carried 
out at three different values of A [Risch 1990] with an upper limit set at 2.8 reflecting the 
observed ratio of risk for siblings in MA families with T2DM. Multipoint analysis at a? of 
1.6 produced a maximum multipoint lodscore of 3.05 for D2S 125, providing evidence of 
linkage with susceptibility with T2DM with an estimated sibling relative risk for T2DM 
accounting for between 21% and 30% of the familial clustering of T2DM in this MA study 
group [Hanis et al 1996]. Furthermore, at this A level exclusion of 71 % of the genome was 
possible including the majority of loci that had nominal evidence in the two-point analysis, 
with only two other regions other than NIDDMI on chromosomes 3 and 15, having 
appreciable positive multipoint lodscores. 
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2.2.2 Positional Cloning of CAPN10 gene 
Further genotyping and refinement of genetic maps placed NIDDMI near D2S 140, with a 
LOD score interval spanning 12cM at 2q37. Analysis for epistasis (ie. evidence for 
statistical interactions between unlinked regions that allows multi-point allele-sharing 
analysis to take the evidence for linkage at one region into account in assessing the evidence 
for linkage over the rest of the genome) with other loci demonstrating nominal evidence of 
linkage, found an interaction of genes on chromosomes 2 (NIDDMI) and 15 (near CYPI9). 
The statistical weighting derived from this interaction increased the LOD score for D2S 125 
from 4.1 to 7.3. This reduced the putative susceptibility region for NIDDMI to 7cM 
between map positions 259-266 cM [Cox et al 1999]. In this chromosomal sub-region 
(2q37.3) 1cM equates to approximately 240kb so the physical distance confronted was 
surprisingly less than the 7Mb normally expected (l cM-1 Mb). There were no obvious 
candidate genes in this interval, but with the utilization of many SNP's identified in this 
region, several genes were localised by LD mapping. 
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Figure 2.2.1 CAPN10 gene coding region with T2DM associated SNP's; 15 exons 
spanning 31 kb 
The selection of those sibships that were concordant for the presence of the `at risk' alleles 
from the linkage data (with `evidence of linkage') allowed further association studies with a 
subset of the polymorphism's. This focused the sequencing to a 66kb span in which three 
genes were subsequently identified. These were a G-protein coupled receptor 35(GPR35), a 
gene encoding a protein with homology to aminopeptidase B (RNPEPLI), and Calpain 10 
(CAPN10) a calpain-like protein. 
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2.2.3 Association of CAPNIO with T2DM 
Two SNPs, UCSNP43, and UCSNP 22 were the only polymorphisms to have a significant 
association and ` evidence for linkage' with T2DM [Horikawa et al 2000]. The application 
of simulation experiments calculated that UCSNP43 was the only SNP to have a highly 
significant association, with some other SNP's, UCSNP19, -25 and -22 nominally 
associated. UCSNPI9 localises to the intron between exons 6 and 7 of CAPNIO, and 
UCSNP22 and -25 both localise to a region inter-genically 3' to CAPN10 and 5' to GPR35. 
The common G allele (allele 1) of UCSNP43 (G/A) located in intron 3 of CAPN10 was 
significantly increased in MA T2DM subjects compared to random controls, although 
homozygosity of the G/G allele was not associated with any additional risk. Mobility shift 
assays using an intronic fragment encompassing UCSNP43 and a second SNP 1lbp 
upstream, UCSNP44 (T/C), identified differences in binding affinity of nuclear proteins 
[Horikawa et al 2000]. Furthermore, transcription studies suggested that these 
polymorphisms may play a role in the regulation of expression of CAPNIO or another gene 
located nearby and the G allele of UCSNP43 was associated with increased promoter 
activity [Baier et al 2000]. In Botnian Finns the frequency of the G allele (allelel) of 
UCSNP43 was also significantly associated, with 77% in T2DM subjects compared to 67% 
in controls (p=0.0049). In Botnian Finns the uncommon T allele (allele 20 of another 
intronic variant UCSNP63 (C/T) was also increased in 7% T2DM vs 3% in controls 
(p=0.017) but not in MA or German populations. The modest association of UCSNP43 in 
MA, could not alone account for the original linkage data, so haplotypes were tested with 
combinations of other SNP's within CAPN10 [Horikawa et al 2000]. Two common 
haplotypes were identified, both with the G allele (allelel) of UCSNP43, and with a 
combination of two other SNPs, UCSNPI9 (32bp Insertion/deletion), a SNP in near perfect 
LD with a group of four CAPNIO intronic SNPS, UCSNP56, -59, -30, and -65 and one 
coding mutation in exon 11, UCSNP48 (silent mutation at codon A620) and the Finnish 
associated UCSNP63 variant. The greatest risk to T2DM in MA was defined by the 
heterozygous haplotype 112 and 121 combination (order UCSNP43, -19, -63) and was 
designated an `at risk' to T2DM haplotype combination. This `at risk' haplotype 
combination conferred an overall 2.8 fold increased risk to T2DM diabetes in MA, and was 
also associated with a 2.55 and 4.97 fold increase in risk in Botnian Finns and Germans 
respectively [Horikawa et al 2000]. 
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2.2.4 Functional role of CAPNIO in T2DM 
The CAPN1O gene is ubiquitously expressed in humans, including skeletal muscle, liver, 
and pancreas, with a complex pattern of post trancription splicing producing at least eight 
transcripts (calpainloa to -10h) [Horikawa et al 2000]. Although nothing is presently known 
of the function of the CAPNIO protein, calpains are a superfamily of calcium- 
activated/dependent nonlysosomal neutral cysteine processing proteases. These proteases 
function intracellularly cleaving specific substrates at a limited number of sites causing the 
activation and inactivation of the function of other specific proteins [Sorimachi et al 1997; 
Saido et al 1994; Carafoli & Molinari 1998]. Calpains have been implicated in the 
regulation of a variety of cellular roles, including influencing intracellular signalling 
pathways including controlling proliferation and differentiation of preadipocytes [Patel & 
Lane 1999], myoblasts [Ueda et al 1998], osteoblasts [Murray et al 1997] and chondrocytes 
[Yasuda et al 1995]. Calpains have also been implicated in apoptosis, ischemia and 
inflammation with possible pathogenic roles in Alzheimers disease, and limb-girdle 
muscular dystrophy type 2A. The latter disorder may result as a consequence of a mutation 
in the CAPN3 gene [Lonjou et at 1998; Permutt et al 2000b]. Functional calpains generally 
have four domains forming a large variable catalytic subunit (80kDa). This subunit 
assembles with a common small subunit (30kDA) to form heterodimers. CAPNIO lacks the 
usual IV domain, the calmodulin-like Cat+binding domain, which may mean CAPN10 lacks 
Ca 2+ modulated activity [Dear et al 1997]. However, other studies suggest that the III 
domain may also be important in activation by calcium [Tompa et al 2001]. 
Insulin Action and Secretion: Inhibition of all calpain protease activity results in reduced 
insulin-mediated glucose transport and diminished incorporation of glucose into glycogen in 
isolated rat muscle [Sreenan et al 2001]. Calpains also appear to influence insulin-induced 
downregulation of insulin receptor substrate-1, a key mediator in insulin action [Smith et al 
1996]. In humans, studies in Pima Indians found no association with the UCSNP43 and 
T2DM. However, investigations in normoglycaemic subjects revealed that homozygotes for 
the G allele of UCSNP43 had reduced (58%) skeletal muscle CAPN1O mRNA levels 
compared to heterozygotes, with subjects homozygous for the A allele having the highest 
mean levels [Baier et al 2000]. Furthermore, genotype at this locus was correlated with 
several metabolic indices with the G/G homozygotes having reduced glucose oxidation 
rates, lower sleeping metabolic rates and a preference to oxidise lipids rather than protein or 
carbohydrates, when these are supplied exogenously in a respiratory chamber. This latter 
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finding may indicate that differences in nutrient partitioning between subjects may be partly 
dependent on CAPN10 genotype [Baier et al 2000]. 
Studies using cysteine protease inhibitors have implicated members of the calpain family, 
although not specifically CAPN10, with either the promotion [Croce et al 1999] or 
inhibition [Yamazaki et al 1997] of protein secretion depending on cell type. Tissue specific 
expression of at least one transcript has been observed in pancreatic islets [Horikawa et al 
2000]. Studies using cell permeable cysteine protease/calpain inhibitors in mouse pancreatic 
islets have been used to elucidate the role of calpains in glucose metabolism and secretion. 
However these studies have produced conflicting results. Short-term exposure (4 hours) of 
the islets to inhibitors leads to doubling of the insulin secretory response due to accelerated 
exocytosis of insulin granules by [Sreenan et al 2001; Zhou et al 2000]. However a 60% 
decrease in response was observed when the same inhibitors were applied for 48 hours. 
Morphologically the mouse islets contained enlarged vesicles containing insulin granules 
with additionally abnormally distended mitochondria and lysosomes [Sreenan et al 2001; 
Zhou et al 2000]. It was therefore suggested by Sreenan et al that the reduced insulin 
secretion may be caused by altered glucose metabolism in the mitochondria as the response 
of intracellular free calcium and rate of glucose metabolism was also diminished with 
calpain inhibitors. 
Concurrent to the studies in this thesis a number of other groups have looked for association 
between CAPNIO and T2DM. These contemporary studies are described in the discussion 
of chapter 7. However, the overall evidence suggests that variation in CAPN10 activity 
could play a pathophysiological role in both insulin action and insulin secretion. Variation in 
activity of the protein might be genetically determined, through mutations influencing, 
splicing, regulation of transcription rates and mRNA stability. 
2.2.5 Aims of the CAPN10 study 
Aims of this study were firstly to replicate the linkage findings for NIDDMI on 
Chromosome 2q, with T2DM in a family collection drawn from the UK and Ireland. 
Secondly, following the positional cloning of the CAPN10 gene to NIDDMJ, variants of 
CAPN10 UCSNP44 UCSNP43, UCSNP19, UCSNP63 and UCSNPI 10 were investigated 
individually, and as haplotypes/haplotype combinations to explore their contribution to the 
susceptibility to T2DM or related intermediate traits in a South Indian population. 
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CHAPTER 3: 
SUBJECTS AND METHODS 
3.1 SUBJECTS STUDIED 
3.1.1 Introduction 
The subjects studied in this thesis comprised of members of two distinct ethnic populations 
and several clinical collections. These included family samples recruited via a T2DM 
proband from both a North European collection and from South India. In addition a random 
population sample were available from the same South Indian Dravidian ethnic group. 
Finally a case/control study group comprising of unrelated British Caucasian obese and lean 
subjects were also utilized. Informed consent was obtained from all subjects involved in the 
studies. This section outlines the selection criteria for these study groups. 
3.1.2 British Diabetic Association Warren 2 Repository 
The British Diabetic Association (Diabetes UK) Warren 2 is a T2DM repository of British 
and Irish pedigrees collected nationally by six centers with The Royal London Hospital a 
participant. The repository comprises of T2DM affected sibpairs and their immediate 
relatives. Overall the sibpairs had a mean (SD) age of diagnosis of 55.6 ± 8.6, mean (SD) 
BMI 28.7±5.4 kg/m2, median waist hip ratio 0.92 (IQR 0.11) and 48% of probands were 
female. Treatment was 20% diet, 64% therapy with oral hypoglycaemic agents (OHA), and 
16% with insulin. 
3.1.3 Ascertainment criteria for pedigrees. 
Principle recruitment criteria were: 
1. Affected sibpair with T2DM diagnosed between the 35 and 70 years of age. 
2. All four grandparents known to be of British origin. Families are excluded if both parents 
and a high proportion of sibships display T1DM. 
Pedigree members were considered affected if they: 
1. Diagnosed having T2DM by WHO criteria, and were on therapy with oral hypoglycaemic 
agents, insulin or on specific diets. 
2. Fasting plasma glucose concentration of >6 mmol/l, that is >3 standard deviations above 
the mean of a normal population. 
3. Plasma glucose concentration of >9.3 mmol/l, after one hour continuous infusion of 
glucose at 5mg/kg weight per minute. 
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Pedigree members were considered unaffected if they had a fasting plasma glucose 
<6mmoUl or had a plasma glucose <9.3 mmol/l, one hour after a continuous infusion of 
glucose 5 mg/kg ideal weight per minute. As this disease has a late age of onset the 
diagnostic certainty of a normal test increases with age and this was taken into account in 
the computation of recombination frequencies. 
3.1.4 Pedigree selection criteria. 
1. Inclusion of families segregating immune-mediated diabetes (i. e. TiDM, LADA) was 
kept to a minimum: by exclusion of sibships with first and second degree relatives with 
Ti DM; requiring at least one year interval between diagnosis and commencement of insulin; 
exclusion of subjects with a history of ketoacidosis and those subjects who were GAD 
positive. 
2. Clinical exclusion of MODY (see 3.1.5) and mitochondria) diabetes was made on the 
basis of personal and family history. 
3. Paternity / family relationships were verified by typing 136 independent markers and 
unsubstantiated families were excluded. 
3.1.5 Criteria for exclusion of pedigrees with MODY 
1. Age at diagnosis of at least two affected members of the family <25 years 
2. Diabetes could be treated for at least 2 years without insulin. 
3. The occurrence of diabetes in a family was suggestive of an autosomal dominant mode of 
inheritance (at least three generations of diabetes, and/or second cousins with T2DM before 
the age of 25 years). 
3.1.6 South Indian Pedigrees 
South Indian subjects, all Tamil -Dravidian in origin, were recruited via the M. V. Hospital 
for Diabetes-Diabetes Research Centre (DRC) in Chennai (formerly Madras), Tamil Nadu, 
India. Dravidians are considered to be Caucasian on the basis of genetic marker studies and 
anthropological parameters eg language [Cavalli-Sforza) and are distinct from other Indo- 
European speaking South Indian populations. Families were ascertained through probands 
clinically diagnosed with T2DM at the MVH-DRC. Families were recruited if both parents 
were alive and had at least one other sibling. All possible siblings were collected when 
available. T2DM was defined by an insidious onset of disease without ketosis and follow-up 
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of >2 years since diagnosis, and if patients were on insulin this had not commenced within 
a year of diagnosis. All other participating members of the families were submitted to 75g 
OGTT if glucose tolerance was unknown. Glucose measurements were performed on 
venous plasma using the glucose oxidase peroxidase method (Roche Mannheim) 
In this population the incidence of, TIDM, MODY and Fibrocalculous pancreatic diabetes 
(FCPD) are comparatively minor cause of diabetes [Mohan et al 1988; Ramachandran et al 
1988]. All diabetic subjects were considered to be T2DM and were included with the 
pedigree unless excluded by the following criteria: 
1. T1DM was excluded on clinical grounds. T1DM diagnosed on the basis of acute onset 
of symptoms before the age of 35 years, a history of ketoacidosis or ketonuria, weight 
loss prior to diagnosis and total dependence on exogenously administered insulin from 
time of diagnosis. None of the diabetics in the family had a family history of T1DM and 
if the proband was insulin treated then this did not commence within a year of diagnosis. 
2. FCPD diagnosed on the basis of clinical history, suspected subjects were investigated for 
the presence of pancreatic calcification and/or ductal dilatation (Kambo et al 1989; 
Mohan et al 1988, WHO 1985) using abdominal x-ray and pancreatic ultrasound. 
3. MODY was excluded essentially the same as for Warren 2 (3.1.5). Additionally 
available data on glucokinase mutations in these subjects also allowed exclusion of the 
MODY 2 locus [McCarthy et al 1994]. 
4. Mitochondrial Diabetes. None of the diabetic probands carry the MELAS mt3243 
mutation, and it is not a common cause of diabetes in this ethnic group [McCarthy et al 
1996] 
5. Exclusion from non-paternity. Families had been previously typed with 5 multi-allelic 
markers from two chromosomes and 11 biallelic loci from four different chromosomes 
[McCarthy et al 1996 &1994]. Families suspected of having an ex-paternity member 
were tested with the paternity/forensic testing kit, PowerPlex 16 (Promega Inc, Madison 
WI USA). This kit uses a panel of 15 short tandem repeat markers (STR) and 
Amelogenin for gender specification, and then typed using a ABI 310 Genetic Analyser 
(ABI, Foster City, CA, USA). This assay was carried out by the Department of 
Haematology, the Royal London Hospital. 
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3.1.7 Anthropometric details of South Indian Trios 
Probands as an entire group had a mean age of onset of T2DM of 33.8 ± 9.9 years, with 
mean BMI 26.6 ± 4.7 kg/m2 and 36% were female. The treatment of the probands was 6% 
diet, 80% oral hypoglycaemics and 14% insulin. Sixty-three percent of probands were male 
and clinical details by gender are provided in Table 3.1.1. The mean (SD) age of fathers 
(n=95) was 65.4 (± 7.6) years, and mean BMI 25.3 (± 9.6) kg/m2 and mean WHR of 0.96 (± 
0.05); the corresponding figures in mothers (n=95) were 58.5 (± 7.1) years, and mean BMI 
25.7 (± 4.3) kg/m2 and mean WHR 0.88(± 0.07). In the parental group 69.6% had T2DM, as 
were 21 % of co-siblings. None of the probands carried the mt3243 mutation [McCarthy et 
al 1996]. 
South Indian T2DM probands 
Male probands Female probands 
Number 60 35 
Age at diagnosis (y) 34 (29-38) 32 (23-37) 
Treatment: 
Diet only n(%) 








BMI (kg/m2) 26.5 (t 4.5) 27.8 (t 4.6) 
Waist hip ratio 0.94 (f 0.05) 0.86 (t 0.07) 
Table 3.1.1: Clinical Characteristics of South Indian T2DM probands. Age at diagnosis 
given as median (range), BMI and WHR as mean (SD). 
3.1.8 South Indian Population Survey 
DNA was extracted from four hundred and sixty-eight South Indian subjects. These subjects 
were originally collected using a cluster analysis design across all socio-economic groups to 
investigate the prevalence of T2DM and associated risk factors in an urban community. The 
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subjects were > 20 years old and were randomly recruited by door to door survey in 
Chennai. This group had the same Dravidian ethnicity as the families as determined by; 
surname, residence, mother language, and when available ancestral history [Ramachamdran 
et al 1992]. 
Participants fasting capillary blood glucose was measured using glucose oxidase test strips 
and 2 hour, 75g OGTT and a Reflolux II Analyser (Boeringer mannheim-Roche). Those 
identified as T2DM underwent OGTT. Anthropometric measurements recorded included 
weight, height, waist, hips and skinfold thickness. 
3.1.9 Anthropometric details of Urban Survey 
The mean age of the subjects were 45 (± 12) years, mean BMI 22.5 ± 4.2 and 48.6% were 
female. Clinical details are provided in table 3.1.2. 
Table 3 
South Indian Urban Survey 
Male Female 
Number 241 227 
Mean Age (years) 47 (40-55) 42 (34-53) 
BMI (kg/m2) 22.0 (t 3.7) 23.1 (± 4.6) 








of recruitment is given as median (range), BMI and WHR as mean (SD). 
In the urban survey for T2DM, impaired glucose tolerance (IGT) and impaired fasting 
glucose (lFG), glucose tolerance was defined by the most recent WHO criteria [Alberti & 
Zimmet 1998a]. 
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IFG/IGT subjects had a mean age of recruitment in males of 52 (±15.3) years, mean BMI 
22.5 (±3.3) and WHR of 0.92 (±0.05); the corresponding figures in females were 44.9 
(±12.5), BMI 24.4 (±4.9) and WHR 0.86 (±0.06). T2DM subjects were recruited at a mean 
age in males of 55yrs (±10.8) with mean BMI 23.4 (±3.3) and a WHR of 0.94 (±0.05) the 
corresponding figures in females were 50.7 (±10.4), BMI 24.1 (±4.1), and WHR 0.87 
(±0.04). Thirty-eight percent of the T2DM were newly diagnosed and 62% had established 
diabetes at the time of the survey. In the latter group, 15% were on diet, 83% on OHA's and 
2% were on insulin. 
3.1.10 Unrelated UK Caucasian Obese\Lean Subjects 
Blood samples were obtained from a cohort of one hundred and fifty-six predominantly 
female, unrelated European (UK) Caucasoid pre-menopausal morbidly obese patients, 
defined by a BMI of greater than 30 kg/m2. These patients were serially recruited from 
either the Obesity Clinic at The Royal London Hospital (n = 116) or recruited as a result of a 
local advertisement (n = 40). The mean BMI (SD) was 40.3 t 6.4 kg/m2 (range 30 - 67), 
mean age was 44.0 ± 11.5 and 86% were female. A dietary review confirmed that no obese 
subject was following a very restrictive diet at the time of venesection and blood samples 
were taken following overnight fast. The majority of the obese subjects had a family history 
of obesity and all had a BMI > 30 kg/m2 preferably over BMI 45 kg/m2. Subjects were 
otherwise healthy having no family history of diabetes, and were not diagnosed diabetic 
following measurement of fasting insulins and OGTT. 
Fasting serum leptin protein levels was analysed in a subset of 83 female obese subjects. 
Plasma leptin levels were determined by radioimmunoassay using a commercially available 
kit (Linco Research, St Louis, MO, USA) carried out by the Department of Clinical 
Biochemistry, The Royal London Hospital. The kit uses a polyclonal antibody against 
highly purified human leptin and both the calibrators and 125 I-labelled tracer are prepared 
with recombinant human leptin. The infra- and the inter-assay coefficients of variation were 
3.4% and 3.6% respectively at a leptin concentration of 25.6 µg/l. 
Indirect calorimetry was performed in a second subset of obese patients by staff at the 
Obesity Clinic, The Royal London Hospital. Energy expenditure was measured as the rate at 
which heat is produced by the body using a Deltatrac II metabolic monitor, and resting 
metabolic rate (RMR) was calculated using de Weir's equation [Weir 1949]. In the same 
subset, bioelectrical impedance, using a Bodystat 1500 monitoring unit (Bodystat Ltd, 
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Douglas, IoM, UK), measured tissue resistance to an electrical current and allowed 
estimation of body composition, ie. fat-free mass (FFM) and fat mass (FM) were calculated 
using predictive algorithms based on regression equations [ Foster& Lukaski , 1996]. 
DNA was extracted from blood samples obtained from one hundred and six slim 
normoglycaemic volunteer controls (males BMI < 27 and females BMI < 25) recruited 
from European Caucasian volunteers amongst staff at The Royal London Hospital, and were 
therefore considered to be from the same geographical area as the obese subjects. Ideal 
weight individuals were classified as non diabetic on the basis of a negative family history, 
normal weight and some random plasma glucose< 6. Ommol/1 and a limited number of 
OGTT's were performed. Their mean BMI was 21.6 ± 2.0 kg/m2 (range 17.3 - 26.3), mean 
age 31.9 ± 9.5 years and 71% were female. 
3.2 GENOMIC DNA FROM PERIPHERAL WHOLE BLOOD. 
3.2.1 DNA extraction from large blood volumes using NUCLEON TM kit 
High blood volume extraction method (Gibco) 
1. Whole blood (5-10 ml) was poured into a 50 ml Falcon tube, an equivolume of reagent A 
added, mixed and allowed to stand for 3-4 min. 
2. Tube was spun 2300 rpm for 4 min, and supernatant discarded. 
3. Pellet was re-suspended in 40 ml reagent A, mixed thoroughly, stood for 4 min and step 2 
repeated. 
4. Pellet was re-suspended in 2.5 ml of reagent B and placed in a5 ml tube. 
5. Sodium perchlorate (5M) 700u1 was added and rotary mixed at RT for 15 min. 
6. Mixture was incubated for 25 min @ 65°C, inverting twice in duration. 
7. Chloroform was added -2.5 ml (kept @ -20°C), rotary mixed for 10 min, and then 
centrifuged at 2,500 rpm for I min. 
8.400µl of nucleon silica suspension was added slowly, and not mixed, then centrifuged at 
4,000 rpm for 3 min. 
9-The upper layer was decanted to a fresh tube, and centrifugation repeated. 
10. The solution was removed to a fresh 50 ml Falcon tube and two volumes of cold 
absolute ethanol added and left at -20°C for 15 min. Precipitated DNA was spooled out 
using a modified glass Pasteur pipette. DNA was re-suspended in 200µ1 sterile distilled 
water overnight. 
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11. The quantity and purity of DNA was determined by a UV spectrophotometer. (Appendix 
II). 
3.2.2 High-through put DNA extraction using QIAamp TM 96 kit 
QIAamp 96 DNA Spin Blood kit ( Qiagen UK Ltd, Crawley Sussex) high-through-put 
method simultaneously extracting two 96 well plates of small peripheral blood volumes in 2 
hours . All centifugation steps were carried out on a Sigma 6K-15 centrifuge (Sigma 
Laborzentrifugen GmbH) 
1.25µ1 of Qiagen Protease stock solution was added to each of the 96 wells of round-well 
block. 
2. A 200µ1 aliquot of each peripheral blood sample was added to each well 
3.200pl of chaotropic solution AL (Qiagen) was added to each well. Wells were capped and 
the block shaken vigorously for 15 seconds. 
4. The 96 well block was centrifuged briefly at 3000rpm. 
5. The block was incubated at 70°C for 10 minutes in an oven and then spun briefly at 3000 
rpm to collect any lysate on the caps. 
6. The caps were removed and 210µl of 100% ethanol was added to each well. The block 
was resealed and shaken vigorously for 15 seconds and then spun briefly at 3000 rpm. 
7. A QlAamp 96 column plate (96 tubes with DNA binding silica gel membranes) was 
prepared by placing it on top of a 96 well receptacle. 
8. The 96 blood and reagent mixtures (now 635µ1/well ) were applied to the QIAamp 96 
column plate . Plate was sealed with an adhesive strip and centrifuged for 6000 rpm for 4 
minutes. 
9.500µl of buffer AW (Qiagen) was added to each of the 96 columns. The plate was 
resealed and centrifuged at 6000rpm for 2 minutes. 
10. Step 9 was repeated again except, centrifuged at 6000rpm for 4 minutes. 
11. The QlAamp 96 column plate was removed from the waste receptacle block and and 
placed on a 96 microtube collecting rack and incubated in an oven at 70°C for 10 minutes to 
dry the silica membrane. 
12.200pl of Buffer AE (Qiagen) preheated to 70'C in a Dri-Block was added to 96 column 
membranes and then sealed and incubated at RT for 5 minutes. 
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13. DNA was eluted from column membranes into the microtubes after centrifugation at 
6000rpm for 4 minutes. This step was repeated with a further 100 µl of preheated AE 
Buffer. 
14. Random samples from the eluted DNA were electrophoresed on an agarose gel to assess 
integrity, uniformity of concentration across plate and to approximate concentration from 
know quantity DNA MW markers. Yields were usually estimated to be approximately 30ng- 
40ng/pl. 
15. Aliquots of DNA were diluted to 5-lOng/µl in 96 -Deep well plates. 
3.3 THE POLYMERASE CHAIN REACTION (PCR) 
3.3.1 Introduction 
The Polymerase Chain Reaction (PCR) is an in vitro method of nucleic acid synthesis by 
which a specific segment of DNA can be replicated exponentially [Saiki et al, 1985; Mullis 
and Faloona, 1987]. The reaction requires a template, usually double-stranded genomic 
DNA, cDNA or mRNA. Synthetic oligonucleotide primers (amplimers), designed to anneal 
to opposite strands of the double stranded DNA and flanking the desired target segment, 
prime the reaction and dictate the direction of synthesis. A DNA polymerase drives the 
synthesis in a reaction buffer with deoxynucleotide triphosphates providing nucleotides and 
magnesium ions providing essential monovalent cations for the enzyme to function. The 
primers guide the polymerisation to produce copies of the two complimentary strands of the 
target segment from one double-stranded DNA template. The resultant copies are also 
capable of binding the primers, and act as a template for further amplification. Thermally 
stable DNA polymerases allow repeated cycles of denaturation of the double-stranded DNA, 
annealing of the primers to their complimentary sequences, and extension of the annealed 
primers. Thus successive cycles will theoretically double the amount of target DNA 
synthesised in the previous cycle. The target DNA segment is exponentially amplified at a 
rate equivalent to approximately 2n, where n is the number of cycles of amplification 
completed. 
3.3.2 Standard PCR conditions 
PCR reaction conditions were standardized, although some target DNA segments required 
optimisation reflecting the length of the target sequence, the magnesium ion concentration, 
and primer annealing characteristics. Molecular applications downstream of the PCR also 
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influenced adjustments in the reaction profile, cycle profile and choice of thermostable DNA 
polymerase used. 
Standard PCR Reaction mix: 
PCR Reaction BUFFER lOx 1/10`h vol 2.0µi 
Magnesium Chloride 1.0-5. OmM variable 
dNTPs 1. OmM mix 200uM 0.2µ1 
Primer 100pmole/ul Forward 5-20pmoles 0. lµ1 
Primer lOOpmole/ul Reverse 5-20pmoles O. 1µ1 
DNA polymerase 5units/ul 1-5units 0.2pl 
Template DNA 10-50ng 5.0µl 
Contaminant free water to volume 20. Oµl reaction vol 
All reaction mixes were made as a single master mix for all samples. 
Standard Cycle Profile: 
94°C for 3minutes 
25-40 cycles of: 
94°C for 20-40 seconds (30 seconds) denaturing 
50-68°C for 20-40 seconds (30 seconds) annealing 
72°C for 30-60 seconds extension 
Followed by 10 minute final extension at 72°C, and then held at 4°C. 
Adjustments to PCR reaction mix: 
Reaction Buffer: Appendix I. Additionally a buffer containing (NH4)2SO4 provide 
stringent primer-annealing conditions over a wider range of annealing temperatures and 
Mg2+ concentrations. 
Mg2+: Monovalent cations are essential for the enzymatic action of DNA polymerases. 
Concentration of MgC1 in the buffer was optimised for each primer set by titrating final 
concentrations of between 0.5mM to 3. OmM, (the concentration window most reactions 
tended to work at). Buffers based on (NH4)2SO4 and containing 1.5mM MgCl, required little 
to no adjustment. 
dNTPs: (1. OmM each dCTP, dY P, dATP, dGTP). These were mixed at an equimolar 
concentration and used in sufficient quantity so as not to be rate limiting but without excess. 
Excess increased the amount of non-specific fragments and could compromise downstream 
applications. 
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Primers (amplimers): Apart from primer design (3.3.3), a minimalist approach was 
adopted. Primary reactions establishing PCR conditions contained excess of each primer, 
20-50 pmoles/20µl reaction subsequently the amount necessary was titrated, usually less 
than 5pmoles/reaction of each primer did not work efficiently. 
Thermostable DNA polymerases: The standard thermostable DNA polymerase isolated 
from Thermus aquaticus (Taq Dna polymerase Promega UK), and recombinants of this 
(HotstarTaq, Qiagen), were used for most PCR experiments. Thermostable DNA 
polymerase with increased thermostability, from Thermus littoralis (Dynazyme-Flowgen) 
was used in some applications. Taq DNA polymerases randomly mis-incorporates dNTPs at 
a level of 5% in the extension phase. Later PCR reactions with downstream DNA 
sequencing applications, it was preferable to use an enzyme combination with a proof- 
reading thermostable DNA polymerase at a ratio of 9: 1 (AB Technologies) to rectify 
mismatched bases. 
Adjustments to Cycle Profile: 
Denaturation: The temperature and time in for this most instances remained constant. 
Increase in temperature and time would only be necessary for very long target DNA 
fragments (>2Kb), or difficult sequences (long tracts of GC repeats). Prolonged higher 
temperatures (>94°C) are detrimental to processivity. The half-life of Taq DNA Polymerase 
is 60 minutes at 94°C, but only 10 minutes at 97°C. 
Annealing: A melting temperature (Tm) based on base composition for each primer was 
either calculated by the design programme (see 3.3.3) or available with the primer database. 
PCR reactions were initially performed at sub-optimal annealing temperatures, 5-10°C 
below primers Tm. The temperature was then sequentially increased initially by increments 
of 5°C and then fine tuned by 1°C increments, until the specificity required was achieved. 
An annealing time of 20-30 seconds was adequate for all templates less than 1 Kb. 
Extension: 72°c is the optimal extension rate for thermostable DNA polymerases, most 
processing 2-4Kb per minute. Target DNA segments used were usually less than 1000bp, so 
a 30 second extension time was more than adequate. 
Cycle number: The cycle number was adjusted in response to the PCR downstream 
application and the efficiency of the primers/PCR reaction combination. Cycle numbers 
above 27 can generate `junk ' non-specific DNA fragments so the fewer cycles the better. 
PCR amplification of fluorescent micosatellite markers required fewer cycles (20-25 cycles) 
as sensitivity of detection was not a limitation and reduced problems of background 
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interference. PCR-RFLP applications required sufficient cycles to generate enough DNA 
(usually 30-40 cycles), so that following restriction endonuclease digestion all resulting 
fragments could be visualised with ethidium bromide staining. 
PCR machines used included: MWG Biotech, MJR, Perkin Elmer 
Quality Control of PCR: 
PCR is an extremely sensitive technique with the potential to produce 1x 106 copies from a 
single copy of target DNA. There was always the possibility of contamination producing 
false-positive amplification results. Contamination from airborne human biological debris, 
such as skin cells or hair roots (>60% content of dust) was avoided by using good aseptic 
techniques in a designated work area. Materials such as plastics, tubes, microtitre plates, 
were virgin and as an extra precaution, exposed to 15 minutes of 254nM UV irradiation to 
degrade any contaminating DNA. HPLC pure water also subjected to UV irradiation before 
use was a preferred source as distilled water was a common source of contamination. 
Contamination was also controlled by using aerosol resistant pipette tips (filter tips) and 
where possible in association with multi-channel pipettes. PCR assay contamination 
controls were included in every assay, using water as a substitute for the DNA template. 
3.3.3 Design of amplimers 
Specific amplification of a DNA fragment (amplicon) by definition requires a unique set of 
primers (amplimers). In some instances, such as with all the microsatellite markers used, 
primer sets have already been designed, tried and tested and information found in databases 
(see 3.4.1). Unique pairs of amplimers were designed using software such as PRIMER v3 at 
the Human Genome Mapping Project web-site (www. hgmp. mrc. ac. uk). Primer criteria were 
as follows: 
1. Optimum primer size 20 bases (min 18bases, max 27 bases). 
2. Optimum Tm annealing temperature 60°C (min. 57°C, max 63`C) 
3. Oligonucleotide melting temperature formula [Rychlik et al 1990] 
4. Maximum Tm difference between primers, preferably 0°C 
5. GC content optimally >50% (20%-80%) 
6. Maximum complementarity, default 8 bases, maximum allowable local 
self-complementarity and between forward and reverse primers, and 
maximum 3' complementarity, default 3 bases, the most 3' part of primer 
most important for annealing specificity. 
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Amplimer pairs identified were checked for cross homology with all other known human 
DNA sequences using the BLASTn search at HGMP resource website. 
3.3.4 Touchdown PCR 
Sometimes PCR reactions under standard conditions do not produce the ideal results. 
Mispriming by one or both primers either internally or externally to the target template can 
produce spurious `shadow ̀  bands, and primer-dimers. These shorter fragments frequently 
dominate possibly due to the repetitive stochastic advantage they have over the longer 
correct products during the reaction cycling. This problem becomes greater after increasing 
number of cycles and when the target template is in small amounts. Adjustment of the PCR 
parameters such as Mg++ and annealing temperatures often solved these problems but in 
some situations the spurious interactions are as stable as the desired ones. Touchdown PCR 
[Don et al 19911 was developed circumvent this problem by exploiting the exponential 
nature of PCR reactions and reduces the need to optimise the reaction conditions. 
Principally: 
1. The initial annealing temperature is set above the calculated annealing Tm eg for an 
annealing Tm 55C a starting point of 65C. 
2. The annealing temperature is decreased 1C every second cycle until 'touchdown' at eg 
55C then 10 cycles are carried out. 
3.3.5 Hotstart PCR 
This is a very simple modification to the standard PCR that was employed in most PCR 
reactions. A considerable amount of mispriming occurs at low reaction temperatures, when 
the completed reaction mix is ramped from room temperature to its first denaturing step of 
the first cycle. Non-specific PCR products were avoided by the addition of one of the 
reaction components (thermostable polymerase, dNTPS, Mg++) just prior to cycling by 
holding the reaction mix at 85°C. The introduction of heat sealed 96 multiwell plate PCR 
reactions prevents this, and there are numerous `Hotstart" systems (HotStarTaq TM Qiagen 
UK Ltd) commercially available that employ the use of a heat labile blocking component to 
inactivate the thermostable polymerase until required. 
Reaction Mix for 20Nl reaction volume: 
lOx PCR Buffer (Tris. Cl, KCL, (NH4)2SO4,15mM MgCl2 pH 8.7) 2.0 pl 
dNTPs x4, I mm each, final concentration 100µM 0.2µI 
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IOOpmole/ul Forward Primer 0.1 µl (-0.3µl) 
lOOpmole/ul Reverse Primer 0.1 µl (-0.3µl) 
HotStarTaq polymerase 5units/µl O. 1µ1 
Genomic DNA lOng/µl 2.0-5.0µl 
UV irradiated HPLC H2O to final 20. Oµ1 volume. 
Reaction mixture is preheated to 95°C for 15 minutes to activate the thermostable 
polymerase prior to first cycle of standardised PCR profile above (3.4.2). 
3.3.7 Visualisation of PCR product. 
In all experiments following completion of PCR, the product was run out on a 10cm x 10cm 
x 0.6cm thick 2.0% agarose gel to ensure that amplification of the target 
1.100ml gel was prepared with 2g agarose (Flowgen) in Ix TBE buffer in a 
polypropylene conical flask. 
2. Agarose and buffer solution and mixed by swirling of the flask. 
3. It was then heated to boiling point in a microwave oven with intermittant mixing. The 
gel was slightly cooled and ethidium bromide added to a concentration of 0.5. tg/ml. 
4. The gel was then poured into a horizontal gel mould, castellated combs inserted, and 
allowed to set. 
5. The gel was subsequently submerged in a horizontal electrophoresis tank filled with Ix 
TBE buffer. 
6.1.0µl of lOx Ficoll Bromophenol blue loading dye was pipetted into a 5. Ogl PCR sample 
and loaded into wells of gel. 
7. The gel was run at 90V (6V per cm) for 30 minutes. 
8. The DNA fragments were then visualised on a UV transilluminator and Alpha Imager 
(Innotec/Flowgen) and sized using a 100bp ladder (Promega UK Ltd) and sizing 
software Permanent records were kept either by a thermal print, or storage as TIFF or 
BMP file. 
3.4 MICROSATELLITE MARKERS. 
3.4.1 Introduction. 
Microsatellites are short tandem repeats (STRs) of between 10 and 50 copies of simple 
sequence and occur abundantly and randomly throughout most eukaryotic genomes. These 
most common form are dinucleotide repeats such as CA, and GA, trinucleotide repeats and 
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tetranucleotide repeats, but can be up to six base pairs. They may be in perfect tandem 
repetition or imperfect, interrupted, or compound repeats. The tandem repeats exhibit a high 
level of length polymorphism, and hence allelic variation. CAn dinucleotide repeats occur 
every 30Kbp, distributed equally in 5' and 3' UTR's and introns, and are the most 
commonly used microsatellites. They are also usually smaller than 100 base pairs and 
ideally suited for PCR. 
The mutation rate of microsatellites is estimated at 5x10-10-5 which is sufficiently low 
enough to allow their use in linkage studies, as probes for linkage disequilibrium, and with 
disease mutations in population association studies [Hearne et al 1992]. The disease 
contribution of the test locus, its recombination distance from the marker and the markers 
polymorphic information content (PIC) [Botstein et al 1980] all affect the power to obtain 
significant evidence of linkage. The PIC value of a marker is calculated from the allele 
frequencies in the population and is related to mean repeat length [Weber 1990] and is a 
useful index of informativeness for genetic mapping, as a high PIC value in pedigrees will 
mean parents are often heterozygous at the micosatellite locus and the segregation of its 
alleles can be observed unambiguously in the progeny. Microsatellites markers in the 
candidate regions of interest used in this thesis were identified from genetic maps at a 
number of websites such as the Genome Database (GDB), Centre d'Etude Polymorphisme 
Humaine (CEPH) and Cooperative Human Linkage Center (CHLC) which provide database 
access to a large number of chromosomally mapped markers with information held on PCR 
primers and conditions (Weber & May 1989; Litt & Luty 1989]. Markers were selected on 
the basis of map position, PIC values higher than 0.7, and ability to unambiguously amplify 
by PCR and allow multiplexing of amplicons. 
3.4.2 Genotyping using Fluorescent Microsatellite Markers 
The ABI 373 Sequencer (Applied Biosystems Incorporated ABI) system uses four distinct 
laser sensitive fluorescent dyes that can be distinguished by wavelength of fluorescence 
(HEX, TET, FAM 540nm, TAMRA580nm). One primer for each amplicon was labelled 
with one of three dyes at the 5' end during oligonucleotide synthesis and the fourth dye was 
used for an internal lane size standard (ABI GS 500 TAMRA size range 30-500bp). Dye- 
labelled primers were purified at source by HPLC to remove unincorporated dye. 
Manipulation of dye and amplicon sizes allowed simultaneous running of a number of 
microsatellites in a single gel (multiplexing). 
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1. Screening was carried out on a 96-well microtitre plate format with 2ng of subject 
genomic DNA pipetted to each well. The plate was divided into three sections for gel 
loading purposes, each gel/section of 32 wells, with 30 wells, for study subjects and 2 
wells with control (CEPH) DNA, the same two consistently used throughout the study to 
control for inter-gel variation. 
2. Each plate of DNA of the study set was used to amplify a single fluorescently labelled 
microsatellite marker using either standard or `Touchdown' PCR. 
3. PCR conditions were optimised for each microsatellite to achieve optimal specificity, 
clarity and signal intensity. 
4. Aliquots of each PCR product from the same study subject but from each micosatellite 
marker plate were combined into a single 'multiplex' 96-well microtitre plate to a 
maximum volume of 4µl. The ratio of amount of each marker product pooled was 
dependent on the previously assessed signal intensity of each marker dye/PCR product 
combination. Generally 500-1000 fluorescent units was sufficient for each marker 
analysis. 
5. Multiplexed labelled PCR products were size separated utilising vertical denaturing 
PAGE on the ABI 373 Sequencer. 
6.0.2 µl of the ready labelled size standard (GeneScan2500 or GS 500 ABI Inc, Foster 
City US) and 1.0 ul of Formamide/dextran blue loading buffer was added to each sample 
well. Samples were then denatured by heating to 94 C for 2 minutes and then placed on 
ice just prior to loading the gel. 
7. The 373 Sequencer Glass plates (12cm well-to-read) were carefully cleaned to 
manufacturers specification. Essentially using non-abrasive, non-dye containing 
detergents (Alconox- Sigma Aldrich), distilled water and then air dried. 
8. A 0.4mm thick 6% acrylamide/bis acylamide 19: 1,8M Urea denaturing polyacrylamide 
gels was made using a two-part ready mix gel, (Sequa 6 gel National Diagnostics Inc). 
40ml of AcylamideBisacrylamide mix was combined with 10 ml Buffer/TEMED mix in 
a 250m1 spouted plastic beaker. Then 200pl of freshly made 10% (W/V) Ammonium 
persulphate (Kodak Chemicals) was added and gently mixed avoiding introduction of air 
bubbles. The gel mix was poured between the glass plates followed by insertion of a 36 
well castellated comb/well former. The gel/glass cassette was laid horizontally and 
allowed to polymerise for at least 2 hours. 
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9. After installation of the gel cassette onto the sequencing machine, 5.0µI aliquot of the 
denatured samples from the multiplex plate were loaded using 0.4mm thick `Duck Bill' 
tips (Anachem) to each well sequentially. One third of a multiplex plate was loaded per 
gel, representing 30 individual subjects, 2 inter-gel controls and as many marker loci 
combined for multiplexing. 
10. Gels were electrophoresed for 4 hours at a constant wattage of 40 watts (1500 volts). 
PCR products are detected using a fixed distance scanning argon ion laser. Fluorescence 
data was digitised and transmitted to a Macintosh Centris computer (Apple Computers 
System 6.0) Data Collection was by GENESCAN ABI 672 software (v 1.1). 
3.4.3 Allele Scoring Software 
The digitised information represents the PCR products/ microsatellite alleles as fluorescent 
peaks (Electrophoretograms). The GENESCAN software automatically calculated 
microsatellite allele sizes by using the Local Southern Method [Southern]. This method 
interpolates allele sizes using the internal lane molecular weight standards flanking the 
microsatellite products to estimate parameters for a model that assumes the mobility of the 
DNA fragments in a gel to be inversely proportional to size in base pairs. This method has 
been previously found to be the most precise method available for allele sizing within this 
system and circumvents problems of inter lane variation in a gel [Ghosh et al 1997]. 
Data from the GENESCAN software was imported into a second software package 
GENOTYPER (ABI 0.02) for allele calling. A category for an individual microsatellite 
marker was generated by superimposing all allele peaks from several gels. Categorisation 
allowed the establishment of the limits of a marker allele size range and the creation of 
individual allele/peak bins within this range. 
Allele bins were derived from the means of the common allele sizes (not necessarily the real 
PCR product sizes) both within gels and between gels. The acceptable base pair deviation 
within an allele bin was determined to allow for the common artefacts including non- 
template polyadenylation, i. e. addition of extra adenosine triphosphate base at the 3' end of 
the amplicon that increases size of all fragments randomly by one base pair. A maximum 
deviation for dinucleotide repeats of 0.9 base pairs greater and smaller than each mean allele 
size was set to prevent overlap of bins. 
Filtering of the peaks using bin/category information and the setting of an adjustable 
minimum peak height /signal intensity eradicated most of the spurious background peaks, 
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promoting scoring of only the major allele peaks. Inter-gel differences were detected with 
the CEPH DNA controls and further external adjustments were made accordingly. Alleles 
correctly scored within a bin were rounded off to the nearest whole number and given an 
integer label equal to that mean size in base pairs and an allele bin letter code. 
Finally, all sample and allele scores culminated into an Excel spreadsheets for databasing 
and subsequent statistical analysis. 
3.5. DI-ALLELIC MARKER ANALYSIS. 
3.51. Introduction 
Di-allelic (or bi-allelic) polymorphisms by definition have only two alleles. Single 
nucleotide polymorphisms (SNP) are the most abundant type of di-allelic variants usually 
with the less frequent allele greater than 1%, less common are the insertion/deletion 
variants, and rare tri- and tetra-allelic polymorphism. Di-allelic SNP density in the human 
genome is estimated to be on average 1 per 1,000 bases, not accounting for regional 
differences in density that can be up to 100 fold. Four types of di-allelic single nucleotide 
polymorphism exist, primarily as transitions, pyramidine base to pyramidine base, C <> T 
and in the second complementary stand purine to purine G <> A. The other three types are 
transversions, pyramidine to purine and the reverse, C<>A (G<>T); C<>G (G<>C); and 
T<>A (A<>T); complementary strands in parentheses. Two-thirds of all SNP's are 
transitions, transversions accounting for the remainder in approximately equal amounts. The 
genetic determinants of disease are frequently SNP's, and they can be therefore causal in 
nature. The majority of SNP's are neutral and their usefulness stems from being proximal to 
a disease causing mutation. The consequence of only having two alleles makes them less 
informative than microsatellites markers, but their increased frequency and mutational 
stability makes them useful for both family or case/control association studies. 
Approximately eighty-five percent of SNP's are common to all human populations albeit 
with differing allele frequencies, and are also potentially useful in mapping diseasecausing 
mutations common to a number of ethnic populations. 
3.5.2 PCR-RFLP 
When polymorphisms disrupted a restriction endonuclease (RE) recognition sequence this 
was exploited to screen for the variants. The target region was PCR amplified from genomic 
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DNA using specific primers, and then the product digested with the appropriate restriction 
enzymes. 
Standard Restriction mix total 25plJsample: 
Sterile, deionised water Xµ1 
RE lOx Buffer 2.5µl 
Acetylated BSA (IOug/ul) 
or spermidine (100mM) 0.25µ1 
RE IOunits/ul O. 75µ1 
PCR product. 5.0-l0. Oµl 
Fragments were digested by incubation of between 5-8 hours at optimal temperature for RE 
either in a heated water bath or dri-block. 
All restriction fragments were size separated, visualised and scored on standard agarose gels 
or metaphor gels, with adjustment of agarose percentage according to size of digested 
fragments. Specific PCR-RFLP assays have been described in the individual chapters. 
3.5.3 PCR-generated RFLP 
Frequently a SNP will not naturally disrupt a RE recognition site, so by modification of 
usually a single base in one of the amplimers a recognition site was generated in the PCR 
product that could be disrupted by polymorphism. Where possible the amplification target 
sequence included a second non-polymorphic cutting site for the RE to facilitate as an 
internal restriction control. When this was not possible it was preferable that the wild-type 
allele of the variant allowed restriction by the restriction endonuclease. 
3.5.4 Mutagenically Separated-PCR 
Mutagenically Separated PCR (MS-PCR) is a single PCR reaction with competition 
between two primers both extending in the same direction on the same template DNA 
region. A constant third primer completes the PCR reaction by extending in the opposite 
direction. One of the competing primers is longer, and each competing primer differs at the 
3' end by one base that represents each allele of the SNP. Nucleotides in each competing 
primer are also sometimes mismatched to the template to improve the allele specificity 
[Newton 1989]. The longer primer is used at a lower concentration than the shorter primer to 
compensate as the shorter one has a lower annealing temperature. The ratio of long to short 
primer is normally between 1: 5 to 1: 15, determined empirically with the best PCR annealing 
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temperature by observation of a known heterozygote, and homozygotes positive controls 
(genotyped by sequencing), until conditions were such that the heterozygotes has two bands 
of equal intensity, and the homozygotes were unambiguous. The common primer is used at 
the same concentration as the short primer so as not to be limiting in the reaction. False 
heterozygotes can be observed, especially if the PCR annealing temperature is too low, 
allowing non-specific annealing of the long primer. The longer primer appears to have a 
greater affinity for the DNA template when PCR conditions are less than ideal. Known 
homozygotes and heterozygotes were included as positive controls in all assays. 
3.5.5 Insertion /Deletion analysis 
Insertion/deletion polymorphisms were analysed by PCR amplification followed by 
electrophoretic size separation on agarose gels. Gel conditions, percentage and type of 
agarose and dependent on the resolution required to differentiate allele size unambiguously 
and were empirically determined. 
3.5.6 PCR Product/Allele Separation and Visualisation 
Separation of PCR products only requiring a low level of resolution were prepared 
essentially as in Section 3.3.7 with adjustments made to percentage of agarose where 
necessary. PCR fragments requiring a higher resolution separation, i. e. fragment size 
differences of less than 10%, specialist agaroses such as MetaPhor TM and Nusieve TM 
Agaroses (FMC Bioproducts USA/Flowgen UK) were used. These agaroses could resolve 
size differences as low as 2% when in a 200-800bp range (minimum of 4 bp difference). A 
rapid gel format employed improved resolution to approximately 1%. 
Gel separation protocol: 
1. A 100ml gel was prepared using 2-4g (2-4%) MetaPhor agarose (FMC-Flowgen) in Ix 
TBE buffer 
2. Agarose and TBE solution were mixed by swirling of the flask and left for at least one 
hour at RT to allow for rehydration. 
3. Mixture was heated to pre-boiled state in a microwave oven, stood for 15 minutes at RT 
and reheated to boiling point. 
4. The gel mixture was allowed to cool sufficiently before adding ethidium bromide to a 
concentration of 0.5pg/ml and then poured into a horizontal electrophoresis gel mould. 
Gels were set at 4°C to increase the rigidity. 
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5. The gel was then submerged in an electrophoresis tank filled with 1x TBE buffer or 
0.5x TBE for Rapid Horizontal Gel format. 
6.1. Oul of lOx Ficoll Bromophenol blue loading dye was pipetted into a 5.0p1 PCR sample 
and loaded into each well of gel. 
7. Gels were run at 90Volts (6V per cm) for 2.5 hours or Rapid format gels were run at 250 
volts (17volts/cm) for less than 1 hour using buffer at 15°C, cooled and circulated by a 
pumped refrigeration unit. 
8. Separated DNA fragments were visualised on a UV transilluminator, and alleles scored 
accordingly after sizing using a combination of 100bp MW ladder (Promega UK Ltd) 
and sizing software using an Alpha IS 1000 Digital Imaging System (Alpha 
Innotec/Flowgen, Lichfield, UK). Permanent records were kept as thermal prints, or 
stored as a TIFF or BMP files. 
3.6 FLUORESCENT CYCLE SEQUENCING OF PCR TEMPLATES: 
3.6.1 Introduction 
Direct sequencing of double stranded PCR generated templates were carried out using an 
ABI 373 Automated Sequencer. The cycle sequencing method used was quintessentially the 
chain termination method of Sanger and Coulson with modification. Typically this DNA 
sequencing uses a modified thermolabile T7 DNA polymerase to extend from a primer 
annealed to a DNAIRNA template. The substitution of this polymerase with a thermostable 
polymerase introduces an amplifying thermal cycling stage in the sequencing reaction. This 
offers a number of advantages over conventional sequencing. 
1. A single oligonucleotide primer in the reaction results in the linear amplification of one 
strand of the double stranded template, reducing template requirement 
2. High denaturation temperature during cycling circumvents the problems of rapid re- 
annealing of linear ds DNA templates. 
3. High annealing temperatures during cycling increase the stringency of primer 
hybridisation. 
4. High polymerisation temperature decreases the secondary structure of DNA templates 
allowing polymerisation through highly structured regions. 
The ABI 373 Automated Sequencer sequencing technology is based on the sensitive laser 
detection of four different fluorescent dyes. The ABI Prism TM DyeDeoxy TM Terminator 
Cycle Sequencing Kits uses each chain terminating dideoxyribonucleotide triphosphates, 
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ddGTP, ddATP, ddTTP, and ddCTP labelled with a different wavelength permiting a single 
reaction tube single gel lane. 
3.6.2 Template Considerations 
The double stranded DNA template was generated by PCR. The length and quality of the 
sequence was determined by a number of factors: 
1. The ABI 373 Automated Sequencer, Well to Read gel plates of 36cm has an ability to 
sequence a maximum of 400-500 bases. 
2. The terminal sequences at both ends of the PCR template were sometimes difficult to 
interpret, often due to excess unincorporated ddNTPS. This was generally overcome by 
amplifying a region in excess of the target sequence, and by overlapping contiguous 
templates. 
3. In some circumstances the PCR Primers were inadequate for sequencing so `nested' 
primers were utilised internal to the original PCR primers. 
4. PCR product template had to be of sufficient quality and quantity, other methods were 
employed (see next sections) if the amplicons did not meet the necessary requirements. 
3.6.3 PCR template purification by Spin Dialysis 
When required templates were concentrated and excess primers and dNTPS were removed 
using spin dialysis columns (Microcon microconcentrators; Amicon-Millipore Ltd). The 
Microcon 100 was used with a membrane molecular weight cut of 125 bp for dsDNA i. e the 
filtrate includes dsDNA smaller than 125bp (and ssDNA < 300 bases) passes through the 
dialysis membrane. 
1. The membrane cartridge device was assembled with a 1.5m1 tube receptacle. 
2. The completed PCR reactions with the identical template DNA were combined and 
made up to a volume of 5O0µ1 with sterile water. 
3. The 500µl mix was added to the top of the membrane cartridge, capped, and centrifuged 
in a (fixed angled rotor) microfuged at 2000xg for 5 minutes at RT. The device was 
removed from centrifuge and the filtrate discarded from collection receptacle. 
4. The device was re-assembled and a further 5O0µ1 of water was added to the top, and step 
3 repeated. 
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5. The membrane cartridge was removed from the waste receptacle, inverted and place in 
to a new tube. The assembled device was centrifuged at 500xg for 1 min, and retentate 
with PCR product collected in the new tube. 
6. A 500µl loading normally resulted in a 5-2Oµ1 retentate. 
7. A diluted sample of the retentate was run on an agarose gel to estimate quantity using a 
pre-quantified DNA MW marker. PCR templates were diluted to a concentration of 10- 
30ng/pl. 
3.6.4 PCR template purification by gel excision 
When multiple non-specific PCR products were unavoidably present, the amplified 
fragments were purified by separation on an agarose gel (1-2%), and the desired template 
band cut out and extracted using Agarose Gel DNA Extraction Kit (Boehringer Mannheim 
GmbH). 
1. Following separation on an agarose gel in 1xTBE buffer, the excised band was placed in 
a pre-weighed 1.5ml tube. 
2. For every 100mg of gel, 300µI of agarose solubilisation buffer (unknown chaotropic 
agent) was added. 
3. The silica suspension provided was resuspended and 10µl added to the gel fragment 
solution and mixed by vortexing to bind the DNA. 
4. The mix was incubated for 10 minutes at 60°C and vortexed every 2-3 minutes. 
5. The sample was then microfuged at 16,000rpm for 30 seconds, and the supernatant 
discarded. 
6. The silica/DNA matrix pellet was then resuspended in 500µ1 nucleic acid binding buffer 
(formula unknown) using a vortex. Microfuged as in Step 5 and the supernatant 
discarded 
7. The pellet was then washed in 500pl of Washing Buffer (formula unknown), centrifuged 
and discarded as in steps, and then repeated. 
8. Final supernatant was carefully removed, tube inverted on tissue and the pellet allowed 
to air dry at RT for 15 minutes, or until bright white indicating fully dry. 
9. Add 25µl of deionised sterile water (pH8-8.5) to the pellet to elute the DNA. Sample 
was vortexed and incubated at 60°C for 10 min, with a further vortex every 2 minutes. 
The sample was microfuged for 30 seconds at 16,000rpm, and supernatant containing 
the DNA template transferred to another tube. 
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10. Step 9 was repeated with another 25. i1 of water and combined with the first elution to 
increase recovery yield. 
3.6.5 Dye Deoxy Terminator Sequencing reaction 
1. Reaction mix components were added and mixed in a 0.5m1 thin walled PCR tube. 
Primers were pre-diluted 1: 100 from lOOpmole/µl to lpmole/µl in water. 
Terminator Ready Reaction Mix (ABI) 8.0µl 
PCR template 10-30ng/pl 5.0µl 
Primer (Forward OR reverse) 3.2pmole 3.2µl 
HPLC water 3.8µl 
Total Reaction Volume 20.0µl 
Reaction was overlayed with a drop of mineral oil. 
2. The reaction was Cycle sequenced on a DNA Thermal Cycler (TC1 or Model 480 -Perkin 
Elmer). Programme profile was: 
Rapid thermal ramp to 96°C; 96°c for 30 seconds; Rapid thermal ramp to 50°c 
50°C for 15 seconds; Rapid thermal ramp to 60°C; 60°C for 4 minutes 
This was repeated for 25 cycles, and then cooled and held at 4°C. 
3. Early sequencing kits (ABI) required more thorough removal of excess dye terminators, 
later kits reduced amounts in reaction so only an ethanol precipitation was necessary see 
Step 10 for alternative purification. 
4.80µl of water was gently added and mixed with the 20pl reaction volume underneath the 
mineral oil layer. The 100µl reaction was removed to a 1.5m1 microfuge tube, avoiding 
transfer/contamination with mineral oil. 
5. l00µ1 of phenol: H20: chloroform mix at RT ( 68: 18: 14 ABI) was added and then 
vortexed to extract terminators. The tube was then microfuged at 16,000rpm for 2 minutes. 
6. The lower organic phase was removed from the reaction extraction, 1OOµ1 of phenol: H20: 
chloroform mix added again, vortexed and microfuged as in step 5. 
7. The upper aqueous phase was removed to new microfuge tube. Extension products were 
precipitated by addition of 15µ12M sodium acetate pH 4.5 and 300 µl of 100% ethanol. 
8. The mixture was microfuged for 15 min at 16,000rpm to pellet products. The ethanol was 
carefully aspirated with a micropipettor to leave pellet intact. 
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9. The pellet was washed carefully (without disturbing the pellet) with 250µl of 70% 
ethanol, and then aspirated off. Remaining ethanol was wiped out with clean tissue paper 
and the pellet dried in a vacuum centrifuge. 
10. Alternative method for later sequencing kits; 2. Oµl of 3M Sodium acetate. PH4.6 and 
50µl of 95% ethanol was added and mixed with the 20µ1 reaction volume. This was 
incubated for 15 minutes on ice and then microfuged at 16,000rpm, at 4°C, for 30 minutes. 
The pellet was then treated as in step 9. 
11. To the pellets 5µl of loading buffer (Appendix I) was added, vortexed vigourously, and 
microfuged. 
12. Shortly before loading of gel, the reaction was denatured by heating for 2 minutes at 
90°C in a heated block and then placed on ice. 
3.6.6 Polyacrylamide Sequencing gel 
A 0.4mm thick 6% acrylamide/bis acylamide 19: 1,8M Urea denaturing PAGE (Sequa 6 
Gel, National Diagnostics/Flowgen) and glass plate preparation for the 373 Automated 
Sequencer was essentially as in section 3.4.4 from Step 7. 
Except: 
1. A 24cm well-to-read glass plates were used and therefore gel volume was 100ml, 80m1 
of Acylamide/Bisacrylamide mix was combined with 20 ml Buffer/TEMED mixed and 
400u1 of freshly made 10% (W/V) Ammonium persulphate (Kodak Chemicals) was 
added to catalyse polymerisation of gel. 
2. Gels were run for 12 hours at 40 Watts constant power at 30C. 
3.6.7 Sequence Analysis Computer Software 
Following visual inspection of the digitised raw sequence data and the attainment of correct 
and optimal base spacing (between 9-12 scans), sample files were imported into the 
Sequence Navigator Software (ABI Inc. ) 
A reference sequence was created from a database sequence (GDB) of the target template, if 
available. The sequence was converted into a sequence string imported into the Sequence 
Navigator program. 
Multiple alignment comparisons were carried out including both forward and reverse 
complementary sequences against the reference sequence using the CLUSTAL software 
program. Mismatched sequence was examined by eye on the electrophoretograms. Putative 
94 
polymorphisms were confirmed by repeating the PCR-sequencing reactions, as false 
positives could be due to random non-template incorporation of dNTPs by Taq polymerase 
during the PCR reaction. 
3.7 ELECTROPHORETIC MOBILITY SHIFT ASSAY 
3.7.1 Generation of ds DNA probes 
Double stranded DNA test fragments were generated either by PCR, using primers designed 
to encompass the region of interest. Alternatively single stranded oligonucleotides were 
synthesised for controls and region of interest, with one oligonucleotide complementary to 
the other. Complementary strands were annealed together to form a double stranded 
fragment. Allele variation was incorporated into each matched pair to allow investigation of 
binding effects of mutations and competition experiments. 
PCR reaction for fragment generation: 
50µl lOx PCR Buffer 
5µl dntps 
3µl F primer 
3µl R primer 
5µl QiagHotStar TAq 
66µl Sterile water to final 100 µl volume 
Hotstart PCR with 50 °C annealing. All reactions were combined and lyophilised to reduce 
volume to facilitate loading on a 1% agarose gel. Bands were cut out and put in pre-weighed 
1.5m1 tubes and DNA extracted using Agarose extraction system (3.6.4) and eluted in 50µ1 
(20µl + 30 µl) ddH2O. 
2. Oµ1 was run on agarose gel to check integrity and estimate quantity, diluted to a 
concentration of approximately 20ng1µl, use IOOng in DIG labelling reaction, 
Single Stranded oligonucleotides were annealed as follows: 
To generate double-stranded DNA probes by annealing synthesised oligonucleotides. 
Oligonucleotides were mixed in an equimolar ratio 1: 1 in TEN buffer (appendix I) and 
incubated for 10 minutes at 95°C. Reactions were cooled slowly to room temperature and 
then diluted with TEN to a concentration of 3-4 pmol/p. l 
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I. Mix single stranded oligos in an equimolar ratio 1: 1 in TEN. 
2. Incubate for 10 minutes at 95C 
3. Cool slowly to room temperature 
4. Dilute with TEN buffer to 3-4pmol/ul 
3.7.2 Digoxigenin-1l-ddUTP (DIG) end-labelling of probes 
Reactions of 20µl, with either 5µl of PCR Probe (20ng/p. l) or I. µ1 of annealed 
oligonucleotide probe or Roche kit control. 
4µl labelling buffer (5x conc Roche-appendix I) 
4µl CoCI2 solution 
5µl of ds PCR Probe 
1µl DIG- 11-ddUTP solution (Roche) 
I g] terminal transferase 
Xgl ddH2O to final volume 
1. Reactions were mixed on ice and then incubated for 15 minutes at 37°C and then placed 
back on ice. 
2. The probe was then precipitated with 2µi of 4M LiCI, and 60111 of ice cold ETOH 
followed by incubation at -70°C for 30 minutes. 
3. The precipitate was pelleted in a micro-centrifuge for 15 min at 4°C, 12,000 RPM. 
4. The supernatant was removed and the pellet washed 3x with 500µ1 of 70% chilled ETOH 
and finally vacuumed dried. 
5. The labelled probe pellet was dissolved in TEN to obtain a concentration of 4ng/µl or 
0.155pmol/µl. 
3.7.3 Test for DIG labelling efficiency 
To test for both DIG labelling and chemiluminescent detection efficiency. 
1. Dilute DIG labelled EMSA probe and kiy labeled control in TEN buffer (appendix I) by 
serial 10 fold dilutions 1: 10 to 1: 100,000. 
2. Spot 1µl (4ng) of undiluted kit labelled control and each serial dilution of control and 
labelled EMSA probe onto dry positively charged nylon membrane (Boehringer Mannheim 
1209 299). DNA was bonded to membrane by baking at 120°C for 30 minutes. 
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3. Spot lµ1 of kit ready DIG labelled DS contol oligonucleotide (0.4ng/pl) as a 
chemiluminescence detection control. 
4. Chemiluminescent detection was performed as per section 3.7.6. A spot should be 
detectable in the 1: 1000 dilution (4pg) of the labelled control DNA and EMSA probe 
fragment. 
3.7.4 Gel Shift Assay 
For EMSA assay's, reactions were carried out as follows in a final volume of 1041: 
1. All reactions were mixed and incubated on ice for 10-15 minutes, then 20 minutes at RT, 
and then placed back on ice. Reaction component volumes were as table 3.7.1: 
2. A control labeled EMSA probe fragment with a known a trans-acting binding site (eg. 
OCT2A) was utilized in preliminary experiments for optimisation of assay and gel 
conditions with the HeLa Nuclear Extract (HNE). 
3. Optimal binding was initially determined for both control and novel EMSA probe 
fragments, by using duplicate sets with either Poly AT or Poly IC which can markedly 
reduce non-specific binding of nuclear extract proteins. 
4. Principally an experiment consisted as follows with reference to table 3.7.1: 
A. DIG labeled control 
B. DIG labeled control + specific trans-acting binding factor or HNE 
C. DIG labeled control + specific trans-acting binding factor or HNE + unlabelled control 
fragment as a specific competitor 
D. DIG labeled novel probe 
E. DIG labeled novel probe + HNE 
F. DIG labeled novel probe+ HNE + unlabelled novel probe at a 100 fold excess as a 
specific competitor 
G. DIG labeled novel probe + HNE + unlabelled non-specific competitor (eg control probe) 
5. Following incubation, 2.5pl of loading buffer (appendix I) without without BPB was 
added per 10µI GS reaction, and then loaded immediately on a pre- electrophoresed 
10cmx 10cm PAGE. One lane of gel was loaded with running buffer plus BPB as a 
tracking lane. 
6.4.1% non-denaturing polyacrylamide gels (40: 1 in 0.5 xTBE) were pre-electrophoresed 
for 1-2 hours before sample loading and then and ran at 80 volts (constant voltage) until 
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tracking lane BPB dye was 3/a way down gel ( MINI protean apparatus Biorad). Running 
buffer (0.5X TBE) and hence gels were kept at 4 °C. 
A B C D E F G 
Binding Buffer (Roche) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Poly d(AT) or d(IC) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Poly L-lysine 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
DIG labeled -novel probe 
or control probe 
2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Unlabelled novel probe 
20n ul 
0 0 0 0 0 3.0 0 
Unlabeled Control probe 0 0 1.0 0 0 0 1.0 
HNE or specific factor 0 2.0 2.0 0 2.0 2.0 2.0 
DdH2O to 10ul 5.0 3.0 2.0 5.0 3.0 0 2.0 
Table 3.7.1: Reaction volumes for EMSA assay 
3.7.5 Capillary transfer from PAGE: 
DNA and DNA/protein complexes were transferred to positively charged nylon membrane 
(Boerhringer Mannheim GmBH) using a positive pressure apparatus, (POSIBLOT 
Stratagene Ltd) overnight in 0.25xTBE buffer. Following transfer nylon membranes were 
rinsed in lOx SSC and baked at 120°C for 15-30 minutes to bond DNA and DNA/protein 
complexes to membrane. 
3.7.6 Chemiluminescent Detection (Boehringer-Mannheim). 
1. Membranes were rinsed briefly (1-5min) in Washing Buffer 
2. Membranes were incubated for 30 minutes in 100ml of Buffer 2 
3. Antibody conjugate solution was diluted to 75mU/ml (1: 10,000 anti-digoxigenin -AP, 
Fab fragments) in Buffer 2. 
4. Membrane was incubated for 30 minutes in 20m1 of antibody conjugate solution. 
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5. Unbound conjugate was removed by washing 2x for 15 minutes in 100ml Washing 
Buffer. 
6. Membranes were equilibrated for 2-5 minutes in 20m1 of Buffer 3. 
7. Membranes were then incubated, DNA side face down, in 10ml CPSDTM substrate 
solution for 5minutes. 
8. Excess substrate solution was drained off, and without allowing membrane to dry, 
placed in plastic wallet and heat sealed whilst avoiding air bubbles. 
9. The sealed membrane was incubated at 37°C for 15 min in an oven and then exposed to 
X-ray film (Roche) in a light proof cassette for between 15minutes and 1 hour at RT. 
The film was then developed using commercial photographic developer and fixer 
reagents. 
3.8 STATISTICAL ANALYSES 
3.8.1 Non-Parametric Linkage Analysis 
Genetic distance (centimorgans cM), and hence the rate, is determined by the probability of 
a meiotic recombination event (recombination fraction 8) occurring between the loci. An 
allele at one locus on one chromosome independently segregates with a given allele at 
another locus on another chromosome with a 50% probability, so for two loci to be 
considered linked or in genetic linkage on the same chromosome the recombination fraction 
must be less than 50%, with distances between loci decreasing with declining recombination 
fraction. Linkage analysis estimates the recombination fraction from counts of the 
recombinants and non-recombinants within pedigrees with a large number of informative 
meioses, and if this is less than 50%, then tests if the observed deviation is statistically 
significant. Typically linkage analysis is used to determine the positions of disease loci 
relative to genetic markers, but is also used to map marker positions relative to each other. 
Linkage analysis generally involves the calculation of the logarithm of odds ratio (LOD 
scores) [Morton 1996]. A lod score of 3.0 for a given recombination fraction means that the 
chances are greater than 1000: 1 that the loci are linked, and by a widely accepted convention 
this is the level at which there is significant evidence for linkage for a simple mendelian 
autosomal disorder [Landers & Kruglyak 1995; Morton 1998a]. A lod score of 2.0 (100: 1) is 
generally assumed to represent a level in which there is only suggestive evidence of linkage. 
Data can also be interpreted inversely to exclude regions of the genome with lod score of 
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less than -2, providing evidence of exclusion of linkage for a given region at a particular 
recombination fraction (0). 
There are theoretical difficulties in the application of Lod score methods to complex 
diseases. Problems stem mainly from that the calculation of classical lod scores requires the 
specification of various aspects of the disease model including the full specification of mode 
of transmission of all the loci involved, combined with allele frequencies and penetrance 
values. This is normally possible when mapping simple Mendelian disease genes and 
markers, however in complex (non-mendelian) diseases it is difficult to estimate penetrance 
values, including phenocopy risks, and also the allele frequency of the disease mutation. It is 
possible that mutations at different loci have different kinds of effect on susceptibility, either 
major or minor, and dominant or recessive. In complex disorders individual families may 
have several different modes of transmission operative and also different loci may interact 
within the same family. Therefore no single model of transmission may be an appropriate 
mode of inheritance. 
In addition, the late age of onset of T2DM and the increased disease-related mortality 
hampers the collection of large multi-generation pedigrees [Panzram 1987]. This is further 
hindered as T2DM patients diagnosed early (between 25-40 years old) have a large 
proportion (83%) of both parents affected and these families are therefore less informative 
[O'Rahilly & Turner 1988b]. 
Therefore a model free non-parametric linkage analysis approaches have been widely used 
in the search for diabetogenic genes. However, compared to conventional linkage analysis 
these non-parametric methods require a large number of affected sibling pairs (ASP) to 
achieve sufficient power to detect disease susceptibility loci. 
The affected sib pair analysis relies on the principle that if a marker is linked to a disease 
locus, consequently the same marker allele will be inherited by both affected siblings more 
often than expected by chance. Methods have been developed that can use parental genotype 
data when available; Identity by Descent (IBD) and without access to parental data; Identity 
by State (IBS) [Risch 1990]. In the context of complex traits with no single major gene, the 
power of a study is a particularly important aspect. Mathematical modeling has determined 
that the likelihood of detecting linkage is a function of the parameter %R or Xs, the affected 
relative risk ratio or sibling relative risk ratio in ASP studies [Risch 1990]. This parameter 
(Xs) is the ratio between the risk to an individual developing the disease (co-sibling) if a 
family member is already affected (Ks) versus the risk to a member of the general 
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population (K) calculated by Ks/K. The higher values of Xs indicate a fewer number of 
causal genes [Risch 1990]. The number of sib-pairs required to detect linkage is both a 
function of X, and density of chromosomal markers and therefore the potential power of a 
study can be assessed [Risch & Merikangas 1996]. 
GENEHUNTER is a nonparametric linkage program in which a mode of inheritance does 
not need to be specified, and can be equally applied to pedigrees and nuclear families and 
affected sibling pairs. This program calculates a non-parametric statistic, measuring the 
sharing among affected individuals, called the NPL (Non-Parametric Linkage) Score, and 
generates an associated p value. A graphical representation can be generated from the NPL 
scores across a map using npl-plot. ps. NPL statistics were plotted on the map, at appropriate 
cM distance increments, regardless of marker positions in the map. 
Linkage analysis has proven to be a very powerful tool in localising disease susceptibility 
loci to chromosomal regions, however it relies on differences in allele sharing of affected 
sibling pairs, in which a quarter will share two alleles purely by chance. Therefore, the 
determination of the map positions of loci based on recombination events in a family could 
be subject to error. Furthermore, siblings are only separated from their parents by one 
meiotic event, hence shared chromosomal regions span over many centimorgans, 
representing millions of base pairs of DNA. The lack of sufficient genetic resolution with 
linkage alone suggests that it may be less than ideal for fine gene mapping purposes and 
final localization of susceptibility loci [Risch 2000]. 
3.8.2 Linkage Disequilibrium and Association Studies 
It has been observed that in randomly mating populations, loci in close proximity with each 
other on the same chromosome remain `linked' over many generations. This occurs as a 
result of an insufficient number of meiotic recombination events to separate loci, thus the 
loci have not yet reached `linkage equilibrium'. This phenomenon is referred to as linkage 
disequilibrium (LD). The extent of LD in proximity of any given loci in a specific 
population is a function of the age of that population. In relatively recent (2000 years) 
populations, such as found in Finland, individuals are only separated by as little as 80 
meioses and hence there is extensive LD [de la Chapelle 19931. However, the degree of 
regional LD is also a consequence of the specific demographic history of the population 
with genetic drift, bottlenecks and cycles of expansion and contraction also having major 
influences [Ott 2000]. 
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Analyses that utilize LD, unlike linkage analysis, do not assess recombination just in the 
observed data, but exploit the consequence of many recombinations between loci over a 
large number of generations. Moreover, the expectation that LD is only observable between 
loci that are tightly linked over short genetic distances suggests that it is a powerful tool that 
can be exploited for fine mapping and disease susceptibility gene discovery purposes [Risch 
& Merikangas 1996]. If there exists sufficient LD between a specific ancestral disease 
causing mutation that has arisen in a given population and a genetic marker in close 
proximity then this can be used to identify disease susceptibility genes. 
Case-Control Association Studies: 
The underlying premise for these studies is that polymorphic sites within a candidate gene or 
in close proximity are either causative of disease or act as markers for the disease by being 
in linkage disequilibrium with the causative pathogenic mutation. Association studies 
investigate whether there are statistically significant differences in allele/genotype 
frequencies of a polymorphic site or series of variants (haplotypes) between unrelated 
ethnically matched unaffected (controls) and affected subjects (cases) within a population. If 
a marker loci and pathogenic mutation are tightly linked ie. in strong LD, then an increase in 
frequency of a marker variant allele in the affected group is indicative of an association with 
disease. Genetic markers can comprise of any type of polymorphisms including 
microsatellites, minisatellites (VNTR's), insertion/deletions, and the more abundant and 
widely spread single nucleotide polymorphisms (SNP). 
Although population association studies can be particularly useful in genetic studies where 
the late onset of disease can impede the collection of multi-generational families, such as in 
T2DM. Case-control type studies are based on non-random statistical associations, which 
may be non-genetic in origin and are prone to Type I errors, ie false-positive associations 
[Ott 1999]. For example high levels of undetected consanguinity, where samples are not 
truly unrelated and epistatic gene-gene interactions can lead to artefactual associations. In 
addition statistical consensus suggests that the major cause of error in these studies is the 
confounding effect of population stratification, with an over-representation of 
allele/haplotype frequencies in cases or controls due to underlying population differences. 
The most likely source of sub-stratification is through lack of homogeneity of ethnicity in 
the two study groups. This could occur by genetic admixture and migration. Ethnic 
differences in the marker and disease loci allele frequencies could give rise to positive 
associations that were not the result of LD between the disease and marker loci if there was 
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an increased frequency of both disease and marker alleles in one of the ethnic groups. Steps 
can be made to avoid some of these false postive results by checking for skews from non- 
random mating by calculating Hardy-Weinberg Equilibrium (section 3.8.3) and with the 
collection of control samples that are truly matched to cases for relevant factors such as 
ethnicity and geographical origin. Cases should also be as genetically homogenous as 
possible to prevent different associations in different ethnic groups masking their effect. 
However, stratification as a confounding factor has never been entirely proven and an 
alternative explanation is that high false positive rates observed result from a low prior 
probability that the few gene polymorphisms examined are causally related to the disease 
[Risch 2000]. 
Furthermore, the close proximity of a polymorphic marker locus to a disease locus does not 
necessitate that it is associated with the pathogenic mutations. The power to detect an 
association between a non-causative polymorphic marker and the disease phenotype is 
entirely dependent on the degree of linkage disequilibrium [Cox & Bell 19891. The level of 
linkage disequilibrium being dictated by both the distance between marker and disease locus 
and the recent evolutional origin of the mutation, with both factors being dependent on 
number of recombination events. A disease association could remain undetectable if the 
candidate gene has multiple disease mutations associating with different alleles at a given 
locus, culminating in the same disease phenotype or if the study design lacks statistical 
power to detect the association through insufficient sample numbers. Hence a single 
population study is not definitive proof or exclusion and requires supporting evidence in the 
form of duplication or confirmation through other study designs. 
Family association Studies: 
Family based association tests were developed to circumvent some of the problems of 
population studies by using matched cases and ̀ pseudocontrols' within families. Tests such 
as the Transmission Disequilibrium Test (TDT) were developed by Spielman & Ewens 
[1996] from the haplotype relative risk method of Rubinstein et al [1981] and utilizes both 
linkage and linkage disequilibrium. 
Disadvantages: To achieve a positive association, the disease allele must be associated (in 
LD) within the population with the test locus marker allele, but also simultaneously there 
must be linkage between the disease and marker for that association to manifest itself in a 
biased transmission to affected offspring. When subjects are related, as with multiple 
affected siblings, it is still a test of linkage, but as these subjects are not independent of each 
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other, it is difficult to know if there is evidence of LD in addition to linkage, and the test of 
association is invalid. The original TDT could only deal with two marker alleles but this has 
now been modified to cope with multiallelic markers in the extended TDT test (ETDT) 
[Sham & Curtis 19951 
Advantages: It is a model-free method and tests for both linkage and LD simultaneously 
[Spielman & Ewens 1996], and has an advantage over population case-control studies is that 
the test is equivalent to a matched case-control design, with case genotype as the affected 
offspring genotype and the `control' genotype ie. the parental alleles not transmitted. 
Therefore it is not prone to the false positives due to population stratification. When the test 
is positive it implicates a very small chromosomal region and was introduced to reduce large 
candidate regions for a disease determined by linkage analysis. 
Case-control and TDT study designs each have specific advantages and disadvantages, so 
ideally they should be utilised complimentarily if both family and population resources are 
available. 
3.8.3 Hardy-Weinberg Equilibrium 
Large completely mixed (panmictic) populations consist of a number overlapping 
generations or mating types, but because the genotypes of new members of the population 
are a function of the allele frequencies of the reproductive age class, the proportion of 
various genotypes at a given locus should remain unchanged from one generation to the next 
unless the population is subjected to selection forces such as non random mating, mortality, 
or migration, or mutation rate is not constant. Genotype frequencies should become 
homogenized across all age classes and sexes and this state is Hardy-Weinberg Equilibrium 
(HWE). Under certain circumstances the frequencies of the genotypes at the locus under 
study can be a function of the allele frequencies alone, and underlying selection forces could 
stratify the population. Therefore it has become standard practice to cross-check genotype 
frequencies in any given population with Hardy-Weinberg expectations as a departure from 
HWE could influence the validity of an association study. For example if the observed 
population allele frequencies significantly differ from the expected as result of increased 
heterozygosity or homozygosity, if not due to genotyping error, would indicate a degree of 
`outbreeding' or `inbreeding' respectively within the study population [REF]. 
Significant departure from HWE was assessed for all loci investigated using an MS-Excel 
sheet prepared by D. Curtis. This incorporated the HWE equation comparing observed and 
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expected genotype frequencies and calculated a Pearson chi-squared statistic with one 
degree of freedom [Pak Sham -Statistics in Human Genetics: Arnold 1998]. 
3.8.4 Analysis of Population Association Studies 
In population association studies the frequencies of alleles/genotypes subjects were 
compared between the genotyped cases and controls using contingency tables and chi- 
squared tests (calculation of asymptotic p values based on a Pearson-Chi squared 
distribution). P-values were corrected using the Bonferroni test for multiple testing where 
appropriate. When alleles were rare or sample sizes too small (less than n=5 per cell) 
homozygous subjects were combined with heterozygous subjects, and presence of the 
mutant allele analysed. In addition, to guard against an overly conservative test, Monte 
Carlo procedures were employed. The SPSS (v 9.0) statistical package was used for all 
analyses. 
3.8.5 Transmission Disequilibrium Tests 
TDT: This test uses parents that are heterozygous or informative at the marker locus and 
compares the frequencies of the marker (M) alleles that are transmitted to the affected 
offspring with the frequencies of marker alleles that are not transmitted, using the test 
statistic (n12-n2 1)2 /(n12+ n21) with reference to table 3.8.1. An asymptotic chi-squared is 
generated with one degree of freedom when the disease and marker loci are unlinked. If an 
allele is transmitted on more than 50% of occasions to affected offspring, then there is 
evidence for both linkage and linkage dsequilibrium between marker and disease loci. 
Transmitted 
Marker (M) allele 
Non-Transmitted Marker allele 
M1 M2 
M1 nil n12 
M2 n21 n22 
Table 3.8.1: Basis of TDT Statistic: 
TDT Haplotypes: To examine the association of haplotypes generated from multiple 
polymorphisms with disease phenotypes in families, the program TRANSMIT 
(www. hgmp. mrc. ac. uk) was employed [Clayton 1999]. This program tests for association 
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between marker and disease by examining transmission of markers to affected offspring as 
for TDT. The program can deal with multi-locus haplotypes even when phase is unknown, 
and unknown parental genotypes and produces asymptotic Chi-squared tests for excess 
transmission of individual haplotypes (ldf) and a global statistic for association with H-1 
df, where H=number of haplotypes. In the analysis untaken in this thesis, the recent 
additional bootstrapping option was also used (1000 bootstraps) to generate more accurate 
p-values than those generated from the chi-square approximations as suggested by Clayton 
[ 1999]. 
QTDT: In complex diseases such as TDM and Obesity, quantitative phenotypes can provide 
more information than can be provided by just dichotomous traits. Therefore programs have 
been designed to test for LD applicable in the analysis of quantitative traits in families. The 
Quantitative TDT program available at (www. well. ox. ac. uklasthmalQTDT) suite contains 
the QTDT5 method of Allison, and orthogonal model of Abecasis based on the Fulker 
model for sib-pairs [Abecasis et al 2000; Fulker et al 1999]. These variance component 
approaches allow simultaneous modelling of means and variances, so all the information in 
a set of related individuals can be used to construct a test of association. The orthogonal 
model has the advantage over similar methods of optionally using data from both parental 
genotype and all available offspring, which if available can substantially increase power to 
detect associations. This test, as with other TDT tests is also free of the confounding effects 
of population-substructure, and robust to other biases including background familiarity 
regardless of the composition of the nuclear families. It can also be applied to markers with 
multiple alleles without modification, and was also capable of analyzing multiple haplotypes 
similarly with appropriate correction for multiple testing (personal communication Goncarlo 
Abecasis). Sex was included as a covariant in analyses where trait variances could be 
influenced by gender. In addition, the "total association" option in QTDT was used in some 
analyses to implement a non-TDT association test that incorporates multiple members of the 
same pedigree, whilst allowing for shared polygenic and environmental variances. 
3.8.6 Power Calculations 
Power Calculations for TDT analyses was performed using an MS Excel sheet kindly 
prepared by D. Curtis. Calculations were based on those published by Risch and Merikangas 
[1996] using a model that assumes a multiplicative relationship between the alleles and 
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accounts for incomplete penetrance. A genotype relative risk (GRR - y), the increased 
chance that an individual with a particular genotype has the disease must be defined if 
known, or tested for different levels of risk with the degree of incomplete penetrance 
determined by the magnitude of y. The frequency of the disease allele and number of test 
families must be provided, and the likely proportion of heterozygous parents are calculated. 
Power of 80% at a given significance value, is the probability of rejecting the null 
hypothesis when it is false. 
3.8.7 Linkage Disequilibrium Tests 
A marker can either be a causative mutation with a direct pathogenic role in the disease or in 
LD with mutations that are causative. Information on LD patterns between loci across a 
chromosomal region can provide useful information in the interpretation of relationships of 
markers/mutations with disease loci particularly in respect of power to detect that 
relationship. The extent of linkage equilibrium across a region will dictate the degree of 
sensitivity of a marker to detect a relationship with disease loci. LD and power being 
dependent on when the mutation/marker evolutionarily arose in the population, with the rate 
towards equilibrium not only affected by number of recombinations but also by the mutation 
rate of the marker itself. Information on the phase of the loci alleles allows some 
interpretation of marker loci and disease relationships. This can be especially important 
when a number of closely linked loci associate with the same disease phenotype, or different 
traits predisposing to the same phenotype, potentially LD data could reveal whether the 
markers are associated with the same or different disease causing mutations. 
In the population collections the EH program (ott@linkage. rockefeller. edu) was used to 
assess LD between markers in haplotypes Xie & Ott 1993]. The program estimates alleles 
frequencies from randomly collected individuals for each marker. Haplotype frequencies are 
estimated with allelic association (Hi) and without (Ho) and an asymptotic chi-square value 
calculated. 
3.8.8 Odds ratios and Relative Risks 
Odds ratio (OR): 
The odds ratio relates the odds of being a case to not being a case for those with the risk 
factor (alb) to these same odds for those without the risk factor (c/d). When the odds in each 
group have equal risk, then odds ratio is equal to the unity. 
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OR= a/b = axd 
c/dbxc where a, b, c, d are as referred to in table 3.8.1 
Relative Risk (RR): 
RR = incidence rate among exposed =a/ (a+b) 
Incidence rate among non-exposed c/ (c+d) 
where a, b, c, d are as referred to in table 3.8.2 
This is a measure of association between exposure to a particular factor and the risk of a 
certain outcome. The relative risk, eg 5, means that an exposed person is 5 times as likely to 
have the disease than one who is not exposed. RR does not measure the probability that 
someone with the factor will develop the disease. 
Population Attributable Risk (PAR): 
The PAR estimates as a percentage the proportion of cases (eg T2DM) in the entire 
population that can be attributed to exposure to a particular factor, eg. variation at a gene 
locus or loci-haplotypes. 
Frequency rate among exposed - Frequency rate among on-exposed 
Frequency rate among exposed 











+ a b a+b a/ (a+b) 
- c d c+d c/ (c+d) 
a+c b+d a+b+c+d=T (a+c)/ T 
Table 3.8.2: Terms for derivation of OR, RR, and PAR calculations 
3.8.9 Analysis of quantitative traits 
The relationships between continuous variables when available and alleles were assessed 
using parametric statistics ie analysis of variance (ANOVA) in unrelated subjects using 
SPSS (v9.0). In each test, normal distribution was assessed by the Levene test for 
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homogeneity of variance. If this was significant, data values were logarithmically 
transformed and the non-parametric Kruskal Wallis test was used. When available co-factors 
was deemed to have an influence on the variance of a particular trait, such as age on BMI or 
WHR, then these were included as a covariant in the analysis (ANCOVA), alternatively in 
the case of known strong dimorphic effects such as gender on BMI and WHR, groups were 
separately analysed. RMR were analysed by ANOVA but were first adjusted for 
covariables by using a linear regression coefficient (a) according to Astrup [19991. The 
linear regression coefficient (a) was derived from the regression line generated from the 
variable to be adjusted and known influencing factors ie RMR with FFM and FM, and leptin 
with BMI. Each value of RMR was then adjusted towards the mean value that intersects the 
regression line according to the equation as follows: 
RMR 
adjusted = RMR actual +[ (FFM mean - FFM actual) xaI (and also FM) 
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CHAPTER 4: 
STUDY OF TWO UCP2 GENE VARIANTS IN CAUCASIAN OBESE AND SOUTH 
INDIAN TYPE 2 DIABETIC SUBJECTS 
4.1 SUBJECTS 
South Indian subjects were used both from the Chennai cross-sectional urban survey 
(n=453) and family collection (n=85 families). In addition a cohort of one hundred and fifty- 
six non-diabetic obese subjects and one hundred and five slim normoglycaemic volunteer 
controls. All previously described in chapter 3. 
4.2 METHODS 
4.2.1 PCR Analysis of UCP2 exon 8 45bp Insertion/ Deletion 
PCR fragments of 412bp or 457bp were amplified using primers: 
Forward Primer 5'-CAGTGAGGGAAGTGGGAGG-3' 
Reverse Primer 5'-GGGGCAGGACGAAGATTC-3' 
Standard 'Hotstart PCR' (3.3.5) in a 25µl reaction volume. 
PCR profile: initial denaturing at 95°C for 3 min; 30 sec at 94 °C; 20 sec at 55°C; 20 sec at 
72°C; for 40 cycles with a final extension of 72°C for 10 min. 
PCR products were resolved on a 2% agarose gel. Homozygotes for the variant were 
verified by sequencing (3.6) 
- -J 
Figure 4.2.1: Image of agarose gel electrophoretic separation of UCP2 exon 8 variant. 
From left; Ins/Del Heterozygote, Ins/Ins, (4x) Del/Del, 100bp DNA Marker. 
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4.2.2 Analysis of the A55V variant 
A PCR fragment of 127bp was amplified using primers: 
Forward Primer 5'-GGGCCAGTGCGCGCTGCAG-3' 
Reverse Primer 5'-CAT17GGCGCTGCAGGCCGG-3' 
Standard `Hotstart PCR' (3.3.5) in a 25µl reaction volume. 
PCR profile: initial denaturing at 95°C for 3 min; 30 sec at 94 °C; 30 sec at 57°C; 30 sec at 
72°C; for 35 cycles with a final extension of 72°C for 10 min. 
PCR-gRFLP: A Bbv I restriction site engineered in the forward PCR primer: 
5'GGOOCAGTGCGCGCTGCAGCCAGCG 
Blue= Primer, G=replaced A in sequence to generate Bbvl site. C -T polymorphism. 
Bbv I Recognition Site 5'... GCAGC(N)g.... 3' 
3'.. . CGTCG(N)12.... 5' 
PCR Products (7µl) were digested in a 25µI volume, including 2.5µl of IOx NEB Buffer 2; 
1 mM spermidine and incubated 5 hours at 37 T. 
Restriction fragments were separated by on a 3% agarose gel GCC =Alanine cuts to give 
100bp and 27 bp fragments, GTC= Valine 127 bp uncut. 
Figure 4.2.2: Gel Image of A55V polymorphism- BbvI restriction digest. Five lanes in 
order from left were; 100bp DNA marker; Ala/Ala; 2x Ala/Val; Val/Val. 
4.3 RESULTS 
4.3.1 Characterisation of the UCP2 exon 8 variant 
Sequencing of five British Caucasians and five South Indians identified a 45bp 
insertion/deletion in exon 8 of the UCP2 gene, 158bp downstream of the the 3' TGA stop 
codon, and located in the non-coding 3'UTR. The insertion (Ins) comprised of a duplication 




Figure 4.3.1: Insertion/Deletion sequence in UCP2 exon 8 3'UTR. Green = 45bp 
Insertion/Deletion; Sequence was essentially the same as subsequently published in French 
Caucasians [Otabe et al 1998] but with discrepancies at T=C and T =A compared to GDB 
sequences (Accession U76367) and in Hispanics [Walder et al 1998]. 
Three UCP2 genotypes (Ins/Ins, Ins/Del and DeUDel) were defined unambiguously 
according to length variation of exon 8 PCR product with insertion (457bp) or deletion 
(412bp). The frequency of alleles in the South Indian survey were; 0.81/ 0.19 for Del /Ins 
alleles accordingly. Similarly in the British Caucasian controls the deletion had a frequency 
of 0.82. The heterozygotes had a frequency of 28% and 30% South Indian and British 
Caucasian cohorts respectively, with homozygosity for the Ins allele at a frequency of 5% 
and 3.6% respectively. The observed frequencies did not significantly depart from those 
expected by Hardy Weinberg equilibrium in either the South Indian survey (p=0.07) or in 
British Caucasian study group (p=0.8). 
4.3.2 Association studies of UCP2 45bplns/Del with T2DM in South Indians 
Family association studies using ETDT, revealed no association between T2DM and the 
45bp Ins/Del variant, with 25 transmissions vs 30 non-transmissions observed for the Del 
allele from heterozygous parents to T2DM probands (Pearson x2 = 0.45, ldf, p= 0.5). 
Calculations of power for TDT carried out under the assumption that the disease related 
allele is the Ins allele with a frequency of 0.19 and with 85 families. There would have been 
85% power to detect ap value z 0.003 if the genotype risk ratio (GRR-y) was equal to 2 or if 
the y =1.5 there would have been only 46% power to detect ap value ; -> 0.06. 
In the South Indian urban survey the allele and genotype frequencies were not significantly 
different between either the T2DM or IGT/IFG subjects, and the normoglycaemic subjects, 
Pearson x2 = 2.41,6 d. f, p= 0.88 (table 4.3.1). There was also no difference between family 
T2DM probands and survey non-diabetics (p=0.9). 
There was also no significant difference in genotype frequencies between male and female 
normoglycaemic subjects p=0.76 (table 4.3.2). Comparison of genotype frequencies of both 
urban survey T2DM subjects and T2DM probands divided by gender either as individual 
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groups or as a single combined group, with all the normoglycaemic subjects or by gender, 
found no significant differences between the groups (p values in range 0.2 to 0.9). 
UCP2 exon 8 Genotype 
Subjects 
n 
Del/Del Ins/Del Ins/Ins 
S Indian Normoglycaemics 318 67.3% (214) 27.4% (87) 5.3% (17) 
S. Indian T2DM 80 68.8% (55) 27.5% (22) 3.8% (3) 
S. Indian IGT/IFG 55 63.6% (35) 32.7% (18) 3.6% (2) 
S. Indian T2DM probands 84 69.0% (58) 25.0% (21) 6.0% (5) 
Table 4.3.1: Genotype Frequencies for UCP2 exon 8 variant in South Indians. Sample 
numbers for each genotype are in parentheses 
UCP2 exon 8 Genotype 
Subjects 
n 
Del/Del Ins/Del Ins/Ins 
Male Normoglycaemics 162 65.4% (106) 29.0% (47) 5.6% (9) 
Female Normoglycaemics 156 69.2% (108) 25.6% (40) 5.1% (8) 
Table 4.3.2: Genotype Frequencies for UCP2 exon 8 variant in Normoglycaemic South 
Indians by gender. 
4.3.3 Analysis of variant with quantitative traits in South Indians 
In the survey South Indians, an association was found between the exon 8 variant and BMI 
in females only (figure 4.3.2, Table 4.3.3; p=0.018), but not in males (p = 0.33). Females 
homozygous for the Ins allele had higher BMIs than either heterozygous or homozygous Del 
subjects. Re-analysis of data using a co-variate of age, still found the main effect was 
between BMI and genotype UCP2 (p=0.015; overall model p=0.036). Similar results were 
found when parents (n=143) from the South Indian families were analysed (table 4.3.3) (p < 














Figure 4.3.2: Boxplot - BMI with Exon 8 genotype in survey South Indian 


















Figure 4.3.3; Boxplot -BMI with Exon 8 genotype in mothers from South Indian 
families. Key as for 4.3.2 
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DD ID II Pvalue 
n MEAN BMI n MEAN BMI n MEAN BMI 
(SD) (SD) (SD) 
Family 41 24.6(±3.0) 28 22.9(±3.4) 2 30.8 (± 2.5) 0.003 
fathers 
Family 50 25.2 (t 3.8) 19 25.7 (t 4.1) 3 33.9 (t 7.1) 0.002 
mothers 
Survey 155 22.1 (t 3.7) 65 22.3 (t 3.6) 13 20.6 (t 3.8) 0.33 
Males 
Survey 149 23.2 (t 4.6) 62 22.1 (t 4.3) 9 26.4 (t 4.5) 0.018 
Females 
Table 4.3.3: Results of ANOVA analysis of BMI -exon 8 genotypes in South Indians. 
BMI was normally distributed in all four groups and were not significant for Levene Test of 
Homogeneity of Variance. 
DD ID II Pvalue 
n MEAN WHR n MEAN WHR n MEAN WHR 
(SD) (SD) (SD) 
Family 41 0.94 (± 0.04) 28 0.94 (± 0.06) 2 0.97 (± 0.02) 0.57 
fathers 
Family 50 0.87 (± 0.06) 19 0.87 (± 0.06) 3 0.82 (± 0.02) 0.31 
mothers 
Survey 153 0.9 (± 0.06) 65 0.92 (± 0.05) 13 0.88 (± 0.09) 0.018 
Males 
Survey 147 0.84(± 0.06) 62 0.85(± 0.07) 9 0.82(± 0.04) 0.32 
Females 
Table 4.3.4 _Results of ANOVA analysis of WHR and exon 8 genotypes in South 
Indians. Survey males were not normally distributed, values were log transformed and non- 
parametric Kruskal-Wallis Test used. 
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In respect of WHR, only the survey males had a significant association with the 
homozygous Ins subject group having a lower mean WHR (table 4.3.4). This association 
was not replicated in fathers or found in female subjects. 
4.3.4 Analysis of variant with quantitative traits in South Indian families 
The transmission of the insertion/deletion was also investigated with traits relating to T2DM 
and obesity in the South Indian families, using Quantitative TDT. Application of the 
Orthogonal model both with and without sex as a covariant found no significant associations 
with transmission of either Ins or Del alleles to offspring with, BMI, Waist, Hip, WHR, age 
of diagnosis, height, fasting plasma glucose levels, and 120 minute OG'IT. The Total 
association method was also applied within the QTDT analysis program, with the null model 
variances based on a non-shared environment and polygenic disease, and again all traits 
tested above were non-significant. 
4.3.5 Analysis of 45bp Ins/Del and A55V variants with obesity 
In obese British Caucasians, both the 45bp Ins/del Insertion allele (0.27 obese vs 0.19 lean 
controls), and the A55V valine allele (0.27 obese vs 0.20 lean) were increased in frequency 
compared to lean subjects (tables 4.3.5 and 4.3.6). 
TOTAL UCP2 45bp Ins/Del Genotype 
n Del/Del Ins/Del Ins/Ins 
Lean subjects 
BMI< 27 
103 68.0% (70) 28.2% (29) 3.9% (4) 
Obese subjects 
BMI>30 
152 53.3% (81) 41.4% (63) 5.3% (8) 
Table 4.3.5: Genotype frequencies of exon 8 variant in British obese/lean subjects 
Statistical analysis by 2x3 contingency tables found association of A55V variant significant, 
(Pearson x2 = 6.65; 2 df, p=0.036) and exon 8 variant borderline non-significant (Pearson 
x2 = 5.48; 2 df, p=0.064). However, the A55V association was not significant following 
correction for multiple testing. 
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TOTAL UCP2 A55V Genotype 
n Ala/Ala Ala/Val Val/Val 
Lean subjects 
BMI< 27 
104 55.8% (58) 38.5% (40) 5.8% (6) 
Obese subjects 
BMI>30 
167 40.1% (67) 49.7% (83) 10.2% (17) 
Table 4.3.6: Genotype frequencies of A55Vvariant in British obese/lean subjects 
Since it was impossible to generate haplotypes with the two variants, as allele phase was 
unknown. Instead an interaction was sought between both genotypes and phenotype. Female 
subjects only were analysed for the presence of both the Ins allele and Val allele (table 
4.3.7). The presence of both the Ins and Val alleles was significantly increased in female 
obese subjects compared to female lean controls, Pearson X2 = 3.92; 1 df, p=0.03), with 
approximately two fold increase in risk to disease (OR =1.88; 95%CI 1.002-3.54. ). There is 
strong linkage disequilibrium between the Ins and Val alleles (table 4.3.14). 
TOTAL UCP2 45bp Ins/Del +A55V combinations 
N 45bp Ins + A55V Val 
combination 
45bp Ins + A55V Val 
combination 
not possible 
Lean subjects BMI< 27 71 26.8% (19) 73.2% (52) 
Obese subjects BMI>30 130 40.8% (53) 59.2% (77) 
Table 4.3.7: UCP2 variant combination frequencies in British female obese/lean 
subjects. 
4.3.6 Analysis of 45bp Ins/Del and A55V variants and traits of obesity 
In the British Caucasoid obese subjects, both the exon 8 variant and the A55V were 
analysed with underlying traits associated with obesity. No association with BMI or WHR 
with either variant was found in female subjects (tables 4.3.8 and 4.3.9) 
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UCP2exon 8 Ins/Del Genotypes 
DD ID II 
MEAN [SD] MEAN [SD] MEAN [SD] P values 
(n) (n) (n) 
BMI 41.0 [± 6.41 39.3 [± 6.4] 39.5 [± 5.2] 0.24 
(84) (66) (8) 
WHR 0.84 [± 0.08] 0.86 [± 0.07] 0.88 [± 0.07] 0.32 
(77) (64) (7) 
Table 4.3.8: ANOVA analysis of anthropometric traits in female British Caucasian 
Obese subjects with exon8 variant. Sample numbers are in parentheses. Levene test of 
homogeneity of variances for, BMI p= 0.87, WHR p=0.86. 
UCP2 A55V Genotypes 
Ala/Ala Ala/Val Val/Val 
MEAN [SD] MEAN [SD] MEAN [SD] P values 
(n) (n) (n) 
BMI 39.8 [±6.61 40.5 (±6.91 40.3 [±6.11 0.8 
(61) (72) (11) 
WHR 0.83[± 0.07] 0.83 [± 0.06] 0.87 [± 0.03] 0.18 
(56) (69) (10) 
Table 4.3.9: ANOVA analysis of anthropometric traits in female British Obese subjects 
with A55V variant. Numbers in parentheses Levene test of homogeneity of variances for, 










Figure 4.3.5: Linear regression RMR correlated with FFM 
Seventy-four obese subjects had both RMR and bioelectrical impediance data allowing 
adjustment of RMR for both fat free mass (FFM) and fat mass (FM). Correction of RMR 
values was performed by simultaneous generation of linear regression coefficients, 
correlating both FFM and FM with RMR (both were significantly correlated Pearson 
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Correlation p<0.0001 for both FFM & FM individual regressions figures 4.3.4 & 4.3.5) 
and application of correction equation (3.8.4). The regression coefficient values (a & b) 
generated for FFM were 24.227 and FM 6.645, and then used in conjunction with 
appropriate means, FFM 57.0 kg and FM 53.58 kg to correct actual RMR. ANOVA of 
adjusted RMR values (Levene test of homogeneity p=0.4) were not significantly associated 
with either the exon 8 Ins/Del or A55V variants (table 4.3.10 & 4.3.11). 
UCP2exon 8 Ins/Del Genotypes 
DD ID II 
MEAN [SD] MEAN [SD] MEAN [SD] P value 
n=37 n=31 n=6 
RMR adjusted 1728 [± 174] 1735 [± 190] 1714 [± 1061 0.96 
Table 4.3.10: Analysis of RMR adjusted for FFM and FM with UCP2 exon8 variant in 
Caucasian Obese subjects. 
UCP2 A55V Genotypes 
Ala/Ala Ala/Val Val/Val 
MEAN [SD] MEAN [SD] MEAN [SD] P value 
n=26 n=40 n=8 
RMR adjusted 1734 [± 175] 1732 [± 182] 1707 [± 158] 0.93 
Table 4.3.11: Analysis of A55V variant in Caucasian Obese subjects with RMR 
adjusted for FFM and FM. 
In ninety-six female obese subjects fasting plasma leptin levels were available. Leptin levels 
were found to be associated with both exon 8 and A55V genotype using ANOVA, p=0.007 
and p=0.03 respectively. Leptin levels are correlated with BMI (Pearson Correlation 
p=0.018), therefore leptin values were corrected by using BMI as a covariant in an 
ANCOVA analysis (tables 4.3.12 and 4.3.13). 
In the obese females the lowest corrected fasting leptin values were significantly associated 
with the heterozygotes for both the 45bp Ins/del and A55V variants (figures 4.3.6 & 4.3.7). 
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Although the mean fasting leptin concentration in the four homozygotes for the exon 8 
variant was higher than the heterozygotes, the 95% confidence limits spanned the 
confidence limits for both the heterozygotes and the homozygote wild. 
UCP2exon 8 Ins/Del Genotypes 
DD ID II 
MEAN [SD] MEAN [SD] MEAN [SD] P value 
n=45 n=36 n=4 
Leptin 43.2 [± 15.4] 32.9 [± 13.7] 45.6 [± 16.9] 0.005 
Table 4.3.12: ANCOVA for UCP2 45bp Ins/Del variant in female Caucasian Obese 
subjects for Leptin corrected for BMI. (Levene test of homogeneity p= 0.7) 
UCP2 A55V Genotypes 
Ala/Ala Ala/Val Val/Val 
MEAN [SD] MEAN [SD] MEAN [SD] P value 
n=34 n=45 n=4 
Leptin 44.1 [t 13.71 35.1 [± 16.6] 38.4 [± 8.11 0.01 
Table 4.3.13: ANCOVA of UCP2 A55V variant in female Caucasian Obese subjects for 


















50 B 37 
2.00 3.00 
Figure 4.3.6: Boxplot -A55V variant and plasma Leptin levels corrected for BMI. 
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Figure 4.3.7: Boxplot -45bplns/Del and plasma Leptin levels corrected for BMI 
Genotype (x-axis) 1.0=Ins/Ins, 2.0 =Ins/Del, 3.0=Del/Del. leptin µg/l (y-axis) 
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4.3.7 Linkage Disequilibrium between UCP2 variants 
Alleles Alleles Haplotype Frequency 
A55V locus Exon 8 locu Independent With Association 
Ala Ins 0.16 0.035 
Ala Del 0.54 0.666 
Val Ins 0.068 0.195 
Val Del 0.23 0.10 
Table 4.3.14: Linkage Disequilibrium (EH) between UCP2 variants 
In Caucasian subjects (n= 256) there was significant LD between the exon 8 45bp Ins/del 
and A55 V variants, x2 = 128.34, ldf, p=0.009x 10"27. 
4.4 DISCUSSION 
The identification of a frequent and novel 45bp deletion /insertion variant in exon 8 (3' 
UTR) of the UCP2 gene following initial sequencing data and in response to a priori 
information (D. Ricquier and C. H. Warden personal communication) led subsequently to 
association studies on this variant. Prior to the identification of this variant the only other 
common variant identified and studied was a missense C to T transition in exon 4 that 
caused an Alanine to Valine amino acid change at codon 55 (A55V) (figure 4.4.1). In 
addition, a number of rare variants have also been identified including: Exon 1: C19T and 
C27G and in Exon2: C97T (5'UTR) were found in three French Caucasians [Otabe et al 
1998]. Exon 4: G to A variation causes a Glycine to Serine substitution at amino acid 
position 85 in one family, but does not segregate with either morbid obesity or T2DM in 
French Caucasians [Otabe et al 1998]. Exon 5: G694A causes an Alanine to Threonine 
amino acid substitution at position 232 in several Japanese subjects but has no association 
with either T2DM or obesity [Kubota et al 1998]. Subsequent to the work in this thesis a 
novel promoter variant was identified, -866 G/A. This variant was found to be associated 
with enhanced adipocyte expression. The common allele conferred a population attributable 
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UNTRANSLATED REGIONS S=Stop Codon TGA & 3'UTR for UCP3S (275aa) 
L=Stop Codon TGA & 3'UTR for UCP3L (312aa) 
Figure 4.4.1: Exon structure and common variants of UCP3/UCP2 genes. 
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4.4.1 T2DM 
Investigations in this thesis of the UCP2 45bp Ins/Del variant in both the South Indian urban 
survey and family collections found no evidence for association with either T2DM or IGT. 
Associations were also negative when analysed by gender. Power calculations for the 
number of families used suggested that there was 85% power to detect an association if this 
variant afforded a doubling of risk to disease to offspring, although if the variant afforded a 
lower relative risk then there would have been insufficient power to detect an association. 
However, the lack of association in the population based study supports the findings in the 
families. These observations are in accord with other reported studies, with no linkage with 
the UCP2/UCP3 cluster with T2DM in North European populations [Elbein et al 1997; 
Ghosh et al 2000; Watanabe et al 2000] or Pima Indians [Hanson et al 1998] and no 
association in obese French Caucasians, Japanese or Pima Indians [Otabe et al 1998; 
Shiinoki et a] 1999; Walder et a] 1998]. The A55V variant although not studied in diabetics 
in this thesis was found to be in strong LD with the 45bp Ins/Del variant in the British 
Caucasians. The A55V was also reported not associated with T2DM in several studies 
including obese French, Danish and Japanese subjects [Otabe et al 1998; Urhammer et al 
1997b; Kubota et al 1998; Shiinoki et al 1999]. 
4.4.2 Obesity 
A number of linkage studies using either overt obesity phenotype and/or related quantitative 
traits (mainly BMI) have found no evidence of linkage to the chromosome 11g13 [Norman 
et al 1998; Elbein et al 1997; Chung et al 1999; Comuzzie et al 1995; Hager et al 1998; Lee 
et al 1999]. However, a majority of these studies probably lacked the power to completely 
exclude the region. Nevertheless, one linkage study in French Canadians did find suggestive 
linkage with percentage fat mass (p=0.02) and also strong linkage with RMR (p=0.00002) 
[Bouchard et al 1997]. Furthermore, the first published linkage disequilibrium studies on 
variants of UCP2 (and UCP3) in Pima Indians found that heterozygotes of the 45bpIns/Del 
had both lower BMI and higher SMR [Walder et al 1998]. 
Case-control studies in British Caucasians in this thesis of the common exon 8 Ins/Del and 
A55V variants found the less common Ins allele (exon 8) and T-allele (A55V-Val) 
respectively both had increased frequencies in the obese subjects compared to lean controls. 
However, only the A55V variant reached formal levels of significance before correction for 
multiple testing. The observed simultaneous increased allele frequencies of both the exon 8 
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Ins/Del insertion allele and the Val allele is most likely a reflection of the LD that was found 
to exist between these alleles (table 4.4.14). This LD relationship has also been confirmed in 
other later studies [Yanovski et at 2000]. 
Comparison of British Caucasian subjects who would be capable of forming possible 
haplotypes with the positively associated insertion and Val (T) alleles (although actual 
chromosomal phase was unknown) with those subjects which could not, conferred a two 
fold increase in risk to obesity. In two contemporary studies in French and Danish 
Caucasians no association was also found between the 45bp Ins/Del variant and overt 
obesity [Otabe et at 1998; Dalgaard et al 1999]. Although in obese Caucasian subjects 
across a number of studies the frequency of the exon 8 Ins allele appeared to be reasonably 
consistent at 0.30,0.25,0.3 land 0.27 in Danish, French, German and British subjects in this 
thesis respectively [Otabe et at 1998; Dalgaard et at 1999; Evans et at 2000]. In contrast, 
whereas the allele frequency in the control lean subjects were similar to obese patients in the 
Danish and French at. 0.29 and 0.23 respectively, in the British lean controls the frequency 
was substantially lower at 0.18. These observations might suggest that the small sample 
number in the British lean control group could have generated an unrepresentative allele 
frequency and hence a type I error. However, a similar allele frequency of 0.19 for the exon 
8 insertion allele was also obtained from nearly a thousand South Indian samples although 
presumably this group are ethnically less similar to the British than the French or Danish 
Caucasians. 
Disparity between the studies could also be due to the differences in gender ratio within 
each study population. The British subjects studied in this thesis were predominantly female 
(86%), whereas in the Danish study they consisted entirely of male subjects, and the French 
group were predominantly male (70%). Interestingly a study in German obese subjects that 
were also predominantly female (81%), the exon 8 insertion allele was significantly 
increased in morbid obese subjects (p=0.002) [Evans et at 2000]. Furthermore, the exon 8 
variant frequencies in the German study in obese and lean controls (0.31vs 0.22) were more 
consistent with the findings in in this thesis than in the Danish or French studies. 
In addition, a lack of replication in some contemporary studies may be the result of 
genotyping misclassification. In the French study no subjects were homozygous for the exon 
8 insertion allele [Otabe et al 1998]. However, in both British and South Indian populations 
studied in this thesis between 3% and 5% were homozygous for this allele. Similarly the 
Ins/Ins genotype was detected at frequencies of 5% to 21% in many other studies including 
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Pima Indians, Danish, African/White-/Asian Americans, Japanese, and in three German 
populations [Walder et al 1998; Dalgaard et al 1999; Yanovski et al 2000; Shiinoki et al 
1999; Evans et a! 2000]. 
Investigations of traits associated with obesity and predisposing to T2DM in the South 
Indian ethnic group found a significant association with the 45bp Ins/Del variant Ins allele 
with increased BMI in the survey female subjects, but not in males. The homozygous Ins/Ins 
subject group had the highest mean BMI compared to either Ins/Del or Del/Del genotype 
groups, although heterozygotes had the lowest mean BMI overall. This association was 
further confirmed by analysis of the parents in the South Indian families, where both 
genders were highly significantly associated. In respect of WHR, a lower mean WHR in the 
survey males homozygous for the Ins allele was also observed. However, the association 
with WHR was not replicated in the families and neither of these findings were replicated in 
South Indian families using QTDT analysis, with the transmission of the Ins or Del alleles to 
offspring uncorrelated with any variance of anthropometric measurements used. 
In studies in both Germans and Pima Indians the Ins allele of the 45bp Ins/Del variant was 
also similarly significantly associated with increased BMI, [Walder et al 1998; Evans et al 
2000]. Moreover, in both studies this relationship was more significant when analysis was 
restricted to subjects greater than 41 (±8.0) and 45 years old respectively. When the trait 
data in the South Indian survey was re-analysed using a co-variate of age the main effect 
was still between BMI and UCP2 45bp Ins/Del variant (p=0.015). 
Heterozygotes for the 45bp Ins/Del also had the lowest BMI in both Pima Indians [Walder 
et al 1998] and North European Caucasians [Cassell et al 2000] consistent with the 
observations in female South Indians. No association with BMI and the 45bp Ins/del variant 
was also observed in the all male Danish study, consistent with the findings in the South 
Indian survey [Dalgaard et al 1999). In contrast a study in normal weight children 
comprising of a mixture of three ethnic groups, Asian, African American, and White found 
that heterozygotes for the 45bp variant significantly had the highest BMI, although del/del 
had the lowest BMI and Ins/Ins were the same as heterozygotes [Yanovski et al 2000]. This 
was also confirmed in that the percentage of overweight children was greatest in the subject 
group that possessed the Ins allele. Interestingly, in this study significant LD (p=0.001) was 
found between the exon 8 45bp variant and the exon 4 A55V with the same Ins-Val allele 
relationship as observed in this thesis. However, although children homozygous Val/Val 
(T/T) for the A55V variant had the highest percentage of overweight individuals consistent 
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with Val in LD with the Insertion allele. Ala/Val heterozygotes incongruously had a similar 
overweight frequency to the subjects with the Ala/Ala genotype. In a study of Danish 
Caucasian subjects a weak association was detected with the A55V variant in with juvenile 
onset obesity (p=0.04), and in a general population study (p=0.07) [Urhammer et al 1997b]. 
Interestingly, heterozygotes for the A55V variant had a lower BMI than A/A homozygotes, 
consistent with the LD relationship between the A55V and the exon 45bp Ins/Del. 
The findings with BMI in the South Indians was not confirmed in the obese female British 
Caucasians cohort with either the 45bp Ins/Del or A55V variants, although there was 
evidence of association with obesity with these variants. However, the extremity of the overt 
obese phenotype in the Caucasian obese patients might possibly obscure the detection of 
subtle associations of traits with genotype. 
The studies in this thesis have shown that variation at the UCP2 exon 8 45bp Ins/Del locus 
(or a variant in strong LD) could account for phenotypic differences in body mass. These 
findings have been replicated in a number of other studies in different ethnic populations 
[Walder et al 1998; Evans et al 2000; Cassell et al 2000; Yanovski et al 2000; Urhammer et 
al 1997b]. However, from the findings in this thesis and other studies it has become 
strikingly apparent that whatever the functional effect of the exon 8 variant (or a variant in 
strong LD) the effect of genotype on phenotype was more pronounced in female subjects. 
Divergence of body mass and fat distribution between genders has been demonstrated both 
in Asian Indians and other ethnic groups, with differences reported being evident both well 
before puberty and in newborns [Snehalatha et al 1997; Taylor et a] 1997; Guihard-Costa et 
al 1997]. Therefore it could be conceivable that there would be gender differences in the 
genes influencing adipose accumulation. 
Correlations between UCP2 mRNA levels and BMI have been demonstrated in obese 
humans in both adipose tissue and skeletal muscle [Millet et al 1997&1998; Bao et al 1998; 
Nordfors et al 1998; Oberkofler et al 1998]. Similar differences in the expression of UCP1 
in intraperitoneal tissue between obese and lean have been previously observed [Oberkofler 
et al 1997] and it was suggested that a common sequence variation in the UCP1 gene 
appears to account for variability of cellular UCP1 mRNA abundance [Esterbauer et al 
1998]. 
A recent study found that subjects homozygous for the more frequent (0.63) G allele of a 
common G/A polymorphism at -866 in the promoter region of UCP2 associated with 
increased BMI in German Caucasians [Esterbauer et al 2001]. This novel variant and the 
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45bp Ins/Del variant appeared also to be in linkage disequilibrium and it was found that 
certain haplotypes of the two variants accounted for a significant increase in risk to obesity, 
with a population attributable risk of 15%. Functional studies found the -866 promoter 
variant associated with enhanced adipose tissue expression of UCP2 both in vivo and in 
reporter studies in adipocyte cell lines. It was further proposed that the promoter variant 
might influence weight gain by modulating the relative abundance ratio of UCP2 mRNA 
species containing either the insertion or deletion allele [Esterbauer et al 2001]. 
Interestingly, there was also further evidence of a gender difference in the allele frequencies 
of the -866 promoter variant. 
4.4.3 RMR 
In the cohort of British Caucasians studied there was no evidence of any association with 
either UCP2 variant with RMR. However, there is evidence for linkage of markers in the 
vicinity to UCP2 with RMR and the 45bp Ins/Del variant was found associated with 
sleeping metabolic rate (SMR) (adjusted for FFM and FM) and 24 hour EE in Pima Indians 
[Bouchard et al 1997; Walder et al 1998]. Pima subjects heterozygous for both the 45bp 
Ins/Del and A55V variant independently had higher SMR than either of the homozygotes. 
Walder et al (1998) suggested that this observed increase in SMR and 24hr EE could 
account for the significant association of the heterozygotes for the 45bp Ins/Del, with lower 
BMI in subjects over 45 years old, as was similarly found in the female South Indians 
studied in this chapter. 
However, close examination of the published Pima Indian data revealed a disparity with 
both the South Indian findings and other contemporary studies [Evans et al 2000; Urhammer 
et at 1997b; Esterbauer et at 2001 ]. In the Pima Indian study, subjects that were homozygous 
for exon 8 Ins/Ins and A55V Val/Val independently have higher SMR and 24hr EE 
compared to Del/Del and Ala/Ala respectively. By inference from the same logical 
conclusion made for the heterozygotes, the Ins/Ins and Val/Val would have been expected to 
have a lower BMI than the homozygous Del/Del and Ala/Ala. This was not only contrary to 
the findings in the South Indians and other studies, but also within the Pima Indian study 
itself, with the highest mean BMI associated with the Ins/Ins genotype (mean BMI ±SD 
Ins\Ins 38.4 ±13.4, Del/Del 34.6 ±14.7, Ins/Del 33.7 ±13.6; p=0.04). 
In contrast to the Pima Indian study and more consistent with observed BMI associations, a 
study in Danish Caucasians found both sleeping EE and 24 hr EE lower in the A55V 
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Val[Va1 carriers than either the AlaNal and Ala/Ala subjects [Astrup et al 19991. When 
measurements of 24hr spontaneous physical activity (SPA) were also taken into account, the 
ValIVal subjects had a normal 24hour EE for body size and composition, but with a 3% 
lower resting EE compared to other two genotypes. These findings were interpreted by the 
authors that carriers of the Val/Val genotype exhibited an enhanced metabolic efficiency and 
lower fat oxidation compared to other genotypes. These findings were further supported by 
the observation that in Danish subjects who were homozygous Valine at A55V had 
increased energy efficiency during exercise [Buemann et al 2001]. 
However, the lack of association with RMR in this thesis study was also complemented by 
two other negative association studies analyzing both common UCP2 variants and a linkage 
study [Klannemark et at 1998; Tu et at 1999a; Chung et al 1999]. Nonetheless, the 
measurement of RMR is not entirely equivalent to the measurements of SMR and 24 hour 
EE, as although RMR is an important determinant of 24hour EE, it only accounts for 
approximately 50-80% of daily energy expenditure [Ravussin et al 1986]. 
4.4.4 Leptin 
Experimental findings for the obese British Caucasian females indicated that heterozygotes 
for both the 45bp Ins/Del and the A55V variant were significantly associated with a lower 
serum leptin concentration corrected for BMI, than either homozygous genotypes in the 
presence of extreme obesity. However, subjects homozygous for A55V Ala/Ala had the 
highest mean leptin levels, with a similar trend in homozygous 45bp Del/Del. These results 
suggest an altered interaction between BMI, leptin and two common UCP2 variants. 
Subjects homozygous for the Ins/Ins (or Val/Val) were also associated with higher BMI in 
South Indian females, Germans [Evans et al 2000], Pima Indians [Walder et al 1998] and 
obesity in the British Caucasians (4.4.2). This may infer that the increased leptin levels 
observed in the Ala/Ala (Del/Del) subjects may be some way protective against weight gain. 
However, observations that subjects heterozygous for either the 45bp Ins/Del or A55V 
tended to have a lower BMI in South Indians, Northern Europeans, Pima Indians and Danish 
Caucasians, also had the lowest leptin levels in British Caucasian subjects was inconsistent 
with this hypothesis [Cassell et a] 2000; Walder et al 1998; Urhammer et al 1997b]. 
In humans plasma leptin concentrations have been correlated with fat mass although there is 
considerable individual variation in levels with comparable degrees of obesity, suggesting 
that some individuals produce relatively lower leptin plasma levels [Ramachandran et al 
130 
1997c]. Variation in leptin levels could dictate eventual body mass outcome, with data in 
non-diabetic Pima Indians showing that lower leptin levels both precede an increased 
tendency to gain weight and are predictive of weight gain, independent of insulin secretion, 
insulin sensitivity and metabolic rate [Ravussin et at 1988 & 1997]. Gender also influences 
plasma leptin concentrations with levels observed to be higher in both obese and non-obese 
females compared to males matched in body composition [Saad et at 1997; Hellstrom et at 
2000; Wauters & Van Gaal 1999]. The gender difference appears not to be entirely due to 
just an increased proportion of adipose tissue but also to higher production rates of leptin per 
unit mass of adipose tissue in females and influences related to reproductive processes. 
Ethnic differences on leptin levels have also been apparent with Japanese having increased 
leptin levels in subjects with a propensity to gain most weight with levels progressively 
increasing with age [Chessler et at 1998]. The age related increase presumably due to 
increasing leptin resistance with age, similar to that observed in rats [Li et at 1997]. 
In rodents a relationship definitely exists between leptin and uncoupling proteins. Leptin 
modulates UCP2 expression both positively in adipocytes (WAT) and pancreatic islets 
independently of dietary intake [Scarpace et at 1998; Zhou et at 1997] and negatively in 
WAT and hepatocytes in the ob/ob and db/db obese animal models [Gimeno et at 1997; 
Chavin et at 1999; Melia et at 1999; Larrouy et at 1997]. Observations that chronically 
infused intra-cerebroventricular (ICV) administration of leptin into rodents effects 
peripheral UCP2 transcript levels, suggests that leptin may regulate UCP2 by a form of 
central action [Cusin et at 1998]. However, ICV infusion of leptin also results in both the 
suppression [Combatsiaris & Charron 1999] and enhancement of UCP2 mRNA levels in 
WAT in rodents [Qian et at 1998; Cusin et al 1998]. A biphasic leptin effect has also been 
shown with younger rats suppressing UCP2 in WAT, whilst older rats have enhanced UCP2 
expression [Qian et at 1998]. These conflicting findings might reflect the possible degrees of 
tissue resistance to leptin, as in older rats the effects on UCP expression were less dramatic 
with higher plasma leptin concentrations [Li et at 1997]. 
Leptin also appears to modulate UCP3 expression in rodent skeletal muscle, with most 
studies showing UCP3 expression consistently up-regulated by leptin, in some cases 
dramatically [Liu et at 1998; Boss et at 1998c]. UCP3 expression in muscle and BAT is 
highly sensitive to the effects of leptin in neonate mice [Villarroya et at 2001]. However, 
there are very few studies in humans investigating the role of leptin in pathways involving 
UCP2 and UCP3. One study shows a complete lack of any correlation between leptin levels 
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and UCP2 expression in intra-peritineal WAT of morbidly obese subjects [Oberkofler et al 
1997]. However, in contrast increased leptin levels, and independently adiposity, were 
inversely correlated with UCP2 mRNA levels in human sub-cutaneous WAT biopsies 
[Pinkney et al 2000]. Moreover, interactions between leptin, PPARs and UCP expression 
have been established [Aubert et al 1997; Qian et al 19981, possibly implicating PPARs in 
mediating these effects via PPAR response cis-elements (PPRE) identified in the 5' 
regulatory regions of both UCP2 and UCP3 [Tu et a] 1999b & 2000; Acin et al 1999; 
Pecqueur et al 1999]. 
It appears with some degree of certainty that leptin might influence uncoupling protein 
mRNA expression however there is currently no evidence to suggest that the reverse is also 
true. Although a quantitative trait locus influencing leptin levels has been identified in a 
mouse model of diet induced obesity and diabetes locating in the same chromosomal region 
as UCP2 and UCP3 [Surwit et al 1998]. 
Leptin receptors have been found on a variety of tissues including the central nervous 
system, pancreatic islet cells, haemopoietic cells and adipocytes. It has been suggested that 
uncoupling proteins could directly influence the function of cells or tissues by at least two 
separate mechanisms [Boss et al 2000]. Firstly, fat induces the expression of UCP2/UCP3 
and this might be linked to a role in preventing the toxic effects of excessive fat metabolism. 
Increased fat oxidation causes an increased provision of electrons for the electron transfer 
transport chain in excess of ATP demands and results in the overproduction of apoptotic 
reactive oxygen species (ROS) [Chavin et al 1999]. Induction of UCP2 could limit this 
toxicity by reducing proton motive force and decreasing the back-pressure on the proton 
pumps in the electron transfer chain. 
Alternatively, UCP2 could limit the effects of lipotoxicity by altering cellular fuel utilization 
[Wang et al 1999]. Excess calorie intake results in the overloading of adipose tissue and 
subsequently other tissues such as liver, pancreas and muscle and is characteristic in obese 
diabetics [McGarry & Dobbins 1999; Danforth 2000]. Increased lipid accumulation in 
various rodent tissues including pancreatic ß-cells, and liver has been shown to impair their 
function [Unger et al 1999]. However, the over-expression of UCP2 in isolated lipid loaded 
pancreatic islets of the fa/fa rat clearly improved glucose stimulated insulin secretion [Wang 
et al 1999]. Impairment of overall uncoupling protein function, either by reduced 
expression, reduced mRNA turnover, or protein activity could compromise the function of 
other endocrine tissues such as adipose tissue, and hence leptin secretion. 
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Impairment of cellular function by ROS could also render cells less sensitive to the action of 
leptin. UCP2 is abundantly expressed in mouse brain tissue, including those tissues involved 
in leptin mediated neuropeptide Y expression [Richard et al 1998&1999]. UCP2 could by 
controlling ROS production influence the process of neural degeneration, post leptin 
receptor signalling transduction pathways, therefore modulating the neuro-endocrine 
appetite pathway [Wang et al 1997]. Reactive H202 have also been shown to induce UCP2 
expression in vitro in pancreatic 3-cells and protect against the detrimental effects of 
oxidative stress in this organ and possibly delay onset of T2DM [Li et a! 20011. 
However, all these mechanisms still remain unclear as up-regulation of UCP2 expression in 
rodents has also been demonstrated to impair pancreatic n-cell function, acting as a potent 
inhibitor of insulin secretion, possibly though the disruption of multiple pathways by 
decreasing cellular ATP production and availability [Chan et al 2001; Zhang et al 2001]. A 
relationship with variants of UCP2 with insulin was not observed in the studies in this thesis 
in South Indians (fasting and 120 min) and British Caucasians. In a number of other studies 
involving hyperinsulinaemic clamps in humans no modulation of UCP2/UCP3 mRNA 
levels by insulin was also observed [Urhammer et al 1997b; Millet et al 1997]. 
Leptin has been shown in rodents to activate energy expenditure, reducing food intake and 
increasing metabolic rate, possibly through changes in thermogenesis causing loss of body 
weight and fat mass [Halaas et al 1995; Pelleymounter et at 1995; Hwa et al 1996 & 1997]. 
Whether uncoupling proteins can enhance or disrupt this pathway and if truly there is an 
interaction between UCP2 genotype and leptin levels in humans still remains to be 
elucidated. However, a genetic determinant that could modulate leptin levels although 
possibly insufficient to lead to overt obesity by itself, but may be a contributor to weight 
gain or even weight loss. 
4.4.5 UCP2 Variants-Functional Effects 
The A55V amino acid substitution in exon 4 has been predicted to occur in the matrix 
orientated extra-membraneous loop between the first and second transmembrane domains 
based on a hydrophiliciy model [Vidal-Puig et al 1997; Klaus et al 1991]. The alanine 
residue is conserved at this position in the mouse UCP2 protein, but is replaced by tyrosine 
and leucine in the respective positions in human UCPI and UCP3 proteins respectively. 
However, this is a conservative amino acid change and no significant functional aberrations 
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were observed when activity of the protein was assessed in a yeast expression vector [Fleury 
et al 1997]. 
The half-lives of most mRNA are influenced by the structure of the 3'UTR, a region that 
can work as an instability determinant independent of the remainder of the mRNA molecule 
[Ross 1995]. Insertion of sequences in the 3'UTR can change the positional relationships of 
important stability determining cis-elements. Therefore it could be envisaged that a 45bp 
insertion or deletion in the 3'UTR could potentially have an effect on mRNA stability. 
Furthermore, there could also be disruption of the intimate cell specific interactions of 
environmental factors affecting mRNA stability and longevity via trans-acting factors and 
hormones [Ross 1995]. 
Variation in mRNA stability as result of genotypic differences could affect protein levels 
and could either enhance or compromise the action of that protein in physiological 
pathways. However, studies by Walder et al [1998] did not find a significant difference in 
UCP2 mRNA levels in skeletal muscle of Pima Indians according to the 45bp Ins/Del 
genotype. Although this does not preclude a possible effect of the 45bp Ins/Del variant on 
post-translational modification, or translation of UCP2 mRNA, which could result in altered 
levels, and/or activity of mature protein, that might be tissue specific. 
Alternatively he 45bp Ins/Del could be in LD with a causative mutation in the UCP3 gene, 
only 8249bp upstream of UCP2 [Pecqueur et al 1999] or with mutations in the important 
regulatory elements of UCP2 that extend 1400bp towards UCP3 [Esterbauer et at 2001; 
Pecqueur et at 1999; Tu et al 1999b]. 
In summary, the findings presented in this chapter show a consistent association between 
BMI and the less common insertion allele of a UCP2 gene exon 8 variant in South Indian 
female subjects. This variant is in LD with the exon 4 A55V variant and the presence of a 
combination of the less frequent Insertion allele and (T)-Valine allele may also confer an 
increased risk to obesity in British Caucasians. However, contemporary replication studies 
both support and refute these findings. The associations observed with the UCP2 variants 
may be the result of linkage disequilibrium with causative mutations either in the promoter 
of UCP2 or in UCP3. Studies in chapter 5 were designed to identify and analyse variants 
within the core promoter and coding regions of the UCP3 gene. 
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CHAPTER 5: 
MUTATION SCREENING OF THE UCP3 GENE: IDENTIFICATION OF A 
NOVEL PROMOTER POLYMORPHISM. 
5.1 SUBJECTS 
A core group of eighteen subjects were sequenced comprising of six subjects identified as 
homozygous for the 45bp insertion at UCP2 exon 8, six homozygous for the deletion, and 
six heterozygous subjects. The group ethnically consisted of 50% South Indian (T2DM and 
non-T2DM) and 50% obese British Caucasian for each UCP2 genotype. However, during 
the course of sequencing extra randomly selected Caucasian and South Indian subjects were 
sequenced for certain exons to verify ambiguities. This resulted in some instances of over 
forty subjects being sequenced for certain regions. 
Subjects used for subsequent screening of any identified variants of were the same as for 
chapter 4 and as described in chapter 3. 
5.2 METHODS 
5.2.1 Direct Sequencing of UCP3 Coding Region 
The seven exons and intron/exon splice junctions of the UCP3 gene (figure 4.4.1) were 
sequenced in all eighteen subjects. PCR primers were designed using PRIMER 3 program 
(www. hgmp. mrc. ac. uk) using the following Genome Database deposited sequences; 
Accession numbers, AF012196 for exon 1; AF012197 for exon 2; AF012198 for exon 3; 
AF012199 for exon 4; AF012200 for exon 5; AF012201 for exon 6; and AF012202 for exon 
7. Direct sequencing was by standard methods using an ABI 373 DNA Sequencer and 
TaqFS Dye terminator cycle sequencing kits (Perkin-Elmer, Applied Biosystems, 
Warrington, UK) or Thermo Sequenase dye terminator cycle sequencing kit-(Amersham 
Life Science Inc, Ohio Cat No US79765). Primers were as for PCR. 
PCR (25µl) reaction conditions were standardised for all exons with adjustments made to 
MgC1 concentration as per as table 5.2.1. 
Standard PCR profile with a pre-denature at 94°C for 5 minutes followed by 30 cycles of: 
30seconds at 95°C; 30seconds annealing at temperatures as per table 5.2.1; and 60 seconds 








PCR FORWARD PRIMERS 5'-3' PCR REVERSE PRIMERS 5'-3' 
Exon 1 56(1.5) 153 AGGAGGGGCCATCCAATC AAGGGATGAGGGAGGAGAAA 
Exon 2a 60(l. 5) 247 AGCCAGGCCAGACATCAC CAGTGGAAAGGTAACGAGG 
Exon 2b 60(1.5) 203 AAAGGGACTGGGCAGAGC AGCCCCTCCTTCCATGTG 
Exon 3 55 (2.0) 345 TGTGCACGCAGCCCCTFC CTAGACTTCCCTGGTCTCTTGAC 
Exon 4 55 (2.0) 381 GCAGCCCCGCAGAGAAC ACGCCATGCTGGGAGTCC 
Exon 5 55 (1.7) 245 CCATTTCTCCCATTTCCC GCCCACTCCACGGAGTTC 
Exon 6 55 (1.5) 242 TTTGCTTGTCCTTCCTCTGC TTCTCTGGGAGGGAGTGCT 
Exon 7 55 (1.0) 250 GCACTCCACCTGATGTGTTG ATGTGTGGGTCTGTGTCCAT 
Table 5.2.1: Primer sequences used for screening of the UCP3 gene exons 
5.2.2 Identification and Sequencing of core promoter region: 
Sequence data, but no functional information was available for the 5' UTR at the inception 
of these studies. Therefore the putative 5' regulatory region for UCP3 was predicted using 
several computer programs [UK HGMP Resource Centre]. Analysis of the UCP3 gene 
sequence (GDB Accession AF032871), using the Prom Predict program identified two main 
putative regulatory regions, numbered from the first codon, at -21 to-300 and -2200 to - 
2400. A second computer program, Neural Net Promoter Prediction (NNPP), identified a 
similar region encompassing part of exon 1 and 400 bases upstream, including both the 
putative TATAA and CCAC boxes. PCR Primers were designed using the PRIMER 3 
program (HGMP), to amplify a region to include the start of the coding region of exon I and 
500 bp upstream. 
Forward Primer 5'-AGAGACCTGGGAGAGCTGTG-3' 
Reverse primer 5'-TGAAAGCCTCCAATGAAAGG-3' 
Both primers had a Tin of 60°C. A standard 25µl PCR reaction was used (3.3.2)). The same 
PCR profile was used essentially as for the UCP3 exons in the preceding section except a 
55°C annealing temperature was used. The 495 bp PCR product was sequenced in the same 
18 subjects used for the coding region mutation screen. 
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5.2.3 PCR-RFLP Analysis 
Exon 6 splice donor site variant: 
PCR profile: HotStart PCR (3.3.5) with Standard PCR protocol (3.3.2) with an annealing 
temperature of (55°C) and 35 cycles. Primers used were: 
Forward Primer 5'-GGGCACTGTGAGAGATATGGA 
Reverse Primer 5'-CAGCTGACCCACGGTAG 
Fok I Restriction Digest: 
Recognition Sequence 5'... (13/9) CATCC... 3' 
Numbers in parentheses indicate point of cleavage as non-palindromic enzyme. 
Restriction mix/sample 25µl: 
Sterile, deionised water 10.5µl 
Fok I RE lOxBuffer(Appendix I) 2.5µl 
Spermidine (10mM) L0µ1 
FokIlenzyme (10units/µl) 1.041 
PCR Product 10.0µl 
Fok I digests were incubated overnight in at 37°C waterbath and products separated on a 3% 
Agarose gel (3.5.6). Product sizes were 396bp for uncut allele and, 316bp and 80bp cut for 
mutant allele. 
UCP3 Va1102 Ile, G304A variant: 
PCR profile: HotStart PCR (3.3.5) with Standard PCR protocol (3.3.2) with an annealing 
temperature of (58°C) and 38 cycles. 
Forward Primer; 5'-CCAGCAGGGTTCCTGTGC 
Reverse Primer; 5'-CCTGGTCTGCCTCTGAGTCT 
Tth III1 Restriction Digest: 
Recognition sequence 5'.. . GACN/NNGTC... 3' 
Restriction mix/sample 251Al: 
Sterile, deionised water 9.0µ1 
TthIHI RE lOxBuffer (appendix I) 2.5µl 
Spermidine (µg/µ1) l. 0µ1 
TthllIlenzyme (4units/µl) 2.5µl 
PCR Product 10.0µl 
PCR products were digested overnight at 65°C and products separated on a 3% MetaPhor 
agarose gel, (3.5.6). Uncut product size was 376 bp. An internal non-polymorphic TthIIII 
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site produced two fragments in the A/A homozygote, of 295bp and 81bp. The G/G 
homozygote gave three fragments of 249,81, and 46bp. The heterozygote should give four 
bands of 295,249,46 and 81 bp (81 bp being a double band). Positive African DNA controls 
kindly provided by Dr PJ Saker (Imperial College, London). 
UCP3 promoter-55c/t polymorphism: 
The -55 cot polymorphism was genotyped using a restriction-generating RFLP assay. 
PCR profile: HotStart PCR (3.3.5) with Standard PCR protocol (3.3.2) with an annealing 
temperature of 57 °C and 35 cycles. 
Forward Primer; 5'- GGATAAGGTTTCAGGTCAGGC-3' 
Reverse Primer; 5'- AAGGGATGAGGGAGGAGAAA-3' 
A Hae III restriction site was engineered into the 194bp PCR product. 
PCR primers Underlined, bold- forward primer with generated restriction site; 
Uppercase -HaeIII restriction recognition sites; 
Red base-C converted to G to create HaeIII site 




HaeIII Restriction Digestion: 
Recognition sequence 5'... GG/CC... 3' 
Restriction mix/sample 25pl: 
Sterile, deionised water 11.0µl 
Hae III RE lOxBuffer (Appendix I)2.5µ1 
Spermidine (10mM) l. 0µ1 
Hae III enzyme (10units/µl) 0.75µ1 
PCR Product l0.0µ1 
The 194bp PCR product was digested overnight at 37°C. A second naturally occurring non- 
polymorphic HaeIII site (uppercase-black) conveniently provided an internal control for 
digestion. The less frequent T variant allele only cuts at the non-polymorphic site giving 
bands of 84 and 110bp: The common C variant gives 20,64 & 110 bp fragments. The 
heterozygote generating 110,84,64 and 20 bp fragments. Restriction fragments were 
separated on 3.5 % Metaphor agarose gel, under Rapid gel run conditions for 1 hour (section 
3.5.6). 
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Figure 5.2.1: UCP3-55 promoter variant. Agarose gel separation of HaeIII digestion 
products. From left to right, homozygous T variant (110bp+84bp); (2x) Heterozygotes 
(110+84+64+20bp not visible); (3x) homozygous C wild type (110+64+20bp not visible); 
homozygous T variant; and DNA size marker. 
5.3 RESULTS 
5.3.1 Variants identified by Sequencing 
Sequencing of the UCP3 in 18 subjects, revealed no new mutations in coding regions. Two 
previously described silent variants, T-C in exon 3 (codon 99 tyrosine to tyrosine) and 
C-->T in exon 5 (codon 210, tyrosine to tyrosine) were identified in the sample group. 
For the Tyr99Tyr, 16 of the 18 subjects had the T allele; the one remaining subject had the 
variant C allele and was a homozygote for the UCP2 45bp Del allele (one no data). In 
respect of the Tyr2lOTyr the most common allele in the 18 subjects (South Indian and 
British Caucasoid) was the T allele present in 5 of the 6 UCP2 45bp Ins/Ins homozygotes 
(one no data), 4 of 6 heterozygotes (one no data) and 2 of 5 Del homozygotes (one no data). 
Although numbers sequenced were small there was little evidence to support that the exon 3 
Tyr99Tyr polymorphism was in linkage disequilibrium (LD) with the UCP2 45bp Ins/Del 
variant, and therefore it was studied no further. However, there was a suggestion that the C 
allele of Tyr2lOTyr may be in LD with the 45bp Del allele, as the C allele appears to be 
absent in Ins/Ins homozygous subjects, although this also could not be tested formally due to 
small numbers. The Tyr210Tyr variant was also not pursued as no contemporary published 
had found any association with this variant with any disease phenotypes or traits. 
In the initial sequencing only the wild type common G allele was observed in both the exon 
3 Val 10211e variant and the exon 6 splice donor mutation in the eighteen obese 
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Caucasian/South Indian sample. This analysis was further extended by PCR-RFLP (5.3.2). 
In addition, analysis of data for all subjects sequenced found only wild type alleles for all 
other rarer UCP3 variants identified in other studies including, Val9Met (3 Obese 
Caucasians, 9 Asians), C288T (8 Obese Caucasians, 8 Asians), G732C (30 Obese 
Caucasians, 17 Asians), Arg282Cys (25 Obese Caucasians, 9 Asians), and C/T intron 4 
mutation (7 obese Caucasians, 4 Asians). 
170D k66 T-C A8 
I 
0 
Figure 5.3.1: Sequencing Electropherogram showing UCP3 promoter C-T transition: 
from top: homozygous T, heterozygote, Homozygous C, 6bp upstream of putative TATA 
box and 4bp downstream of a putative PPAR/RXR site. 








3121 CTTCTCCTTG ' '" ' ""'"": "' ' ;''. ' '^". .. ''' , GAGAGCAGCCCCGAGCAGTCAGGGC 
Figure 5.3.2 UCP3 Promoter sequence showing position of novel mutation. From GDB 
Accession AF032871: Homo sapiens UCP3 gene, exonl and partial exon 2.1'CR and 
sequencng Primers, putative tata box at 2939-2945, 
2988=1 (Start of exon 1, first base transcibed) Novel c to t polymorphism at-55. 
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However, in the putative regulatory region (exon I and 400 base pairs upstream) a novel 
variant was identified consisting of aC to T transition located 6 bases upstream of the 
putative TATA box (figures 5.3.1 & 5.3.2) [Vidal-Puig 1997; Solanes 1997], at nucleotide 
position -55 within the putative core promoter of the UCP3 gene. LD with the UCP2 45bp 
Ins/del variant was difficult to ascertain at this stage due to small numbers, but preliminary 
data suggested the T allele could be weakly in LD with the Del allele (table 5.3.1). The 
location of this polymorphism and its possible association with UCP2 prompted further 
investigation. 
5.3.2 RFLP analysis of UCP3 Variants 
The mutant A alleles of the common African exon 3 variant Va1102Ile and the important 
exon 6 splice donor mutation were not observed by sequencing in either South Indian or 
British Caucasian subjects, but as numbers were small both variants were further analysed 
by PCR-RFLP. RFLP analysis revealed no variant alleles in either the Va1102Ile (total 
subjects including sequencing; 0/9 Obese Caucasians, 0/39 Asians) or the exon 6 splice 
donor site (total subjects; 0/30 Obese Caucasians, 0/38 Asians). This further confirmed that 
both variants are probably absent or at an extremely low frequency in South Indian and 
White North European populations. 
5.3.3 -55 variant association with diabetes in South Indians 
The frequency of the variant t-allele was 18% in the South Indian urban survey, 21% in the 
South Indian trios and 21% in unrelated British Caucasians. There was no statistically 
significant deviation from the expected genotype values for Hardy-Weinberg equilibrium in 
either the South Indian survey, x2 =0.58, p=0.44, or British Caucasians, x2 =2.94, p=0.09. 
TDT analysis in the South Indian families revealed no evidence for excess transmission of 
either allele to the T2DM offspring. In 58 heterozygous parents, 31 transmitted the t-allele 
and 27 the c-allele (x2 =0.184, p=0.67). Power calculations were performed under the 
assumption that the disease related allele was the t allele with a frequency of 0.21 (n= 85 
families). Using a muliplicative model, with ay (GRR) equal to 2 (double the risk), there 
would an 87% power to detect ap value >_ 0.002, however if 'y = 1.5, there would be only 
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48% power to detect p>0.05. If the disease related allele was the C allele at a population 
















BOC DD CC TT GG CC 
BOC DD CT CC GG TT 
BOC DD CT TT GG -- 
SI DD CC TT GG CC 
SI DD CC TT GG TT 
SI DD CC TT GG CC 
BOC ID CC TT GG -- 
BOC ID CT TT GG CT 
BOC ID CT TT GG TT 
SI ID CC TT GG TT 
SI ID CC TT GG TT 
SI ID CT TT GG TT 
BOC II CC TT GG TT 
BOC II CC -- GG TT 
BOC II CT TT GG TT 
SI II CC TT GG TT 
SI II CC TT GG TT 
SI II CC TT GG -- 
Table 5.3.1 Comparison of UCP3 variants with UCP2 45bp Ins/Del variant 
BOC=British Obese Caucasian; SI= South Indian 
In the South Indian survey, the t allele had a frequency of 17.6% in normoglycaemic 
subjects, 15% in IGT, and 21% in T2DM subjects There was no significant association 
between -55 cot genotype and glucose tolerance status (table 5.3.2; survey NGT, IGT/IFG, 
T2DM, and T2DM probands) for both genotypes and allele frequencies, Pearson X2 =1.7, 
4df p=0.80; and x2 =1.44 2df, p=0.49 respectively. When subjects were separated by gender, 
no difference (p=0.8) was observed in the genotype frequencies between sexes in the survey 
normoglycaemic subjects (table5.3.3). There was also no significant difference in the 
genotype frequencies between male and female T2DM subjects (survey and probands n= 98; 
p=0.6; survey and probands n=67; p=0.7 respectively) compared to normoglycaemics. 
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UCP3 -55 C/T Genotype 
CC CT TT (n) 
Survey NGT 67.3% (212) 29.2% (92) 3.5% (11) 315 
Survey IGT/IFG 72.7% (32) 25.0% (11) 2.3% (1) 44 
Survey T2DM 62.8% (49) 32.1% (25) 5.1% (4) 78 
T2DM probands 61.4% (51) 37.3% (31) 1.2% (1) 83 
Table 5.3.2: UCP3 -55 variant frequencies in South Indian subjects. Sample numbers in 
parentheses. NGT= Normoglycaemic. 
UCP3 -55 C/T Genotype 
CC CT TT (n) 
Survey male NGT 66.9% (109) 30.1% (49) 3.1% (5) 163 
Survey female NGT 67.8% (103) 28.3% (43) 3.9% (6) 152 
Table 5.3.3: UCP3 -55 variant frequencies between sexes in South Indian survey 
normoglycaemic subjects. 
5.3.4 -55 variant analysis with quantitative traits in South Indians. 
Analysis of quantitative traits in both South Indian families and survey subjects revealed 
that the less frequent UCP3 -55 t-allele was associated with increased WHR (table 5.3.4; 
Figures 5.3.3 & 5.3.4). This observed association was only significant in female subjects but 
was similar across three groups, mothers (p = 0.036), female probands (p=0.032), and 
survey females (p=0.039). This association was not seen in any complementary male groups 
(table 5.3.4). Families were further analysed using the "total association" method 
implemented by QTDT program irrespective of offspring gender, but including sex as a 
covariate. Shared environment effects were also taken into account in this analysis. 
Interestingly, the association between the UCP3-55 variant and WHR was confirmed 
(p=0.029). However, using QTDT (Allison's QTDT5 model) to assess transmission from 
heterozygous parents to offspring, no significant effects were seen for WHR. 
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UCP3 -55 cot genotype P values 
n cc ct/tt 
South Indian trios 
Fathers 85 0.95 (0.05) 0.95 (0.06) 0.81 
Mothers 85 0.87 (0.07) 0.90 (0.08) 0.036 
Male probands 54 0.93 (0.04) 0.95 (0.05) 0.10 
Female probands 31 0.84 (0.07) 0.89 (0.06) 0.032 
South Indian urban survey 
Males 235 0.91(0.06) 0.91(0.06) 0.63 
Females 220 0.84(0.06) 0.86(0.07) 0.039 
Table 5.3.4: ANOVA analysis of UCP3 -55 variant with WHR in South Indians. 
Homozygous t-allele subjects were very rare (I. 4%), so were pooled with the heterozygous 
subjects. WHR data is given as mean (SD). 
No association was found between the UCP3 -55 variant and BMI with either gender (table 
5.3.5). However, surprisingly given the absence of any genotype-related differences in the 
BMI means (table 5.3.5), evidence for the skewed transmission of the -55 c+t variant was 
seen for BMI (p=0.028 with sex as covariate) in families using QTDT, with higher BMI 













Figure 5.3.3: Boxplot of association of -55 variant with WHR in South Indian mothers. 
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Figure 5.3.4: Boxplot of association of -55 variant with WHR in South Indian survey 
females. 1.00=C homozygous, 2.00=presence of T allele (C/T & T/T) 
UCP3 -55c4t genotype P values 
n cc ct/tt 
South Indian trios 
Fathers 85 23.9 (20.6-27.8) 24.2 (21.2-27.6) 0.74 
Mothers 85 25.4 (21.5-30.0) 25.4 (21.6-29.9) 1.0 
Male probands 54 25.7 (22.3-29.7) 27.0 (22.6-32.3) 0.28 
Female probands 31 26.4 (22.6-30.9) 26.3 (21.2-32.5) 0.94 
South Indian urban survey 
Males 235 21.6 (18.0-25.9) 21.9 (18.6-25.7) 0.57 
Females 220 22.5 (18.4-27.4) 23.0 (18.8-28.1) 0.40 
Table 5.3.5: ANOVA analysis of UCP3 -55 variant with BMI in South Indians. BMI 
data is given in kg/m2 as geometric mean (SD range). 
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5.3.5 Case/control study of -55 variant in obese Caucasians 
The allele frequency of the UCP3 -55 variant t-allele in lean was 21%, and in obese 22%. 
Analysis for differences in genotype frequencies by 3x2 contingency tables, were not 
significant, Pearson x2 =0.023,2df, p=0.99 (table 5.3.6) 
UCP3 -55 variant Genotypes TOTALS 
cc ct tt (n) 
Lean Subjects 58.4% (45) 40.3% (31) 1.3% (1) 77 
Obese Subjects 57.4% (81) 41.1%(58) 1.4% (2) 141 
TOTALS (n) 57.8% (126) 40.8% (89) 1.4% (3) 218 
Table 5.3.6: Genotype frequencies for UCP3 -55 variant in British Obese and lean 
subjects. Sample numbers in parentheses 
5.3.6 Study of variant with intermediate traits in obese subjects 
Quantitative traits related to obesity were assessed in unrelated female obese subjects only. 
RMR was adjusted for both FFM and FM, and fasting leptin was corrected for BMI in 
subjects with available data. No significant association was observed with any of the traits 
analysed with the UCP3 -55 variant (table 5.3.7) 











BMI 39.4 [±6.3] (78) 40.5 [±6.9] (52) 41.9 [±0.0] (1) 0.63 
WHR 0.83[±0.06] (72) 0.84 [±0.06] (49) 0.78 [±0.00] (1) 0.51 
leptin (adj) 39.0 [±16.7] (52) 38.1[±14] (41) 40.3 [±0.0] (1) 0.95 
RMR (adj) 1703.7[±156] (40) 1765 [±195] (33) (0) 0.14 
Table 5.3.7: Analysis of quantitative traits with UCP3 -55 variant, in female British 
Obese. Levene test pvalues BMI=0.8, WHR=0.3, RMR= 0.4, Leptin=0.3. 
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5.3.7 Linkage Disequilibrium with UCP2 variants 
Linkage disequilibrium (LD) between alleles of UCP2 exon8 Ins/Del and the UCP3-55 
variant was explored using the EH program by comparing the frequencies of the haplotypes 
with that expected from allelic frequencies, under a null hypothesis assuming no LD. 
Alleles Alleles Haplotype Frequency 
UCP2 45bp UD UCP3-55 c-t Independent With Association 
I C 0.18 0.22 
I T 0.48 0.01 
D C 0.61 0.57 
D T 0.16 0.19 
Table 5.3.8: Linkage Disequilibrium UCP3 -55 and UCP2 Ins/Del variants. 
Alleles Alleles Haplotype Frequency 
UCP2 A55V UCP3 -55 c-t Independent With Association 
A C 0.55 0.57 
A T 0.14 0.12 
V C 0.23 0.21 
V T 0.06 0.08 
Table 5.3.9: Linkage Disequilibrium UCP3 -55 and UCP2 A55V variants. 
In the South Indian survey (n=443), the less common t-allele at UCP3 -55 was in significant 
LD with the more frequent UCP2 45bp Del allele, x2 = 14.7, p=0.00012 (table 5.3.7). In the 
British Caucasian cohort (n= 243) this was also confirmed, X2= 11.79, ID. F p=0.0006. 
However, there was no significant LD between the UCP2 A55V variant and UCP3-55 in the 
British Caucasian cohort (n= 239), x2 = 2.78,1D. F p=0.095 (table 5.3.8), despite the fact 
the two UCP2 variants were shown to be in strong LD (4.3.7). 
5.3.8 UCP2-UCP3 haplotype analysis in South Indian families 
Haplotypes of UCP2 45bp Ins/Del and UCP3 -55 variants were analysed for excess 
transmission to T2DM offspring using the TRANSMIT program. No significant 












Ins /c 26.77 27.2 0.019 0.87 
Del /c 104.8 99.9 1.22 0.23 
Ins /t 2.2 3.2 0.79 0.37 
Del /t 26.1 29.6 1.0 0.25 
Table 5.3.10: UCP2 45bp Ins/Del-UCP3-55 haplotype analysis in South Indian 
families. bs= number of bootstrapping calculations performed. 
5.4 DISCUSSION 
The associations found with two common variants of UCP2 in chapter 4 with intermediate 
quantitative traits leading to obesity and T2DM in South Indians and British Caucasians 
respectively, suggested that variants of UCP2 may influence certain physiological pathways 
to predispose an individual to weight gain. Alternatively the findings with UCP2 variants 
might represent linkage disequilibrium with causative mutations in other genes nearby. The 
UCP3 gene was found to be in close proximity to UCP2 and therefore could be considered a 
strong potential candidate gene [Pecqueur et al 1999]. Consequently, the coding and core 
promoter regions of the UCP3 gene were sequenced for novel variants in this chapter. 
The subsequent identification of several common UCP3 gene coding variants and a number 
of rare or ethnically specific variants in contemporary studies also allowed the incorporation 
of these into the thesis study where justified. 
Known UCP3 variants are listed below. Amino acids and nucleotides are numbered I from 
the first residue Methionine, using the sequence submitted by Boss et al (GDB; Accession 
number U84763). 
Missense Mutations: 
Exon2: Val9Met; G25A; Rare, only identified in one morbidly obese French Caucasian 
[Otabe et al 19991, one lean, two obese Caucasians [Chung et al 1999b]. 
Exon 3: Gly84Ser; Rare, only identified in two Danish healthy controls [Urhammer et al 
1998] 
Exon 3: Va1102Ile (G304A); Common in Africans [Argyropoulos et al 1998b] 
Exon 4: Argl43X; Rare, premature stop codon in one African family. [Argyropoulos et al 
1998b] 
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Exon 7: Arg282Cys (C844T); In one lean Asian, three lean and three obese Caucasians, one 
lean hispanic [Chung et al 1999b]. 
Exon 7: Arg308Trp; Rare, one morbidly obese French Caucasian [Otabe et al 1999] 
Silent Mutations: 
Exon 3: C288T; Rare, one obese Hispanic subject [Chung et al 1999b] 
Exon 3: Tyr99Tyr (TAT-TAC) T297C: Common in several ethnic groups [Chung et al 
1999; Otabe et al 1999; Urhammer et al 1998]. 
Exon 3: Ala83Ala; Rare, one control subject [Otabe et al 1999]. 
Exon 5: Tyr200Tyr (TAC-TAT) C630T. Common variant in Europeans [Otabe et al 1999; 
Urhammer et al 1998]. 
Exon 6: G732C; Rare, one obese Caucasian [Chung et al 1999b] 
Intronic variants: 
Intron 4: C-T 36bp upstream of 5' splice site of exon 5 in French Caucasians [Otabe et al 
1999]. 
Intron 3: Four rare single nucleotide polymorphisms identified in Danish subjects 
[Urhammer et al 1998] 
Other Variants: 
Splice donor site exon 6: (GGT-GAT) 1 bp downstream of exon 6 3' splice site, generating 
a transcript and truncated protein equivalent to the UCP3S transcript found in populations of 
African ethnicity [Argyropoulos et al 1998b; Chung et al 1999b]. 
5.4.1 UCP3 variants and LD with UCP2 45bplns IDel 
Sequencing of the coding regions of UCP3 in both obese British Caucasians and South 
Indians did not identify any new variants, but as the mutation screen was limited to small 
numbers, mutations at very low frequencies (<5%) could have been missed. 
Studies comparing the biochemical activity of the truncated UCP3S protein generated by the 
exon 6 splice donor site [Chung et al 1999b; Argyropoulos et al 1998b] found that UCP3S 
had a greatly reduced uncoupling activity [Hagen et al 1999] and might be responsible for a 
reduced efficiency in fat oxidation in obese subjects [Argyropoulos et al 1998b]. The 
Arg282Cys mutation, also converts a basic residue to a reactive cysteine residue, and 
appears to slightly reduce uncoupling capacity, whereas neutral variations at Vall02Ile and 
Val9Met have no effect on uncoupling activity [Hagen et al 1999]. The mutant alleles of the 
variants Val9Met, Arg282Cys, Val1021le, and the exon 6 splice variant, were not detected in 
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either the South Indian or British Caucasian subjects studied. The absence or very low 
frequency of the Vall02Ile and the exon 6 splice variants in South Indians and British 
Caucasians, was also further confirmed in North Europeans [Cassell et al 2000] and other 
ethnic groups [Chung et al 1999b; Argyopoulous et al 1998b]. These findings suggest that 
these two variants are exclusive to populations of African extraction. 
In respect of the known common silent variants, only one individual was identified with the 
C allele of the Tyr99Tyr variant, an Obese British Caucasian subject who was homozygous 
C/C and also homozygous Del/Del for the UCP2 45bp variant. All others typed (n=16) were 
T homozygous, irrespective of the UCP2 genotype. French Caucasians homozygous C/C for 
the Tyr99Tyr variant were previously found weakly associated with BMI within obese 
subjects [Otabe et al 1999], but in the South Indians and British Caucasians it is the UCP2 
45bp Ins allele that associated with increased BMI and obesity, not the deletion allele. 
However, the association in the French obese cohort was not statistically significant 
following correction for multiple testing and was also not replicated in Danish subjects with 
juvenile onset obesity [Otabe et al 1999; Urhammer et al 1998]. Superficially there appears 
to be little evidence of LD between UCP2 45bp Ins/Del and UCP3 Tyr99Tyr variants, 
although numbers were too small to evaluate formally. 
In respect of the second common silent coding polymorphism in exon 5, numbers were also 
small, but there was some evidence to suggest LD with the UCP2 variant. The C allele of 
the Tyr2lOTyr was only present in individuals carrying the UCP2 45bp Del allele. It was 
also more frequent in the Del/Del homozygotes and completely absent in subjects 
homozygous for Ins/Ins in both British Caucasians and South Indians (table 5.3.1). No 
associations with disease phenotypes or disease predisposing traits have been reported with 
the UCP3 Tyr2l OTyr variant to date. 
5.4.2 Novel UCP3 -55 variant -T2DM and obesity 
Sequencing of 500bp of the putative core promoter region of UCP3 identified a novel C to T 
transition at position -55 relative to the first codon. According to the original designation of 
transcription initiation [Vidal-Puig et al 1997; Solanes et al 1997], this -55 c/t 
polymorphism lies in the proximal promoter immediately adjacent and 6 bp upstream to the 
putative TATA box [Schrauwen et al 1999b; Otabe et a! 2000]. 
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The initial sequencing data and subsequent genotyping of a large number of South Indian 
and British Caucasoid subjects found the common UCP2 45bp Del allele was in LD with the 
less frequent t-allele of the UCP3 -55 C/T variant. However, the UCP3-55 variant in British 
Caucasians was unexpectedly not in LD with the UCP2 A55V variant, which is in strong LD 
with the UCP2 45bp Ins/Del variant and is chromosomally positioned between 5'of UCP3 
and the UCP2 3'UTR. This data might suggest that the UCP2 A55V and the UCP3-55 
variants arose phylogenetically at different times in the evolutional history of the British 
population. 
The relationship between the variation at the UCP3 -55 variant and susceptibility to 
diabetes, obesity and related anthropometric traits was further investigated in both the South 
Indian study groups and the British Caucasoid Obese/lean cohort used for the UCP2 dataset. 
The t-allele had an approximate frequency of 0.18- 0.21 in both South Indians and British 
Caucasians, however t/t homozygotes were relatively rare in both ethnic groups. However, 
neither UCP3 allele was associated with either T2DM or IGT in the South Indians. 
Furthermore the promoter variant was not associated with obesity in the British Caucasians. 
One contemporary study in French Caucasians has found a weak association with T2DM 
and the UCP3 -55 variant with that the t-allele being less frequent in diabetics compared to 
controls in two separate datasets. In contrast, in a second study in a French population no 
association with T2DM was found [Otabe et al 2000; Meirhaeghe et a] 2000]. In the positive 
French study frequencies of 0.13 vs 0.22 and 0.18 vs 0.25 were obtained in diabetics and 
controls respectively [Meirhaeghe et al 20001. This frequency of the t-allele was also similar 
(0.21) in the British Caucasian cohort non-diabetic lean subjects studied and also in two 
other studies using non-diabetic British and Danish Caucasians, at 0.21, and 0.23-0.33 
respectively [Halsall et al 2001; Dalgaard et al 2001]. However, these findings are in 
contrast to the South Indian data. The frequency of the t-allele was 0.18 in the survey non- 
diabetic subjects, similar to that of the French diabetics, but with a non-significant increased 
frequency of 0.21 in the South Indian T2DM patients. Similar frequencies were also 
observed in diabetic parents from the South Indian families utilized and also in North 
European Caucasian families, at 0.21and 0.24 respectively [Cassell et al 2000]. This 
suggests that there may be ethnic differences in allele frequencies of this variant, although 
all groups referred to above are of Caucasian extraction, the t-allele does appear to be at a 
lower frequency in the South Indian populations. 
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In another replication study using White North European T2DM families (n= 150) there was 
also no excess transmission of either allele to T2DM offspring (55 transmitted the t-allele, 
and 71 the c-allele p=0.15) confirming the findings in South Indian families in this thesis 
[Cassell et al 2000]. These findings suggest that the UCP3-55 variant is unlikely to be 
causative or in LD with a causative mutation for T2DM. 
Analysis of intermediate traits in the South Indians identified a significant association with 
WHR, but not BMI in female South Indians (mothers, female probands and females in the 
urban survey). The presence of the less frequent t-allele of UCP3 -55 was associated with an 
elevated WHR compared to subjects in which it was absent. The Ins allele of the UCP2 
45bp variant was found to be associated with increased BMI (but not with WHR) in female 
South Indian subjects in chapter 4. Since the UCP2 45bp less common Ins allele is in LD 
with the common C allele of UCP3-55, the pattern of linkage disequilibrium suggests that 
the trait associations seen with the UCP2 45bp Ins/Del and UCP3 -55 variants are 
independent of each other. However, another study in a predominantly female French cohort 
found that homozygosity for the t-allele associated with increased BMI within both obese 
and control cohorts (but without any difference in allele frequencies between the two 
groups) [Otabe et al 2000]. This association apparently conferred a 1.75 fold increased risk 
to higher BMI within the obese (OR1.75, p=0.03). The t-allele was also in LD phase with 
the C allele at exon 3 Tyr99Tyr variant and it was suggested that this might explain the 
previously reported weak association between this variant and BMI [Otabe et al 1999]. In 
the South Indians and British Caucasians studied, although numbers were small, there was 
no evidence of LD between the UCP3 Tyr99Tyr and the -55 variant. However, in European 
families a weak association was observed in male probands, with the UCP 45bp Del allele 
and increased BMI (p=0.02) [Cassell et al 2000] and given that the Del allele is in phase 
with the UCP3-55 t-allele this would support the observations in the French Caucasians 
[Otabe et al 2000] but not by the South Indian data. 
In contrast in another replication study using `free-living' female and male British 
Caucasians, the Ely collection, the t-allele was associated with a reduced BMI [Halsall et al 
2001]. Based on the LD observations in this thesis for both the British Caucasian and South 
Indian populations, these findings would be in agreement with the UCP2 exon 8 data. The 
UCP-55 variant t-allele segregates with the UCP2 45bp Del allele and is congruent with the 
association of the UCP2 45bp Del allele with a lower BMI in female South Indians. In 
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another contemporary study of Danish Caucasians with the UCP3 -55 variant comprising of 
several study groups, there was no association with either BMI or % body fat [Dalgaard 
2001]. However, the largest group in this study was entirely male. 
In replication studies involving the -55 variant, none have investigated the effect of 
genotype on fat distribution (WHR) [Otabe et at 2000; Halsall et at 2001; Dalgaard et at 
2001]. It also cannot be excluded that the either one or both of the positive results with 
UCP2 or UCP3 in the South Indians are spurious and there may be the result of confounding 
effects of population substructure that can give rise to Type 1 errors. 
QTDT analysis, that should theoretically circumvent this confounding problem, did not 
provide additional support for the WHR association. Albeit, the lack of replication in the 
families might be due to the very few informative meioses (31), as a result of low parental 
variant heterozygosity. The fact that the WHR association was confirmed in the South 
Indian families using the Total Association analysis option, suggests this interpretation was 
correct. Moreover, a concurrent parallel study on the -55 promoter variant in a large number 
of European Caucasian T2DM families also found a significant association with the t-allele 
with increased WHR in mothers (cc: 0.86(0.07) vs ct/tt 0.88(0.08), p=0.037) and by 
restricted analysis of trios with female probands (p=0.0025) [PJ Saker -Cassell et al 2000]. 
Furthermore, a similar pattern of linkage disequilibrium between UCP2-UCP3 variants was 
observed in the Europeans. This consistent relationship with the t-allele and raised WHR in 
female subjects, across two ethnically distinct populations and three independent datasets 
argues in favour of the association with WHR being genuine. 
Finally, analysis of the UCP3 -55 variant in the British Caucasian cohort found that it did 
not account for the positive correlations observed with the UCP2 exon 8 Ins/Del variant with 
leptin. No correlation was also observed with RMR, and together with UCP2 gene variants 
did not provide any evidence that either UCP locus influences metabolic rate. 
5.4.3 Functional roles of UCP3 variants 
The original sequencing data of the promoter region of UCP3 [Vidal-Puig et al 1997; 
Solanes et al 1997] positions the -55 variant at 6bp upstream of the putative TATA box. 
However, further detailed analysis of the 5' flanking region has suggested that the first exon 
extends a further 581bp upstream than previously thought, placing the site of potential 
transcription initiation further upstream [Acin et al 1999]. Potentially the UCP3 -55 variant 
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still might influence UCP3 function and/or regulation, by possible effects on cis-acting 
elements within the 5'UTR. In non-diabetic Pima Indian subjects homozygous for the -55 
c-allele, subjects had reduced skeletal muscle UCP3 mRNA expression although there was 
no difference in genotype frequencies between obese and non-obese subjects [Schrauwen et 
al 1999b]. Nevertheless, this study design did not localise the effect to the UCP3-55 
polymorphism specifically. In a study in French Caucasians it was suggested that this 
reported t-allele related increased expression may be protective against insulin resistance as 
its allele frequency was significantly reduced in T2DM patients [Meirhaeghe et al 2000]. 
The authors postulated that a diminished induction of UCP3 expression due to 
hyperinsulinaemia suppression of NEFA levels could in part influence progression to 
T2DM. However, in contrast in the same study French subjects who were homozygous for 
the t-allele also had a more atherogenic lipid profile, characterised by significantly higher 
total plasma cholesterol, LDL-cholesterol and apolipoprotein B concentrations [Meirhaeghe 
et al 2000]. 
Whereas studies in humans show that the -55 t-allele may be associated with increased 
expression of UCP3 which may detemine either an increased or decreased BMI, lower risk 
to T2DM or increased tendency to central obesity (increased WHR) as found in the study in 
this chapter [Schrauwen et al 1999b; Meirhaeghe et al 2000; Otabe et al 2000; Halsall et at 
2001]. In transgenic mice the over-expression of UCP3 in skeletal muscle causes the mice to 
become hyperphagic but they weigh less than their littermates. The striking reduction in 
adipose tissue mass observed was also combined with lower fasting plasma glucose and 
insulin levels and increased glucose clearance rates. This has provided evidence that in 
rodents an increased expression of UCP3 in skeletal muscle potentially can influence 
metabolic rate, glucose homeostasis and influence overall body mass [Clapham et al 2000]. 
Although studies have demonstrated that UCP3 displays uncoupling activity [Liu et al 1998; 
Gong et al 1997; Boss et al 1998] and skeletal muscle UCP3 expression has been negatively 
correlated with BMI, and positively correlated with metabolic rate in Pima Indians 
[Schrauwen et al 1999a]. The physiological importance of UCP3 in human energy balance 
remains controversial [Chung et al 1999]. Studies of UCP3 expression have also proved 
hard to interpret, with publications variously reporting that UCP3 mRNA levels are 
increased [Bao et al 1998], decreased [Schrauwen et al 1999b) or unchanged [Millet et a] 
1997 &1998; Boss et al 1998a; Nodfors et al 1998] in obese individuals compared to 
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controls. Thus, whilst some have interpreted elevated mRNA levels as indicative of 
compensatory UCP3 up-regulation in the face of obesity [Bao et al 1998], others have 
suggested that reduced UCP3 expression contributes to the pathogenesis of obesity 
[Schrauwen et al 1999b]. Studies in healthy male humans suggest that expression of skeletal 
muscle UCP3 (and UCP2 in both adipose and muscle tissues) is poorly correlated with 
variability in resting energy expenditure [Boivin et al 2000]. UCP3 expression in humans 
also consistently increases during acute fasting when thermogenesis is decreasing and when 
there is a decrease in resting and non-resting energy expenditure [Millet et al 1997; Boss et 
al 1998a; Weigle et al 1998; Leibel et al 1995]. 
Gender differences in associations with phenotypic traits were also observed with the UCP3 
promoter variant as with UCP2 in chapter 4 and similar arguments could also be applied. In 
addition, human muscle sympathetic nerve activity also appears to be greater in males due to 
increased abdominal-visceral fat deposition, suggesting both gender and fat depot 
differences could determine muscle thermogenic activity [Jones et al 1996]. Sympathetic 
activity is an important regulator of expression of UCP3 (and UCP2) in skeletal muscle 
[Boivin et al 2000], particularly ß-adrenergic stimulation [Oliver et a! 2000], and the degree 
of SNS activity in muscle is strongly correlated with %body fat in humans [Jones et al 
1996]. Gender differences have also been observed in ß-adrenergic stimulation of BAT 
thermogenesis in response to high fat diet in rats, with males having a greater thermogenic 
capacity and less weight gain. The more pronounced effect of UCP3/UCP2 genotype in 
female humans in determining increased fat mass and fat distribution compared to males 
observed in this thesis may reflect this gender determined diminished muscle sympathetic 
innervation and decreased thermogenesis. It is possible that under conditions of suppressed 
muscle uncoupling activity in females the ability to detect the effect of UCP2/UCP3 genetic 
aberrations could be greater as they would be more phenotypically penetrant. Moreover, the 
combined effect of a UCP2/UCP3 genetic defect and a gender/fat deposition determined 
reduction in UCP3-UCP2 expression /thermogenic activity could exacerbate an individual's 
propensity to weight gain. 
Furthermore, some of the tissue specific differences in UCP2/UCP3 expression particularly 
evident in different muscle types, and with the influence of adipose deposition patterns and 
gender effects [Schrauwen et at 2001; Jones et at 1996] this may account for the 
inconsistencies observed in many mRNA expression studies. 
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It has been hypothesised that the primary physiological role of UCP3 may be more related to 
fatty acid metabolism rather than non-shivering thermogenesis [Samec et al 1998a]. This 
based on observations that skeletal muscle UCP3 expression (and UCP2) is up-regulated by 
in vivo administration of fatty acids in both humans and rodents [Khalfallah et al 2000; 
Weigle et al 1998; Brun et al 1999b] and also high fat diet has a more pronounced effect in 
type IIA fibres [Schrauwen et al 2001]. In addition, no major impairment of regulatory 
thermogenesis was found after targeted disruption of the UCP3 gene in mice, despite altered 
mitochondrial proton leak [Gong et al 2000; Vidal-Puig et al 2000]. However, these mice 
did appear to have an impaired starvation-induced shift in muscle fatty acid partitioning 
between oxidation and storage [Muoio et al 1997]. Studies on UCP3 mRNA expression in 
human skeletal muscle biopsies also found no relationship with either RMR or insulin 
induced thermogenesis although expression positively correlated with carbohydrate 
oxidation and respiratory quotient (RQ), and negatively correlated with lipid oxidation 
[Willi et al 1998]. Interestingly this was only observed in female subjects. Furthermore, 
over-expression of UCP3 in primary human muscle cell lines promotes nutrient oxidation 
and enhances fatty-acid-dependent inhibition of glucose oxidation [Garcia-Martinez et al 
2001], further supporting a role of UCP3 in fuel partitioning. The UCP3 exon 6 splice 
variant that generates a protein equivalent to the UCP3S isoform has also been associated 
with an increased RQ and reduction in fat oxidation [Argyropoulos et al 1998b]. 
The UCP3S isoform is still capable of inserting itself into the inner mitochondrial membrane 
and is probably biochemically active but may have either reduced or enhanced activity 
[Hagen et al 1999; Hinz et al 1999b; Renold et al 2000; Bouillard et al 1994]. Differential 
expression of the two splice isoforms could potentially modulate skeletal muscle uncoupling 
activity. The ratio of the UCP3S isoform to the UCP3L isoform in muscle appears to be 
significantly increased in diabetics compared to normoglycaemic controls [Vidal et al 1999]. 
However, further studies on the relevance of the splice variants and common gene variants 
on mRNA or protein abundance and function are necessary. In this respect preliminary 
analysis of the UCP3-55 promoter variant's effect on transcription factor binding was 
untaken in Chapter 6. 
156 
CHAPTER 6: 
FUNCTIONAL ANALYSIS OF UCP3 PROMOTER POLYMORPHISM 
6.1 SUBJECTS 
Allelic specific dsDNA EMSA probes were either generated by PCR amplification of the 
UCP3 -55 variant in randomly selected subjects homozygous for the variant or dsDNA 
probes were constructed by annealing synthesised oligonucleotides. 
6.2 METHODS 
A Homo sapiens UCP3 gene, exonl sequence GDB Accession AF032871 [Solanes; Bowen] 
flanking the UCP3 promoter variant at -55 was scanned for possible putative transcription 
factor cis-acting elements using the Transcription Element Sequence Search program 
(TESS) using Transfac database v3.3, and Matlnspector (v3.2) computer programmes 
(www. hgmp. mrc. uk). 
6.2.1 EMSA UCP3 -55 probe generation 
A 92bp double-stranded EMSA DNA probe was generated by PCR (figure 6.2.1 (a)). This 
probe encompassed both the -55 variant and flanking putative cis-elements. Fifteen 25µl 
replicate PCR reactions were carried out to generate sufficient probe using Hotstart PCR 
(3.3.5) reactions and Standard PCR programme (3.3.2) with a 50°C annealing temperature 
as described in Chapter 3.7.1. Reactions were combined, lyophilised to reduce volume, 
loaded on 1% agarose gels and bands extracted (3.6.4). 
Subsequently short 20bp ds UCP3 promoter probes were generated (3.7.1) containing both 
the putative PPAR and TATA cis binding sites with a probe representing either the T or C 
allele at -55 (figure 6.2.1 (b)). Specific and non-specific competitor ds DNA fragments were 
also generated from oligonucleotides (figure 6.2.1 (c-f)). 
6.2.2 UCP3-55 EMSA assay 
Electrophoretic mobility shift assays (EMSA) were carried out as described in Chapter 
3.7.4. Poly IC was found to be optimal for the labelled kit control probe with an OCT2A 
binding site. However inclusion of Poly AT showed a marked reduction in non-specific 
binding with the UCP3-55 PCR generated probe compared to Poly IC, hence this was used 
instead. In this experiment the UCP-55 probe had the wild-type C allele. 
157 
(a) UCP3 promoter EMSA PCR generated ds probe 
TCCCCTCTCACCTCACTGCCCTCACCAGCCAGCCTCTTGTCAAGTGATCA 
GGCTGTCAACCAACTTCTCTAGGA ,ý ; GTTTCAGGTCAG000GTGTG'I'A 
'I'AAGACCAGTGCCAAGCCAGAAGCAGCAGAGACAACAGTGAATGACAA 
GGAGGG 
KEY: Probe underlined; PCR Primers and -55 C-T variant. Putative cis-acting elements: 
PPRE; TATA b0'; 
(b) Sequence of two short UCP3 promoter probes generated from oligonucleotides 
5 '-TAAGGTTTCAGGTC AGCCC/TGTGTG'I 'ATAAGAC 
ATTCCAAAGTCCAGTCGGG/ACACAC ATATTCTG 
(c) Specific competitor fragment for PPAR (DR1) binding site 
5'-TCTAGGATAAGGTTTCAGGTCAG 
AGATCCTATTCCAAAGTCCAGTC 
(d) Specific competitor fragment for TFIID binding site (TATA binding protein) 
5'-GCAGAGCATATAAGGTGAGGTAGGA 
CGTCTCGTATATTCCACTCCATCCT 




(f) Non-specific competitor fragment for consensus AP2 binding site 
5'-GATCGAACTGACCGCCCGCGGCCCGT 
CTAGCTTGACTGGCGGGCGCCGGGCA 
Figure 6.2.1: EMSA probes generated 
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ddH2O to IOµ1 final 
reaction volume 
1 2 3 4 5 6 7 
Binding Buffer (Roche) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
PoIyAT -- -- -- 0.5 0.5 
0.5 0.5 
Poly IC 0.5 0.5 0.5 -- -- -- -- 
Poly L-lysine 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Labelled -55 frag-(c) 
5n 1 
-- -- -- 2.0 2.0 2.0 2.0 
Unlabelled-55 frag (c) 
20n I 
-- -- -- -- -- 3.0 -- 
Hela Nuclear Extract -- 1.0 1.0 -- 2.0 2.0 2.0 
Labelled OCT2A probe 2.0 2.0 2.0 -- -- -- -- 
Unlablleled OCT2A -- -- 1.0 -- -- -- 1.0 
Table 6.2.1: EMSA UCP3 Experiment 1 reaction conditions 
ddH2O to 1Oµ1 final 
reaction volume 
1 2 3 4 5 6 7 
Binding Buffer 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
PolyAT 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Poly L-lysine 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
labelled Short 20bp 
probe (t ) 4n 1 
1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Unlabelled- short 
probe (t) 33n &I 
-- -- 2.0 -- -- -- -- 
Unlabelled- short 
probe (c) 33n 1 
-- -- -- 2.0 -- -- -- 




-- -- 0.2 -- -- 
Unlab TFHDfragment 
1.75 mote/ l 
-- -- -- -- -- 2.0 -- 
Unlablleled AP2 
1.75 mole/ 1 
2.0 
Table 6.2.2: EMSA UCP3 Experiment 2 reaction conditions 
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ddH2O to 10µl final 1 2 3 4 5 6 7 8 
reaction volume 
5x Binding Buffer 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
PolyAT 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Poly L-lysine 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
labelled short probe 2.0 2.0 2.0 2.0 -- -- -- -- 
(t ) 4n 1 
labelled- short probe -- -- -- -- 2.0 2.0 2.0 2.0 
(c) 4n 1 
Unlabelled- short -- -- 2.5 -- -- -- 2.5 -- 
probe (t) 33n 1 
Unlabelled- short -- -- -- 2.5 -- -- -- 2.5 
probe (c) 33n 1 
Hela Nuclear -- 1.0 1.0 1.0 -- 1.0 1.0 1.0 
Extract 
Table 6.2.3: EMSA UCP3 Experiment 3 reaction conditions 
6.3 RESULTS 
The TESS program identified the nearest putative transcription factor binding site 4 bp 
upstream to the variant at -59 AGGTCA-64, peroxisome proliferator-activated receptor 
element (PPRE). This cis-acting element binds to members of the peroxisome proliferator- 
activated receptor (PPAR) family of trans-acting factors. This was overlapped by several 
other putative binding sites including (1) TGT3 (TGTTTGT) motif a weak affinity site for 
hepatic nuclear factor 3 (HNF3); (2) Urokinase transcription factor binding element (URTF) 
also referred to as an AP1/CRE like binding site; (3) an orphan receptor of the nuclear 
receptor family chicken ovalbumin upstream promoter (COUP); (4) a Retinoid-X receptor 
(RXR-alpha) element, RXR a member of the hormone receptor superfamily that is activated 
by retinoic acid. The Matlnspector program (v3.2) identified a Retinoic acid receptor (RAR) 
related orphan receptor alpha 1 (-69 GGTC), and at-70 to -74 TAAG a putative muscle 
enhancing factor -3 MEF3 site. The putative TATA box was also identified by both 
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Figure 6.3.1: EMSA (Expl) using 92 bp UCP3 promoter fragment (C). 
Control Lanes 1-3: Labelleled OCT2A probe mobility was retarded with nuclear factor 
extract present (Lane 2-Bands underlined) compared to lane I without (arrowed). Bound 
complexes were successfully disassociated by competition with a specific competitor in 
Lane 3 (125x fold excess unlabelled OCT2A DNA probe). Control experiment confirms 
assay conditions are capable of supporting stable interaction between specific proteins and 
DNA (figure 6.3.1). 
UCP3 promoter fragment lanes 4-7: 
Labelled 92bp UCP3 -55 wild type (c) probe had unhindered mobility in Lane 1 and was 
retarded in lane 2 with HeLa cell nuclear extract presumably because of formation of 
DNA/Protein complexes. The appearance of multiple bands (at least 4) suggests the binding 
of more than one trans-acting factor. 
Addition of excess specific competitor (25 fold excess of unlabelled UCP3 (c) probe) in lane 
6 showed successful competition for interaction with proteins. However, some DNA/protein 
complexes remained intact possibly as a result of insufficient excess of unlabelled specific 
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competitor. Competition with an excess of unlabelled non-specific DNA competitor (125 
fold excess OCT2A probe) in lane 7 did not disassociate DNA/protein complexes. These 
results suggest that nuclear factors within HeLa nuclear extract specifically bind sites within 
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Figure 6.3.2: EMSA (Exp2) using short UCP3 promoter probes. 
For easy interpretation a diagrammatic representation was produced to right. 
-- 
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Competition with excess of either of the specific short probes (c or t allele) in lanes 3 and 4 
specifically prevented retardation of the labeled `t' probe by bound protein complexes 
compared to the retardation observed in lane 2 with no competitors. Competition appeared 
to be specific in that the AP2 consensus oligo did not compete for bound protein complexes 
in lane 7. 
DNA fragments containing motifs specific for either PPAR or TATA binding protein 
(TFIID) sites also successfully competed for nuclear proteins that bound the UCP3 `t' probe 
(lanes 5 and 6 respectively). Notably the upper retarded hands in these lanes 5 had different 
mobilities suggesting competition was for different nuclear proteins. 
Experiment 3: 
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Figure 6.3.3: EMSA (Exp3) using short UCP3 promoter probes. 
Lanes 1 to 4, and lanes 5 to 8 were duplicate sets using the `t' allele and `c' allele short 




either the `t'allele or the `c' allele probes were in competition with excess unlabelled `t' 
short probe (lanes 3 and 7 respectively) compared to competition with unlabelled `c' probe 
at identical concentrations (lanes 4 and 8). This was also confirmed by pixel densitrometry 
(table 6.3.1) with increase in intensity of over 25% of the non-complexed DNA probe when 
competing with unlabelled 't' allele relative to the `c' allele competitor. This suggested that 
the UCP3 promoter fragment with the `t' allele had a higher binding affinity for certain 
nuclear factors in HeLa cell nuclear extract compared to the wild-type `c' fragment. 
Non-retarded 
UCP3 probe band 




Lane 3 T T 21,358 
Lane 4 T C 16,779 
Lane 7 C T 22,277 
Lane 8 C C 16,630 
Table 6.3.1: EMSA band densitrometry values. Intensity values were derived using a 
digital camera and software to quantify pixels in a constant band sample area from 
autoradiographs (Alpha Innotec Inc). 
In summary, nuclear proteins from HeLa cells that would include an array of trans-acting 
factors bind to elements within the UCP3 gene promoter in close proximity to the -55 
sequence variation. Evidence was produced to suggest that two factors (possibly PPAR and 
TBP) might be targeting this region. Furthermore, the complexing of at least one, but 
possibly more nuclear factors to this UCP3 promoter region appeared to be compromised by 
the sequence variation at -55. 
6.4 DISCUSSION 
The novel previously unpublished UCP3 -55 promoter variant discovered in Chapter 5 was 
located only 6bp upstream to a putative TATA box identified and positioned at -45 to -49 in 
several studies [Solanes et al 1997; Vidal-Puig et at 1997; Tu et at 2000]. However, two 
further studies on UCP3 transcription initiation suggested that there could be second or 
alternative initiation sites with exon 1 extending upstream by a further 581bp or an 
alternative TATA box at -187 [Acin et al 1999; Tu et al 2000]. Although there appears to be 
some disparity in the exact structure of the 5' UTR, the scan of DNA sequence including 
and flanking the UCP3 -55 promoter variant by software that can identify sequence motif's 
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to putative trans-acting factor cis elements, identified a number of potential candidate sites. 
Putative TATA box, PPRE, RAR, RXR and MEF3 sites were all identified in close 
proximity to the variant. The presence of all these cis-element motif's within a few base 
pairs of the -55 variant suggests that variation of this polymorphism could modify the 
binding of nuclear trans-acting factors to their respective DNA sites and potentially exert an 
effect on transcription of the UCP3 gene. 
The work carried out in this chapter was a preliminary investigation to establish whether 
trans-acting factors could potentially bind to a UCP3 promoter region in close proximity to 
the-55 variant. The preliminary EMSA experiments carried out strongly suggested that at 
least one but possibly more trans-acting factors contained within the HeLa nuclear extract 
bind in a highly specific manner to this promoter region. The subsequent experiments using 
a short promoter probe that was more restricted to DNA sequence harbouring the putative 
PPRE/RXR, MEF3, TATA and variant confirmed that there were nuclear factors that have 
affinities for both the PPRE/RXR and TATA box cis-elements. Nuclear factors such as these 
are ubquituous and found in many cell types. However, the utilization of a HeLa cell nuclear 
extract instead of a skeletal muscle nuclear extract in which UCP3 specifically expresses 
would mean some other interactions could be missed, such as with the muscle specific 
MEF3. However, the location of the variant between two different trans-acting binding sites 
could potentially make it very important in the transcriptional activity of the UCP3 gene. 
The trans-acting factor search programs identified a putative PPRE site within 4bp of the - 
55 variant, and a RXR site also in very close proximity. RXR frequently heterodimerises 
with PPAR to form a DNA bound protein comlex [Mangelsdorf & Evans 1995]. Putative 
PPAR sites have been reported in the promoter region of UCP2 [Tu et al 2000; Pecqueur et 
al 1999]. A putative PPARy site amongst others has been suggested to locate to between -67 
to -56 adjacent to an upstream putative thyroid response element (TRE) at -71 to -65 [Tu et 
al 2000]. Members of the PPAR family are expressed at high levels in human skeletal 
muscle with PPARCt and PPAR3 the predominant sub-types [Auboeuf et al 1997; Costet 
1998]. UCP2 and UCP3 expression in rodents muscle and adipose cell lines has been 
separately regulated by PPARoc, PPARß and PPAR'y agonists such as 
thiazlidinediones/troglitazone, bezafibrate, WY-14.643, and known fatty acid ligands of 
PPAR's such as Linoleic acid [Camirand et al 1998; Aubert et al 1997; Matsuda et al 1998; 
Gong et al 1997; Brun et al 1999a; Pedraza et al 2000; Cabrero et al 1999; Teruel et al 
2000]. In human skeletal muscle PPAR's are potential candidates mediating the effects of 
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fatty acids on uncoupling proteins. However, the regulation of UCP2 and UCP3 could be 
controlled by intracellular metabolism and oxidation of lipids, without recruitment of 
specific nuclear receptors or these nuclear receptors could influence transcription without 
the involvement of fatty acids. Furthermore, thyroid hormone is recognised as a thermogenic 
hormone thought to exert its effect through a generalised stimulation of the metabolic 
activity of many tissues. Thyroid hormones consistently up-regulate UCP expression [Lanni 
et al 1999; de Lange et al 2001]. 
During the course of my investigation, an extensive functional study of the UCP3 gene 
promoter in muscle cell lines was reported [Solanes et al 2000). Deletion and point mutation 
analysis of the human UCP3 promoter revealed an important direct-repeat element separated 
by one base pair (DR1) between positions -71 to -59. The DRI element locates to a 
previously described putative TRE-PPRE site [Tu et al 2000]. Using EMSA this study 
demonstrated that the DR1 site bound nuclear proteins from muscle cells and that the DR1 
site is most likely comprised of both RAR and RXR cis-elements [Solannes et al 2000]. 
Furthermore, in deletion mutant reporter gene studies retinoic acid (RA) was found to be a 
transcriptional activator of the UCP3 gene transcription, but only when the DR1 element 
was present in the promoter fragment. Interestingly, this is the same site that the 
transcription factor element identification program suggested that putative PPRE, RAR and 
RXR receptors cis-elements were located. However, DRI elements are highly promiscuous 
and could be mediating responsiveness either as a retinoic acid response element (RARE) 
with a heterodimer of RAR/RXR, or alternatively as a heterodimer with PPAR/RXR, or 
with HNF-4 or COUP-TF or even as a RXR homodimer. In the studies of Solanes [2000] 
the observed increased response from all-trans RA over that of 9-cis RA, suggests that DR1 
site is most likely to be a RARE consisting of a RAR/RXR heterodimer. The DR I element 
is only 4bp upstream to the -55 variant and was included in the sequence of the EMSA 
probe used in my study. RAR an RXR nuclear factors would not be restricted to muscle 
tissue alone and would almost certainly be present in the HeLa cell nuclear extract. It is 
therefore highly probable that one or several of the nuclear factors binding to the UCP3 
probes could be doing so via the DR1 site. 
As mentioned above the limitations in experimental design in this thesis would make it 
incapable of demonstrating binding to some other important putative cis-elements that were 
recognized by the transcription element search computer software. In this respect a putative 
muscle enhancer factor (MEF3) cis-element was predicted in close proximity to the -55 
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variant and immediately adjacent and upstream to the DR1 element at -71 to -74. Although 
MEF3 is an important nuclear factor in muscle cell specific transcription of some genes it is 
unlikely to be present in the Hela cells. In the Solanes [2000] study UCP3 expression was 
largely dependent on the action of the MyoD factor via an E-box site, an important factor 
that appeared to a prerequisite for muscle specific expression of this gene. The putative 
MEF3 motif was also located in deletion fragments that appeared to be important in 
regulating UCP3 transcriptional activity [Solanes et al 2000; Tu et al 2000]. Although the 
distance of the -55 variant from this site makes it unlikely to affect binding affinities. A 
replication of EMSA experiments in this chapter using skeletal muscle nuclear extract could 
reveal other yet undetected DNA/protein complexes. 
Preliminary studies in this thesis also showed that a UCP3 promoter fragment with the -55 
t-allele appeared overall to have a greater affinity (> 25%) for nuclear factors compared with 
a promoter fragment with the c-allele. Although, these experiments could not identify which 
trans-acting factor complexes proteins were affected by the -55 variation. The differences in 
binding capacity observed could potentially either increase or decrease transcription rates 
depending on whether the trans-factors acted in an enhancer or suppressor mode. In the 
Solanes et al [2000] study, as far as can be ascertained, the human UCP3 promoter clone 
used possessed the t-allele of the -55 variant but the effect on binding to the DR1 element 
by the -55 variant was not investigated. However, in the Solannes deletion mutant 
transcription studies the most important transcription regulatory elements were found to be 
located upstream 3kb 5' of base -61 [Solanes et al 2000; Tu et al 2000]. Moreover, 
elements that might be present in DNA sequence downstream of -61 (-61 to +47) appeared 
only to have minor effects on transcription rates above basal levels suggesting that the -55 
variants may have relatively little effect on regulation of transcription [Solanes et al 2000]. 
In contrast, studies in humans have shown that in non-diabetic Pima Indian subjects 
homozygous for the -55 c-allele there is a reduced skeletal muscle expression of UCP3 
mRNA [Schrauwen et al 1999b]. Further EMSA studies are necessary to identify which of 
the trans-acting factors has its binding affinity icompromised by the -55 variation, and in 
vitro transcription assays are required to determine whetherit actually influences the 
regulation of UCP3 gene expression. 
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CHAPTER 7: 
CALPAIN 10 GENE; TYPE 2 DIABETES SUSCEPTIBILITY GENE IN A SOUTH 
INDIAN POPULATION 
7.1 SUBJECTS. 
Linkage Studies: Two hundred and twenty-four pedigrees (471 affected siblings with 278 
possible sib pairs) of North European Caucasian extraction were studied from the BDA 
Warren 2 ASP repository as described in chapter 3. These families were part of the initial 
collection of the Warren 2 and were derived from three of the six collecting centres. 
Association Studies: Subjects used were from both the South Indian urban survey (n=468) 
and family collection (n=97 families). These have all been described in Chapter 3. 
7.2 METHODS. 
7.2.1 Microsatellite markers for Linkage Study 
D2S336 AFM64zf9 D2S338 D2S2285 D2S125 D2S140 
Centromere Telomere 
116c-4 4 gc1M± * 3cW4- 3cM+ 
Figure7.2.1: Map of six linkage markers used on for studies on Chromosome 2q 
Fourteen microsatellite markers (table 7.2.1), including D2S125, were originally selected 
with reference to the Mexican American (MA) genome scan [Hanis et al 1996]. In the MA 
study markers D2S338 MLS=0.84, D2S140 MLS=1.30, and D2S395=1.78 all had nominal 
evidence for linkage [Hanis et al 1996]. Markers with high PIC values within the 20cM 
region spanning the telomeric region were selected from Genebank/Genethon databases. Six 
microsatellites (Figure 7.2.1) were finally selected (table 7.2.1 *) by map position, robustness 
of PCR, ability to score alleles unambiguously and appropriateness for multiplexing. 
Microsatellite markers were labelled, Touchdown PCR amplified and genotyped as per 
Methods section in Chapter 3. Two CEPH controls were used on every gel to control for 
inter-gel variation. 
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D2S125* 95 by TET 62 64 
D2S336* 134bp FAM 64 52 
AFMB333XG9 150bp HEX 56 52 
D2S395 155bp TET 54 56 
D2S 140* 167bp FAM 58 64 
D2S2338* 169bp HEX 52 54 
D2S407 194bp FAM 58 68 
AFMA064ZF9 227bp TET 60 56 
D2S2253 229bp HEX 66 58 
D2S2202 234bp FAM 58 58 
D2S427 245bp FAM 58 58 
D2S345 256bp HEX 48 56 
D2S2285* 262bp HEX 52 52 
D2S338 282bp FAM 60 58 
Table 7.2.1: Microsatellite markers for NIDDMI linkage analysis. 
7.2.2 Typing the UCSNP43G/A polymorphism 
Subjects were genotyped using the MS-PCR method (3.5.4). 
Primer sequence: 
Common forward primer 5'-CATCCATAGCTTCCACGCCTC 
Allele 1 (G) 5'-GCTTAGCCTCACCTTCAATC 
Allele 2 (A) 5'- ATCCTCACCAAGTCAAGCGTTAGCCTCACCTTCAAGT 
Allele specificity indicated in red and underlined nucleotides show bases mismatched with 
the template to improve the allele specificity. 
The common primer was used at a concentration of 1000 nmol/l and allelic specific forward 
primers were used at a ratio of 10: 1 (short allele 1 primer 1000 nmol/1: long allele 2 primer 
100 nmol/1). 
Hot-Start PCR (3.3.5) was carried out in a 10µ1 reaction volume: 
lOX PCR Buffer L0µ1 1.5mmol/1 MgCl2, 
dNTPS (25mM) 0.1µl 200Vmol/l each dNTP 
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Primer Forward (100pmole/pl) O. 1µ1 1000 nmol/1 
Short Reverse Primer (100pmole/µl) 0. lµ1 1000 nmol/l 
Long Reverse Primer (100pmole/µl) O. 01µl 100 nmol/1 
Qiagen Hotstar Taq Polymerase (5u/µl) O. 1µ1 
UV treated HPLC water 3.6µl 
Genomic DNA (5-lOng/pl) S. Opl 
Standard PCR amplification profile used (3.3.2) with an annealing temperature of 57°C. 
Cycling conditions were 96 °C for 15 min; and 35 cycles of 94 °C for 30sec; 57 °C for 30sec; 
and 72 °C for 30sec; followed by 10 min at 72 T. PCR fragments were separated using a 3% 
Metaphor agarose gel (3.5.6). PCR product sizes were 134bp (allele 1) and 152bp (allele 2) 
(figure 7.2 2) 
7.2.3 Typing the UCSNP44T/C polymorphism: 
This polymorphism was also typed using a MS-PCR method (3.5.4) 
Primers: 
Common reverse primer: 5'-CTCATCCTCACCAAGTCAAGGC, 
Allele 1 (T) primer 5'-CAGGGCGCTCACGCTTGCTAT, 
Allele 2 (C) primer 5'-GTGGGCAGAGGACTGGTGGGCGCTCACGCTTGCTTC. 
The reaction PCR cycling conditions were the same as for UCSNP43 except annealing at 
60°C. PCR fragments were size separated on a 4% Metaphor agarose gel (3.5.6). PCR 
product sizes were 60bp (allele 1) and 75bp (allele 2) (Figure 7.2.3). 
7.2.4 Typing the UCSNP19 Ins/Del polymorphism 
PCR Primer sequences: 
Forward 5'- GTTTGGTTCTCTTCAGCGTGGAG 
Reverse 5'- CATGAACCCTGGCAGGGTCTAAG 
Hot-start PCR (3.3.5): PCR was carried out in a 20µl reaction volume with 40ng of genomic 
DNA. PCR profile (3.3.2): 94°C for 12 min, and 35 cycles of 94°C for 30sec; 60°C for 
30sec; and 72°C for 30sec; followed by 10 min at 72°C The 32bp insertion/deletion was size 
separated on a 3% Metaphor agarose gel (Flowgen) (3.5.6). PCR product sizes were 155bp 
(allele 1) and 187bp (allele 2) (figure 7.2.4). 
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Upper hand 
Figure 7.2.2: UCSNP43 MS-PCR genotyping gel. Homozygotes allele 1 upper band 
(134/134bp), heterozygotes two bands, and homozygotes allele 2 lower bands (154/154bp) 
Figure 7.2.3: UCSNP44 MS-PCR genotyping gel. Homozygous allele 2 (75/75bp) lower 
bands, homozygous allele I (60/60bp) upper band, and heterozygotes two bands. 
Figure 7.2.4: UCSNP19 Ins/Del Genotyping gel. Lower band=homozygous (155/155bp), 
upper band=homozygous insertion (I 87/187bp), and heterozygotes have both bands. 
7.2.5 Typing the UCSNP63C/T polymorphism: 
PCR Primer sequences: 
Forward 5'-AAGGGGGGCCAGGGCCTGACGGGGGTGGCG 
Reverse 5'-AGCACTCCCAGCTCCTGATC 
PCR conditions were the same as for UCSNP19 except that the annealing temperature was 
62°C, Standard PCR protocol (3.3.2) and HotStart PCR (3.3.5). 
PCR-RFLP -Hha I Restriction digest: 
Recognition Sequence 5' ... GCG/C... 3' 
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Restriction mix total 25µl/sample comprised of: 
Sterile, deionised water 11.5µl 
Hha IRE IN Buffer (Appendix I) 2.5µ1 
Acetylated BSA (lOug/pl) 0.25µl 
Hha I enzyme IOunits/µl 0.75µl 
PCR product. 10.0111 
Restrictions digests were incubated overnight at 37°C and products separated on a 3% 
MetaPhor agarose gel (3.5.6). Digest product sizes were 162bp + 30bp for allele I (C) and 
192bp for allele 2 (T) (figure 7.2.5). 
Figure 7.2.5: UCSNP63 PCR-RFLl' genotyping gel. Upper band=homozygous allelel 
(192/192bp), lower band=homozygous allele2 (162/162bp, 30bp bands not visible), and 
heterozygotes two bands. 
7.2.6 Typing the UCSNP110 (T504A) polymorphism: 
Primer sequences for this polymorphism were: 
forward 5'-CGCCATCAGGGCAGTGGCCAAGAACAGC 
reverse 5'-CAGAGTGATGCGGACGCAGCG. 
PCR was carried out as for UCSNPI9, PCR-RFLP Hhal digest as for UCSNP63. Products 
were separated on 3% Metaphor agarose (Flowgen), the common unrestricted allele is 
196bp, variant is digested to 172bp + 24bp. 
7.2.7 Additional Statistical Analysis 
Statistical analysis for linkage, association, and quantitative traits was carried out as 
previously described in Chapter 3.8. In addition some analyses had to be modified or 
extended and these are described below. 
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Haplotype assignment in urban survey subjects: 
Haplotype frequencies and phase in the South Indian families was deduced unambiguously 
from the genotype data utilising both parental and multiple sibling genotype data with the 
TRANSMIT program (Chapter 3). Haplotype frequency information from the families also 
permitted unambiguous deduction of haplotype frequencies and phase in the vast majority of 
South Indian survey subjects without family data. In a small number of the population based 
subjects more than one haplotype phase combination was possible. Within this group the 
percentage of individuals with particular haplotype combinations were estimated based on 
the haplotype frequencies derived from the families. The assignment of haplotypes to the 
survey subjects was carried out without the use of a population haplotype phase estimation 
computer programs because programs that were widely available were based on the EM 
algorithm such as the EH program [Xie & Ott 1993]. These programs have a bias towards 
estimating in favour of the common haplotypes with a tendency to ignore rare haplotypes (< 
1% frequency). In addition these programs do not allow the inclusion of important a priori 
information, such as knowledge of haplotype frequencies from ethnic family data to improve 
efficiency in estimating haplotype frequencies. 
Analysis for transmission of `haplotype combinations: Available TDT methods were 
only capable of analysing the effect of transmission of a single allele or haplotype to 
affected offspring in families. To allow analysis of disease transmission in families as result 
of haplotype combinations a novel statistical approach was designed by Dr D. Curtis. 
Families were selected on the basis that the parents must carry at least one of the two 
haplotypes comprising the `disease risk' haplotype combination and could potentially create 
the `at risk' haplotype combination in offspring. In order to detect transmission distortion of 
a haplotype combination, the number of transmissions were counted for a haplotype 
combination to affected offspring as a proportion of the total number of parents who could 
potentially passed the combination to their offspring (i. e. those where one parent had at least 
one haplotype and the other parent the other haplotype). 
7.3. RESULTS 
7.3.1 Linkage Results 
The study in this thesis found no evidence of linkage with any marker on chromosome 2q. 
An exclusion map (Figure 7.3.1) generated by plotting non- parametric linkage (NPL) scores 
173 
against map distance, shows that NPL scores were negative across the entire 20-25cM 
region (maximum NPL score of -0.79). If the T2DM siblings had shared more of their 
alleles than would be expected by Mendelian inheritance, the NPL score would have been 
positive with a threshold significance value of NPL= 2.0 or greater. There were some 
inconsistencies in the map order with relative distances of the six markers dependent on the 
source of map information (map order in Figure 7.2.1 is based on the Whitehead Institute 
YAC map). Compared to the Genethon map, markers D2S 140 and D2S 125 were reversed 
and D2S 140 placed approximately 16cM from D2S338. However this variability made no 
difference to the final results. 
7.3.2 Allele/haplotype Frequencies in South Indians 
Allele frequencies in the urban survey for the four bi-alleleic variants were (allele1/2), 
UCSNP44,0.81/0.19, UCSNP43,0.86/0.14, UCSNP19,0.44/0.56, UCSNP63 0.97/0.03 and 
UCSNP110 0.81/0.19. Similarly in the parents from the families by gene counting the allele 
frequencies were UCSNP44 0.85/0.15; UCSNP43 0.89/0.11; UCSNPI9 0.41/0.59; 
UCSNP63 0.97/0.03. 
UCSNP110 was found to be in perfect LD with UCSNP44 and as it provides no additional 
information this locus was not analysed further. 
Three loci UCSNP44 (p=0.96), UCSNP43 (p=0.84), and UCSNP63 (p=0.36) were in Hardy 
Weinberg equilibrium, whereas UCSNP19 was not (p=0.009). This was unlikely to be due 
to genotyping error as analysis of the 32bp Ins/Del UCSNP19 was easy to interpret (figure 
7.2.4). The deviation from HWE was also not due to inbreeding, as this skew observed 
resulted from increased heterozygosity rather than homozygosity (UCSNP19 genotype 
frequency AA/Aa/aa, observed 77/260/132, and expected 91/231/146 values). In addition 
within the same population group there was no deviation from HWE either in the other three 
CAPNIO loci that are in very close proximity, or with any polymorphisms identified in both 
UCP2 and UCP3 in chapters 4 and 5. This tends to suggest that the deviation from HWE for 
UCSNPI9 is most likely due to chance. 
Haplotypes were constructed from the four loci in order UCSNP44, -43, -19, and -63. The 
assignment of haplotypes in those South Indian families with only one possible parental 
haplotype, found only 8 of the possible 16 haplotypes represented. Furthermore, only five of 
the 8 representative haplotypes had a frequency greater than 1% (table 7.3.1). The 
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identification of only five common haplotypes allowed the unambiguous assignment of 
haplotypes in a vast majority of survey subjects. In these subjects for all but four genotype 
configurations there was only one possible haplotype phase and in the four exceptions there 
was just two possible phases. Based on the family haplotype frequencies the proportion of 
individuals with one or other phase was estimated. In these groups, one possible phase 
always included one of the three rare haplotypes that in reality only applied to more or less a 
single individual. Compared with other ethnic groups (Table 7.3.1) the absence of 8 
haplotypes was consistent with other populations of similar ethnic background, with 
haplotype frequencies in the South Indians not unlike those found in Northern Europeans. 
CM NPL p info 
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Figure 7.3.1: Exclusion map for telomeric region of Chr 2q. Marker order D2S336- 
AFM-D2S338-D2S2285-D2S 125-D2S 140 
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Two three locus haplotypes, 121 and 112 constituted the Mexican-American `at risk' 
haplotype combination [Horikawa et al 2000]. Using haplotypes inclusive of UCSNP44 
these haplotypes are more or less represented by the 1121 and 1112 haplotypes here 
(table 7.3.1). This conclusion was based on the lack of a 2112 split of 1112, and the 
2121 haplotype that would split the 1121 only had a frequency of 0.3%-0.5%. The latter 
split affecting only two or three subjects in the total study. 
Haplotypes Estimated Haplotype Frequencies 
44/43/19/63 South India South India t UK $Mexican 
Family parents Survey Europeans Americans 
(n=172) (n=452) 
1121 0.37 0.42 0.36 0.32 
2121 0.00 0.005 0.00 NK 
1221 0.18 0.14 0.26 0.27 
1111 0.19 0.21 0.16 0.17 
2111 0.19 0.19 0.16 0.006 
2211 0.00 0.00 0.00 0.00 
1122 0.007 0.00 0.00 0.01 
1112 0.03 0.03 0.07 0.23 
Table 7.3.1: Population comparison of haplotype frequencies for CAPN10 SNPs: 
Mexican American data based on three loci haplotypes and T2DM risk haplotypes are in 
bold. 
7.3.3 Linkage disequilibrium of SNP's 
Pairwise linkage disequilibrium statistics (LD) statistics calculated by the EH program (table 
7.3.2) found that UCSNP's43, -44 and -19 were all in tight LD. UCSNP43 and -44 are in 
weak LD with UCSNP63, whereas UCSNP19 is in tight LD with UCSNP63; this is 
consistent with their respective map positions. 
SNP's UCSNP44 UCSNP43 UCSNP19 UCSNP63 
UCSNP44 - p<0.0001 p<0.0001 p=0.034 
UCSNP43 p<0.0001 - p<0.0001 p=0.015 
UCSNP19 p<0.0001 p<0.0001 - p<0.0001 
UCSNP63 p=0.034 p=0.015 p<0.0001 - 
Table 7.3.2: Linkage Disequilibrium of four calpain 10 loci in South Indians. 
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7.3.4 Association/linkage in families 
Family based association studies by ETDT in South Indians did not reveal any excess 
transmission from heterozygous parents for any of the four individual SNP's to probands 
with T2DM (Table 7.3.3). 
TDT-Type 
II 
Transmitted Non Transmitted p value 
UCSNP44 21 31 0.17 
UCSNP43 25 26 0.89 
UCSNPI9 31 42 0.2 
UCSNP63 11 8 0.49 
Table 7.3.3: TDT Analysis in South Indian Families 
Haplotype analysis (tables 7.3.4 and 7.3.5) in the families using the TRANSMIT program 
also found no evidence of excess transmission of any haplotype to T2DM or IGT/IFG 
offspring (global p values 1.0 and 0.3 respectively, generated by a 1000 bootstrap iterations). 
Individually (ldf) the MA `at risk' combination haplotypes, the 1121 (p=0.18), and 1112 












p values ; ldf 
1121 91 100 0.18 
2121 1.0 1.5 0.26 
1221 40 39 0.81 
1111 45 41 0.32 
2111 53 49 0.34 
2211 <1 <1 0.29 
1122 <1 1.3 0.28 
1222 <1 <1 1.0 
1112 12 10 0.56 
GLOBAL p value based on a 1000 bootstrap sample=1.0 













p values ;I df 
1121 27 25 0.57 
2121 <1 <1 0.28 
1221 13 11 0.23 
1111 5 8 0.24 
2111 10 10 0.73 
2211 <1 <1 0.26 
1122 <1 <1 1.0 
1222 <1 <1 1.0 
1112 <1 1 0.26 
GLOBAL p value based on a 1000 bootstrap sample=0.3 
Table 7.3.5: Transmission of CAPN10 haplotypes to IGT/IFG offspring 
7.3.5 Population Association studies 
Analysis of the five common haplotypes in survey subjects and family probands, found the 
frequency of the 1112 haplotype significantly increased in the survey IGT/IFG subjects 
(Global chi square p=0.001,4df, 99% CI 0.0001-0.001) and the probands (Global chi square 
p= 0.004; 4df; 99% CI 0.002-0.005) compared to controls. There was also a slight non- 
significant increase in frequency of the 1112 in survey diabetics (Table 7.3.6). No other 
observed haplotype frequencies were significantly different from survey normoglycaemic 
subjects. 
HAPLO >1% URBAN-NGT URBAN- URBAN- T2DM 
FREQ IGT/IFG T2DM PROBANDS 
1121 42.8% (267) 42% (48) 41.6% (70) 35% (66) 
2111 19% (120) 13% (15) 18.4% (31) 22.9% (43) 
1221 13% (82) 15.8% (18) 12.5% (21) 17.5% (33) 
1111 23% (145) 19.3% (22) 24.4% (41) 18% (34) 
1112 1.6% (10) 9.6% (11) 3.0% (5) 6.3% (12) 
Table 7.3.6: Haplotype frequencies for Case control studies. NGT=normal glucose 
tolerance. 
To tease out whether the association observed with the 1112 haplotype was due to an 
individual SNP, these were analysed individually. In the contingency table analysis if 
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homozygosity for any locus allele was rare (< 5/cell), then subjects were analysed for the 
prescence of the uncommon allele, ie heterozygous and uncommon homozygous genotypes 
were combined. Analysis of the individual polymorphisms revealed no difference in 
frequencies between the genotype frequencies for normoglycaemic controls, IGT/IFG and 
T2DM for the UCSNP44, -43 and -19 variants (table 7.3.7). 
UCSNP44 UCSNP43 UCSNP19 n 
1/1 1/22/2 1/1 1/22/2 1/1 1/2 2/2 
NGT 64.4% 35,6% 75.5% 24.5% 17.2% 53.2% 29.6% 323 
IGT/IFG 72.9% 27.1% 71.2% 28.8% 13.6% 59.1% 27.2% 60 
T2DM 65.9% 34.1% 75.3% 24.7% 14.8% 61.7% 23.5% 85 
P values 0.45 0.77 0.33 
Table7.3.7: Survey case-control genotype frequencies for UCSNP44, -43, -19 
However the presence of the uncommon allele 2 (T) of UCSNP63 was significantly 
increased in both survey IGT/IFG subjects, with a frequency of 16.7% (p=0.001) and in 
T2DM probands 11.7% (p=0.005) compared to 4% in controls (Table 7.3.8). There was 
also again only a slight non-significant increase in frequency in survey T2DM subjects 
(5.9%). T2DM parents from the families also had a significant increase in the frequency of 
the UCSNP63 allele 2 (11.9%) compared to controls (p=0.002), although they cannot be 
considered strictly a separate group from the probands. This positive association with 
UCSNP63 allele 2 was not entirely surprising as this allele is almost invariably (99.5%) 











1/1 96% (310) 83.3% (50) 94.1% (80) 88.3% (83) 
1/2 2/2 4%(13) 16.7%(10) 5.9%(5) 11.7% (11) 
P values 0.001 0.55 0.005 
Table 7.3.8: UCSNP63 case-control genotype frequencies 
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7.3.6 Analysis of Haplotype Combinations 
Global chi-square analysis of 14 haplotype combinations identified in South Indians, found 
the Mexican-American `at risk' haplotype combination 1112/1121 to have a significantly 
increased frequency in the survey IGT/IFG subjects (9.0%) compared to normoglycaemic 
controls (0.9%), with a global p value [99% confidence limits] p=0.02 [0.019-0.023] (Table 
7.3.9). Furthermore, there was also a significant increase in the frequency of the same 
haplotype combination in the T2DM probands (5%) global p= 0.015 [0.012-0.018] and a 
similar trend in survey T2DM subjects (6%) global p value= 0.27 [0.26-0.28]. Further 
analysis found the 1112/1121 combination associated with an increased risk in survey 
IFG/IGT subjects (Odds Ratio (OR) 10.74; Yates corrected chi-square (ldf), p=0.001 and 
Relative Risk (RR)=4.4 [1.75-6.6]), T2DM subjects (OR 6.52; p=0.015; RR=3.07 [1.23- 
4.5]) and probands (OR 5.78; p=0.025; RR=2.79 [1.13-4.11]) (table 7.3.9). A second 
combination 1112/1221 in the survey was completely absent in both the normoglycaemic 
and T2DM subjects, but was present in both the IGT/IFG subjects (global p=0.018) and the 
probands (global p=0.003). This suggested that a heterozygous haplotype combination of the 
1112 haplotype with either 1121 or 1221 might influence susceptibility to glucose tolerance. 
In diabetic parents (n=132) there was also a concomitant increase in risk attributed to both 
the 1112/1121 and 1112/1221 haplotype combinations (OR 4.05 [95% CI 0.83-21.7] and 
OR 6.58 [95%CI Infinite] respectively, although these subjects cannot strictly be treated as a 
separate dataset from the probands. In addition, in the parents the 1121 haplotype in 
combination with 1221 also contributed to significantly increased risk (OR 1.88, [95%CI 
1.02-3.45] p=0.04), but in combination with 2111 appeared to decrease risk (OR 0.49, 
[95%CI 0.25-0.94] p=0.03). 
TDT analysis of haplotypes (TRANSMIT) revealed no excess transmission of any haplotype 
(Table 7.3.4 and 7.3.5). However, this analysis could not address the effect of an increased 
transmission of the 1112/1121haplotype combination to affected offspring. Therefore a 
novel statistical approach was applied (7.2.7). Four sets of parents were identified and three 
T2DM probands did receive the `at risk' haplotype combination and one did not compared 
with the one quarter expected proportion with no excess transmission (p=0.05). Although 
the number of families were small, the observed frequency of the simultaneous transmission 
of both haplotypes to the T2DM probands was greater than the expected one-quarter 
probability for transmissions under the null hypothesis that affection is not associated with 
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the haplotype combination. In addition, there was transmission of the `at risk' haplotype 
combination from a fifth set of parents where one parent was homozygous for 1121 and the 
other parent had the 1112 haplotype. 
To estimate what proportion of diabetics in the entire South Indian population that could be 
attributed to exposure to the 'at risk' haplotype combination, the population attributable risk 
(PAR) was calculated. The PAR's for survey T2DM subjects and T2DM probands were 
6.3% and 7% respectively. 
7.3.7 Quantitative Trait analysis 
Analysis of the five common haplotypes in the families using the QTDT Orthogonal model 
[Abecasis et al 2000] and sex as a covariant, found that the transmission of the 1121 
haplotype to offspring was associated with a decrease in BMI (p=0.019), a narrower hip size 
(p=0.007), and weakly with a decreased FBG (p=0.03) (Table 7.3.10). In contrast 
transmission of the 1221 was associated with larger hips p=0.008. Following correction for 
the number of haplotypes analysed, only the hip remained significantly associated. Tests for 
parent of origin effect, found the 1121 and 1221 haplotype associations with hip, were both 
paternal in origin (p=0.02, p=0.016, respectively). Transmission of the 1112 haplotype to 
offspring was associated with a decrease in WHR (p=0.03), further confirmed by the "total 
association" analysis option within the QTDT program (p= 0.003) incorporating adjustment 
for non-shared environment and polygenic disease (table 7.3.11). Analysis of the individual 
CAPN10 polymorphisms by QTDT, also with sex as a covariant, found the transmission of 
the allele 1 of UCSNP43 to T2DM offspring was associated with a decrease in BMI 
(p=0.04), and hip (p=0.0056). Analysis of the individual variants using the "Total 
Association" option, found that UCSNP63 was associated with variance in both waist 
circumference (p=0.02) and WHR (p=0.004) (table7.3.12). Following correction for the four 
loci analysed, only associations with hip and WHR remained significant confirming the 
haplotype data. 
Analysis of the same intermediate quantitative traits in the urban survey samples found no 
relationships with either individual loci or the four loci haplotypes, including weight, height, 
BMI, waist circumference, hip, WHR, fasting blood glucose, and 2-hour glucose. Haplotype 
combinations were similarly assessed and associations were also all negative 
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HAPLOTYPES >1% POPULATION FREQUENCY 
TRAIT 1121 2111 1221 1111 1112 
BMI 0.019 NS NS NS NS 
Waist NS NS NS NS NS 
Hip 0.007 NS 0.008 NS NS 
WHR NS NS NS NS 0.03 
age diag NS NS NS NS NT 
Height NS NS NS NS NS 
FBG 0.03 NS NS NS NS 
Table 7.3.10: Quantitative Trait haplotype Analysis in South Indian families. NS = Not 
statistically significant; NT = Not tested due to low haplotype frequency/numbers 
CAPN 10 Four Loci haplotypes 
Traits 1121 2111 1221 1111 1112 
BMI 0.079 NS NS NS NS 
Waist NS NS NS NS NS 
Hip NS NS NS NS NS 
WHR NS NS NS NS 0.003 
age diag NS NS NS NS NS 
Table 7.3.11: Total Association analysis of five common CAPN 10 haplotypes 
CAPN 10 loci 
Traits UCSNP44 UCSNP43 UCSNP19 UCSNP63 
BMI NS NS NS NS 
Waist NS NS NS 0.041 
Hip NS NS NS NS 
WHR NS NS NS 0.002 
Age Diag NS NS NS NS 
Table 7.3.12: Total Association analysis of four CAPN 10 loci individually 
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7.3.8 TDT POWER CALCULATIONS 
Analysis of the power to detect an association in the TDT studies was examined for 
UCSNP63. Based on the genotype frequencies and relative risk conferred by UCSNP63 in 
the South Indian survey there would have been only 39% power to detect an effect 
significant at p=0.05 with 97 families used. 
7.4 DISCUSSION 
7.4.1 Linkage data 
The linkage study in this thesis failed to find excess allele sharing in 278 T2DM affected sib 
pairs, although this sample number almost certainly lacked sufficient power to exclude the 
NIDDM 1 region on Chromosome 2q. However, an extension of my study using an 
additional 556 affected sibling pairs from the Warren 2 repository (a total of 834 ASP) also 
produced a negative non-parametric linkage score (NPL) of -0.31 (Zlr score- 
GENEHUNTER-PLUS) confirming my result [Evans et al 2001]. Concurrent studies with 
the original MA genome scan also found no evidence of linkage with D2S125 in both non- 
Hispanic whites (147 ASP's) and Japanese (140 ASP's) with MLS scores of 0.03 and 0.00 
respectively [Hanis et al 1996]. Three other linkage studies in MA populations, including 
one using samples from the same geographical region as the Hanis [1996] study, also failed 
to detect linkage to Chromosome 2q [Stern et al 1996a & b; Duggirala et al 1999]. 
However, a fourth genome scan for T2DM in MA families did find nominal evidence of 
linkage with D2S125 (LOD score 0.88) and a combined T2DM and Impaired Glucose 
homeostasis phenotype (IH; consisting of both IGT and 1FG) in the primary phase of 
analysis with a marker density of 10cM intervals [Ehm et al 2000]. This finding was not 
entirely surprising as a high proportion of the nuclear families used in this study were the 
same as for Hanis study. Furthermore, analysis of additional markers at a density of 5cM 
intervals, although increasing the LOD score to 1.66 shifted the peak 27cM centromeric 
from position 259cM (D2S125-260.6cM) to position 232cM, near marker D2S362 [Ehm et 
al 2000]. The majority of linkage studies in other ethnic groups have not replicated the 
Chromosome 2q linkage result of Hanis et al, with negative studies in Botnian Finnish 
[Mahtani et al 1996], American-whites, -blacks, -Japanese [Ehm et al 2000], European 
Caucasians from Utah [Elbein et al 1999], Sardinians [Ciccarese et al 1997], Finnish [Ghosh 
et al 2000; Wanatabe et al 2000], and British Caucasians [Thomas et al 1997; Evans et al 
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2001]. In a relatively early study in Finnish families although the distal telomeric region of 
Chromosome 2q was excluded, positive single-locus MLS values with the proximal markers 
D2S 126 (MLS 1.05; positioned at 214.4cM) and D2S338 (MLS 0.92; positioned at 
240.8cM) were found [Ghosh et al 1998]. Interestingly, D2S126 had the second strongest 
evidence for linkage after D2S 125 in the MA genome scan and nominal evidence of linkage 
was observed for D2S338 (MLS of 1.15 (p<0.025) in non-Hispanic white subjects [Hanis et 
al 1996]. Furthermore suggestive linkage was found in close proximity to D2S126 in 
another MA study [Ehm et al 2000]. Although these markers have been positioned 10.2cM- 
16cM proximal to D2S 125 [Ghosh et al 1998; Hanis et al 1996] it was suggested that a weak 
susceptibility locus might be present in this region in non-Hispanic Caucasians [Ghosh et al 
1998]. In respect of the markers more proximal to D2S 125 studied in this thesis, NPL's for 
D2S338 and the most centromeric marker used D2S336, which is between 6cM-24cM distal 
to D2S126 (depending on the map used) were less than a NPL score of -1.5. Linkage 
studies in T2DM French Caucasian families failed to find linkage to D2S125, but did found 
some evidence of linkage with a marker D2S140,3cM distal to D2S125 [Hani et al 1997]. 
Although the markers used in this thesis generated progressively less negative NPL's 
approaching the telomeric region of Chromosome 2q, the only marker D2S 140, used 
thought to be distal to D2S125 had a negative NPL score of -0.7. 
The lack of replication of contemporary genome scans, assuming that the positive evidence 
of linkage for Chromosome 2q is not merely due to the 5% false positive rate considered to 
be present in genome scans [Landers & Kruglyak 1995] could be due to several reasons. 
Firstly, there might be ethnic differences at this locus with respect to predisposition to 
T2DM as well substantial genetic heterogeneity underlying the phenotypic expression of 
T2DM in diverse ethnic populations. Secondly, there also may be differences in family 
ascertainment and diagnosis of T2DM between the studies in addition to stochastic factors 
[Suarez & Hampe 1994]. Finally, there are power considerations whereby the number of 
sibling pairs would only have the power to detect a locus that contributes a specific 
variability to T2DM, and therefore could not exclude genes within the NIDDMI region 
from having a minor role in the disease process. Simulation studies on interval mapping 
suggest that the probability of falsely excluding region is very small for a range of X values 
[Hauser et al 1996]. However, the majority of the linkage studies mentioned above including 
the present study in this thesis, most probably had insufficient power to exclude a gene with 
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a relative sibling risk of 1.37 that was found in Mexican Americans. Nevertheless, three 
recent studies have provided evidence for exclusion of the region in UK and Finnish 
Caucasians at sibling relative risk ratio levels of ? 1.25 and 1.37 respectively [Evans et al 
2001; Ghosh et al 2000; Watanabe et al 2000]. 
Indeed, the subsequent degree of association seen with CAPN10 UCSNP43 variant with 
T2DM in MA [Horikawa et al 2000], would render all studies including that of Hanis et al 
inadequate in terms of power to detect the increased risk afforded to the increased frequency 
of G allele of UCSNP43 (MA controls 0.75 vs T2DM MA 0.80). Altshuler et al [2000] 
suggested that a population group of 100,000 affected sib pairs would be necessary to have 
been able to attribute this association with the 4.03 lodscore obtained originally by Hanis et 
al [1996]. Never the less subsequently a putative T2DM gene (CAPNIO) was positionally 
cloned to the NIDDMI region [Horikawa et al 2000]. Furthermore, in many of the ethnic 
populations that failed to find evidence of linkage to the NIDDMI region, the utilization of 
linkage disequilibrium based studies have since demonstrated positive associations with 
T2DM and variants of the CAPNIO gene. Examples include studies in Botnian Finnish, 
Saxon Germans, Utah Caucasians and UK Caucasians [Horikawa et al 2000; Schwarz et al 
2001; Ren et al 2000; Evans et al 2001]. Therefore supporting the view that most of the 
different linkage studies discussed above most probably lacked the statistical power to detect 
minor diabetogenic loci. However, in the few studies in which there was sufficient power for 
exclusion of linkage at levels of ? of 1.25, it is consistent with CAPN 10 being a minor 
susceptibility gene in those populations. 
7.4.2 CAPN10 variant haplotype frequencies 
In South Indian families only 8 of the possible 16 four loci haplotypes were present, with 
only five haplotypes with a frequency of greater than 1%. In reference to the available 
population data, globally there only appears to be four common three locus haplotypes 
(UCSNP43, -19, -63) [Horikawa et al 2000; Schwarz et al2001; Evans et al 20011. Inclusion 
of a fourth SNP, UCSNP44, causes a near equal split of haplotype 111, and therefore five 
common haplotypes are observed in both South Indians and UK Caucasians [Evans et al 
2001J. These findings suggest that there is still very strong disequilibrium across the 
CAPN10 gene in most ethnic populations. This was also confirmed in this thesis for the 
South Indians, implying overall that these mutations are relatively recent in human 
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evolution. However, there are differences in the population frequencies of certain 
haplotypes, which is often reflected in the ethnic ancestry of the individual populations. The 
South Indians, ethnically Caucasian, unsurprisingly have frequencies not unlike those 
present in European Caucasians [Horikawa et at 2000; Evans et at 2001]. One of the 
haplotypes the constitutes the MA `at risk' haplotype combination 121, represented by the 
1121 haplotype in the South Indians, is the most common haplotype in virtually all 
populations so far investigated with frequencies of 0.32 in MA, 0.42 in Germans, 0.56 in 
Chinese/Japanese Asians, 0.42 in USA Europeans, 0.36 in the Pima Indians [Horikawa et al 
2000], 0.36 in UK Europeans [Evans et at 2001], and 0.37-0.41 in South Indians in my 
study. However in Botnian Finnish and the Zapoteca Indians the 111 (0.35), and 221 (0.52) 
respectively are the most frequent, but the 121 haplotype is still common at 0.29 and 0.17 
respectively. In contrast, the second haplotype of the MA `at risk" haplotype combination, 
the 112, is relatively common (0.23) in the MA population, and in Pima Indians, Zapoteca 
Indians, Chinese and Japanese with frequencies of 0.29,0.24,0.31 and 0.25 respectively. 
However, the 112 haplotype, represented solely by 1112 in the South Indians is at a very 
low frequency (0.05) similar to that found in Europeans (0.03-0.07) [Horikawa et al 2000; 
Evans et al 2001]. 
7.4.3 Case-Control Studies 
The most important finding from the studies in this chapter, is that in the South Indian 
epidemiological based urban survey, the presence of the 1112/1121 heterozygous haplotype 
combination confers both an 10.7 fold increase in risk to abnormal glucose tolerance and a 
6.3 fold and 5.8 fold increased risk to T2DM in unrelated subjects and probands 
respectively. Furthermore, the risk for T2DM was also increased in the T2DM parents from 
the families (4 fold) although failing to reach conventional levels of statistical significance. 
In the seminal publication analysing CAPN10 [Horikawa et al 2000] the modest association 
of UCSNP43 in MA could not alone account for the original linkage data [Hanis et al 19961, 
so haplotypes were tested with combinations of other CAPN10 SNP's identified. In MA the 
two most important haplotypes identified were, 121 and 112 which both have the disease 
associated G allele of UCSNP43 but also included two other variants, UCSNPI9 and 
UCSNP63. UCSNP19 is in near perfect LD with a cluster of four intronic SNP's UCSNP56, 
-59, -30, and -65 and one coding mutation in exon 11, UCSNP48 a silent mutation at codon 
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A620. UCSNP63 was also found individually associated with an increased risk to T2DM in 
Botnian Finnish subjects. In MA the heterozygous combination of these two haplotypes 
conferred a three fold increased (Odds Ratio's 2.8 and 3.58, from two datasets) risk to 
T2DM. In the Horikawa et al [2000] study it was suggested that there was also a 
concomitant 2.5 fold and 5.0 fold increase in risk to T2DM with the 112/121 haplotype 
combination in both Finnish and Germans respectively, although the odds ratio's achieved 
were not statistically significant. Nevertheless in the same Saxon German ethnic population 
but combined with a Czech study group found a 3.48 fold increased risk to T2DM, hence 
confirming these findings [Schwarz et al 2001]. The 1112/1121 combination in this South 
Indian study is equivalent to this Mexican American `at risk" 112/121 combination, as 
explained in the results section. Therefore these haplotype associations therefore both 
replicate and extend those previously published in the seminal publication of Horikawa et al 
[2000]. In the South Indian population a second haplotype combination, 1112/1221 also 
appeared to be associated with increased risk to both AGT and T2DM, although the numbers 
involved are very small and the haplotype combination is completely absent in the 
normoglycaemic subjects (n=312). The 1221 haplotype in combination with the 1121 also 
afforded a 2.0 fold increase in risk to T2DM in the parents of the T2DM probands. 
Homozygosity for these haoplotypes (1121,1112,1221) were not associated with an 
increased risk for disease, although only 2 subjects in the study were homozygous for the 
1112 haplotype. These findings are in agreement with the MA data, emphasising the 
importance of heterozygous combinations of CAPN10 gene haplotypes in determining 
susceptibility to disease [Horikawa et al 2000]. However, contrary to the findings of 
Horikawa, I found no underlying association for T2DM with the G allele of UCSNP 43, or 
individually with UCSNP44 and UCSNPI9. 
In my study in a South Indian population the presence of the uncommon allele 2 (T) of 
UCSNP63 was significantly increased in both IGT/IFG subjects (p=0.001) and T2DM 
probands (p=0.005). This allele was also concomitantly increased in T2DM parents from 
the families (p=0.002). There are only two haplotypes detected in South Indians that carry 
the allele 2 (T) of UCSNP63; these are 1112 and 1122. The 1122 haplotype has only a 
frequency of 0.005 in the South Indians, with a similar low frequency in Mexican 
Americans (0.01) and UK Europeans (undetected) [Horikawa et al 2000; Evans et al 2001]. 
Therefore not surprisingly the 1112 haplotype, was also significantly increased in both 
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IGT/IFG subjects (p=0.0001, OR 6.5) and T2DM probands (p=0.001, OR 4.1) (Table 
7.3.5). Allele 2 of UCSNP63 is in linkage disequilibrium with allele I of the other three 
SNP's USNP44, -43 and -19. The G allele of UCSNP43 was the strongest underlying 
variant within the `at risk' haplotype combination that associated with an increased risk to 
T2DM in MA's, Germans and Botnian Finns [Horikawa et al 2000]. However in the South 
Indians, the LD relationship between UCSNP63 and UCSNP44/ -43 is much weaker, 
suggesting that the uncommon T allele (2) of UCSNP63 may be marking a separate disease 
susceptibility determinant to UCSNP44 and UCSNP43, and additionally contributes to 
disease susceptibility associated with the `at risk' haplotype combination. Allele 2 of 
UCSNP63 was also strongly associated with increased risk to T2DM in Botnian Finnish 
subjects, but not in Germans or MA's, suggesting that there is some divergence in the 
importance of individual variants between ethnic populations possibly as a result of 
variation in LD marker relationships with causative mutations [Horikawa et al 2000]. This 
view is further supported in that, whereas in the MA population study the affected sib pairs 
who were conconcordant for the UCSNP43 G/G genotype accounted for all the `evidence 
for linkage' to NIDDMI region [Horikawa et al 2000]. In contrast, investigations of 
UCSNP43 and `evidence for linkage' to the NIDDM1 region in UK Europeans using the 
Warren 2-NIDDMI linkage data generated in the linkage studies in this Chapter, found no 
increase in allele sharing at NIDDM I (p=0.92) in a subset of 79 families (maximum 122 sib 
pairs) in which the probands were UCSNP43 homozygous for the G allele (Evans et al 
2001]. Furthermore, in the UK Europeans there was also no evidence of epistatic 
interactions, such as those found with Chromosome 15 in the MA studies [Cox et al 1999]. 
Case/control studies in the UK population using the affected sibpair probands (n=269) also 
found no difference in the UCSNP43 G/G allele frequency between T2DM subjects and 
controls [Evans et al 20011. 
An extension of these studies to the Warren 2 UK European family trios also confirmed the 
lack of association with the UCSNP43 (or UCSNP63) variant, and also found no 
associations with the MA `at risk' haplotypes. This study was estimated to have 90% power 
to detect the odds ratio of 2.86 seen with the 112/121 combination in MA at a one tailed p 
value of 0.05 [Evans et al 2001]. However, in the family trios a significant increased 
transmission of UCSNP44 allele 2 to T2DM offspring was observed. The haplotype 
combination 2111/2111(p=0.038) in contrast to both the MA and South Indian data was 
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found to have the most important effect, although its effect was entirely due to the 
UCSNP44 locus. The result was further replicated in the European families with the 
UCSNP110 variant (p=0.033), which is in 100% LD with UCSNP44, but not replicated in 
the case-control group [Evans et at 20011. UCSNP44 and UCSNP110 were also found to be 
in perfect LD in South Indians in this thesis, although no association with disease was 
observed with UCSNP44/110 variants either in families or in the urban survey samples. It 
was suggested by the authors that one possible explanation for the lack of association with 
the `at risk' haplotype combination in UK Europeans might be due to the low frequency of 
the 1112 in this population (0.07) compared to 0.23 in MA [Evans et at 2001]. However, in 
my studies a significant association was detected in the South Indians despite only a 
frequency of 0.05 for the 1112 haplotype. Similarly in the German/Czech study positive 
associations with T2DM were also achieved with population frequencies ranging from 0.02 
to 0.08 for 1112 [Schwarz et at 2001]. 
Stimulation studies comparing the relative power of haplotype and SNP analysis [Bader 
2001], suggest that under certain circumstances haplotype analysis is more powerful than 
analysis of individual SNPs, this being dependent on the number of `causative' SNP's 
within the haplotypes and number of common haplotypes present (> 5% in frequency). 
Bader [2001] illustrated this by using data from one particular study [Liggett et at 2000], and 
demonstrated the effectiveness of haplotype-based analysis by finding positive association 
with phenotype amongst the four common haplotypes, in spite of there being no individual 
association with any of the 13 SNP loci that were constituent of these haplotypes. Under 
these circumstances the effect of individual loci on phenotype was undetectable unless the 
`additive' contribution of individual variant alleles were analysed as a whole ie. haplotype 
effect. In this thesis study although there was an association with phenotype with UCSNP63 
individually. However, interpretation of the results in the manner suggested by Bader 
[2001], haplotype-based analysis should have provided increased power to detect an 
association, and this appears to be the case with the 1112 haplotype. 
From these observations it might be postulated that the overall susceptibility to T2DM and 
related phenotypes results from the compounded `additive' effect of a number of 
`independent' causative mutations present either in the CAPN 10 gene or in another gene in 
close proximity, in which the relative importance of individual variants has been ethnically 
determined. Furthermore, there also appears to be synergistic effect of different haplotypes 
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on each other in detemining the overall risk to disease, and this is discussed later in section 
7.4.6. 
The (1)112/(1)121 haplotype combination in MA type2 diabetics was estimated to account 
for 14% of the population attributable risk to T2DM, but this was only 4% in two European 
population groups, namely Botnian Finns and Saxon Germans [Horikawa et al 2000]. 
Further studies in Saxon Germans and Czechs suggested the PAR might be as high as 13% 
using combined data [Schwarz et a! 2001]. However in South Indians with AGT/T2DM, the 
population attributable risk appears to be intermediate for this haplotype combination 
calculated at between 6% and 7%. 
7.4.4 Family association studies 
Family association studies in the South Indians found no excess transmission of any SNP 
allele or haplotype to T2DM offspring using the ETDT and TRANSMIT programs 
respectively [Sham & Curtis 1995; Clayton et al 1999]. These results do not confirm the 
association study findings for UCSNP63 and haplotype 1112 in South Indians. At present 
there have only been two contemporary family-type association studies for CAPN10 
variants performed and results have been inconsistent. In one study using UK European 
Caucasian parent-T2DM offspring trios, only the uncommon C allele of UCSNP44 was 
excessively transmitted to T2DM offspring [Evans et at 2001]. In the second family study, 
also in subjects of Northern European extraction (Mormons, Utah, USA), there was an 
excess transmission of the less common A allele of UCSNP43 from diabetic parents to 
diabetic offspring, but this was only significant when all parents were used and when only 
transmitted to male diabetic offspring (p=0.003) and not to female diabetics offspring 
[Quianfang et al 2000]. This latter result is in complete contradiction of the MA data for 
UCSNP43 [Horikawa et al 2000]. 
The failure to detect an association with T2DM using TDT based methods for either the 
1112 or 1121 haplotypes individually or SNP63 allele 2 could be for several reasons. Firstly, 
a calculation of power for the TDT study based on the UCSNP63 allele frequencies from the 
South Indian population study group, found that there would be insufficient power (39%) to 
detect an association at this locus. The 1112 haplotype was found at a substantially lower 
frequency in the South Indians, as in European populations [Evans et al 2001] compared to 
the Mexican Americans (Horikawa et al 2000] and this could have also further impeded the 
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TDT analysis. Secondly, family association methods could also have a reduced power to 
detect a disease association, under other specific circumstances. An `at risk' haplotype 
combination (1)112/ (1)121 is attributed to the greatest risk to T2DM in both MA and South 
Indians with homozygosity for the individual haplotypes not associated with an increased 
risk to T2DM in either ethnic group [Horikawa et al 2000]. Furthermore, in MA other 
haplotype combinations with either the `at risk' 112 or 121 haplotypes included were found 
either to be neutral or protective to disease susceptibility. Consequently, unless the 
independent transmission of the two individual haplotypes can be assessed collectively, then 
observations of association in the offspring are less likely unless an individual haplotype 
association is strong enough. Interestingly, using a novel statistical approach to examine 
families where simultaneous transmission of both `at risk' haplotypes was possible, there 
was a significant increased transmission to offspring with T2DM. Although the number used 
in the analysis was small it complements and confirms the positive case-control haplotype 
combination data. 
7.4.5 Quantitative Trait analysis: 
T2DM is likely to be polygenic disease in which susceptibility determinants are determined 
by associations between intermediate traits and diabetes susceptibility genes. Having found 
associations between CAPN10 and diabetes it was therefore important to determine whether 
any of the associations can be accounted for association with related intermediate traits. 
Quantitative trait analysis of haplotypes in the South Indian families applying the 
Orthogonal model [Abecasis et al 2000] within the QTDT program revealed significant 
associations with only three haplotypes. Coincidentally these three haplotypes were the 
same as those implicated in increased risks to both AGT and T2DM in both case-control and 
family studies in South Indians. The transmission of the 1121 haplotype was associated with 
a decrease in BMI, and narrower hip size. Independently the 1221 also associated with 
larger hip measurements. Analysis of the individual variants with traits provided evidence 
that UCSNP43 may contribute in part to this association, as UCSNP43 allele I was 
individually also associated with decreased BMI and hip measurement. The transmission of 
the 1112 to offspring was also associated with a reduction in the WHR, which in part was 
due to the presence of less common allele 2 of UCSNP63 that individually significantly 
associated with variance in WHR and waist circumference. From these findings one might 
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predict that South Indian subjects with the 1112/1121 haplotype would have a low BMI and 
WHR, with a smaller hip measurement. However, contrary to the findings in South Indians, 
lower sleeping metabolic rate was associated with the UCSNP43 G/G genotype in Pima 
Indians (Baier et al 2000] and therefore this allele might be expected to be associated with 
an increased body mass. This association was also supported by a Chinese study in which 
control subjects homozygous for allele 1 (G/G) of UCSNP43 had increased BMI and WHR 
[Ji et al 2001]. Although increased BMI, waist circumference and WHR are widely 
recognised as predisposing factors towards the development of T2DM, this is not the case 
for hip measurements. Nevertheless, it has been suggested that narrow hips reflect a 
decrease in leg muscle mass and this has been found to be a predisposing factor for T2DM 
independent of waist circumference and irrespective of stature, particularly in males [Seidell 
et al 1997]. It was suggested that the more apparent effect in males was possibly due to a 
reduced gluteal subcutaneous fat mass compared to females. However the findings in female 
subjects also suggested that the associated increase in risk attributable to WHR was not only 
a result of larger waists but independently also smaller hips than would be expected. 
Furthermore, in another study comparing body tomographic cardiovascular risk factors 
between Swedish and Asian Indian subjects the higher frequency of impaired glucose 
tolerance in the Asian Indian subjects, was not related to the preponderance of visceral fat 
but to a lower leg muscle to total muscle ratio [Chowdhury et al 1996]. It has been further 
advocated that the specific effects of girth measure are poorly captured with WHR [Seidell 
et al 2001]. Waist and hip measure different aspects of body composition and fat 
distribution, and in relation to cardiovascular disease risk factors have been shown to have 
both independent and often opposite effect [Seidell et al 2001]. Therefore, the observed trait 
associations with CAPN10 variants, although they do not necessarily conform to what might 
be expected, might represent a genuine genotype-phenotype relationship and should not be 
unjustifiably disregarded. 
7.4.6 Functional effects of UCSNP 63 and haplotype combination 
There is no direct evidence of causality for UCSNP63 as these studies have yet to be carried 
out. UCSNP63, UCSNP43 and UCSNP44 are all non-coding, non-splice junction intronic 
polymorphisms. The potential functional effect of UCSNP43 variant has been investigated 
by using EMSA with human pancreatic islet and human heptoma nuclear extracts [Horikawa 
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et al 2000]. Competition experiments demonstrated that the A allele did have an increased 
affinity for an unknown binding factor, presumably a trans-acting factor compared to the G 
allele, which had little to no binding. UCSNP44 11 bp upstream to UCSNP43 implicated in 
the European studies [Evans et al 2001) was also included in the intron 3 test fragment, but 
the presence of either C or T allele made no difference to factor binding. Further studies 
found chimeric reporter gene constructs with cloned CAPN10 intronic fragments with the 
UCSNP43 A allele had a 1.6 fold greater transcriptional activity than fragments with the G 
allele, and this was also modulated by the C/T alleles at UCSNP44. This suggested that 
these variants could be involved in the regulation of expression of CAPN10 or a nearby 
gene. Regulatory elements can inflict their effect over considerable distances demonstrated 
by regulatory element in Chromosome 5 controlling at least three genes extending over 
120kb [Loots et al 2000]. In two other studies it was found that subjects homozygous for 
UCSNP43 G-allele associated with a reduction in CAPN 10 mRNA levels in skeletal muscle 
biopsies with a specific reduction in the two predominantly expressed splice variants [Baier 
et al 2000; Yang et al 2001]. CAPN10 intronic variants may influence abundance of the 
alternate splice variants, some of which may lack protease activity [Ma et al 2001], and 
individually may have varying biological functions. Alternatively these variants may 
influence transcription initiation rates and /or mRNA stability [Yang et al 2001]. The 
UCSNP44 is also in perfect LD with a missense mutation in exon 10, UCSNPI 10, a coding 
region of as yet unknown function. This mutation causes a conversion from a Threonine 504 
residue to an Alanine. However, in mice this amino acid residue is a Serine suggesting it is 
not highly conserved. Furthermore, UCSNP19 is in near perfect LD with a group of four 
CAPN10 intronic SNP's (UCSNP 56, -59, -30, and -65) and also a silent coding mutation 
in exon 11, UCSNP 48 at codon A620, but again the function of this coding region is 
unknown. 
One important question that stills remains to be elucidated is how a heterozygous haplotype 
combination is involved in the aetiology of the disease. The effect of combinations of 
haplotypes on the penetrance of disease phenotypes is not without precedence. In type 1 
diabetes (T1DM) several HLA haplotypes determine susceptibility [Dorman & Bunker 
2000; Undlien et al 2001]. These include the DR41DQ8 and DR3/DQ2 haplotypes that 
determine susceptibility and the DR2/DQ6 haplotype determining dominant protection even 
in the presence of DR4/DQ8 or DR3/DQ2. Individuals homozygous for DR3/DQ2 or 
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DR4/DQ8 are not at increased risk of disease, whereas subjects with a combination of DR3 
and DR4 haplotypes do have an increased risk of disease. The analogy can be further 
extended as there are likely to be several T1DM associated susceptibility determinants 
carried on multiple HLA haplotypes over a 3500kb distance and covering a large number of 
genes in the HLA Class I, II, III and IV regions. Furthermore, in different ethnic groups 
different susceptibility haplotypes are found. Whilst there is some evidence that 
UCSNP43/-44 polymorphisms might have an effect on gene expression, it does not exclude 
other susceptibility determinants on disease associated CAPNIO haplotypes nor indeed with 
a closely linked locus as yet unidentified. The analogy supports the importance of the 
haplotype combination rather than individual haplotype or SNP, although the strength of the 
overall association in T1DM with HLA is far greater than with CAPN10 and T2DM. This 
might also explain why preliminary data suggests varying associations with different SNP's. 
Thus, for instance UCSNP63 associates with T2DM in Botnian Finns and South Indians but 
not in Mexican Americans. UCSNP44 associates with T2DM in British/Irish subjects 
[Evans et al 20011 but not confirmed in other ethnic groups and the UCSNP43 association 
with T2DM appears so far to be unique to Mexican Americans [Horikawa et al 2000]. 
Further effects on how haplotype combinations can modulate the phenotype can be drawn 
by analogy with the most common genetic lipid disorder in Caucasians, namely familial 
combined hyperlipidaemia (FCH). Five polymorphic variants in the apoAl-CIII-AIV gene 
cluster have been implicated in the disease in FCH families. These variants have no primary 
causal effect and individually there was no excess transmission of any variant allele to 
affected offspring by TDT analysis [Groenendijk et al 1999]. However, in association 
studies certain high-risk haplotype combinations associated with a more severe 
hyperlipidaemic phenotype. These findings are not unlike those observed with the CAPN10 
variants and AGT and T2DM in South Indians. In addition there are other similarities with 
combinations of haplotypes demonstrated to confer varying degrees of susceptibility or 
neutrality with homozygousity for haplotypes also not associated with an increased 
susceptibility to disease. In the FCH study the degree of susceptibility conferred by a 
haplotype combinations appeared to be the result of a synergistic effect of both haplotypes, 
influenced by both dominant and permissive effects of individual haplotypes. Furthermore, 
specific combinations were shown to associate with underlying sub-phenotypic traits that 
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could contribute to the overt FCH clinical phenotype, such as plasma concentrations of 
apoC-III, cholesterol, and triglycerides. 
A similar situation could also exist with the CAPNIO haplotype combinations. Associations 
were found with a haplotype combination and abnormal glucose tolerance in the South 
Indians studied in this thesis. The data also suggests that the `at risk' 1112 haplotype is 
dominant in certain haplotype combinations, but its effect is possibly neutralised in other 
combinations. In the MA study the (1)112 in combination with the (1)221 haplotype 
reduced risk toT2DM (OR 0.36 95% CI 0.15-0.86), and with (1/2)111 it had a neutral 
effect. There was an eight-fold difference in risk between highest and lowest risk haplotype 
combinations [Horikawa et al 2000]. Similarly in the South Indians the haplotype 1121 in 
combination with 2111 reduced risk to T2DM (OR 0.49,95% CI 0.25-0.94, p=0.03) in 
diabetic parents. Whilst in combination with either 1112 or 1221 it increased risk to AGT 
and/or T2DM. In the FCH studies specific alleles of the individual variants also influenced 
the phenotypic effect of haplotypes, and due to strong linkage disequilibrium between alleles 
of some variants, some variant alleles were invariably never found on the same chromosome 
with specific allele combinations of the other variants. This was also observed with 
CAPN10 with the uncommon allele 2 of UCSNP63 virtually never found on the same 
chromosome with allele 2 of either UCSNP44, -43, or -19 in the South Indians, and this was 
also the case in other populations [Evans et al 2001; Horikawa et al 2000]. Whether, the 
predominance of only a few CAPN10 haplotypes as a result of strong LD within populations 
globally reflects an evolutionary selective advantage or results from phenomenia such as 
population `bottlenecks', remains to be seen [Nordborg & Tavare 2001]. 
7.4.7 Conclusion 
There have been a number of studies relating CAPN10 genotype to effects on insulin 
secretion and insulin action, these have been inconsistent, and none include UCSNP63, few 
used extended variant haplotypes and none assessed haplotype combinations. In 
normoglycaemic Chinese, subjects who were either heterozygous or homozygous for the A- 
allele of UCSNP43 had increased insulin levels under glucose load [Xiang et al 2001]. 
Furthermore in agreement with these findings, in four other studies analysing Chinese non- 
diabetics and non-diabetic first degree relatives of diabetics [Xiang et al 2001; Ng et al 
2001], non-diabetic PCOS subjects [Ehrmann et at 2000] and in non-diabetic North 
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Europeans [Lynn et al 2002] UCSNP43 G/G homozygotes were associated with reduced 
insulin secretion in response to glucose load with the latter study also showing a decreased 
early insulin response in GIG UCSNP43-UCSNP44 haplotypes. In contrast, Germans 
subjects with the UCSNP43 G allele had higher glucose stimulated insulin secretion and 
more efficient proinsulin conversion to insulin [Stumvoll et al 2001]. Similar inconsistencies 
have also been observed between ethnic groups with insulin resistance, with UCSNP43 G 
and A allele associated with decreased and increased insulin resistance respectively in non- 
diabetic Chinese, whereas in normoglycaemic Pima Indians G/G homozygotes had increased 
insulin resistance [Baier et al 2000; Xiang et al 2001; Ng et al 2001]. These findings have 
been particularly confusing in respect of the Chinese studies where subjects with the 
UCSNP43 G allele appears to have both reduced insulin secretion and insulin resistance, and 
yet the G allele was increased in T2DM patients only in one study [Ji et al 2001], whereas in 
the two other contemporary studies, UCSNP43, -19, -63 variants were either not associated 
with either T2DM or IGT [Xiang et al 2001] or the G allele frequency was actually 
significantly lower in the T2DM subjects [Ng et al 2001]. However, one constant aspect of 
many of these studies although there was inconsistent association with the T2DM 
phenotype, evidence was detected for an underlying relationship with CAPN10 genotype 
and insulin secretion or action only in normal glucose tolerant or prediabetics subjects. This 
possibly suggests that the true CAPN10 clinical phenotype is masked by deterioration to 
IGT and diabetes with the induction of secondary changes in insulin secretory function and 
glucose metabolism due to increased plasma glucose levels. 
The observed associations with CAPN10 genotype and insulin resistance may be related to 
the reduction in skeletal muscle CAPN10 mRNA, specifically a decrease in the two 
predominant splice transcripts observed in Pima Indian UCSNP43 G/G homozygotes [Baier 
et al 2000; Yang et al 20011. The homozygous UCSNP43 G allele subjects also appeared to 
preferentially oxidise lipids, rather than protein or carbohydrates when supplied 
exogenously, indicating significant differences in nutrient partitioning between genotype 
groups [Baier et al 20001. 
Despite the evidence of linkage and association between CAPN 10 and diabetes, the biology 
of CAPN10 and its role in the pathogenesis of diabetes is still not understood. Studies using 
cysteine protease inhibitors have implicated members of the calpain family as being 
involved in either the promotion [Croce et al 1999] or inhibition of protein secretion 
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[Yamazaki et al 1997], depending upon the cell type. A role of calpains in insulin secretion 
from mouse pancreatic islets has been demonstrated with protease inhibitors acting on 
exocytosis of insulin [Sreenan et al 2001; Zhou et al 2000; Yun-Ping et al 2000]. Inhibition 
of calpain has also been found to modify insulin mediated glucose transport in both muscle 
and adipocytes [Zhou et al 2000; Yun-Ping et al 2000]. However, these studies have not 
specifically targeted CAPN10. Finally, calpains have been implicated in influencing 
signalling pathways that control differentiation of myoblasts [Ueda et al 1998], osteoblasts 
[Murray et al 1997], chondrocytes [Yasuda et al 1995] and preadipocytes to adipocytes 
[Patel et al 1999]. Effects on the differentiation of tissues such as pancreas, adipose and 
muscle tissues could have major consequences on insulin secretion and action and 
progression to T2DM. The knockout of the HMGIC gene in mice prevents adipocyte 
differentiation [Anand & Chada 2000] and the resulting inadequacy of the tissue to 
accommodate excess energy promotes storage of calories in the liver and muscles. This was 
proposed to be in part responsible for the development of diabetes in these mice. Based on 
this evidence Danforth [2000] suggested that too few adipocytes could predispose to T2DM. 
Furthermore, factors that influence the development and differentiation of cell types within 
the pancreas will have crucial influences on its eventual endocrine function [St-Onge 1999]. 
It is therefore clear that future work should now be directed at understanding the biology of 
CAPN10. 
In summary: CAPNIO appears to be a minor gene in the susceptibility to T2DM in South 
Indians. Contemporary studies have provided evidence that this gene may influence glucose 
tolerance status in a subset of individuals, and hence progression to overt T2DM. 
Observations in this thesis that an `at risk' haplotype combination of this gene conferred a 
substantial increased risk to both IGT/IFG and T2DM supports this view. In addition, 
CAPN10 genotype appeared to be associated with physiological factors that lead to impaired 
glucose tolerance which are separate from factors that influence progression to T2DM such 
as weight gain, as subjects with the predisposing haplotypes tended to be thin. Alternatively, 
the observation of association of CAPNIO variants with disease may be the result of linkage 





8.1 RETROSPECTIVE REVIEW OF STUDY DESIGN 
8.1.1 Linkage Study 
The non-parametric linkage study performed on the NIDDMI region of chromosome 2q in 
this thesis did not provide evidence for a T2DM disease susceptibility gene in British/Irish 
subjects, as previously found in a genome scan for T2DM in Mexican Americans [Hanis et 
at 1996]. Indeed, these findings are in keeping with a majority of the other linkage studies 
(table 1.4.3) that have failed to find even nominal linkage to 2q. However, the replication of 
linkage results although extremely important can be problematic. Simulations have 
demonstrated that to attain sufficient power in replication studies sample sizes must be 
substantially greater than those used in the study that detected the original linkage [Suarez et 
al 1994]. If this was applied to the linkage study in this thesis study and contemporary 
studies, most lacked sufficient power to replicate the linkage results. Nonetheless, 
subsequent analysis of a larger dataset from the same study group used in this thesis has 
confirmed the negative linkage result in North Europeans [Evans et at 2001]. 
There have been remarkable successes in positionally cloning disease susceptibility loci by 
linkage analysis when applied to simple Mendelian disorders. Moreover, linkage analysis 
has proven to be robust with low false positive rates even when stringent levels of 
significance have been applied in these studies [Rao et at 1978; Morton et al 1998a]. 
However, in the case of non-mendelian complex disorders there has been a notable lack of 
success in identifying genes by linkage analysis, with the possible exception of Crohn's 
disease [Ogura et al 2001]. 
One potential reason for the hindered progress may be the underlying genetic architecture of 
the complex disease undermining the ability to detect linkage. For example, non-allelic 
heterogeneity is rare in Mendelian diseases but in complex non-mendelian disorders this 
may not be the case. Linkage would be difficult to detect if there were a large number of 
distinct loci with alleles at different loci each independently capable of increasing 
susceptibility to the same disease phenotype. Moreover, if any single gene only accounted 
for a small proportion of the disease segregating in families and with the high allelic 
diversity expected in most populations, even the most significant risk alleles would account 
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for only a few percent of the total variance in disease liability. Extremely large families or 
huge numbers of ASP's would be necessary to obtain robust evidence of linkage. The 
expected allelic diversity combined with high false positive rates and lack of replication, 
suggests that linkage analysis overall might have only a limited potential in mapping disease 
susceptibility genes in non-mendelian complex diseases [Risch 2000]. 
The complexity and magnitude of the problem that may well be encountered in the hunt for 
genes in complex diseases has been alluded to in a recent review discussing the mapping of 
complex diseases [Wright et al 1999]. It was postulated that at least 100 loci might affect 
susceptibility to coronary artery disease, and less than one third of cases of pigmentary 
retinopathy are caused by more than 600 mostly rare disease alleles at more than 55 loci. 
However, if a disease susceptibility gene has common alleles that cause sufficiently large 
displacement (ie. has a high relative risk) then detection by linkage analysis is possible. In 
TIDM, susceptibility genes have been found using linkage studies including the 
phylogenetically ancient polymorphic risk alleles of HLA and Insulin genes [Concannon et 
al 1998, Cucca et al 2001]. Furthermore, in contrast to the negative predictions, a T2DM 
susceptibility gene was found as a result of a genome scan, namely CAPN10 in the 
NIDDMI region [Horikawa et al 2000]. The identification of the CAPN10 was even more 
remarkable when considering that based on the eventual observed association of the 
CAPN10 variant UCSNP43 with increased risk to T2DM in Mexican Americans, 
theoretically 100,000 sib pairs would have been required to have detected the original level 
of linkage [Altshuler et al 2000]. However, the final location of the gene relied heavily on 
the utilisation of methods based on linkage disequilibrium. 
8.1.2 Candidate gene approach 
Association studies can be a much more effective genetic tool than linkage as they can 
provide adequate power to identify genes with low to moderate relative risks (<1.5), even 
with stringent levels of significance and in diseases that are both aetiologically and 
genetically heterogeneous [Risch & Merikangas 1996]. Simulation experiments have shown 
that LD has an increased power to detect susceptibility genes in complex disorders [Lenin & 
Clerget-Darpoux 1996]. Consequently, candidate gene approaches using association studies 
have been widely used to study complex disorders. However, association studies are also 
only in reality statistical arguments that are dependent on generating correlations between 
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two or more events, characteristics or variables. The statistical outcome of these studies 
could be entirely due to unknown underlying confounding factors and could be influenced 
by a number of other statistical, clinical and genetic factors. Caution therefore has to be 
applied in association studies. In this respect as part of a retrospective overview of the study 
design a number of aspects were considered: 
(1) Sample Size: The population/sample size used must be adequate to provide sufficient 
power to detect an association, especially if the disease related alleles have a low frequency 
and/or relative risk. Calculation of power for the loci studied in this thesis found that the 
South Indian urban survey in most cases did provide adequate power. In contrast the South 
Indian families and obese/slim cohort in some circumstances were underpowered. In 
epidemiological studies statistical power based on sample size can often be determined 
prospectively. Unfortunately a priori knowledge of a candidate locus such as relative risk, 
disease related alleles, allele frequencies and regional patterns of linkage disequilibrium (for 
haplotype construction) are not usually available within the same ethnic group. Hence most 
genetic studies must be performed before power of the study can be determined. 
(2) Misclassification: The associations statistically generated in this thesis relied entirely on 
the correct classification of both genotype and phenotype. Laboratory methods were 
instigated to guard against genotype misclassification. However, all the statistical analyses 
were made under the assumption that there was no phenotypic misclassification, as there 
was no provision to do otherwise. 
(3) Population Dynamics: The South Indian population appeared to be ethnically 
homogeneous and had no obvious evidence of a high degree of consanguinity or skewed 
population dynamics (observed genotype frequencies for all loci studied did not deviate 
from expected Hardy-Weinberg values, bar one [CAPN10 UCSNP19] that had increased 
heterozygosity suggestive of genotyping error or possible `outbreeding']. However, even if 
some `inbreeding', is present in this South Indian Dravidian population it may not be 
detrimental as some geneticists believe this to be advantageous as it can increase the rates of 
fixation for risk alleles, cause polarisation of phenotypic effects, and reduce non-allelic 
heterogeneity [Wright et al 1999]. 
201 
The relative merits of the South Indian urban population survey compared to a conventional 
case-control study could be questionable. Populations that are derived from a peripheral part 
of a larger epidemiological study that were not originally designed for examination of 
genetic factors, such is the case for the South Indian urban survey have been criticised for a 
`lack of thoroughness' [Tabor et al 2002]. However, an across the board random collection 
of subjects within an ethnic population would go some way in avoiding the selection bias 
possible in a conventional case-control study design. 
(4) Replication: Candidate gene approaches have frequently suffered from a lack of 
reproducibility both within and between different ethnic groups [Tabor etal 2002]. Non- 
replication of association of specific locus alleles between populations of different ethnic 
background could be due to a number of reasons including both allelic and non-allelic 
heterogeneity giving rise to the same disease phenotype. In addition, if the variant is merely 
a disease marker and not causative then differences in chromosomal linkage disequilibrium 
due to demographic variation between ethnic populations could produce different results. 
Alternatively association with the same variant allele may be undetectable or different 
between ethnic groups due to differences in relative risks or pleiotropic genotype effects on 
phenotypic traits. In this respect replication studies within the same ethnic group would be 
more robust. In this thesis a second data set using South Indian families not only allowed the 
opportunity to replicate findings within the same ethnic group but also facilitated the 
application of a different study design to complement the population association study. In 
addition it provided an enriched resource for case-control studies, with recruitment selection 
increasing the probability of an individual carrying a disease allele. 
Family based TDT analysis where both linkage and association must be simultaneously 
present to attain a positive correlation has certain advantages over population association 
study designs. Firstly, the TDT test utilises non-disease but related individuals from within 
the families as `pseudocontrols', therefore theoretically avoiding the confounding effects of 
population stratification. Power studies have also shown that the detection of linkage in 
complex traits by TDT has much greater power than allele sharing methods used by non- 
parametric linkage analysis [Risch & Merikangas 1996]. 
However, a TDT approach can also be fraught with problems and the traditional case- 
control approach even with its confounding problems of population stratification and high 
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false positive rates still offers distinct advantages [Morton & Collins 1998b]. For example, 
TDT tests fail to take into account an `inbreeding coefficient' which reduces its efficiency 
[Morton & Collins 1998b], whereas extensive studies in large population samples found this 
to be a negligible problem [Morton et al 1991]. Morton also contends that the stratification 
argument in favour of TDT is purely mathematical and not based on genetic evidence and is 
only actually true under certain population conditions [Morton & Collins l998b]. 
Consequently failure for a TDT to replicate a positive population association result might 
mean a classical Type I error in the population study, but could also equally reflect a type II 
error in an inefficient family based test. 
In the studies in this thesis TDT analysis of disease phenotypes did not always support 
associations demonstrated in the population sample. Certainly in the case of the CAPN10 
gene this was due to the low disease allele frequency of UCSNP63, lack of heterozygosity, 
too few families and hence lack of statistical power. The strength of the TDT test is 
determined by the degree of linkage disequilibrium between the polymorphic sites 
examined. This is at its most efficient when the disease concerned is rare and the allele 
frequency differential between the disease and the normal chromosome is at its greatest 
[Xiong & Guo 1997]. 
Furthermore, during the course of my studies on CAPN10 an additional limitation of the 
TDT test was exposed. The observations in the population association studies that 
heterozygous haplotype combinations of CAPN10 were more important than individual 
haplotypes for risk to disease would not have been detected solely by using a family based 
approach. As a consequence of the positive association in the population sample the TDT 
test had to be modified to allow analysis of the simultaneous transmission of two risk 
haplotypes in families. Using this adaptation the positive result in the population association 
study was confirmed. 
Overall this argues in favour of the simultaneous use of both family and population sample 
resources if available. 
(5) Enhancement of detection: In complex disorders such as T2DM and obesity with 
potentially large number of susceptibility loci (and alleles), the disease state is complex and 
an insensitive indicator of the underlying pathogenic process. Unless variation in a candidate 
gene has a major impact on susceptibility to the idiopathetic phenotype then false negative 
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studies are possible. In this respect the analysis of intermediate quantitative traits can prove 
to be more sensitive especially if an effect on sub-phenotypic traits can be predicted based 
on possible gene function. However, such studies are limited to available sub-phenotypic 
data that may not always be comprehrensive or the most appropiate. For example, studies in 
South Indians in this thesis on UCP2 and UCP3 found gene variants associated with 
available data on variation in body mass (BMI) and fat distribution (WHR) which would not 
be incongruous with the potential role of uncoupling proteins in body weight homeostasis. 
Importantly an increase in risk to T2DM and related metabolic syndromes in South Indians 
appears to be strongly influenced by progessive central obesity [Davey et al 2000]. Even 
relatively small gains in abdominal adiposity can increase propensity to disease. However, 
in South Indians the measurement of sagittal diameter rather than BMI and WHR would 
have been a much more sensitive indicator of variation in central obesity in this ethnic group 
[Davey et al 2000]. 
In contrast other intermediate trait data ie. IFG/IGT in the South Indian population provided 
additional information that many other studies have missed through omission of clinical 
diagnosis of this sub-clinical grouping. The association in this thesis with CAPNIO was 
found in both subjects with IFG/IGT and T2DM. However, only a proportion of the 
IFG/IGT go on to become overtly diabetic, which suggests that CAPN 10 could be one of the 
genes that broadly underlie glucose intolerance within a population. 
The power to detect an association is not only enhanced by clinical sub-grouping but also if 
the ethnic group has a reduced environmental risk [Wright et al 1999]. The South Indian 
population presumably have not been fully subjected to the impact of environmental factors 
that `westernised' populations have. Therefore in this respect this resource is potentially 
more useful in studying subtle genotype-phenotype interactions. Feasably, the lack of 
replication of the significant South Indian association with the UCP2 variants and BMI in 
White European obese subjects (notably only negative after statistical correction for multiple 
comparisons) might be indicative of a masking effect. Alternatively, genotype-subphenotype 
relationships have often been more readily detectable in non-disease or pre-disease subjects 
rather than in the overt disease state. For example, studies on intermediate traits such as 
insulin sensitivity and secretion with CAPN1O gene variants were only correlated in 
normoglycaemic subjects and not in diabetics [Lynn et al 2002; Baier et al 2000]. The South 
Indian study population were recruited cross-sectionally without prior selection criteria apart 
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from ethnicity. Therefore, it would be expected that the whole broad spectrum of the non, 
pre, and disease state are represented possibly making it more sensitive in studying the effect 
of the genetic variation on phenotype. 
(6) Haplotypes: The generation of haplotype data is proving to be increasingly important in 
respect of providing information on linkage disequilibrium patterns particularly between 
different ethnic populations. In the context of population association studies it is believed 
that analysis of haplotypes can be statistically advantageous in terms of providing increased 
power to detect association, but only under certain circumstances [Bader 2001]. Simulation 
studies have suggested that there is a `crossover' of the statistical usefulness of analysing 
individual SNP's verses haplotypes and this is determined by both the number of possible 
haplotypes in a given population and the number of `causative' SNP's within the haplotype 
[Bader 2001]. If this model had been applied to the CAPN10 study, then haplotype analysis 
should have been more powerful than individual SNP analysis. In contrast, there would not 
have been any great benefit in analysing haplotypes of the UCP2-UCP3 variants. However 
these simulations did not take into account scenario where it would be necessary to 
investigate the effects of haplotype combinations as in the CAPN10 gene. 
In pedigrees haplotype phase can be readily determined but in unrelated subjects this usually 
has to be estimated. Many of the current statistical methods that estimate haplotype 
frequency in population samples rely entirely on the expectation-maximisation (EM) 
algorithm, such as the EH program [Ott 2000]. It has been suggested that this method is 
inefficient and prone to bias and ideally experimentally derived haplotype phase data is 
preferable [Hodge et al 1999; Douglas et al 2001]. The practicalities in producing 
experimentally derived haplotype data in the South Indian survey subjects would have 
involved a monumental task based on the techniques available at the time. Fortunately, yet 
again having both a family and population resource from the same ethnic group proved to be 
useful. Invaluable knowledge of patterns of linkage and disequilibrium and hence haplotype 
frequencies derived from the families allowed the unambiguous assignment of haplotype 
phase to a majority of the urban survey subjects. Certainly alternative methods using 
estimations would have been less reliable in downstream analyses. 
However, it has also been suggested that haplotypes should not be analysed alone, because if 
selection processes are present, haplotypes conferring an extreme phenotype are eliminated 
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at a faster rate than the underlying SNPs, with this negative selection tending to eliminate 
the extreme multi-hit haplotypes from the population. However, the individual causative 
alleles may still have considerable population frequency [Bader 2001]. This supports the 
view that analysis in the thesis of both individual variants and as haplotypes was fully 
warranted. 
8.2 DISSECTION OF A COMPLEX TRAIT 
Rich [1990] suggested that the best-fit genetic model for T2DM involved only a few genes 
with a moderate effect, superimposed on a polygenic background. However, Risch [2000] 
intimates that this actually reflects geneticist's preference for a oligogenic/multigenic model, 
as it has a tractable degree of complexity. Complex disease models that have infinite genetic 
complexity, resulting from numerous effector genes, but each only contributing a modest 
effect, would represent a monumental task in the identification of susceptibility loci. 
However, whatever the genetic model of the disease it will be necessary to break it down 
into its simplest components. Theoretically, the identification of all the susceptibility genes 
and an understanding of their individual underlying biological contribution of each gene to 
the overall disease pathophysiology would eventually provide a means to determine an 
individuals risk to disease. The work in this thesis using a candidate gene approach has 
attempted to address this paradigm. 
8.2.1 Uncoupling Protein Genes 
There is reasonable certainty based on the evidence presented in chapter 2 that uncoupling 
proteins UCP1, UCP2 and UCP3 uncouple oxidative phosphorylation at the inner 
mitochondrial membrane. However, the exact physiological role of either UCP2 or UCP3 in 
either thermoregulation, modulation of ATP synthesis, control of oxidative stress, or fatty 
acid/glucose oxidation still remains to be fully elucidated [Boss et al 2000; Adams 2000; 
Simonyan & Skulachev 1998; Richard et al 1998; Rippe et al 2000; Samec et al 1998a]. 
Studies in this thesis found associations with variants of UCP2 and UCP3 with variation in 
fat mass (BMI) and in fat distribution respectively. These findings suggests that variations in 
these genes in humans may predispose an individual to either a reduced efficiency in 
modulating body weight or may be instrumental in influencing regional fat deposition. 
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In the previous section one highlighted important aspect of association studies was the need 
for replication studies to further substantiate positive findings. To date five studies, 
including the study in this thesis, have reported positive associations with BMI and the 
UCP2 Ins/Del variant in exon 8 (and also A55V in some instances) with p values ranging 
from 0.001-0.007 [Cassell et al 1999; Evans et al 2000; Yanovski et al 2000; Zheng et al 
2000; Buemann et al 2001]. Moreover, these associations have been found across a number 
of diverse ethnic populations including Caucasians, Africans, Chinese and Asians. In 
addition, the UCP2 exon 8 variant has been correlated with variation in sleeping metabolic 
rate in Pima Indians [Walder et al 1998]. Recently a promoter polymorphism at position - 
866 in UCP2 has been identified that appears to control the transcription of the UCP2 gene 
and may determine the preferential expression of the exon 8 insertion or deletion allele 
[Esterbauer et al 2001]. The variant was attributed to causing 15% of the variation in 
adiposity in the population group studied. However, this association was not confirmed in 
one other population studied [Dalgaard et al 2001 a]. 
Similarly variants of UCP3, particularly the promoter -55 variant have also been associated 
with variation in BMUobesity in three studies although this has not been as consistent as the 
UCP2 exon 8 variant studies [Cassell et al 2000; Otabe et al 2000; Halsall et al 2001]. 
Although the -55 promoter variant was not associated with BMI in the South Indians in this 
thesis instead it was positively associated with variation in WHR. The observed BMI 
associations could reflect linkage disequilibrium with the UCP2 gene. However, the -55 
variant has also been significantly associated with higher LDL-cholesterol levels in French 
and fasting blood glucose in the Western Pacific Ocean Palauan islanders [Meirhaeghe et al 
2000; Yanagisawa et al 2001]. In addition, other UCP3 variants have correlated with basal 
fat oxidation (exon 6 splice variant) and levels of resting energy expenditure (the exon 5 
Tyr2IOTyr) in African -American populations [Argyropoulos et al 1998; Kimm et al 2002]. 
In addition, a newly identified UCP3 intronic variant (GAIVS6) that has not been screened 
in any other population including the South Indians was found to be significantly associated 
with BMI, fat mass, percentage fat, skinfold thickness, and leptin levels in French Canadians 
[Lanouette et al 2001]. 
Overall the findings from genetic studies provide compelling evidence that UCP2 and UCP3 
could be involved in the regulation of body-weight homeostasis in humans. Whether 
UCP2/UCP3 have roles in mediating fuel partitioning and/or adaptive energy expenditure, 
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an inherited inability to efficiently remove surplus calories by thermogenic wastage, or a 
deficiency in skeletal muscle to utilise lipids as fuel substrates would both promote 
increased fat deposition. Even only a small persistent discrepancy between daily intake and 
energy output could result in substantial weight gain over time. 
However, there have been a number of negative studies for both UCP2 and UCP3, which 
must be considered especially in light of the widely perceived view that there tends to be 
positive publication bias [Klannemark et al 1998; Urhammer et at 1997 & 1998; Chung et a1 
1999; Kubota et al 1998; Otabe et al 1998; Dalgaard et al 1999]. It is possible that either the 
positive or negative associations represent statistical error as a result of underlying 
confounding factors. Alternatively, the differences observed between the studies may reflect 
both or either differences in the gender or ethnicity of the study populations. A number of 
factors that could determine a studies ability to detect an association including those 
dependent on the ethnic background of the population were discussed in the previous section 
(8.2.1). Certainly genetically determined differences in fat distribution patterns can be 
influenced by both ethnicity and gender [Park et al 2001; Snehalatha et al 1997; Bouchard et 
al 1990]. 
The South Indian subjects studied in this thesis possess a high degree of heritability for 
infra-abdominal fat deposition compared to other ethnic groups [Davey et al 2000]. This 
tendency in South Asians to accumulate visceral fat is likely to have a central role in 
associated metabolic disturbances with even small increases shown to be predictive of an 
increased risk to T2DM [Snehalatha et al 1997; McKeigue et al 1991& 1992; Ramachandran 
et al 1997a & 1998]. Furthermore, a recent study that tested the hypothesis that an effect on 
resting energy expenditure by variation in UCP1, UCP2 and UCP3 may be different across 
racial groups found that variation in UCP3 (strongest effect exon 5 Tyr2lOTyr) had a more 
pronounced effect in African-Americans than in White Europeans [Kimm et al 2002]. 
Interestingly, most of the negative studies with variants of UCP2 and UCP3 have been in 
White Europeans. 
In respect of gender it is widely recognised that men and women differ in fat deposition 
(discussed in chapter 1). In the discussion of chapter 4 and 5 attention was drawn to the fact 
that the subjects used in most of the negative studies were either predominantly or entirely 
male. In contrast, many of the positive findings including those in this thesis were either 
with females or in study groups with an increased proportion of females. Accumulating 
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evidence suggests that gender determined differences in regional fat distribution could have 
important ramifications in respect of physiological processes. Men under weight reduction 
regimes have increased mobilisation and loss of infra-abdominal fats compared to women 
who predominantly lose subcutaneous fat (SC) (Wirth & Steinmetz 1998]. This loss of intra- 
abdominal fat rather than SC appears to be associated with a pronounced improvement in 
metabolic profile, in respect of lipids, lipoproteins and blood pressure. Observations that 
human omental adipocytes display a range of biochemical properties that distinguish them 
from subcutaneous adipocytes combined with the existence of fat depot specific effects on 
gene expression infers that different fat deposits may function very differently [Minocci et al 
2000; Montague et al 1998]. Important examples include the significantly increased 
expression of leptin in SC fat compared to omental fat deposits, and fat depot variation in 
the expression Alanine Transaminase, and the apoptosisprotein-2 (cIAP2) genes [Montague 
et al 1998; Thulsrup et al 1999]. 
Gender and ethnically determined differences in adipose tissue deposition could exacerbate 
the phenotypic effect of UCP2, hence influencing the ability to detect an association. 
However, although UCP3 is not transcribed in adipose tissue it may also be indirectly 
affected by fat deposition. UCP3 expression varies considerably depending on the type of 
muscle fibres [Hesselink et al 2001; Schrwauen et al 2001]. UCP3 activity in different 
muscle fibres may be modulated by variation in muscle cell sympathetic nerve activity and 
03-adrenergic stimulation, which has also been correlated with gender differences in fat 
distribution [Jones et al 1996; Rodriguez et al 2001]. In addition, it has been postulated that 
reduced muscle sympathetic nervous activity is a potential mechanism in predisposing 
humans to body weight gain and obesity possibly as a result of diminished thermogenic 
response to stimuli which is particularly evident in older individuals [Spraul et al 1993; 
Kerckhoffs et al 1998]. 
One interesting aspect of the thesis study was the observed relationship of UCP2 genotype 
with plasma leptin levels. Although, there are no equivalent replicate studies to support these 
findings, an intronic variant in UCP3 (GAIVS6) has been significantly associated with leptin 
levels in French-Canadians [Lanouette et al 2001]. These findings might indicate the 
existence of a biological pathway whereby uncoupling proteins influence body weight 
regulation via the action of leptin. 
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Leptin, in addition to its anorectic effect has a stimulatory effect on energy expenditure, 
affects several neuroendocrine mechanisms and regulates multiple hypothalamic-pituitary 
axes [Tritos & Mantzoros 1997]. Pre-obese subjects tend to have low leptin levels but most 
obese humans paradoxically have over expression of leptin, suggesting the presence of a 
`leptin resistance' [Ravussin & Gautier 1999; Lonnquist et al 1995]. In this thesis it was 
demonstrated that lower leptin levels than would be expected by weight (BMI) were 
associated with variation in UCP2 genotype in the British Caucasian cohort. This might 
suggest that dysfunctional UCP2 expression could also have possible effects on either leptin 
action or secretion in peripheral tissues. 
However, whereas Leptin modulates UCP expression in a number of tissues in rodents but at 
present there is no evidence to suggest the existence of a direct feedback pathway with 
UCP's influencing leptin action [thou et al 1997; Gimeno et al 1997; Larrouy et al 1997; 
Scarpace et al 1998; Chavin et al 1999; Melia et al 1999; Commins et al 1999; Gomez- 
Amrosi et al 1999; Sivitz et al 1999; Ceddia et al 2000; Villarroya et al 2001]. If UCP2 
genotype does influence leptin action then several possible mechanisms might be postulated 
to support the association observed. 
In several rodent studies involving the individual knockout of UCPI, UCP2 or UCP3 genes, 
mice do not become obese, and alternative physiological roles have been suggested for both 
UCP2 and UCP3 [Enerback; Gong 2000; Vidal-Puig2000; Arsenijic]. Two alternative 
physiological roles have been widely proposed, but are still speculative as all three 
uncoupling genes have not be knocked out in unison, therefore compensatory interactions 
between these genes cannot be entirely eliminated and may account for some of their 
findings. Firstly, a role in limiting the overproduction of apoptotic ROS to maintain cellular 
integrity, with the main source of ROS being from mitochondria due to increased proton 
availability from fat oxidation. 
Secondly the reduction in the effects of lipotoxicity on tissues by altering fuel utilization 
within the cells, with this probable action of UCP2 having been already demonstrated in 
adipocytes [Wang et al 1999; Chavin et al 1999; Arsenijic et al 2000; Boss et al 2000]. 
Hepatic steatosis and excess lipid in muscle and pancreas are characteristic in obese 
diabetics. It has been hypothesised that excess calorie intake beyond the capacity of the 
adipose tissue, itself becoming insulin resistant when filled to capacity (_3. t g lipid/cell), 
increases the abnormal deposition of lipids in liver, muscle and blood [McGarry & Dobbins 
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1999; Danforth et a] 2000]. In skeletal muscle an increase in tissue FFA content interferes 
with insulin transport via blood across endothelium [Baron 1994; Steinberg et al 1997]. This 
can stem the access of insulin to insulin sensitive tissues causing insulin resistance and also 
disrupt insulin stimulated glucose utilisation [Bergman 1997; Hamilton-Wessler et al 2000; 
Randle et al 1994; Baldeweg et al 2000; Boden et al 1997]. Muscle insulin resistance 
combined with the other deleterious effects of lipotoxicity, such as over-production of 
glucose by liver, and blunted secretion in pancreas, are characteristic of T2DM [McGarry & 
Dobbins 1999; Unger et al 1999]. Uncoupling activity could modulate either the levels of 
ROS production or degree of lipotoxicity and hence directly protect tissues such as 
pancreatic (3-cells, skeletal muscle and liver from their deleterious effects [Wang et al 1999; 
McGarry & Dobbins 1999; Unger et al 1999; Mohanty et al 2000; Chen et al 2001; Pessayre 
et al 2001]. 
The control of either ROS or lipotoxicity by UCP2 in adipocytes and other target tissues 
could have effects on both leptin secretion and post leptin receptor transduction pathways. 
Leptin acts at least in part by mediating the release of the orexigenic neuropeptide Y (NPY), 
propiomelanocortin (POMC), and melanocyte stimulating hormone ((x-MSH) in the 
hypothalamic arcuate nuclei. UCP2 is abundantly expressed in these hypothalamic nuclei 
[Richard et al 1999; Diano et al 2000]. Therefore UCP2 could be crucial in preventing 
neural tissues becoming leptin insensitive from the deleterious effects of increased ROS 
levels or lipotoxicity, with the latter affecting either the passage of leptin across the blood 
brain barrier or on cell surface leptin receptors [Caro et al 1996; Kalra et al 1999]. Ageing in 
rodents causes an impairment of hypothalamic nuclei uptake of leptin independently of 
increasing adiposity, which is commensurate with elevated mitochondrial ROS production 
augmented by ageing and a decline in cellular UCP2 activity [Wallace 2001; Fernandez- 
Galaz et al 2001; Yamashita et al 1999]. Studies in rodents have suggested that ageing 
induced reduction in UCP2 expression and physical activity are responsible for observed 
increased cold sensitivity and obesity [Yamashita et al 1999]. ROS also appears to be able to 
modulate both gene expression and signal transduction pathways within cells, although these 
mechanisms are still not completely known [Shih et al 2001]. UCP2 could control 
expression of other genes by influencing levels of ROS and hence brain tissue function. 
Further studies on the neuronal expression of UCP2 also suggest that heat generated by 
axonal UCP2 can modulate neurotransmission in homeostatic centres and thereby coordinate 
211 
the activity of the brain circuits that regulate daily energy balance and related autonomic and 
endocrine processes [Horvath et al 1999]. 
Interestingly, studies in humans have shown that adipose tissue UCP2 expression is 
inversely correlated with both leptin and increasing adiposity [Pinkney et al 2000]. 
Therefore, increasing adiposity in humans would suppress the very mechanisms that may be 
designed to correct the damage caused by lipid saturation of tissues, this would be 
exacerbated by the reduced control of tissue ROS production that increases with age and 
thus opening the way to further progression to the obese and diabetic state [Bergman & Ader 
2000; Wang et al 1999]. 
However, the arguments for these alternative physiological roles for uncoupling protein 
functions are largely pivotal on experimental findings in rodents. Although, the regulation of 
human and rodent UCP1, UCP2, and UCP3 expression does appear to be mediated by a 
variety of similar stimuli, there are evidently differences in tissue specific response between 
species. This is illustrated by differences observed in the induction of UCP2 expression in 
WAT between rodents and humans. In rodents, whereas food intake, plasma insulin, PPAR 
agonists, fatty acids and leptin overall appear to induce UCP2 expression, although not 
always entirely consistently [Qian et al 1998; Zhou et al 1997; Aubert et al 1997; Villarroya 
et al 2001]. In humans, plasma leptin, insulin and fatty acids suppress UCP2 expression in 
WAT, with food intake having no effect at all [Pinkney et al 2000]. 
The uncoupling protein family are highly conserved with orthologs discovered in many 
species of mammal and also in fish, birds, insects and even plants suggesting an evolutional 
importance in their metabolic function [Argyropoulos& Harper 2002]. However, there are 
fundamentally considerable differences in the environmental conditions and requirements 
for adaptive mechanisms between animal species, suggesting that the physiological roles of 
these genes could be quite different. The function of non-shivering thermogenesis for UCP1 
in BAT is an important adaptive response essential for the survival of hibernating rodents, 
penguins, cold adapted and possibly new-born mammals [Rothwell & Stock 1981; Duchamp 
et al 1991; Bouchard et al 19971. However, its role in adult humans existing under very 
different thermoneutral-environmental conditions appears to be largely redundant. Although 
there is a high degree of homology between the UCP3 proteins, the promoter region of 
UCP3 in humans is very different to that in rodents, [Esterbauer et al 2000; Yoshitomi et al 
1998b]. This would not only suggest that there has been major functional diversification of 
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uncoupling proteins between species as a result of rapid phylogenetic evolution of these 
genes, but in addition the trans-acting factors and hence other downstream mechanisms 
controlling expression of this gene are also very different. Furthermore, UCP2 and UCP3 
genes are both in close chromosomal proximity and have a high degree of cross homology in 
both humans and rodents, suggesting that they may be the result of an evolutionary gene 
duplication event. Evidence of functional differences and the differential tissue expression 
of UCP2 and UCP3 suggest they might have also developed very different physiological 
roles. 
However, a similarity in function between species cannot be totally disregarded. A 17 
month-old girl that had profound isolated episodes of hypothermia had both deficiencies in 
skeletal muscle mitochondrial respiratory chain complexes III and IV and also demonstrated 
decreased muscle UCP3 function, inferring that UCP3 may also still be important in cold 
adaptation processes in humans [Cholley et al 20011. 
In conclusion the findings in this thesis and contemporary genetic studies provide substantial 
evidence that the uncoupling protein homologues UCP2 and UCP3 influence underlying 
physiological processes that alter an individual's propensity to weight gain. However, more 
research is necessary to establish the true functional roles of both UCP2 and UCP3 in 
humans. 
8.2.1 CAPN10 gene 
The findings in thesis that sequence variation of the CAPN10 gene can increase risk to the 
development of T2DM are in agreement with both the seminal and some contemporary 
studies [Horikawa et al 2000; Evans et al 2001; Schwarz et al 2001; Baier et al 2000]. 
However, it is evident from all these studies that the resulting disease phenotype is not 
determined by a single gene variant, but by a culmination of the combined effects of a 
cluster of mainly intronic polymorphisms. These variants at present have not been linked 
anyway to causality. These CAPN10 gene variants are all in considerable linkage 
disequilibrium and hence globally generate only a few haplotypes [Fullerton et al 2002]. 
However, the varying degree of individual risk to disease is conferred not only by certain 
haplotypes but is also dependent on interactions or synergistic effects between the 
haplotypes. 
213 
The importance of the CAPN10 gene in susceptibility to disease varies between different 
ethnic groups and appears to be determined by the frequencies of `risk' haplotypes. The low 
frequency of one of the main `risk' haplotypes in South Indians suggests that CAPN10 is 
only a minor T2DM susceptibility gene in this population. Geographic and evolutional 
studies on the distribution of CAPN10 polymorphisms/haplotypes in humans and non- 
human primates have to some degree illustrated the global diversity that may be expected 
[Fullerton et al 2002]. For example these investigations found that the alleles of UCSNP19 
and UCSNP63 (C) may have had a selective advantage in non-African populations and 
because of this they have persisted in these populations. In contrast, one of the `at risk' 
haplotypes (121) that is common in Europeans and Asians was found to be rare to 
completely absent in Africans suggesting other `at risk' haplotype combinations would be 
responsible for susceptibility at this locus in subjects in this ethnic group. 
Studies on the function of the CAPN10 protein are presently scarce to non-existent. 
However, preliminary studies correlating phenotypic variation to genetic variation for 
CAPN10 support a role for the protein in both influencing insulin action and secretion 
[Baier et al 2000; Sreenan et al 2001; Elbein et al 2002; Lynn et al 2002]. There are again 
clearly ethnic differences in the effect of the variant loci on phenotype. Whereas UCSNP43 
associates with insulin sensitivity in Pima Indians, the UCSNP19 and UCSNP63 variants 
have a more significant effect in Caucasians [Baier et al 2000; Elbein et al 2002]. The 
observed decreases in skeletal muscle insulin sensitivity and reduced insulin mediated 
glucose transport could be due to variation in expression of specific splice variants, with 
some isoforms possibly being biologically inactive [Yang et al 2001; Ma et al 2001]. 
Diabetogenic effects by the CAPN10 protein have also been proposed through modulation 
of insulin exocytosis in the pancreatic ß-cells and hence possible effects on insulin secretion 
or by regulation of glucose metabolism in peripheral tissues such as adipocytes [Sreenan et 
al 200; Hoffstedt et al 2002]. 
Although little is known of the function and pathophysiological effect of CAPN10, other 
members of the calpain superfamily have been investigated and associated with disease. 
Members of the calpain superfamily are important proteases that have been demonstrated to 
be downstream molecules of hormone receptors, membrane-type tyrosine kinases and 
adhesion molecules [Sato & Kawashima 2001]. Calpains proteolyse and regulate the activity 
of many signalling related substrates, such as protein kinase (PKC), alpha subunit of G- 
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proteins and protein tyrosine phosphatases. Consequently, calpains may modulate signal 
transduction pathways in a number of molecules including growth factors, T-cell receptors 
and integrins [Sato & Kawashima 2001]. 
Calpain proteases have already been implicated in several disease processes. In limb-girdle 
muscular dystrophy a dysfunctional skeletal muscle specific CAPN3 appears to have direct 
effects on the progressive atrophy of limb and trunk muscles [Huang et al 2001]. In addition, 
over-activation of calpains have also been implicated in a number of other pathological 
processes, with CAPN1/ CAPN2 associated with stroke, traumatic brain injury and 
Alzheimer's disease and CAPN9 with gastric cancer [Huang et al 2001]. One possible 
`disease causing' factor that has been implicated in these degenerative disorders, are the 
increased amounts of the `unusually stable' calpain-mediated cleavage break-down products 
(BDPs). BDP's appear to be related to apoptotic processes mediated by the caspase family 
of proteases and are increased in normal ageing and Alzheimer's disease [Vanderklish & 
Bahr 2000]. 
The study on CAPN10 in this thesis provides preliminary evidence supporting a role for this 
gene in contributing to susceptibility to T2DM. Ultimately extensive functional work is 
required to prove conclusively whether the CAPNIO gene actually play's a primary role in 
the development of T2DM or is secondary in nature by facilitating the progression to the 
overt disease state. 
The positive findings in this thesis from a `hypothesis-driven' candidate gene approach have 
contributed to another step forward in the knowledge of which genes might influence 
susceptibility to T2DM and obesity. Moreover, the studies in this thesis still endorse 
Risch's definition for a complex trait by confirming the degree of complexity and genetic 
heterogeneity that had been expected fRisch 2000]. CAPN10, UCP2 and UCP3 are only 
minor genes for disease susceptibility, each individually insufficient to give rise to either the 
overt T2DM or obesity phenotype. Thus, in both multifactorial disorders to be able to 
eventually generate a genetic risk profile of an individuals disease susceptibility would 
require the knowledge of a large proportion of these minor contributing genes, combined 
also with the relative contribution of each individual gene, and any gene-gene, and gene- 
environmental interactions. This is unfortunately further complicated in that unlike 
mendelian disease phenotypes where a culmination of "a gene with a large displacement, 
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giving rise to a (near) one-to-one correspondence between genotype at a single locus and 
phenotype". In complex non-mendelian disorders "genes are without large displacement, 
giving rise to significant overlap of genotype distributions with a lack of one-to one 
correspondence between genotype and phenotype" [Risch 2000]. Considerable overlap of 
phenotypic traits were observable just in the three genes studied in this thesis, with 
correlations in common in other studies for insulin secretion, insulin action, fuel oxidation / 
fuel partitioning and sleeping metabolic rate [Baier et at 2000; Walder et al 1998; Chan et at 
2000; Screenan et at 2001; Stumvoll et at 2001; Argyopopoulos et at 1998ab; Willi et at 
1998]. Consequently, for complex diseases there will never be simple cause-and- 
effect/genotype-phenotype interactions that are evident in simple Mendelian disorders with 
any T2DM phenotype or sub-phenotypes an aggregate of multiple gene effects. This overall 
suggests that the task ahead will be a challenging one. 
8.3 GENE DISCOVERY AND DISEASE PREVENTION 
The ultimate rationale for studying a disease is to manage, treat and eventually prevent 
disorders. The identification of these susceptibility loci that are responsible for the genetic 
component of T2DM and /or obesity could greatly assist in the elucidation of the underlying 
pathophysiological mechanisms leading to the diseases and is central to the development of 
more effective preventative and therapeutic strategies for this condition. 
An understanding of an individual genetic risk profiles in combination with established 
clinically defined predisposing factors could be used as part of a primary prevention in 
reducing risk of onset of disease. The identification of the genes responsible for MODY that 
accounts for 1% of T2DM in the UK (approximately 20,000 people) have allowed the 
development of diagnostic and predictive genetic tests for 80% of MODY families 
[Shepherd et al 20011. Families with a history of T2DM would presumably be enriched in 
specific T2DM susceptibility alleles/genes and information on the sharing and transmission 
of a majority of the susceptibility polygenes could feasibly allow an overall determination of 
risk and early preventive measures. In the future, the risk of first-degree relatives may be 
determined in families with a history of T2DM similar to that of MODY. In terms of both 
primary and secondary prevention the identification of susceptibility genes could not only 
identify new biological pathway's that may permit specific intervention, but also facilitate 
the individual tuning of treatments. 
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The field of pharmacogenomics is emerging as a relatively new sub-discipline of molecular 
genetics. Future developments in this field will be largely dependent on the information 
made available through analysis of the Human Genome. Drug response is under the control 
of multiple genetic factors, and a better understanding of complex traits would permit 
stratification of patient populations presenting a single disease phenotype into subclasses 
whose disorders might have differing genetic components or different responses to particular 
therapeutics. Clinical trials to associate genotypes in relation to individual variations in 
therapeutic drug response and in the occurrence of adverse drug reactions are becoming 
more common with the eventual view to produce customised drugs and treatments [Marshall 
1997]. 
Whether following the elucidation of true functional roles of either UCP2, UCP3 or 
CAPN10 they can be exploited to develop treatments for obesity or T2DM remains to be 
seen. No susceptibility genes identified so far relating to either of these multifactorial 
diseases have permitted the development of preventive treatments. 
A recent study was designed using transgenic mice over-expressing UCP1 in skeletal muscle 
to determine whether controlling mitochondrial uncoupling oxidative phosphorylation in 
skeletal muscle could possibly be a suitable treatment for obesity and T2DM [Li et al 20001. 
In these studies skeletal muscle oxygen consumption was increased by 98% in low 
expressing mice, and 246% higher in high expressing mice compared to the wild type strains 
on the same dietary regime. The transgenic mice also weighed less, had lower levels of 
glucose and triglycerides combined with better glucose tolerance than the control mice. In 
addition, low UCP1 expressing mice were resistant to obesity under two different high fat 
diets and had lower glucose, insulin and cholesterol levels. There was also a concomitant 
increase in metabolic rate both at rest and during exercise. Furthermore, the mice were also 
more responsive to insulin, and had enhanced glucose transport in skeletal muscle, despite 
an increased muscle triglyceride content. 
Whether modulation of UCP2/UCP3 in humans could have a similar impact remains to be 
seen. In the 1930's agents that increased mitochondrial proton conductance were clinically 
administered in humans as a treatment for obesity. In 1934 it was estimated that 100,000 
people in the USA were using a classic uncoupling agent, dinitrophenol, with dramatic 
success [Tainter et al 1934]. However, due to the occasional problems with cataracts and 
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some fatal overdoses its popularity declined and it was eventually withdrawn from use 
[Parascandola et a] 1974]. 
How useful the uncoupling protein homologues could be in disease prevention in humans all 
depends on the eventual elucidation of their true physiological roles. The manipulation of 
UCP2 gene expression in two recent studies in rodents produces conflicting observations 
resulting in it being referred to both as an `adiposity angel and diabetes devil' [O'Rahilly 
2001]. Rodents over-expressing uncoupling proteins made mice resistant to diet induced 
obesity and improved pancreatic ß-cell function in Zucker diabetic rats [Clapham et al 
2000; Wang et al 1999]. Whereas, in other studies over-expression of UCP2 in rat and mice 
pancreatic islets caused impaired cellular function, causing a reduction in insulin secretion 
and contributed to increased obesity [Chan et al 1999; Zhang et al 2001]. Indirectly the 
UCP2 and UCP3 proteins may already be involved some treatment processes. UCP2 and 
UCP3 both have putative PPAR sites in their promoter regions [Tu et at 1999; Solanes et al 
2001]. Two classes of drugs presently used in humans, fibrates and thiazolidinediones 
control hyperlipidaemic and insulin insensitivity respectively. These drugs exert their effect 
as synthetic ligands activating or up-regulating PPAR's and modulating the expression of 
other genes [Park et al 1998; Michalik & Wahli 2001; Schoonjans et at 1996; Spiegelman 
1998]. 
8.4 EXTENSION OF STUDIES 
8.4.1 UCP2 and UCP3 genes 
In respect of future research on the human uncoupling protein homologues, this will 
primarily involve functional studies on the UCP2 exon8 insertion/deletion and the UCP3 -55 
promoter polymorphisms. Preliminary data in chapter 6 suggested that the UCP3 promoter 
variant might modify trans-acting factor binding. These findings need to be verified with 
further studies to examine whether this polymorphism actually disrupts cis-elements and 
thus influences transcription rates of the gene using gene reporter studies in skeletal muscle 
cell lines. 
The effect of the 45bp insertion/deletion in the 3'UTR of UCP2 also requires functional 
investigation. Evidence is accumulating that variation in the 3'UTR sequences of genes can 
also have major effects beyond influencing mRNA stability. This can take the form of either 
disruption of 3'UTR cis-acting elements and cleavage sites or by determining the length of 
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polyadenylated tails [Ross 1995]. Simple mutations in the 3'UTR can cause enhanced 
mRNA 3'end formation leading to increased cleavage site recognition, enhanced 3' end 
processing and elevated mRNA accumulation and protein synthesis. A single base mutation 
in the 3'UTR of the prothrombin gene (coagulation factor II gene) causes a deleterious 
`gain-of-function' and is thought to be central in the pathophysiology of the genetic disorder 
hereditary thromobphilia [Gehring et al 2001]. Furthermore, myotonic dystrophy (DM) is 
caused by a trinucleotide repeat expansion in the 3'UTR of the DM protein kinase gene, 
with the increased nuclear accumulation of the expanded allele thought to contribute 
significantly to the pathogenesis of the disease [Savkur et al 2001]. 
In addition two novel polymorphisms identified in the promoter of the UCP2 gene and in an 
intronic region of UCP3 (GAIVS6) have been both positively associated with obesity and 
intermediate traits leading to obesity in White Europeans [Esterbauer et al 2000; Lanouette 
et al 2001] Clearly, both these novel variants deserve further investigation in other ethnic 
populations such as the South Indians. 
8.4.2 CAPN10 gene 
The association of the CAPNIO 'at risk' haplotype combination in South Indians will be 
further confirmed by investigations in other available population groups. The positive 
associations with T2DM observed with the CAPN10 gene variants identified in this thesis 
and other studies could quite conceivably be the result of linkage disequilibrium with 
causative mutations in a gene nearby [Horikawa et al 2000; Schwarz et al 2001]. In the 
seminal study the SNP UCSNP22 also had significant `evidence of linkage' and localized 
inter-genetically 3' to CAPN10 and 5' to a G-protein receptor 35 gene (GPR35) identified in 
close proximity to the CAPN10 gene [Horikawa et al 2000]. Analysis of the degree of 
linkage disequilibrium to determine the point of decay and pairwise analysis of all available 
polymorphisms across this whole region in different ethnic groups should indicate whether 
CAPN10 is the true susceptibility gene. Furthermore, determination of the ethnic variation 
in LD relationships in this chromosomal region may clarify some of the observed 
differences in association studies. 
There is also accumulating evidence supporting potential mechanisms near the chromosomal 
telomeric regions that alter the expression of genes in sub-telomeric regions. These effects 
appear to be the result of a reduction of telomere length through ageing, and could have a 
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physiological impact in humans as it does in yeast [Baur et al 2001]. CAPN10 gene localizes 
to the sub-telomeric region of chromosome 2q and investigations in this respect might 
therefore be warranted. 
Functional studies are still lacking for CAPN10 and presently studies on whether a 
dysfunctional protein could affect insulin production and secretion in rat pancreatic (3-cells 
are currently under way in our research group. 
8.4.3 Future Directions 
As previously discussed linkage analysis has a limited potential for mapping complex non- 
mendelian diseases, it will only succeed if an aetiological variant contributes a moderate to 
large effects to disease predisposition [Risch & Merikangas 1996; Collins et al 1997]. Risch 
succinctly summarises the problem " the low hanging fruit were easy to harvest, but we are 
now left with a great deal of fruit at top of tree with no obvious way to reach it" [Risch 
2000]. Genome scan strategies utilising large scale SNP genotyping and LD for mapping 
genes of complex diseases have been proposed using a number of different approaches 
[Roses 2000; Risch & Merikangas 1996; Collins et al 1997]. The number of SNP's required 
for entire genome searches would be dependent on the extent of LD in the human genome. 
In humans LD may extend 5kb-100kb [Krugliyak 1999; Collins 1999, Abecasis et al 20011 
with varying irregularly across the whole genome [Abecasis et al 2001]. Some genetic 
statisticians contend that it is as little as 3kb [Kugliyak & McAllister 1998] and 500,000 
SNPs would be necessary to achieve adequate power for mapping even in isolated 
populations. Contrarily others have predicted LD extending 60kb [Ott 2000; Lee 2001]. 
Potentially genome scans would still require hundreds of thousands of SNP's and study 
populations numbered in the thousands to obtain adequate power to detect association in 
complex diseases [Fulker et al 1999; Abecasis et al 2000; Sham et al 2000]. Therefore, 
Risch [2000] argues in favour of a strategy involving selection of SNP's that are more likely 
to be causative or located in close proximity to causative mutations, ie coding mutations, 
and non-coding 3'UTR, 5'UTR variants. It is estimated there are at least 60,000 non- 
conservative coding mutations in the human genome in the entire world population, of 
which a substantial fraction are already known. This approach could however potentially 
miss mutations that have other effects, such as those that cause alteration in the gene 
environment in relation to the more tightly wound heterochromatic structure and less 
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condensed euchromatic states ie Position Effect Variegation (PEV) [Kleinjan & Van 
Heyningen 1998]. 
The selection of a study population group would also be important with founder populations 
that have remained small over demographic history requiring fewer markers and would be 
more adept to detect rare disease alleles with a greater LD per base pair [Wright et al 1999; 
Laan & Paabo 1997; Lonjou et al 1999]. However they would not necessarily have a greater 
advantage when common alleles are related to disease [Wright et a] 1999]. There could also 
be problems in regions of chromosomes where there is little or no LD, unless the causative 
mutation is selected in the analysis purely by chance, in contrast to linkage analysis, 
evidence of no association would not allow exclusion of the region for the absence of a 
disease gene [Nickerson et al 1998]. 
The recent publication of the first comprehensive analysis of human genome with 93% 
coverage and with 50% in uninterrupted sequence contigs [Nature Feb 2001]] revised the 
projected total number of human genes from 100,000 to only 32,000 [Lee 2001]. The 
ramifications of this projection and the added fact that at least 40% of human genes have 
alternate splice functional isoforms, suggests that there are other orders of genetic 
complexity to accommodate all necessary proteome function [Collins 2000]. In other 
species this appears to be the case with the genome of Drosophila melanogaster having less 
genes than a simpler organisms such as eg. Caenorhabditis elegans, but this is compensated 
by having an expanded proteome diversity with alternate splicing generating many 
transcripts from a single gene [Graveley et al 2001 ]. 
In humans alternate splice sites are primarily in protein coding regions and are particularly 
common in genes for membrane receptors, and genes specific for immune and nervous 
systems [Dredge et a] 2001]. The vascular endothelial growth factor (VEGF) that induces 
microvascular permeability [Robinson & Stringer 2001], the integrin family of 
transmembrane proteins [de Melker & Sonnenberg 1999] and a number of cytokines 
[Atamas et al 1997] all have a number of distinct splice isoforms that differ not only in their 
expression patterns but also in their biochemical and biological properties. CAPNIO has at 
least 10 splice variant isoforms that are differentially expressed. In skeletal muscle two 
splice isoforms predominate, and variation in their levels could be related to the 
polymorphic variants associated with increased risk to T2DM, particularly as some isoforms 
might be biologically inactive [Yang et al 2001; Ma et al 2001]. The UCP3 gene also 
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produces two transcripts with one lacking an important transmembrane domain yet still 
appears to be functional in terms of proton conductance. Whether any of these splice 
isoforms have similar or completely different biological functions still remains to be seen. 
However, even with the complete sequence of the human genome eventually being 
available, it is by no means the endgame. Downstream studies will still be necessary for all 
identified transcribed genes to establish tissue specific expression and function. Finally, the 
roles of genes/proteins in physiological pathways will need to be elucidated to permit 
genetic variation to be connected with phenotype variation [Nadeau & Dunn 1998]. 
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APPENDICES: 
APPENDIX I: BUFFERS AND REAGENTS 
Nucleon DNA extraction kit reagents: 
Reagent A: (10 mM Tris-HCI, 320 mM sucrose, 5 mM MgCI2,1 % Triton X-100; adjust to 
pH 8.0 with 2M NaOH. 
Reagent B: 400 mM Tris-HCI, adjust to pH to 8.0 with 2 MNaOH, 60 mM EDTA, 150 mM 
NaCl, 1% SDS). 
Sequencing loading Buffer: 5: 1 mix of Deionised Formamide: 25mm EDTA pH8.0 with 
50mg/m1 Blue Dextran. 
TEN buffer: 10 mMTris-HCL; ImM EDTA; 0.1 M NaCl ; pH 8.0 
EMSA Reasents: 
Binding buffer 5x concentrate: 100mM Hepes, pH7.5,5mM EDTA, %OmM (NH4)2 SO4, 
5mM DTT, 1 %(w/v) Tween 20, l50mMKC1. 
Gel loading Buffer: iml volume 60%-0.25xTBE, 40%glycerol, ± 0.2% Bromophenol Blue. 
EMSA 10cm x 10cm non-denaturing polyacrylamide gel: 4.1%, 40: 1 (acrylamide: bis- 
acrylamide) in 0.5x TBE. 
20m1 gel mix 
2. Oml 40% Acrylamide 
1.0 ml 2% BisAcrylamide 
2.0 ml 5x TBE 
0.625 ml 80% glycerol 
0.010 ml TEMED 
0.150 ml 10% APS 
5.785 
14.3 ml H20 
Chemiluminescent Detection Reagents: 
lOx SSC : 1.5M NaCl; 0.15M Sodium citrate; pH7.0. 
Buffer 1: 0.1M Malefic acid; 0.15M NaCl, pH7.5 adjusted with NaOH, autoclaved 
Blocking Solution: Blocking reagent (Roche), 1O%w/v in Bufferl and autoclaved. 
Washing Buffer: Buffer 1+0.3%v/v Tween 20. 
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Buffer 2: Blocking solution, 1: 10 diluted in Buffer 1 
Buffer 3: 0.1M Tris-HCL; 0. IM NaCl, pH 9.5. 
CPSD Substrate Solution: CPSD stock solution (10mg/ml) diluted 1: 100 in Buffer 3. 
Restriction Enzyme Buffers: 
Fok I lOx buffer (New England Biolabs): 
200mM Tris-acetate, 
100mM magnesium acetate 
500mM potassium acetate 
10mM Dithiothreitol (pH 7.9) 
TthIII1 lOx buffer (New England Biolabs): 
100mM Bis Tris Propane-HCI 
100mM MgC12 
10mM DTT (pH 7.0) 
Hae III lOx buffer (Amersham Pharmacia): 




Hha I IOx buffer (Promega UK Ltd): 
100mM Tris-HCL (pH 7.9) 
500mM NaCl 
100mM Dithiothreitol (DTT). 
APPENDIX II: QUANTIFICATION OF DNA 
Absorbance was read at 260 and 280 nm using a tin 30 dilution of DNA (l0µ1 in 290µl). 
The OD260 of 1.0 gives an indication of the quantity, corresponding to a concentration of 
50ug/ml of double stranded DNA, consequently values were multiplied by 1.5 to get DNA 
concentration in gg/µl. Quality can be determined by the ratio of the OD at 260nm and 
280nm (OD260/OD280). A ratio of 1.8 or greater indicates a pure preparation of DNA, a ratio 
significantly less than 1.8 indicates contamination with protein. 
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Cassell. P. G, Jackson A. E, North. B. V, Evans J. C, Syndecombe-Court. D, Phillips. C, 
Ramachandran A, Snehalatha C, Hattersley AT, and Hitman. G. A. Haplotype combinations 
of Calpain 10 gene polymorphisms associate with increased risk to impaired glucose 
tolerance and Type 2 Diabetes mellitus in South Indians. Diabetes 2002 May; 51(5): 1622-8. 
Evans JC*, Frayling TM*, Cassell PG*, Saker PJ*, Hitman GA, Walker M, Levy JC, 
O'Rahilly S, Rao PV, Bennett AJ, Jones EC, Menzel S, Prestwich P, Simecek N, Wishart M, 
Dhillon R, Fletcher C, Millward A, Demaine A, Wilkin T, Horikawa Y, Cox NJ, Bell GI, 
Ellard S, McCarthy MI, Hattersley AT. Studies of association between the gene for calpain- 
10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001 Sep; 
69(3): 544-52 (*cited as contributed equally) 
P. G. Cassell, P. J. Saker, S. J. Huxtable, E. Kousta, A. E. Jackson, A. T. Hattersley, T. M. Frayling, 
M. Walker, P. G. Kopelman, A. Ramachandran, C. Snehelatha, G. A. Hitman and 
M. I. McCarthy. Evidence that single nucleotide polymorphism in the uncoupling protein 3 
(UCP3) gene influences fat distribution in women of European and Asian origin. 
Diabetologia (2000) 43: 1558-1564 
P. Cassell, M. Neverova, S. Janmohamed, N. Uwakwe, A. Qureshi, M. I. McCarthy, P. J. Saker 
L. Albon, P. Kopelman, K. Noonan, J. Easlick, A. Ramachandran, C. Snehalatha, C. 
Pecqueur, D. Ricquier, C. Warden and G. A. Hitman. An uncoupling protein 2 gene variant 
is associated with a raised body mass index but not Type II diabetes. Diabetologia (1999) 
42: 688-692 
(ii) Other Published Articles 
Cassell PG and Hitman GA 
Chapter titled Genetics of Type 2 Diabetes in book Diabetes: Perspectives and Advances in 
Diagnosis and Treatment. Edited by E. Shafrir and I. Raz. Pub. Martin Dunitz 2002. 
227 
(iii) Published Abstracts: 
P. G. Cassell, A. E. Jackson, J. Evans, A Ramachandran, C Snehalatha, G. Hitman. A 
Haplotype Combination of the Calpain10 Gene Polymorphisms is a Determinant of 
Abnormal Glucose Tolerance in South Indians. Diabetes June 2001, Volume 50, Suppl2, 
115-OR 
P. G. Cassell, A. E. Jackson, J. C. Evans, A. Ramachandran, C. Snehalatha, and G. A. Hitman. 
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P. Cassell, N. C. Uwakwe, P. G. Kopelman, A. Ramachandran, C. Snehalatha, and G. A. Hitman. 
An association between a novel variant of the UCP3 gene and fat distribution in South 
Indian females. Diabetic Med, Vol 17, Suppl 1; P87 
P. G. Cassell, N. C. Uwakwe, P. G. Kopelman, A. Ramachandran, C. Snehalatha, and 
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